Rifampin and warfarin: a drug interaction.
Rifampin	0-7	warfarin	13-20	int

The drug interaction between warfarin and rifampin is not well known.
warfarin	29-36	rifampin	42-49	int

Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
Rifampin	0-7	warfarin	43-50	mechanism

The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
rifampin	34-41	warfarin	47-54	mechanism
rifampin	34-41	warfarin	119-126	false
warfarin	47-54	warfarin	119-126	false

Withdrawal of rifampin decreased the warfarin requirement by 50%.
rifampin	14-21	warfarin	37-44	mechanism

This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
rifampin	46-53	warfarin	113-120	mechanism

The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
rifampin	14-21	warfarin	30-37	effect
rifampin	14-21	rifampin	125-132	false
rifampin	14-21	rifampin	178-185	false
warfarin	30-37	rifampin	125-132	false
warfarin	30-37	rifampin	178-185	false
rifampin	125-132	rifampin	178-185	false

To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM).
arginine	216-223	glucose	233-239	false
arginine	216-223	theophylline	275-286	false
glucose	233-239	theophylline	275-286	false

Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals.
Glucose	0-6	theophylline	38-49	false

Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics.
Arginine	0-7	glucose	29-35	false
Arginine	0-7	theophylline	41-52	false
glucose	29-35	theophylline	41-52	false

Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
Arginine	0-7	glucose	28-34	false
Arginine	0-7	theophylline	39-50	false
glucose	28-34	theophylline	39-50	false

Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.
theophylline	108-119	glucose	156-162	false

The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
ketamine	15-22	Innovar	31-37	false
ketamine	15-22	digitalis	53-61	false
Innovar	31-37	digitalis	53-61	false

In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
digitalis	19-27	ketamine	65-72	false
digitalis	19-27	Innovar Vet	75-85	false
digitalis	19-27	pentobarbital	91-103	false
digitalis	19-27	ouabain	120-126	false
digitalis	19-27	ouabain	213-219	false
digitalis	19-27	ketamine	227-234	false
digitalis	19-27	Innovar	239-245	false
digitalis	19-27	pentobarbital	257-269	false
ketamine	65-72	Innovar Vet	75-85	false
ketamine	65-72	pentobarbital	91-103	false
ketamine	65-72	ouabain	120-126	effect
ketamine	65-72	ouabain	213-219	false
ketamine	65-72	ketamine	227-234	false
ketamine	65-72	Innovar	239-245	false
ketamine	65-72	pentobarbital	257-269	false
Innovar Vet	75-85	pentobarbital	91-103	false
Innovar Vet	75-85	ouabain	120-126	effect
Innovar Vet	75-85	ouabain	213-219	false
Innovar Vet	75-85	ketamine	227-234	false
Innovar Vet	75-85	Innovar	239-245	false
Innovar Vet	75-85	pentobarbital	257-269	false
pentobarbital	91-103	ouabain	120-126	effect
pentobarbital	91-103	ouabain	213-219	false
pentobarbital	91-103	ketamine	227-234	false
pentobarbital	91-103	Innovar	239-245	false
pentobarbital	91-103	pentobarbital	257-269	false
ouabain	120-126	ouabain	213-219	false
ouabain	120-126	ketamine	227-234	false
ouabain	120-126	Innovar	239-245	false
ouabain	120-126	pentobarbital	257-269	false
ouabain	213-219	ketamine	227-234	false
ouabain	213-219	Innovar	239-245	false
ouabain	213-219	pentobarbital	257-269	false
ketamine	227-234	Innovar	239-245	false
ketamine	227-234	pentobarbital	257-269	false
Innovar	239-245	pentobarbital	257-269	false

Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
ouabain	35-41	Innovar	111-117	effect
ouabain	35-41	ketamine	120-127	effect
ouabain	35-41	droperidol	133-142	effect
ouabain	35-41	fentayl	176-182	false
ouabain	35-41	pentobarbital	199-211	false
Innovar	111-117	ketamine	120-127	false
Innovar	111-117	droperidol	133-142	false
Innovar	111-117	fentayl	176-182	false
Innovar	111-117	pentobarbital	199-211	false
ketamine	120-127	droperidol	133-142	false
ketamine	120-127	fentayl	176-182	false
ketamine	120-127	pentobarbital	199-211	false
droperidol	133-142	fentayl	176-182	false
droperidol	133-142	pentobarbital	199-211	false
fentayl	176-182	pentobarbital	199-211	false

The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.
antihistaminics	83-97	analgesic agents	111-126	false
antihistaminics	83-97	analgesic adjuvants	141-159	false
analgesic agents	111-126	analgesic adjuvants	141-159	false

Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.
diphenhydramine	51-65	hydroxyzine	68-78	false
diphenhydramine	51-65	orphenadrine	81-92	false
diphenhydramine	51-65	pyrilamine	95-104	false
diphenhydramine	51-65	phenyltoloxamine	107-122	false
diphenhydramine	51-65	promethazine	125-136	false
diphenhydramine	51-65	methdilazine	139-150	false
diphenhydramine	51-65	tripelennamine	157-170	false
hydroxyzine	68-78	orphenadrine	81-92	false
hydroxyzine	68-78	pyrilamine	95-104	false
hydroxyzine	68-78	phenyltoloxamine	107-122	false
hydroxyzine	68-78	promethazine	125-136	false
hydroxyzine	68-78	methdilazine	139-150	false
hydroxyzine	68-78	tripelennamine	157-170	false
orphenadrine	81-92	pyrilamine	95-104	false
orphenadrine	81-92	phenyltoloxamine	107-122	false
orphenadrine	81-92	promethazine	125-136	false
orphenadrine	81-92	methdilazine	139-150	false
orphenadrine	81-92	tripelennamine	157-170	false
pyrilamine	95-104	phenyltoloxamine	107-122	false
pyrilamine	95-104	promethazine	125-136	false
pyrilamine	95-104	methdilazine	139-150	false
pyrilamine	95-104	tripelennamine	157-170	false
phenyltoloxamine	107-122	promethazine	125-136	false
phenyltoloxamine	107-122	methdilazine	139-150	false
phenyltoloxamine	107-122	tripelennamine	157-170	false
promethazine	125-136	methdilazine	139-150	false
promethazine	125-136	tripelennamine	157-170	false
methdilazine	139-150	tripelennamine	157-170	false

It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
picrotoxin	117-126	diazepam	174-181	effect
picrotoxin	117-126	phenazepam	184-193	effect
picrotoxin	117-126	phenibut	196-203	effect
picrotoxin	117-126	amizyl	209-214	effect
picrotoxin	117-126	phentolamine	242-253	effect
diazepam	174-181	phenazepam	184-193	false
diazepam	174-181	phenibut	196-203	false
diazepam	174-181	amizyl	209-214	false
diazepam	174-181	phentolamine	242-253	false
phenazepam	184-193	phenibut	196-203	false
phenazepam	184-193	amizyl	209-214	false
phenazepam	184-193	phentolamine	242-253	false
phenibut	196-203	amizyl	209-214	false
phenibut	196-203	phentolamine	242-253	false
amizyl	209-214	phentolamine	242-253	false

[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]

It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	16-23	3H-spiroperidol	75-89	false
cerulein	16-23	neuroleptics	137-148	false
cerulein	16-23	haloperidol	269-279	false
cerulein	16-23	pyreneperone	298-309	false
cerulein	16-23	3H-spiroperidol	368-382	false
cerulein	16-23	apomorphine	419-429	false
cerulein	16-23	3H-spiroperidol	466-480	false
cerulein	16-23	apomorphine	527-537	false
3H-spiroperidol	75-89	neuroleptics	137-148	false
3H-spiroperidol	75-89	haloperidol	269-279	false
3H-spiroperidol	75-89	pyreneperone	298-309	false
3H-spiroperidol	75-89	3H-spiroperidol	368-382	false
3H-spiroperidol	75-89	apomorphine	419-429	false
3H-spiroperidol	75-89	3H-spiroperidol	466-480	false
3H-spiroperidol	75-89	apomorphine	527-537	false
neuroleptics	137-148	haloperidol	269-279	false
neuroleptics	137-148	pyreneperone	298-309	false
neuroleptics	137-148	3H-spiroperidol	368-382	false
neuroleptics	137-148	apomorphine	419-429	false
neuroleptics	137-148	3H-spiroperidol	466-480	false
neuroleptics	137-148	apomorphine	527-537	false
haloperidol	269-279	pyreneperone	298-309	false
haloperidol	269-279	3H-spiroperidol	368-382	false
haloperidol	269-279	apomorphine	419-429	false
haloperidol	269-279	3H-spiroperidol	466-480	false
haloperidol	269-279	apomorphine	527-537	false
pyreneperone	298-309	3H-spiroperidol	368-382	false
pyreneperone	298-309	apomorphine	419-429	false
pyreneperone	298-309	3H-spiroperidol	466-480	false
pyreneperone	298-309	apomorphine	527-537	false
3H-spiroperidol	368-382	apomorphine	419-429	false
3H-spiroperidol	368-382	3H-spiroperidol	466-480	false
3H-spiroperidol	368-382	apomorphine	527-537	false
apomorphine	419-429	3H-spiroperidol	466-480	false
apomorphine	419-429	apomorphine	527-537	false
3H-spiroperidol	466-480	apomorphine	527-537	false

After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.
neuroleptics	34-45	cerulein	72-79	false
neuroleptics	34-45	3H-spiroperidol	164-178	false
cerulein	72-79	3H-spiroperidol	164-178	false

It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
3H-spiroperidol	49-63	apomorphine	101-111	false
3H-spiroperidol	49-63	neuroleptics	190-201	false
apomorphine	101-111	neuroleptics	190-201	false

Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.
ouabain	15-21	palytoxin	30-38	false

Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens.
Palytoxin	0-8	PTX	11-13	false

In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
ouabain	19-25	PTX	39-41	effect

When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
ouabain	5-11	phentolamine	58-69	effect
ouabain	5-11	PTX	119-121	false
phentolamine	58-69	PTX	119-121	false

Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
ouabain	26-32	PTX	68-70	effect

The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain.
ouabain	93-99	ouabain	299-305	false

[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports.
neuroleptics	50-61	neuroleptics	173-184	false

The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique.
arsenate	29-36	As(V)	38-42	false

By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM.
arsenate	40-47	As(V)	123-127	false

At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines.
As(V)	10-14	As(V)	90-94	false

However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V).
As(V)	39-43	As(V)	137-141	false

Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level.
arsenate	13-20	phosphate	26-34	false

Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
Vitamin D3	0-9	arsenate	95-102	mechanism

By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone.
spermidine	13-22	putrescine	35-44	false

Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.
Spermine	0-7	spermidine	34-43	false

Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
Slow-channel calcium blockers	0-28	verapamil	39-47	false
Slow-channel calcium blockers	0-28	diltiazem	50-58	false
Slow-channel calcium blockers	0-28	nifedipine	64-73	false
verapamil	39-47	diltiazem	50-58	false
verapamil	39-47	nifedipine	64-73	false
diltiazem	50-58	nifedipine	64-73	false

Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
naloxone	36-43	beta-endorphin	111-124	false
naloxone	36-43	morphine	130-137	false
beta-endorphin	111-124	morphine	130-137	false

The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
naloxone	64-71	beta-endorphin	144-157	false
naloxone	64-71	morphine	163-170	false
beta-endorphin	144-157	morphine	163-170	false

Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats.
beta-endorphin	30-43	morphine	49-56	false

Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
naloxone	25-32	beta-endorphin	184-197	effect
naloxone	25-32	naloxone	219-226	false
naloxone	25-32	beta-endorphin	317-330	false
beta-endorphin	184-197	naloxone	219-226	false
beta-endorphin	184-197	beta-endorphin	317-330	false
naloxone	219-226	beta-endorphin	317-330	effect

On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
naloxone	31-38	morphine	145-152	effect

Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
naloxone	30-37	beta-endorphin	173-186	effect
naloxone	30-37	morphine	192-199	effect
beta-endorphin	173-186	morphine	192-199	false

The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	35-42	beta-endorphin	109-122	false
naloxone	35-42	morphine	132-139	false
naloxone	35-42	beta-endorphin	206-219	false
naloxone	35-42	morphine	225-232	false
beta-endorphin	109-122	morphine	132-139	false
beta-endorphin	109-122	beta-endorphin	206-219	false
beta-endorphin	109-122	morphine	225-232	false
morphine	132-139	beta-endorphin	206-219	false
morphine	132-139	morphine	225-232	false
beta-endorphin	206-219	morphine	225-232	false

descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
beta-endorphin	38-51	morphine	57-64	false

Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	52-95	MPTP	98-101	false
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	52-95	methamphetamine	108-122	false
MPTP	98-101	methamphetamine	108-122	false

The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration.
MPTP	56-59	methamphetamine	144-158	false

It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
MPTP	21-24	pargyline	143-151	effect

The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
MPTP	4-7	amphetamine	83-93	effect
MPTP	4-7	apomorphine	147-157	effect
amphetamine	83-93	apomorphine	147-157	false

Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
Methamphetamine	0-14	MPTP	22-25	false
Methamphetamine	0-14	pargyline	107-115	effect
MPTP	22-25	pargyline	107-115	false

Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
Dexamethasone	0-12	retinyl acetate	18-32	false
Dexamethasone	0-12	EGF	66-68	effect
Dexamethasone	0-12	insulin	74-80	effect
retinyl acetate	18-32	EGF	66-68	effect
retinyl acetate	18-32	insulin	74-80	effect
EGF	66-68	insulin	74-80	false

Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).
transferrin	101-111	EGF	131-133	false
transferrin	101-111	insulin	151-157	false
EGF	131-133	insulin	151-157	false

Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
dexamethasone	17-29	retinyl acetate	35-49	false
dexamethasone	17-29	transferrin	125-135	false
dexamethasone	17-29	EGF	180-182	effect
dexamethasone	17-29	insulin	188-194	effect
retinyl acetate	35-49	transferrin	125-135	false
retinyl acetate	35-49	EGF	180-182	effect
retinyl acetate	35-49	insulin	188-194	effect
transferrin	125-135	EGF	180-182	false
transferrin	125-135	insulin	188-194	false
EGF	180-182	insulin	188-194	false

Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
Dexamethasone	0-12	retinyl acetate	30-44	false
Dexamethasone	0-12	EGF	105-107	effect
retinyl acetate	30-44	EGF	105-107	effect

Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
dexamethasone	25-37	retinyl acetate	62-76	false
dexamethasone	25-37	EGF	136-138	effect
retinyl acetate	62-76	EGF	136-138	effect

Dexamethasone had a similar effect in the presence of insulin.
Dexamethasone	0-12	insulin	54-60	false

However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
retinyl acetate	9-23	insulin	105-111	effect

These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
dexamethasone	32-44	retinyl acetate	50-64	false
dexamethasone	32-44	glucocorticoids	86-100	false
dexamethasone	32-44	retinoids	106-114	false
dexamethasone	32-44	insulin	223-229	effect
dexamethasone	32-44	EGF	235-237	effect
retinyl acetate	50-64	glucocorticoids	86-100	false
retinyl acetate	50-64	retinoids	106-114	false
retinyl acetate	50-64	insulin	223-229	effect
retinyl acetate	50-64	EGF	235-237	effect
glucocorticoids	86-100	retinoids	106-114	false
glucocorticoids	86-100	insulin	223-229	effect
glucocorticoids	86-100	EGF	235-237	effect
retinoids	106-114	insulin	223-229	effect
retinoids	106-114	EGF	235-237	effect
insulin	223-229	EGF	235-237	false

For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved.
calcium-entry blocking agents	8-36	verapamil	74-82	false
calcium-entry blocking agents	8-36	nifedipine	85-94	false
calcium-entry blocking agents	8-36	diltiazem	100-108	false
verapamil	74-82	nifedipine	85-94	false
verapamil	74-82	diltiazem	100-108	false
nifedipine	85-94	diltiazem	100-108	false

by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements;
verapamil	45-53	diltiazem	59-67	false
verapamil	45-53	nifedipine	87-96	false
diltiazem	59-67	nifedipine	87-96	false

Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
pentazocine	22-32	tripelennamine	38-51	false

The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine
pentazocine	68-78	tripelennamine	84-97	false

Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
heroin	74-79	pentazocine	93-103	false
heroin	74-79	tripelennamine	109-122	false
pentazocine	93-103	tripelennamine	109-122	effect

Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine.
tripelennamine	105-118	pentazocine	200-210	effect

aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S.
pentazocine	22-32	tripelennamine	38-51	false

Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
digoxin	34-40	amiodarone	42-51	false

Amiodarone is known to raise serum digoxin levels.
Amiodarone	0-9	digoxin	35-41	mechanism

The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks.
digoxin	34-40	digoxin	93-99	false
digoxin	34-40	amiodarone	140-149	false
digoxin	93-99	amiodarone	140-149	false

During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
amiodarone	7-16	digoxin	56-62	mechanism

Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics.
Amiodarone	0-9	digoxin	172-178	false

These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
digoxin	21-27	amiodarone	58-67	mechanism
digoxin	21-27	digoxin	99-105	false
amiodarone	58-67	digoxin	99-105	false

Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
Misonidazole	0-11	CCNU	80-83	effect

Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole.
nitrosourea	12-22	CCNU	24-27	false
nitrosourea	12-22	CCNU	184-187	false
nitrosourea	12-22	misonidazole	246-257	false
CCNU	24-27	CCNU	184-187	false
CCNU	24-27	misonidazole	246-257	false
CCNU	184-187	misonidazole	246-257	false

Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
Misonidazole	0-11	CCNU	53-56	effect

Misonidazole has a complex effect on oral CCNU pharmacokinetics.
Misonidazole	0-11	CCNU	42-45	mechanism

We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
CCNU	98-101	misonidazole	119-130	mechanism

Enhanced theophylline clearance secondary to phenytoin therapy.
theophylline	9-20	phenytoin	45-53	mechanism

This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
theophylline	41-52	phenytoin	102-110	mechanism

With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
phenytoin	52-60	theophylline	157-168	effect

The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
N-allylnormetazocine	47-66	NANM	69-72	false
N-allylnormetazocine	47-66	phencyclidine	103-115	false
N-allylnormetazocine	47-66	PCP	118-120	false
NANM	69-72	phencyclidine	103-115	false
NANM	69-72	PCP	118-120	false
phencyclidine	103-115	PCP	118-120	false

Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;
(+)-NANM	22-29	PCP	34-36	false

In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.
(-)-NANM	12-19	(+)-NANM	57-64	false
(-)-NANM	12-19	(-)-NANM	111-118	false
(-)-NANM	12-19	(+)-NANM	146-153	false
(+)-NANM	57-64	(-)-NANM	111-118	false
(+)-NANM	57-64	(+)-NANM	146-153	false
(-)-NANM	111-118	(+)-NANM	146-153	false

In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
(-)-NANM	17-24	(+)-NANM	35-42	false
(-)-NANM	17-24	morphine	88-95	effect
(+)-NANM	35-42	morphine	88-95	false

In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
(-)-NANM	27-34	(+)-NANM	45-52	false
(-)-NANM	27-34	PCP	57-59	false
(-)-NANM	27-34	naloxone	82-89	effect
(+)-NANM	45-52	PCP	57-59	false
(+)-NANM	45-52	naloxone	82-89	false
PCP	57-59	naloxone	82-89	false

the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
naloxone	13-20	(-)-NANM	60-67	effect
naloxone	13-20	morphine	150-157	effect
(-)-NANM	60-67	morphine	150-157	false

In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP.
naloxone	12-19	(-)-NANM	65-72	false
naloxone	12-19	(+)-NANM	75-82	false
naloxone	12-19	PCP	87-89	false
(-)-NANM	65-72	(+)-NANM	75-82	false
(-)-NANM	65-72	PCP	87-89	false
(+)-NANM	75-82	PCP	87-89	false

Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
Haloperidol	0-10	(+)-NANM	106-113	effect
Haloperidol	0-10	PCP	118-120	effect
Haloperidol	0-10	NANM	250-253	false
(+)-NANM	106-113	PCP	118-120	false
(+)-NANM	106-113	NANM	250-253	false
PCP	118-120	NANM	250-253	false

Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
acetaminophen	28-40	caffeine	75-82	effect

Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen.
caffeine	6-13	acetaminophen	50-62	false
caffeine	6-13	caffeine	115-122	false
caffeine	6-13	acetaminophen	149-161	false
acetaminophen	50-62	caffeine	115-122	false
acetaminophen	50-62	acetaminophen	149-161	false
caffeine	115-122	acetaminophen	149-161	false

Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
acetaminophen	58-70	caffeine	91-98	effect

High-dose cisplatin with sodium thiosulfate protection.
cisplatin	10-18	sodium thiosulfate	25-42	effect

Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
Sodium thiosulfate	0-17	cisplatin	47-55	effect

To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.
thiosulfate	34-44	cisplatin	75-83	false
thiosulfate	34-44	thiosulfate	130-140	false
thiosulfate	34-44	cisplatin	221-229	false
cisplatin	75-83	thiosulfate	130-140	false
cisplatin	75-83	cisplatin	221-229	false
thiosulfate	130-140	cisplatin	221-229	false

Cisplatin was administered over the last two hours of the thiosulfate infusion.
Cisplatin	0-8	thiosulfate	58-68	false

Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.
cisplatin	14-22	thiosulfate	83-93	false
cisplatin	14-22	thiosulfate	147-157	false
cisplatin	14-22	cisplatin	281-289	false
thiosulfate	83-93	thiosulfate	147-157	false
thiosulfate	83-93	cisplatin	281-289	false
thiosulfate	147-157	cisplatin	281-289	false

This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
thiosulfate	58-68	cisplatin	136-144	mechanism

Failure of neomycin to modify ACTH induced hypertension in sheep.
neomycin	11-18	ACTH	30-33	false

Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
neomycin	32-39	adrenocortical steroid	84-105	false
neomycin	32-39	ACTH	141-144	effect
adrenocortical steroid	84-105	ACTH	141-144	false

The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep.
neomycin	20-27	ACTH	32-35	false

Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.
Neomycin	0-7	ACTH	71-74	false

Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.
synthetic steroidal estrogen	42-69	synthetic steroidal progestogen	42-60;75-85	false

The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine.
ethynyl estradiol	53-69	levonorgestrel	75-88	false

The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol.
levonorgestrel	149-162	ethynyl estradiol	219-235	false

Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle.
trimethyl lead	109-122	TML	125-127	false

The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol.
alcohol	24-30	ethanol	83-89	false

These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
lead	53-56	alcohol	129-135	effect

Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol.
alcohol	151-157	alcohol	228-234	false

In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days.
ethanol	110-116	physostigmine	130-142	false
ethanol	110-116	atropine	159-166	false
physostigmine	130-142	atropine	159-166	false

Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
Physostigmine	0-12	alcohol	62-68	effect
Physostigmine	0-12	alcohol	123-129	effect
alcohol	62-68	alcohol	123-129	false

Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2.
Atropine	0-7	alcohol	46-52	false

Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
disulfiram	31-40	ethanol	42-48	false

Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER).
disulfiram	88-97	ethanol	99-105	false

Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
ethanol	71-77	disulfiram	117-126	effect
ethanol	71-77	ethanol	147-153	false
disulfiram	117-126	ethanol	147-153	false

The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol.
ethanol	58-64	ethanol	142-148	false

Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol.
ethanol	47-53	ethanol	97-103	false

Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
neurotensin	50-60	enkephalins	66-76	effect
neurotensin	50-60	tuftsin	81-87	effect
enkephalins	66-76	tuftsin	81-87	false

The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
neurotensin	59-69	enkephalins	80-90	false
neurotensin	59-69	D-Ala2-metenkephalinamide	118-142	false
neurotensin	59-69	tuftsin	148-154	false
enkephalins	80-90	D-Ala2-metenkephalinamide	118-142	false
enkephalins	80-90	tuftsin	148-154	false
D-Ala2-metenkephalinamide	118-142	tuftsin	148-154	false

It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
neurotensin	18-28	enkephalins	82-92	effect

On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
neurotensin	17-27	tuftsin	33-39	effect

It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
neurotensin	21-31	tuftsin	132-138	effect

Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.
thiabendazole	92-104	melarsoprol	143-153	effect

Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.
anti-helminthic	59-73	melarsoprol	171-181	false

Interactions of cobalt and iron in absorption and retention.
cobalt	16-21	iron	27-30	mechanism

The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats.
cobalt	34-39	iron	45-48	false
cobalt	34-39	Co	271-272	false
cobalt	34-39	Fe	297-298	false
iron	45-48	Co	271-272	false
iron	45-48	Fe	297-298	false
Co	271-272	Fe	297-298	false

Cobalt excretion was enhanced by supplementary cobalt;
Cobalt	0-5	cobalt	47-52	false

Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
iron	11-14	cobalt	58-63	mechanism
iron	11-14	cobalt	81-86	mechanism
cobalt	58-63	cobalt	81-86	false

The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
Fe	60-61	Fe	83-84	false
Fe	60-61	cobalt	141-146	mechanism
Fe	83-84	cobalt	141-146	false

Consequently, the effect of iron on the retention of cobalt was lower than on absorption.
iron	28-31	cobalt	53-58	mechanism

Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred.
cobalt	27-32	iron	67-70	false
cobalt	27-32	cobalt	108-113	false
cobalt	27-32	iron	118-121	false
iron	67-70	cobalt	108-113	false
iron	67-70	iron	118-121	false
cobalt	108-113	iron	118-121	false

Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)
iron	15-18	Fe	189-190	false

Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.
estradiol	10-18	endotoxin	23-31	false

We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin.
estradiol	36-44	endotoxin	141-149	false
estradiol	36-44	endotoxin	216-224	false
endotoxin	141-149	endotoxin	216-224	false

Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
estradiol	13-21	endotoxin	56-64	effect
estradiol	13-21	endotoxin	129-137	false
endotoxin	56-64	endotoxin	129-137	false

The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
estradiol	37-45	endotoxin	49-57	mechanism
estradiol	37-45	endotoxin	109-117	false
endotoxin	49-57	endotoxin	109-117	false

The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%
estradiol	37-45	endotoxin	49-57	false
estradiol	37-45	endotoxin	117-125	false
endotoxin	49-57	endotoxin	117-125	false

Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
estradiol	10-18	endotoxin	65-73	effect

These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.
estrogen	61-68	estrogens	108-116	false

The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction.
16,16-dimethylprostaglandin E2	4-33	dmPGE2	36-41	false

On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration.
dmPGE2	62-67	dmPGE2	179-184	false

Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.)
Loperamide	0-9	morphine	15-22	false

Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
Loperamide	0-9	morphine	15-22	false
Loperamide	0-9	dmPGE2	64-69	effect
morphine	15-22	dmPGE2	64-69	effect

N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
N-methyllevallorphan	0-19	loperamide	85-94	effect
N-methyllevallorphan	0-19	morphine	133-140	effect
loperamide	85-94	morphine	133-140	false

Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
99mTc-methylene diphosphonate	71-99	gentamicin	107-116	effect

Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys.
Gentamicin	0-9	aminoglycoside antibiotic	17-41	false

Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy.
gentamicin	27-36	99mTc-MDP	84-92	mechanism

Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients.
gentamicin	37-46	99mTc-MDP	89-97	false
gentamicin	37-46	radiopharmaceutical	106-124	false
99mTc-MDP	89-97	radiopharmaceutical	106-124	false

The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.
gentamicin	79-88	gentamicin	127-136	false

This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	41-63	corticosteroids	74-88	false
immunosuppressive drugs	41-63	cyclosporin	91-101	false
immunosuppressive drugs	41-63	azathioprine	104-115	false
immunosuppressive drugs	41-63	methotrexate	118-129	false
immunosuppressive drugs	41-63	cyclophosphamide	132-147	false
corticosteroids	74-88	cyclosporin	91-101	false
corticosteroids	74-88	azathioprine	104-115	false
corticosteroids	74-88	methotrexate	118-129	false
corticosteroids	74-88	cyclophosphamide	132-147	false
cyclosporin	91-101	azathioprine	104-115	false
cyclosporin	91-101	methotrexate	118-129	false
cyclosporin	91-101	cyclophosphamide	132-147	false
azathioprine	104-115	methotrexate	118-129	false
azathioprine	104-115	cyclophosphamide	132-147	false
methotrexate	118-129	cyclophosphamide	132-147	false

Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages.
ethanol	98-104	acetaldehyde	129-140	false

Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;
ethanol	111-117	methanol	120-127	false
ethanol	111-117	alcohols	137-144	false
ethanol	111-117	acetaldehyde	150-161	false
methanol	120-127	alcohols	137-144	false
methanol	120-127	acetaldehyde	150-161	false
alcohols	137-144	acetaldehyde	150-161	false

These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
ethanol	47-53	acetaldehyde	128-139	effect

Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
vitamin D	61-69	antiestrogens	75-87	false

1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
25-Dihydroxycholecalciferol D3	2-31	1,25(OH)2D3	34-44	false
25-Dihydroxycholecalciferol D3	2-31	vitamin D	73-81	false
1,25(OH)2D3	34-44	vitamin D	73-81	false

In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.
1,25(OH)2D3	71-81	antiestrogen	91-102	false
1,25(OH)2D3	71-81	4-hydroxytamoxifen	104-121	false
1,25(OH)2D3	71-81	TAM	124-126	false
antiestrogen	91-102	4-hydroxytamoxifen	104-121	false
antiestrogen	91-102	TAM	124-126	false
4-hydroxytamoxifen	104-121	TAM	124-126	false

Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
TAM	22-24	1,25(OH)2D3	92-102	effect

Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
1,25(OH)2D3	24-34	TAM	40-42	effect

These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.
vitamin-D	90-98	estrogen	137-144	false

We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice.
caffeine	63-70	theophylline	73-84	false
caffeine	63-70	8-phenyltheophylline	87-106	false
caffeine	63-70	8-cyclopentyl-1,3-dipropylxanthine	113-146	false
caffeine	63-70	DPCPX	149-153	false
theophylline	73-84	8-phenyltheophylline	87-106	false
theophylline	73-84	8-cyclopentyl-1,3-dipropylxanthine	113-146	false
theophylline	73-84	DPCPX	149-153	false
8-phenyltheophylline	87-106	8-cyclopentyl-1,3-dipropylxanthine	113-146	false
8-phenyltheophylline	87-106	DPCPX	149-153	false
8-cyclopentyl-1,3-dipropylxanthine	113-146	DPCPX	149-153	false

The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
theophylline	26-37	CGS 21680	73-81	effect
theophylline	26-37	N6-cyclopentyladenosine	120-142	false
theophylline	26-37	CPA	145-147	false
CGS 21680	73-81	N6-cyclopentyladenosine	120-142	false
CGS 21680	73-81	CPA	145-147	false
N6-cyclopentyladenosine	120-142	CPA	145-147	false

However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
theophylline	31-42	CGS21680	74-81	effect
theophylline	31-42	DPCPX	142-146	false
theophylline	31-42	CGS 21680	200-208	false
theophylline	31-42	CPA	217-219	false
CGS21680	74-81	DPCPX	142-146	false
CGS21680	74-81	CGS 21680	200-208	false
CGS21680	74-81	CPA	217-219	false
DPCPX	142-146	CGS 21680	200-208	false
DPCPX	142-146	CPA	217-219	false
CGS 21680	200-208	CPA	217-219	false

The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied.
sandimmune	15-24	immunodepressant	119-134	false
sandimmune	15-24	sandimmune	146-155	false
immunodepressant	119-134	sandimmune	146-155	false

The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
cimetidine	15-24	verografin	52-61	false
cimetidine	15-24	iodamide	67-74	false
cimetidine	15-24	cimetidine	115-124	false
cimetidine	15-24	verografine	157-167	false
cimetidine	15-24	iodamide	173-180	false
verografin	52-61	iodamide	67-74	false
verografin	52-61	cimetidine	115-124	false
verografin	52-61	verografine	157-167	false
verografin	52-61	iodamide	173-180	false
iodamide	67-74	cimetidine	115-124	false
iodamide	67-74	verografine	157-167	false
iodamide	67-74	iodamide	173-180	false
cimetidine	115-124	verografine	157-167	mechanism
cimetidine	115-124	iodamide	173-180	mechanism
verografine	157-167	iodamide	173-180	false

The higher verografine and iodamide excretion was due to their increased renal tubular secretion.
verografine	11-21	iodamide	27-34	false

In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport.
cimetidine	9-18	cardiotrast	47-57	false

Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
cimetidine	44-53	verografine	58-68	false
cimetidine	44-53	iodamide	74-81	false
verografine	58-68	iodamide	74-81	false

Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
magnesium	36-44	magnesium	75-83	false
magnesium	36-44	magnesium	144-152	false
magnesium	36-44	magnesium	193-201	false
magnesium	36-44	magnesium	230-238	false
magnesium	36-44	magnesium	302-310	false
magnesium	75-83	magnesium	144-152	false
magnesium	75-83	magnesium	193-201	false
magnesium	75-83	magnesium	230-238	false
magnesium	75-83	magnesium	302-310	false
magnesium	144-152	magnesium	193-201	false
magnesium	144-152	magnesium	230-238	false
magnesium	144-152	magnesium	302-310	false
magnesium	193-201	magnesium	230-238	false
magnesium	193-201	magnesium	302-310	false
magnesium	230-238	magnesium	302-310	false

Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy.
magnesium	22-30	magnesium	98-106	false

It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.
magnesium	94-102	magnesium	140-148	false
magnesium	94-102	magnesium	184-192	false
magnesium	94-102	magnesium	260-268	false
magnesium	94-102	magnesium	336-344	false
magnesium	140-148	magnesium	184-192	false
magnesium	140-148	magnesium	260-268	false
magnesium	140-148	magnesium	336-344	false
magnesium	184-192	magnesium	260-268	false
magnesium	184-192	magnesium	336-344	false
magnesium	260-268	magnesium	336-344	false

Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment.
magnesium	19-27	magnesium	77-85	false

Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure.
magnesium	19-27	magnesium salt	110-123	false

Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium.
magnesium	37-45	magnesium sparing diuretics	86-112	false
magnesium	37-45	vitamin B6	140-149	false
magnesium	37-45	vitamin D	175-183	false
magnesium	37-45	selenium	192-199	false
magnesium sparing diuretics	86-112	vitamin B6	140-149	false
magnesium sparing diuretics	86-112	vitamin D	175-183	false
magnesium sparing diuretics	86-112	selenium	192-199	false
vitamin B6	140-149	vitamin D	175-183	false
vitamin B6	140-149	selenium	192-199	false
vitamin D	175-183	selenium	192-199	false

There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).
magnesium	79-87	magnesium	155-163	false

Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.
magnesium	71-79	cardioplegic solutions	100-121	false

Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
glycine	20-26	glutamate	32-40	effect

The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
glycine	30-36	glutamate	75-83	effect
glycine	30-36	glutamate	246-254	false
glutamate	75-83	glutamate	246-254	false

The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium.
isoproterenol	20-32	norepinephrine	64-77	false

The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
cocaine	22-28	desipramine	34-44	false
cocaine	22-28	norepinephrine	108-121	effect
desipramine	34-44	norepinephrine	108-121	effect

Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).
mazindol	70-77	norepinephrine	135-148	false

This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only.
cocaine	99-105	desipramine	111-121	false

Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine.
norepinephrine	12-25	cocaine	90-96	false
norepinephrine	12-25	desipramine	102-112	false
cocaine	90-96	desipramine	102-112	false

[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion]

Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion.
angiotensin	45-55	angiotensin 1	184-196	false
angiotensin	45-55	angiotensin 2	202-214	false
angiotensin	45-55	pentagastrin	219-230	false
angiotensin	45-55	histamine	237-245	false
angiotensin 1	184-196	angiotensin 2	202-214	false
angiotensin 1	184-196	pentagastrin	219-230	false
angiotensin 1	184-196	histamine	237-245	false
angiotensin 2	202-214	pentagastrin	219-230	false
angiotensin 2	202-214	histamine	237-245	false
pentagastrin	219-230	histamine	237-245	false

It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine.
pentagastrin	89-100	histamine	113-121	false

Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.
angiotensins	127-138	angiotensin	167-177	false

Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
Antacids	0-7	kaolin	13-18	false
Antacids	0-7	Antacids	21-28	false
Antacids	0-7	kaolin	34-39	false
Antacids	0-7	chloroquine	66-76	false
kaolin	13-18	Antacids	21-28	false
kaolin	13-18	kaolin	34-39	false
kaolin	13-18	chloroquine	66-76	false
Antacids	21-28	kaolin	34-39	false
Antacids	21-28	chloroquine	66-76	mechanism
kaolin	34-39	chloroquine	66-76	mechanism

Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
Cimetidine	0-9	Cimetidine	12-21	false
Cimetidine	0-9	chloroquine	53-63	false
Cimetidine	12-21	chloroquine	53-63	mechanism

Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
Ampicillin	0-9	chloroquine	46-56	false
Ampicillin	0-9	ampicillin	103-112	false
chloroquine	46-56	ampicillin	103-112	mechanism

Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
Cyclosporin	0-10	chloroquine	35-45	false
Cyclosporin	0-10	cyclosporin	87-97	false
chloroquine	35-45	cyclosporin	87-97	mechanism

Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.
cyclosporin	37-47	chloroquine	89-99	false

- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur
Alcohol	2-8	barbiturates	11-22	false
Alcohol	2-8	narcotics	28-36	false
barbiturates	11-22	narcotics	28-36	false

- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required
Antidiabetic drugs	2-19	insulin	39-45	false
Antidiabetic drugs	2-19	antidiabetic drug	73-89	false
insulin	39-45	antidiabetic drug	73-89	false

- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
Cholestyramine	2-15	colestipol	21-30	false
Cholestyramine	2-15	resins	32-37	false
Cholestyramine	2-15	Cholestytamine	40-53	false
Cholestyramine	2-15	colestipol	59-68	false
Cholestyramine	2-15	resins	70-75	false
Cholestyramine	2-15	thiazide diuretics	107-124	false
Cholestyramine	2-15	diuretic	139-146	false
colestipol	21-30	resins	32-37	false
colestipol	21-30	Cholestytamine	40-53	false
colestipol	21-30	colestipol	59-68	false
colestipol	21-30	resins	70-75	false
colestipol	21-30	thiazide diuretics	107-124	false
colestipol	21-30	diuretic	139-146	false
resins	32-37	Cholestytamine	40-53	false
resins	32-37	colestipol	59-68	false
resins	32-37	resins	70-75	false
resins	32-37	thiazide diuretics	107-124	false
resins	32-37	diuretic	139-146	false
Cholestytamine	40-53	colestipol	59-68	false
Cholestytamine	40-53	resins	70-75	false
Cholestytamine	40-53	thiazide diuretics	107-124	mechanism
Cholestytamine	40-53	diuretic	139-146	false
colestipol	59-68	resins	70-75	false
colestipol	59-68	thiazide diuretics	107-124	mechanism
colestipol	59-68	diuretic	139-146	false
resins	70-75	thiazide diuretics	107-124	false
resins	70-75	diuretic	139-146	false
thiazide diuretics	107-124	diuretic	139-146	false

- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia
Corticosteroids	2-16	ACTH	19-22	false

- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant
Skeletal muscle relaxants	2-26	tubocurarine	52-63	false
Skeletal muscle relaxants	2-26	muscle relaxant	108-122	false
tubocurarine	52-63	muscle relaxant	108-122	false

- Lithium: Generally should not be given with diuretics.
Lithium	2-8	diuretics	46-54	advise

Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
Diuretic agents	0-14	lithium	46-52	mechanism
Diuretic agents	0-14	lithium	77-83	mechanism
lithium	46-52	lithium	77-83	false

Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
lithium	32-38	chlorothiazide	90-103	advise

- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
Non-steroidal Anti-inflammatory Drugs	2-38	non-steroidal anti-inflammatory agent	83-119	false
Non-steroidal Anti-inflammatory Drugs	2-38	loop diuretics	191-194;228-236	false
Non-steroidal Anti-inflammatory Drugs	2-38	potassium-sparing diuretics	197-213;228-236	false
Non-steroidal Anti-inflammatory Drugs	2-38	thiazide diuretics	219-236	false
non-steroidal anti-inflammatory agent	83-119	loop diuretics	191-194;228-236	effect
non-steroidal anti-inflammatory agent	83-119	potassium-sparing diuretics	197-213;228-236	effect
non-steroidal anti-inflammatory agent	83-119	thiazide diuretics	219-236	effect
loop diuretics	191-194;228-236	potassium-sparing diuretics	197-213;228-236	false
loop diuretics	191-194;228-236	thiazide diuretics	219-236	false
potassium-sparing diuretics	197-213;228-236	thiazide diuretics	219-236	false

Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
chlorothiazide	16-29	non-steroidal anti-inflammatory agents	35-72	advise
chlorothiazide	16-29	diuretic	179-186	false
non-steroidal anti-inflammatory agents	35-72	diuretic	179-186	false

Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
Chlorotrianisene	0-15	antidepressants	35-49	int
Chlorotrianisene	0-15	aspirin	52-58	int
Chlorotrianisene	0-15	barbiturates	61-72	int
Chlorotrianisene	0-15	bromocriptine	75-87	int
Chlorotrianisene	0-15	calcium	90-96	int
Chlorotrianisene	0-15	corticosteroids	111-125	int
Chlorotrianisene	0-15	corticotropin	128-140	int
Chlorotrianisene	0-15	cyclosporine	143-154	int
Chlorotrianisene	0-15	dantrolene	157-166	int
Chlorotrianisene	0-15	nicotine	169-176	int
Chlorotrianisene	0-15	somatropin	179-188	int
Chlorotrianisene	0-15	tamoxifen	191-199	int
Chlorotrianisene	0-15	warfarin	206-213	int
antidepressants	35-49	aspirin	52-58	false
antidepressants	35-49	barbiturates	61-72	false
antidepressants	35-49	bromocriptine	75-87	false
antidepressants	35-49	calcium	90-96	false
antidepressants	35-49	corticosteroids	111-125	false
antidepressants	35-49	corticotropin	128-140	false
antidepressants	35-49	cyclosporine	143-154	false
antidepressants	35-49	dantrolene	157-166	false
antidepressants	35-49	nicotine	169-176	false
antidepressants	35-49	somatropin	179-188	false
antidepressants	35-49	tamoxifen	191-199	false
antidepressants	35-49	warfarin	206-213	false
aspirin	52-58	barbiturates	61-72	false
aspirin	52-58	bromocriptine	75-87	false
aspirin	52-58	calcium	90-96	false
aspirin	52-58	corticosteroids	111-125	false
aspirin	52-58	corticotropin	128-140	false
aspirin	52-58	cyclosporine	143-154	false
aspirin	52-58	dantrolene	157-166	false
aspirin	52-58	nicotine	169-176	false
aspirin	52-58	somatropin	179-188	false
aspirin	52-58	tamoxifen	191-199	false
aspirin	52-58	warfarin	206-213	false
barbiturates	61-72	bromocriptine	75-87	false
barbiturates	61-72	calcium	90-96	false
barbiturates	61-72	corticosteroids	111-125	false
barbiturates	61-72	corticotropin	128-140	false
barbiturates	61-72	cyclosporine	143-154	false
barbiturates	61-72	dantrolene	157-166	false
barbiturates	61-72	nicotine	169-176	false
barbiturates	61-72	somatropin	179-188	false
barbiturates	61-72	tamoxifen	191-199	false
barbiturates	61-72	warfarin	206-213	false
bromocriptine	75-87	calcium	90-96	false
bromocriptine	75-87	corticosteroids	111-125	false
bromocriptine	75-87	corticotropin	128-140	false
bromocriptine	75-87	cyclosporine	143-154	false
bromocriptine	75-87	dantrolene	157-166	false
bromocriptine	75-87	nicotine	169-176	false
bromocriptine	75-87	somatropin	179-188	false
bromocriptine	75-87	tamoxifen	191-199	false
bromocriptine	75-87	warfarin	206-213	false
calcium	90-96	corticosteroids	111-125	false
calcium	90-96	corticotropin	128-140	false
calcium	90-96	cyclosporine	143-154	false
calcium	90-96	dantrolene	157-166	false
calcium	90-96	nicotine	169-176	false
calcium	90-96	somatropin	179-188	false
calcium	90-96	tamoxifen	191-199	false
calcium	90-96	warfarin	206-213	false
corticosteroids	111-125	corticotropin	128-140	false
corticosteroids	111-125	cyclosporine	143-154	false
corticosteroids	111-125	dantrolene	157-166	false
corticosteroids	111-125	nicotine	169-176	false
corticosteroids	111-125	somatropin	179-188	false
corticosteroids	111-125	tamoxifen	191-199	false
corticosteroids	111-125	warfarin	206-213	false
corticotropin	128-140	cyclosporine	143-154	false
corticotropin	128-140	dantrolene	157-166	false
corticotropin	128-140	nicotine	169-176	false
corticotropin	128-140	somatropin	179-188	false
corticotropin	128-140	tamoxifen	191-199	false
corticotropin	128-140	warfarin	206-213	false
cyclosporine	143-154	dantrolene	157-166	false
cyclosporine	143-154	nicotine	169-176	false
cyclosporine	143-154	somatropin	179-188	false
cyclosporine	143-154	tamoxifen	191-199	false
cyclosporine	143-154	warfarin	206-213	false
dantrolene	157-166	nicotine	169-176	false
dantrolene	157-166	somatropin	179-188	false
dantrolene	157-166	tamoxifen	191-199	false
dantrolene	157-166	warfarin	206-213	false
nicotine	169-176	somatropin	179-188	false
nicotine	169-176	tamoxifen	191-199	false
nicotine	169-176	warfarin	206-213	false
somatropin	179-188	tamoxifen	191-199	false
somatropin	179-188	warfarin	206-213	false
tamoxifen	191-199	warfarin	206-213	false

Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.
CNS depressants	37-51	MAO inhibitors	54-67	false
CNS depressants	37-51	tricyclic antidepressants	70-94	false
CNS depressants	37-51	phenothiazines	97-110	false
MAO inhibitors	54-67	tricyclic antidepressants	70-94	false
MAO inhibitors	54-67	phenothiazines	97-110	false
tricyclic antidepressants	70-94	phenothiazines	97-110	false

Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
azole antifungals	27-43	ciprofloxacin	46-58	false
azole antifungals	27-43	clarithromycin	61-74	false
azole antifungals	27-43	diclofenac	77-86	false
azole antifungals	27-43	doxycycline	89-99	false
azole antifungals	27-43	erythromycin	102-113	false
azole antifungals	27-43	imatinib	116-123	false
azole antifungals	27-43	isoniazid	126-134	false
azole antifungals	27-43	nefazodone	137-146	false
azole antifungals	27-43	nicardipine	149-159	false
azole antifungals	27-43	propofol	162-169	false
azole antifungals	27-43	protease inhibitors	172-190	false
azole antifungals	27-43	quinidine	193-201	false
azole antifungals	27-43	verapamil	208-216	false
ciprofloxacin	46-58	clarithromycin	61-74	false
ciprofloxacin	46-58	diclofenac	77-86	false
ciprofloxacin	46-58	doxycycline	89-99	false
ciprofloxacin	46-58	erythromycin	102-113	false
ciprofloxacin	46-58	imatinib	116-123	false
ciprofloxacin	46-58	isoniazid	126-134	false
ciprofloxacin	46-58	nefazodone	137-146	false
ciprofloxacin	46-58	nicardipine	149-159	false
ciprofloxacin	46-58	propofol	162-169	false
ciprofloxacin	46-58	protease inhibitors	172-190	false
ciprofloxacin	46-58	quinidine	193-201	false
ciprofloxacin	46-58	verapamil	208-216	false
clarithromycin	61-74	diclofenac	77-86	false
clarithromycin	61-74	doxycycline	89-99	false
clarithromycin	61-74	erythromycin	102-113	false
clarithromycin	61-74	imatinib	116-123	false
clarithromycin	61-74	isoniazid	126-134	false
clarithromycin	61-74	nefazodone	137-146	false
clarithromycin	61-74	nicardipine	149-159	false
clarithromycin	61-74	propofol	162-169	false
clarithromycin	61-74	protease inhibitors	172-190	false
clarithromycin	61-74	quinidine	193-201	false
clarithromycin	61-74	verapamil	208-216	false
diclofenac	77-86	doxycycline	89-99	false
diclofenac	77-86	erythromycin	102-113	false
diclofenac	77-86	imatinib	116-123	false
diclofenac	77-86	isoniazid	126-134	false
diclofenac	77-86	nefazodone	137-146	false
diclofenac	77-86	nicardipine	149-159	false
diclofenac	77-86	propofol	162-169	false
diclofenac	77-86	protease inhibitors	172-190	false
diclofenac	77-86	quinidine	193-201	false
diclofenac	77-86	verapamil	208-216	false
doxycycline	89-99	erythromycin	102-113	false
doxycycline	89-99	imatinib	116-123	false
doxycycline	89-99	isoniazid	126-134	false
doxycycline	89-99	nefazodone	137-146	false
doxycycline	89-99	nicardipine	149-159	false
doxycycline	89-99	propofol	162-169	false
doxycycline	89-99	protease inhibitors	172-190	false
doxycycline	89-99	quinidine	193-201	false
doxycycline	89-99	verapamil	208-216	false
erythromycin	102-113	imatinib	116-123	false
erythromycin	102-113	isoniazid	126-134	false
erythromycin	102-113	nefazodone	137-146	false
erythromycin	102-113	nicardipine	149-159	false
erythromycin	102-113	propofol	162-169	false
erythromycin	102-113	protease inhibitors	172-190	false
erythromycin	102-113	quinidine	193-201	false
erythromycin	102-113	verapamil	208-216	false
imatinib	116-123	isoniazid	126-134	false
imatinib	116-123	nefazodone	137-146	false
imatinib	116-123	nicardipine	149-159	false
imatinib	116-123	propofol	162-169	false
imatinib	116-123	protease inhibitors	172-190	false
imatinib	116-123	quinidine	193-201	false
imatinib	116-123	verapamil	208-216	false
isoniazid	126-134	nefazodone	137-146	false
isoniazid	126-134	nicardipine	149-159	false
isoniazid	126-134	propofol	162-169	false
isoniazid	126-134	protease inhibitors	172-190	false
isoniazid	126-134	quinidine	193-201	false
isoniazid	126-134	verapamil	208-216	false
nefazodone	137-146	nicardipine	149-159	false
nefazodone	137-146	propofol	162-169	false
nefazodone	137-146	protease inhibitors	172-190	false
nefazodone	137-146	quinidine	193-201	false
nefazodone	137-146	verapamil	208-216	false
nicardipine	149-159	propofol	162-169	false
nicardipine	149-159	protease inhibitors	172-190	false
nicardipine	149-159	quinidine	193-201	false
nicardipine	149-159	verapamil	208-216	false
propofol	162-169	protease inhibitors	172-190	false
propofol	162-169	quinidine	193-201	false
propofol	162-169	verapamil	208-216	false
protease inhibitors	172-190	quinidine	193-201	false
protease inhibitors	172-190	verapamil	208-216	false
quinidine	193-201	verapamil	208-216	false

The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
antipsychotic drug	82-99	chlorpromazine	106-119	false
antipsychotic drug	82-99	antiparkinsonian drug	126-146	effect
antipsychotic drug	82-99	trihexyphenidyl	153-167	effect
antipsychotic drug	82-99	tricyclic antidepressant	180-203	effect
antipsychotic drug	82-99	amitriptyline	210-222	effect
chlorpromazine	106-119	antiparkinsonian drug	126-146	effect
chlorpromazine	106-119	trihexyphenidyl	153-167	effect
chlorpromazine	106-119	tricyclic antidepressant	180-203	effect
chlorpromazine	106-119	amitriptyline	210-222	effect
antiparkinsonian drug	126-146	trihexyphenidyl	153-167	false
antiparkinsonian drug	126-146	tricyclic antidepressant	180-203	effect
antiparkinsonian drug	126-146	amitriptyline	210-222	effect
trihexyphenidyl	153-167	tricyclic antidepressant	180-203	effect
trihexyphenidyl	153-167	amitriptyline	210-222	effect
tricyclic antidepressant	180-203	amitriptyline	210-222	false

Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
anti-depressants	48-63	anti-anxiety drugs	65-82	false
anti-depressants	48-63	beta-blockers	128-140	false
anti-depressants	48-63	propranolol	149-159	false
anti-depressants	48-63	sparfloxacin	163-174	false
anti-depressants	48-63	grepafloxacin	177-189	false
anti-depressants	48-63	guanethidine	192-203	false
anti-depressants	48-63	guanadrel	206-214	false
anti-depressants	48-63	metrizamide	217-227	false
anti-depressants	48-63	cabergoline	230-240	false
anti-depressants	48-63	lithium	243-249	false
anti-depressants	48-63	narcotic	252-259	false
anti-depressants	48-63	codeine	284-290	false
anti-depressants	48-63	antihistamines	338-351	false
anti-depressants	48-63	diphenhydramine	360-374	false
anti-anxiety drugs	65-82	beta-blockers	128-140	false
anti-anxiety drugs	65-82	propranolol	149-159	false
anti-anxiety drugs	65-82	sparfloxacin	163-174	false
anti-anxiety drugs	65-82	grepafloxacin	177-189	false
anti-anxiety drugs	65-82	guanethidine	192-203	false
anti-anxiety drugs	65-82	guanadrel	206-214	false
anti-anxiety drugs	65-82	metrizamide	217-227	false
anti-anxiety drugs	65-82	cabergoline	230-240	false
anti-anxiety drugs	65-82	lithium	243-249	false
anti-anxiety drugs	65-82	narcotic	252-259	false
anti-anxiety drugs	65-82	codeine	284-290	false
anti-anxiety drugs	65-82	antihistamines	338-351	false
anti-anxiety drugs	65-82	diphenhydramine	360-374	false
beta-blockers	128-140	propranolol	149-159	false
beta-blockers	128-140	sparfloxacin	163-174	false
beta-blockers	128-140	grepafloxacin	177-189	false
beta-blockers	128-140	guanethidine	192-203	false
beta-blockers	128-140	guanadrel	206-214	false
beta-blockers	128-140	metrizamide	217-227	false
beta-blockers	128-140	cabergoline	230-240	false
beta-blockers	128-140	lithium	243-249	false
beta-blockers	128-140	narcotic	252-259	false
beta-blockers	128-140	codeine	284-290	false
beta-blockers	128-140	antihistamines	338-351	false
beta-blockers	128-140	diphenhydramine	360-374	false
propranolol	149-159	sparfloxacin	163-174	false
propranolol	149-159	grepafloxacin	177-189	false
propranolol	149-159	guanethidine	192-203	false
propranolol	149-159	guanadrel	206-214	false
propranolol	149-159	metrizamide	217-227	false
propranolol	149-159	cabergoline	230-240	false
propranolol	149-159	lithium	243-249	false
propranolol	149-159	narcotic	252-259	false
propranolol	149-159	codeine	284-290	false
propranolol	149-159	antihistamines	338-351	false
propranolol	149-159	diphenhydramine	360-374	false
sparfloxacin	163-174	grepafloxacin	177-189	false
sparfloxacin	163-174	guanethidine	192-203	false
sparfloxacin	163-174	guanadrel	206-214	false
sparfloxacin	163-174	metrizamide	217-227	false
sparfloxacin	163-174	cabergoline	230-240	false
sparfloxacin	163-174	lithium	243-249	false
sparfloxacin	163-174	narcotic	252-259	false
sparfloxacin	163-174	codeine	284-290	false
sparfloxacin	163-174	antihistamines	338-351	false
sparfloxacin	163-174	diphenhydramine	360-374	false
grepafloxacin	177-189	guanethidine	192-203	false
grepafloxacin	177-189	guanadrel	206-214	false
grepafloxacin	177-189	metrizamide	217-227	false
grepafloxacin	177-189	cabergoline	230-240	false
grepafloxacin	177-189	lithium	243-249	false
grepafloxacin	177-189	narcotic	252-259	false
grepafloxacin	177-189	codeine	284-290	false
grepafloxacin	177-189	antihistamines	338-351	false
grepafloxacin	177-189	diphenhydramine	360-374	false
guanethidine	192-203	guanadrel	206-214	false
guanethidine	192-203	metrizamide	217-227	false
guanethidine	192-203	cabergoline	230-240	false
guanethidine	192-203	lithium	243-249	false
guanethidine	192-203	narcotic	252-259	false
guanethidine	192-203	codeine	284-290	false
guanethidine	192-203	antihistamines	338-351	false
guanethidine	192-203	diphenhydramine	360-374	false
guanadrel	206-214	metrizamide	217-227	false
guanadrel	206-214	cabergoline	230-240	false
guanadrel	206-214	lithium	243-249	false
guanadrel	206-214	narcotic	252-259	false
guanadrel	206-214	codeine	284-290	false
guanadrel	206-214	antihistamines	338-351	false
guanadrel	206-214	diphenhydramine	360-374	false
metrizamide	217-227	cabergoline	230-240	false
metrizamide	217-227	lithium	243-249	false
metrizamide	217-227	narcotic	252-259	false
metrizamide	217-227	codeine	284-290	false
metrizamide	217-227	antihistamines	338-351	false
metrizamide	217-227	diphenhydramine	360-374	false
cabergoline	230-240	lithium	243-249	false
cabergoline	230-240	narcotic	252-259	false
cabergoline	230-240	codeine	284-290	false
cabergoline	230-240	antihistamines	338-351	false
cabergoline	230-240	diphenhydramine	360-374	false
lithium	243-249	narcotic	252-259	false
lithium	243-249	codeine	284-290	false
lithium	243-249	antihistamines	338-351	false
lithium	243-249	diphenhydramine	360-374	false
narcotic	252-259	codeine	284-290	false
narcotic	252-259	antihistamines	338-351	false
narcotic	252-259	diphenhydramine	360-374	false
codeine	284-290	antihistamines	338-351	false
codeine	284-290	diphenhydramine	360-374	false
antihistamines	338-351	diphenhydramine	360-374	false

The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
sulfonylurea	27-38	nonsteroidal anti-inflammatory agents	86-122	effect
sulfonylurea	27-38	salicylates	171-181	effect
sulfonylurea	27-38	sulfonamides	184-195	effect
sulfonylurea	27-38	chloramphenicol	198-212	effect
sulfonylurea	27-38	probenecid	215-224	effect
sulfonylurea	27-38	coumarins	227-235	effect
sulfonylurea	27-38	monoamine oxidase inhibitors	238-265	effect
sulfonylurea	27-38	beta adrenergic blocking agents	272-302	effect
nonsteroidal anti-inflammatory agents	86-122	salicylates	171-181	false
nonsteroidal anti-inflammatory agents	86-122	sulfonamides	184-195	false
nonsteroidal anti-inflammatory agents	86-122	chloramphenicol	198-212	false
nonsteroidal anti-inflammatory agents	86-122	probenecid	215-224	false
nonsteroidal anti-inflammatory agents	86-122	coumarins	227-235	false
nonsteroidal anti-inflammatory agents	86-122	monoamine oxidase inhibitors	238-265	false
nonsteroidal anti-inflammatory agents	86-122	beta adrenergic blocking agents	272-302	false
salicylates	171-181	sulfonamides	184-195	false
salicylates	171-181	chloramphenicol	198-212	false
salicylates	171-181	probenecid	215-224	false
salicylates	171-181	coumarins	227-235	false
salicylates	171-181	monoamine oxidase inhibitors	238-265	false
salicylates	171-181	beta adrenergic blocking agents	272-302	false
sulfonamides	184-195	chloramphenicol	198-212	false
sulfonamides	184-195	probenecid	215-224	false
sulfonamides	184-195	coumarins	227-235	false
sulfonamides	184-195	monoamine oxidase inhibitors	238-265	false
sulfonamides	184-195	beta adrenergic blocking agents	272-302	false
chloramphenicol	198-212	probenecid	215-224	false
chloramphenicol	198-212	coumarins	227-235	false
chloramphenicol	198-212	monoamine oxidase inhibitors	238-265	false
chloramphenicol	198-212	beta adrenergic blocking agents	272-302	false
probenecid	215-224	coumarins	227-235	false
probenecid	215-224	monoamine oxidase inhibitors	238-265	false
probenecid	215-224	beta adrenergic blocking agents	272-302	false
coumarins	227-235	monoamine oxidase inhibitors	238-265	false
coumarins	227-235	beta adrenergic blocking agents	272-302	false
monoamine oxidase inhibitors	238-265	beta adrenergic blocking agents	272-302	false

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
thiazides	24-32	diuretics	44-52	false
thiazides	24-32	corticosteroids	55-69	false
thiazides	24-32	phenothiazines	72-85	false
thiazides	24-32	estrogens	106-114	false
thiazides	24-32	contraceptives	122-135	false
thiazides	24-32	phenytoin	138-146	false
thiazides	24-32	nicotinic acid	149-162	false
thiazides	24-32	sympathomimetics	165-180	false
thiazides	24-32	calcium channel blocking drugs	183-212	false
thiazides	24-32	isoniazid	219-227	false
diuretics	44-52	corticosteroids	55-69	false
diuretics	44-52	phenothiazines	72-85	false
diuretics	44-52	estrogens	106-114	false
diuretics	44-52	contraceptives	122-135	false
diuretics	44-52	phenytoin	138-146	false
diuretics	44-52	nicotinic acid	149-162	false
diuretics	44-52	sympathomimetics	165-180	false
diuretics	44-52	calcium channel blocking drugs	183-212	false
diuretics	44-52	isoniazid	219-227	false
corticosteroids	55-69	phenothiazines	72-85	false
corticosteroids	55-69	estrogens	106-114	false
corticosteroids	55-69	contraceptives	122-135	false
corticosteroids	55-69	phenytoin	138-146	false
corticosteroids	55-69	nicotinic acid	149-162	false
corticosteroids	55-69	sympathomimetics	165-180	false
corticosteroids	55-69	calcium channel blocking drugs	183-212	false
corticosteroids	55-69	isoniazid	219-227	false
phenothiazines	72-85	estrogens	106-114	false
phenothiazines	72-85	contraceptives	122-135	false
phenothiazines	72-85	phenytoin	138-146	false
phenothiazines	72-85	nicotinic acid	149-162	false
phenothiazines	72-85	sympathomimetics	165-180	false
phenothiazines	72-85	calcium channel blocking drugs	183-212	false
phenothiazines	72-85	isoniazid	219-227	false
estrogens	106-114	contraceptives	122-135	false
estrogens	106-114	phenytoin	138-146	false
estrogens	106-114	nicotinic acid	149-162	false
estrogens	106-114	sympathomimetics	165-180	false
estrogens	106-114	calcium channel blocking drugs	183-212	false
estrogens	106-114	isoniazid	219-227	false
contraceptives	122-135	phenytoin	138-146	false
contraceptives	122-135	nicotinic acid	149-162	false
contraceptives	122-135	sympathomimetics	165-180	false
contraceptives	122-135	calcium channel blocking drugs	183-212	false
contraceptives	122-135	isoniazid	219-227	false
phenytoin	138-146	nicotinic acid	149-162	false
phenytoin	138-146	sympathomimetics	165-180	false
phenytoin	138-146	calcium channel blocking drugs	183-212	false
phenytoin	138-146	isoniazid	219-227	false
nicotinic acid	149-162	sympathomimetics	165-180	false
nicotinic acid	149-162	calcium channel blocking drugs	183-212	false
nicotinic acid	149-162	isoniazid	219-227	false
sympathomimetics	165-180	calcium channel blocking drugs	183-212	false
sympathomimetics	165-180	isoniazid	219-227	false
calcium channel blocking drugs	183-212	isoniazid	219-227	false

Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
barbiturates	48-59	chlorpropamide	94-107	effect
barbiturates	48-59	barbiturates	110-121	false
chlorpropamide	94-107	barbiturates	110-121	false

In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.
disulfiram	20-29	alcohol	81-87	false

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
miconazole	37-46	hypoglycemic agents	57-75	effect

Chlorprothixene may increase the plasma-level of concomitantly given lithium.
Chlorprothixene	0-14	lithium	69-75	mechanism

In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.
lithium	18-24	lithium	40-46	false

If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
chlorprothixene	3-17	opioids	47-53	advise
chlorprothixene	3-17	opioid	60-65	false
chlorprothixene	3-17	chlorprothixene	116-130	false
chlorprothixene	3-17	opioids	186-192	false
opioids	47-53	opioid	60-65	false
opioids	47-53	chlorprothixene	116-130	false
opioids	47-53	opioids	186-192	false
opioid	60-65	chlorprothixene	116-130	false
opioid	60-65	opioids	186-192	false
chlorprothixene	116-130	opioids	186-192	effect

Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
chlorprothixene	29-43	tramadol	49-56	advise
chlorprothixene	29-43	Ultram	59-64	advise
tramadol	49-56	Ultram	59-64	false

Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
chlorprothixene	72-86	benzodiazepines	102-116	effect
chlorprothixene	72-86	barbituates	121-131	effect
benzodiazepines	102-116	barbituates	121-131	false

Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
chlorprothixene	38-52	anticholinergic drugs	65-85	advise
chlorprothixene	38-52	tricyclic antidepressants	88-112	advise
chlorprothixene	38-52	antiparkinsonian agents	118-140	advise
anticholinergic drugs	65-85	tricyclic antidepressants	88-112	false
anticholinergic drugs	65-85	antiparkinsonian agents	118-140	false
tricyclic antidepressants	88-112	antiparkinsonian agents	118-140	false

Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
Chlorthalidone	0-13	antihypertensive drugs	60-81	effect

Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
Chlorthalidone	0-13	tubocurarine	68-79	effect

Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
Chlorthalidone	0-13	norepinephrine	73-86	effect

The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
alcohol	23-29	central nervous system depressants	40-73	false

Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
vitamin D	17-25	Vitamin D2	38-47	false
vitamin D	17-25	Vitamin D3	50-59	false
vitamin D	17-25	Calcitriol	62-71	false
vitamin D	17-25	Calcidiol	78-86	false
vitamin D	17-25	Cholestyramine	90-103	false
vitamin D	17-25	Cholestyramine	106-119	false
vitamin D	17-25	fat soluble vitamins	174-193	false
Vitamin D2	38-47	Vitamin D3	50-59	false
Vitamin D2	38-47	Calcitriol	62-71	false
Vitamin D2	38-47	Calcidiol	78-86	false
Vitamin D2	38-47	Cholestyramine	90-103	false
Vitamin D2	38-47	Cholestyramine	106-119	false
Vitamin D2	38-47	fat soluble vitamins	174-193	false
Vitamin D3	50-59	Calcitriol	62-71	false
Vitamin D3	50-59	Calcidiol	78-86	false
Vitamin D3	50-59	Cholestyramine	90-103	false
Vitamin D3	50-59	Cholestyramine	106-119	false
Vitamin D3	50-59	fat soluble vitamins	174-193	false
Calcitriol	62-71	Calcidiol	78-86	false
Calcitriol	62-71	Cholestyramine	90-103	false
Calcitriol	62-71	Cholestyramine	106-119	false
Calcitriol	62-71	fat soluble vitamins	174-193	false
Calcidiol	78-86	Cholestyramine	90-103	false
Calcidiol	78-86	Cholestyramine	106-119	false
Calcidiol	78-86	fat soluble vitamins	174-193	false
Cholestyramine	90-103	Cholestyramine	106-119	false
Cholestyramine	90-103	fat soluble vitamins	174-193	false
Cholestyramine	106-119	fat soluble vitamins	174-193	mechanism

Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
Phenytoin	0-8	Phenobarbital	10-22	false
Phenytoin	0-8	phenytoin	49-57	false
Phenytoin	0-8	phenobarbital	62-74	false
Phenytoin	0-8	vitamin D	117-125	false
Phenytoin	0-8	calcitriol	171-180	false
Phenobarbital	10-22	phenytoin	49-57	false
Phenobarbital	10-22	phenobarbital	62-74	false
Phenobarbital	10-22	vitamin D	117-125	false
Phenobarbital	10-22	calcitriol	171-180	false
phenytoin	49-57	phenobarbital	62-74	false
phenytoin	49-57	vitamin D	117-125	false
phenytoin	49-57	calcitriol	171-180	false
phenobarbital	62-74	vitamin D	117-125	false
phenobarbital	62-74	calcitriol	171-180	false
vitamin D	117-125	calcitriol	171-180	false

Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
calcitriol	21-30	Rocaltrol	80-88	false

Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
Thiazides	0-8	Thiazides	11-19	false

Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
thiazides	63-71	vitamin D	78-86	effect

Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
Digitalis	0-8	Vitamin D	11-19	false
Digitalis	0-8	digitalis	95-103	false
Vitamin D	11-19	digitalis	95-103	advise

Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
Ketoconazole	0-11	Ketoconazole	14-25	false
Ketoconazole	0-11	vitamin D	79-87	false
Ketoconazole	14-25	vitamin D	79-87	mechanism

However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
ketoconazole	45-56	vitamin D	63-71	false

Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
Corticosteroids	0-14	vitamin D	72-80	false
Corticosteroids	0-14	corticosteroids	131-145	false
vitamin D	72-80	corticosteroids	131-145	effect

Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
Vitamin D	0-8	vitamin D	46-54	false

Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
Calcium	0-6	calcium	55-61	false

Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
Magnesium	0-8	Magnesium	11-19	false
Magnesium	0-8	antacids	50-57	false
Magnesium	0-8	vitamin D	140-148	false
Magnesium	11-19	antacids	50-57	false
Magnesium	11-19	vitamin D	140-148	effect
antacids	50-57	vitamin D	140-148	effect

Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
Cholestyramine	0-13	resin	15-19	false
Cholestyramine	0-13	phenylbutazone	95-108	mechanism
Cholestyramine	0-13	warfarin	111-118	mechanism
Cholestyramine	0-13	thiazide diuretics	121-138	mechanism
Cholestyramine	0-13	propranolol	152-162	mechanism
Cholestyramine	0-13	tetracycline	184-195	mechanism
Cholestyramine	0-13	penicillin G	197-208	mechanism
Cholestyramine	0-13	phenobarbital	211-223	mechanism
Cholestyramine	0-13	thyroxine	238-246	mechanism
Cholestyramine	0-13	estrogens	262-270	mechanism
Cholestyramine	0-13	progestins	276-285	mechanism
Cholestyramine	0-13	digitalis	292-300	mechanism
resin	15-19	phenylbutazone	95-108	false
resin	15-19	warfarin	111-118	false
resin	15-19	thiazide diuretics	121-138	false
resin	15-19	propranolol	152-162	false
resin	15-19	tetracycline	184-195	false
resin	15-19	penicillin G	197-208	false
resin	15-19	phenobarbital	211-223	false
resin	15-19	thyroxine	238-246	false
resin	15-19	estrogens	262-270	false
resin	15-19	progestins	276-285	false
resin	15-19	digitalis	292-300	false
phenylbutazone	95-108	warfarin	111-118	false
phenylbutazone	95-108	thiazide diuretics	121-138	false
phenylbutazone	95-108	propranolol	152-162	false
phenylbutazone	95-108	tetracycline	184-195	false
phenylbutazone	95-108	penicillin G	197-208	false
phenylbutazone	95-108	phenobarbital	211-223	false
phenylbutazone	95-108	thyroxine	238-246	false
phenylbutazone	95-108	estrogens	262-270	false
phenylbutazone	95-108	progestins	276-285	false
phenylbutazone	95-108	digitalis	292-300	false
warfarin	111-118	thiazide diuretics	121-138	false
warfarin	111-118	propranolol	152-162	false
warfarin	111-118	tetracycline	184-195	false
warfarin	111-118	penicillin G	197-208	false
warfarin	111-118	phenobarbital	211-223	false
warfarin	111-118	thyroxine	238-246	false
warfarin	111-118	estrogens	262-270	false
warfarin	111-118	progestins	276-285	false
warfarin	111-118	digitalis	292-300	false
thiazide diuretics	121-138	propranolol	152-162	false
thiazide diuretics	121-138	tetracycline	184-195	false
thiazide diuretics	121-138	penicillin G	197-208	false
thiazide diuretics	121-138	phenobarbital	211-223	false
thiazide diuretics	121-138	thyroxine	238-246	false
thiazide diuretics	121-138	estrogens	262-270	false
thiazide diuretics	121-138	progestins	276-285	false
thiazide diuretics	121-138	digitalis	292-300	false
propranolol	152-162	tetracycline	184-195	false
propranolol	152-162	penicillin G	197-208	false
propranolol	152-162	phenobarbital	211-223	false
propranolol	152-162	thyroxine	238-246	false
propranolol	152-162	estrogens	262-270	false
propranolol	152-162	progestins	276-285	false
propranolol	152-162	digitalis	292-300	false
tetracycline	184-195	penicillin G	197-208	false
tetracycline	184-195	phenobarbital	211-223	false
tetracycline	184-195	thyroxine	238-246	false
tetracycline	184-195	estrogens	262-270	false
tetracycline	184-195	progestins	276-285	false
tetracycline	184-195	digitalis	292-300	false
penicillin G	197-208	phenobarbital	211-223	false
penicillin G	197-208	thyroxine	238-246	false
penicillin G	197-208	estrogens	262-270	false
penicillin G	197-208	progestins	276-285	false
penicillin G	197-208	digitalis	292-300	false
phenobarbital	211-223	thyroxine	238-246	false
phenobarbital	211-223	estrogens	262-270	false
phenobarbital	211-223	progestins	276-285	false
phenobarbital	211-223	digitalis	292-300	false
thyroxine	238-246	estrogens	262-270	false
thyroxine	238-246	progestins	276-285	false
thyroxine	238-246	digitalis	292-300	false
estrogens	262-270	progestins	276-285	false
estrogens	262-270	digitalis	292-300	false
progestins	276-285	digitalis	292-300	false

Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
Cholestyramine	0-13	resin	15-19	false
Cholestyramine	0-13	cholestyramine	132-145	false
Cholestyramine	0-13	resin	147-151	false
Cholestyramine	0-13	digitalis	219-227	false
Cholestyramine	0-13	cholestyramine	300-313	false
Cholestyramine	0-13	resin	315-319	false
resin	15-19	cholestyramine	132-145	false
resin	15-19	resin	147-151	false
resin	15-19	digitalis	219-227	false
resin	15-19	cholestyramine	300-313	false
resin	15-19	resin	315-319	false
cholestyramine	132-145	resin	147-151	false
cholestyramine	132-145	digitalis	219-227	mechanism
cholestyramine	132-145	cholestyramine	300-313	false
cholestyramine	132-145	resin	315-319	false
resin	147-151	digitalis	219-227	false
resin	147-151	cholestyramine	300-313	false
resin	147-151	resin	315-319	false
digitalis	219-227	cholestyramine	300-313	false
digitalis	219-227	resin	315-319	false
cholestyramine	300-313	resin	315-319	false

Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.
cholestyramine	8-21	cholestyramine	41-54	false
cholestyramine	8-21	resin	56-60	false
cholestyramine	8-21	fat soluble vitamins	152-171	false
cholestyramine	41-54	resin	56-60	false
cholestyramine	41-54	fat soluble vitamins	152-171	false
resin	56-60	fat soluble vitamins	152-171	false

When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.
cholestyramine	5-18	resin	20-24	false
cholestyramine	5-18	fat-soluble vitamins	134-153	false
resin	20-24	fat-soluble vitamins	134-153	false

SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
CHOLESTYRAMINE	6-19	RESIN	21-25	false
CHOLESTYRAMINE	6-19	CHOLESTYRAMINE	162-175	false
CHOLESTYRAMINE	6-19	RESIN	177-181	false
RESIN	21-25	CHOLESTYRAMINE	162-175	false
RESIN	21-25	RESIN	177-181	false
CHOLESTYRAMINE	162-175	RESIN	177-181	false

In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic acid, indicating no potential for protein binding-based drug interactions.
des-ciclesonide	65-79	warfarin	101-108	false
des-ciclesonide	65-79	salicylic acid	113-126	false
warfarin	101-108	salicylic acid	113-126	false

In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.
ciclesonide	65-75	erythromycin	86-97	false
ciclesonide	65-75	des-ciclesonide	185-199	false
ciclesonide	65-75	erythromycin	204-215	false
erythromycin	86-97	des-ciclesonide	185-199	false
erythromycin	86-97	erythromycin	204-215	false
des-ciclesonide	185-199	erythromycin	204-215	false

In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
ciclesonide	71-81	ketoconazole	92-103	mechanism
ciclesonide	71-81	des-ciclesonide	181-195	false
ciclesonide	71-81	ciclesonide	256-266	false
ketoconazole	92-103	des-ciclesonide	181-195	false
ketoconazole	92-103	ciclesonide	256-266	false
des-ciclesonide	181-195	ciclesonide	256-266	false

Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
ketoconazole	11-22	ciclesonide	76-86	advise

Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
Probenecid	0-9	Probenecid	13-22	false
Probenecid	0-9	acetaminophen	113-125	false
Probenecid	0-9	acyclovir	128-136	false
Probenecid	0-9	angiotensin-converting enzyme inhibitors	139-178	false
Probenecid	0-9	aminosalicylic acid	181-199	false
Probenecid	0-9	barbiturates	202-213	false
Probenecid	0-9	benzodiazepines	216-230	false
Probenecid	0-9	bumetanide	233-242	false
Probenecid	0-9	clofibrate	245-254	false
Probenecid	0-9	methotrexate	257-268	false
Probenecid	0-9	famotidine	271-280	false
Probenecid	0-9	furosemide	283-292	false
Probenecid	0-9	nonsteroidal anti-inflammatory	295-324	false
Probenecid	0-9	theophylline	334-345	false
Probenecid	0-9	zidovudine	352-361	false
Probenecid	13-22	acetaminophen	113-125	mechanism
Probenecid	13-22	acyclovir	128-136	mechanism
Probenecid	13-22	angiotensin-converting enzyme inhibitors	139-178	mechanism
Probenecid	13-22	aminosalicylic acid	181-199	mechanism
Probenecid	13-22	barbiturates	202-213	mechanism
Probenecid	13-22	benzodiazepines	216-230	mechanism
Probenecid	13-22	bumetanide	233-242	mechanism
Probenecid	13-22	clofibrate	245-254	mechanism
Probenecid	13-22	methotrexate	257-268	mechanism
Probenecid	13-22	famotidine	271-280	mechanism
Probenecid	13-22	furosemide	283-292	mechanism
Probenecid	13-22	nonsteroidal anti-inflammatory	295-324	mechanism
Probenecid	13-22	theophylline	334-345	mechanism
Probenecid	13-22	zidovudine	352-361	mechanism
acetaminophen	113-125	acyclovir	128-136	false
acetaminophen	113-125	angiotensin-converting enzyme inhibitors	139-178	false
acetaminophen	113-125	aminosalicylic acid	181-199	false
acetaminophen	113-125	barbiturates	202-213	false
acetaminophen	113-125	benzodiazepines	216-230	false
acetaminophen	113-125	bumetanide	233-242	false
acetaminophen	113-125	clofibrate	245-254	false
acetaminophen	113-125	methotrexate	257-268	false
acetaminophen	113-125	famotidine	271-280	false
acetaminophen	113-125	furosemide	283-292	false
acetaminophen	113-125	nonsteroidal anti-inflammatory	295-324	false
acetaminophen	113-125	theophylline	334-345	false
acetaminophen	113-125	zidovudine	352-361	false
acyclovir	128-136	angiotensin-converting enzyme inhibitors	139-178	false
acyclovir	128-136	aminosalicylic acid	181-199	false
acyclovir	128-136	barbiturates	202-213	false
acyclovir	128-136	benzodiazepines	216-230	false
acyclovir	128-136	bumetanide	233-242	false
acyclovir	128-136	clofibrate	245-254	false
acyclovir	128-136	methotrexate	257-268	false
acyclovir	128-136	famotidine	271-280	false
acyclovir	128-136	furosemide	283-292	false
acyclovir	128-136	nonsteroidal anti-inflammatory	295-324	false
acyclovir	128-136	theophylline	334-345	false
acyclovir	128-136	zidovudine	352-361	false
angiotensin-converting enzyme inhibitors	139-178	aminosalicylic acid	181-199	false
angiotensin-converting enzyme inhibitors	139-178	barbiturates	202-213	false
angiotensin-converting enzyme inhibitors	139-178	benzodiazepines	216-230	false
angiotensin-converting enzyme inhibitors	139-178	bumetanide	233-242	false
angiotensin-converting enzyme inhibitors	139-178	clofibrate	245-254	false
angiotensin-converting enzyme inhibitors	139-178	methotrexate	257-268	false
angiotensin-converting enzyme inhibitors	139-178	famotidine	271-280	false
angiotensin-converting enzyme inhibitors	139-178	furosemide	283-292	false
angiotensin-converting enzyme inhibitors	139-178	nonsteroidal anti-inflammatory	295-324	false
angiotensin-converting enzyme inhibitors	139-178	theophylline	334-345	false
angiotensin-converting enzyme inhibitors	139-178	zidovudine	352-361	false
aminosalicylic acid	181-199	barbiturates	202-213	false
aminosalicylic acid	181-199	benzodiazepines	216-230	false
aminosalicylic acid	181-199	bumetanide	233-242	false
aminosalicylic acid	181-199	clofibrate	245-254	false
aminosalicylic acid	181-199	methotrexate	257-268	false
aminosalicylic acid	181-199	famotidine	271-280	false
aminosalicylic acid	181-199	furosemide	283-292	false
aminosalicylic acid	181-199	nonsteroidal anti-inflammatory	295-324	false
aminosalicylic acid	181-199	theophylline	334-345	false
aminosalicylic acid	181-199	zidovudine	352-361	false
barbiturates	202-213	benzodiazepines	216-230	false
barbiturates	202-213	bumetanide	233-242	false
barbiturates	202-213	clofibrate	245-254	false
barbiturates	202-213	methotrexate	257-268	false
barbiturates	202-213	famotidine	271-280	false
barbiturates	202-213	furosemide	283-292	false
barbiturates	202-213	nonsteroidal anti-inflammatory	295-324	false
barbiturates	202-213	theophylline	334-345	false
barbiturates	202-213	zidovudine	352-361	false
benzodiazepines	216-230	bumetanide	233-242	false
benzodiazepines	216-230	clofibrate	245-254	false
benzodiazepines	216-230	methotrexate	257-268	false
benzodiazepines	216-230	famotidine	271-280	false
benzodiazepines	216-230	furosemide	283-292	false
benzodiazepines	216-230	nonsteroidal anti-inflammatory	295-324	false
benzodiazepines	216-230	theophylline	334-345	false
benzodiazepines	216-230	zidovudine	352-361	false
bumetanide	233-242	clofibrate	245-254	false
bumetanide	233-242	methotrexate	257-268	false
bumetanide	233-242	famotidine	271-280	false
bumetanide	233-242	furosemide	283-292	false
bumetanide	233-242	nonsteroidal anti-inflammatory	295-324	false
bumetanide	233-242	theophylline	334-345	false
bumetanide	233-242	zidovudine	352-361	false
clofibrate	245-254	methotrexate	257-268	false
clofibrate	245-254	famotidine	271-280	false
clofibrate	245-254	furosemide	283-292	false
clofibrate	245-254	nonsteroidal anti-inflammatory	295-324	false
clofibrate	245-254	theophylline	334-345	false
clofibrate	245-254	zidovudine	352-361	false
methotrexate	257-268	famotidine	271-280	false
methotrexate	257-268	furosemide	283-292	false
methotrexate	257-268	nonsteroidal anti-inflammatory	295-324	false
methotrexate	257-268	theophylline	334-345	false
methotrexate	257-268	zidovudine	352-361	false
famotidine	271-280	furosemide	283-292	false
famotidine	271-280	nonsteroidal anti-inflammatory	295-324	false
famotidine	271-280	theophylline	334-345	false
famotidine	271-280	zidovudine	352-361	false
furosemide	283-292	nonsteroidal anti-inflammatory	295-324	false
furosemide	283-292	theophylline	334-345	false
furosemide	283-292	zidovudine	352-361	false
nonsteroidal anti-inflammatory	295-324	theophylline	334-345	false
nonsteroidal anti-inflammatory	295-324	zidovudine	352-361	false
theophylline	334-345	zidovudine	352-361	false

Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
Zidovudine	0-9	probenecid	98-107	advise
Zidovudine	0-9	VISTIDE	123-129	false
probenecid	98-107	VISTIDE	123-129	false

Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
VISTIDE	51-57	aminoglycosides	116-130	advise
VISTIDE	51-57	tobramycin	139-148	advise
VISTIDE	51-57	gentamicin	151-160	advise
VISTIDE	51-57	amikacin	167-174	advise
VISTIDE	51-57	amphotericin B	178-191	advise
VISTIDE	51-57	foscarnet	194-202	advise
VISTIDE	51-57	pentamidine	217-227	advise
VISTIDE	51-57	vancomycin	230-239	advise
VISTIDE	51-57	non-steroidal anti-inflammatory agents	246-283	advise
aminoglycosides	116-130	tobramycin	139-148	false
aminoglycosides	116-130	gentamicin	151-160	false
aminoglycosides	116-130	amikacin	167-174	false
aminoglycosides	116-130	amphotericin B	178-191	false
aminoglycosides	116-130	foscarnet	194-202	false
aminoglycosides	116-130	pentamidine	217-227	false
aminoglycosides	116-130	vancomycin	230-239	false
aminoglycosides	116-130	non-steroidal anti-inflammatory agents	246-283	false
tobramycin	139-148	gentamicin	151-160	false
tobramycin	139-148	amikacin	167-174	false
tobramycin	139-148	amphotericin B	178-191	false
tobramycin	139-148	foscarnet	194-202	false
tobramycin	139-148	pentamidine	217-227	false
tobramycin	139-148	vancomycin	230-239	false
tobramycin	139-148	non-steroidal anti-inflammatory agents	246-283	false
gentamicin	151-160	amikacin	167-174	false
gentamicin	151-160	amphotericin B	178-191	false
gentamicin	151-160	foscarnet	194-202	false
gentamicin	151-160	pentamidine	217-227	false
gentamicin	151-160	vancomycin	230-239	false
gentamicin	151-160	non-steroidal anti-inflammatory agents	246-283	false
amikacin	167-174	amphotericin B	178-191	false
amikacin	167-174	foscarnet	194-202	false
amikacin	167-174	pentamidine	217-227	false
amikacin	167-174	vancomycin	230-239	false
amikacin	167-174	non-steroidal anti-inflammatory agents	246-283	false
amphotericin B	178-191	foscarnet	194-202	false
amphotericin B	178-191	pentamidine	217-227	false
amphotericin B	178-191	vancomycin	230-239	false
amphotericin B	178-191	non-steroidal anti-inflammatory agents	246-283	false
foscarnet	194-202	pentamidine	217-227	false
foscarnet	194-202	vancomycin	230-239	false
foscarnet	194-202	non-steroidal anti-inflammatory agents	246-283	false
pentamidine	217-227	vancomycin	230-239	false
pentamidine	217-227	non-steroidal anti-inflammatory agents	246-283	false
vancomycin	230-239	non-steroidal anti-inflammatory agents	246-283	false

Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
PLETAL	6-11	PLETAL	105-110	false
PLETAL	6-11	ketoconazole	164-175	false
PLETAL	6-11	erythromycin	181-192	false
PLETAL	6-11	omeprazole	227-236	false
PLETAL	105-110	ketoconazole	164-175	advise
PLETAL	105-110	erythromycin	181-192	advise
PLETAL	105-110	omeprazole	227-236	advise
ketoconazole	164-175	erythromycin	181-192	false
ketoconazole	164-175	omeprazole	227-236	false
erythromycin	181-192	omeprazole	227-236	false

Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
omeprazole	47-56	erythromycin	62-73	false
omeprazole	47-56	cilostazol	124-133	mechanism
erythromycin	62-73	cilostazol	124-133	mechanism

Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
cilostazol	67-76	diltiazem	119-127	mechanism

Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to C.P.A. inhibition.
Pletal	0-5	lovastatin	120-129	false

Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
Tagamet	0-6	warfarin-type anticoagulants	130-157	mechanism
Tagamet	0-6	phenytoin	160-168	mechanism
Tagamet	0-6	propranolol	171-181	mechanism
Tagamet	0-6	nifedipine	184-193	mechanism
Tagamet	0-6	chlordiazepoxide	196-211	mechanism
Tagamet	0-6	diazepam	214-221	mechanism
Tagamet	0-6	tricyclic antidepressants	232-256	mechanism
Tagamet	0-6	lidocaine	259-267	mechanism
Tagamet	0-6	theophylline	270-281	mechanism
Tagamet	0-6	metronidazole	287-299	mechanism
warfarin-type anticoagulants	130-157	phenytoin	160-168	false
warfarin-type anticoagulants	130-157	propranolol	171-181	false
warfarin-type anticoagulants	130-157	nifedipine	184-193	false
warfarin-type anticoagulants	130-157	chlordiazepoxide	196-211	false
warfarin-type anticoagulants	130-157	diazepam	214-221	false
warfarin-type anticoagulants	130-157	tricyclic antidepressants	232-256	false
warfarin-type anticoagulants	130-157	lidocaine	259-267	false
warfarin-type anticoagulants	130-157	theophylline	270-281	false
warfarin-type anticoagulants	130-157	metronidazole	287-299	false
phenytoin	160-168	propranolol	171-181	false
phenytoin	160-168	nifedipine	184-193	false
phenytoin	160-168	chlordiazepoxide	196-211	false
phenytoin	160-168	diazepam	214-221	false
phenytoin	160-168	tricyclic antidepressants	232-256	false
phenytoin	160-168	lidocaine	259-267	false
phenytoin	160-168	theophylline	270-281	false
phenytoin	160-168	metronidazole	287-299	false
propranolol	171-181	nifedipine	184-193	false
propranolol	171-181	chlordiazepoxide	196-211	false
propranolol	171-181	diazepam	214-221	false
propranolol	171-181	tricyclic antidepressants	232-256	false
propranolol	171-181	lidocaine	259-267	false
propranolol	171-181	theophylline	270-281	false
propranolol	171-181	metronidazole	287-299	false
nifedipine	184-193	chlordiazepoxide	196-211	false
nifedipine	184-193	diazepam	214-221	false
nifedipine	184-193	tricyclic antidepressants	232-256	false
nifedipine	184-193	lidocaine	259-267	false
nifedipine	184-193	theophylline	270-281	false
nifedipine	184-193	metronidazole	287-299	false
chlordiazepoxide	196-211	diazepam	214-221	false
chlordiazepoxide	196-211	tricyclic antidepressants	232-256	false
chlordiazepoxide	196-211	lidocaine	259-267	false
chlordiazepoxide	196-211	theophylline	270-281	false
chlordiazepoxide	196-211	metronidazole	287-299	false
diazepam	214-221	tricyclic antidepressants	232-256	false
diazepam	214-221	lidocaine	259-267	false
diazepam	214-221	theophylline	270-281	false
diazepam	214-221	metronidazole	287-299	false
tricyclic antidepressants	232-256	lidocaine	259-267	false
tricyclic antidepressants	232-256	theophylline	270-281	false
tricyclic antidepressants	232-256	metronidazole	287-299	false
lidocaine	259-267	theophylline	270-281	false
lidocaine	259-267	metronidazole	287-299	false
theophylline	270-281	metronidazole	287-299	false

therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
anticoagulant	86-98	Tagamet	127-133	advise

Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.
phenytoin	17-25	lidocaine	28-36	false
phenytoin	17-25	theophylline	42-53	false
lidocaine	28-36	theophylline	42-53	false

However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
Tagamet	64-70	theophylline	146-157	mechanism
Tagamet	64-70	Theo-Dur	160-167	mechanism
Tagamet	64-70	theophylline	243-254	false
theophylline	146-157	Theo-Dur	160-167	false
theophylline	146-157	theophylline	243-254	false
Theo-Dur	160-167	theophylline	243-254	false

Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.
Sensipar	10-17	Sensipar	86-93	false

Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.
flecainide	143-152	vinblastine	155-165	false
flecainide	143-152	thioridazine	168-179	false
flecainide	143-152	tricyclic antidepressants	190-214	false
vinblastine	155-165	thioridazine	168-179	false
vinblastine	155-165	tricyclic antidepressants	190-214	false
thioridazine	168-179	tricyclic antidepressants	190-214	false

Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
Amitriptyline	0-12	cinacalcet	60-69	false
Amitriptyline	0-12	amitriptyline	82-94	false
Amitriptyline	0-12	amitriptyline	106-118	false
Amitriptyline	0-12	nortriptyline	133-145	false
cinacalcet	60-69	amitriptyline	82-94	mechanism
cinacalcet	60-69	amitriptyline	106-118	false
cinacalcet	60-69	nortriptyline	133-145	false
amitriptyline	82-94	amitriptyline	106-118	false
amitriptyline	82-94	nortriptyline	133-145	false
amitriptyline	106-118	nortriptyline	133-145	false

Effect of other drugs on Sensipar : Sensipar  is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2.
Sensipar	25-32	Sensipar	36-43	false

Ketoconazole: Sensipar is metabolized in part by CYP3A4.
Ketoconazole	0-11	Sensipar	14-21	false

Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
ketoconazole	21-32	cinacalcet	75-84	mechanism
ketoconazole	21-32	Sensipar	128-135	false
cinacalcet	75-84	Sensipar	128-135	false

Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
Sensipar	19-26	ketoconazole	198-209	advise
Sensipar	19-26	erythromycin	212-223	advise
Sensipar	19-26	itraconazole	226-237	advise
ketoconazole	198-209	erythromycin	212-223	false
ketoconazole	198-209	itraconazole	226-237	false
erythromycin	212-223	itraconazole	226-237	false

Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
theophylline	26-37	quinolones	87-96	mechanism

There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
theophylline	27-38	theophylline	88-99	false
theophylline	27-38	quinolone	101-109	false
theophylline	88-99	quinolone	101-109	effect

Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
theophylline	25-36	theophylline	87-98	false

Quinolones have also been shown to interfere with the metabolism of caffeine.
Quinolones	0-9	caffeine	68-75	mechanism

Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
cinoxacin	53-61	cinoxacin	97-105	false
cinoxacin	53-61	caffeine	135-142	false
cinoxacin	97-105	caffeine	135-142	advise

Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
Antacids	0-7	sucralfate	12-21	false
Antacids	0-7	quinolones	75-84	mechanism
sucralfate	12-21	quinolones	75-84	mechanism

Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
quinolones	36-45	iron	72-75	mechanism
quinolones	36-45	multivitamins	78-90	false
quinolones	36-45	zinc	103-106	mechanism
quinolones	36-45	Videx	112-116	mechanism
quinolones	36-45	didanosine	119-128	mechanism
iron	72-75	multivitamins	78-90	false
iron	72-75	zinc	103-106	false
iron	72-75	Videx	112-116	false
iron	72-75	didanosine	119-128	false
multivitamins	78-90	zinc	103-106	false
multivitamins	78-90	Videx	112-116	false
multivitamins	78-90	didanosine	119-128	false
zinc	103-106	Videx	112-116	false
zinc	103-106	didanosine	119-128	false
Videx	112-116	didanosine	119-128	false

Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
Quinolones	0-9	cinoxacin	22-30	false
Quinolones	0-9	anticoagulants	65-78	effect
Quinolones	0-9	warfarin	89-96	effect
cinoxacin	22-30	anticoagulants	65-78	effect
cinoxacin	22-30	warfarin	89-96	effect
anticoagulants	65-78	warfarin	89-96	false

Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
quinolone class antimicrobial	55-83	nonsteroidal anti-inflammatory drug	93-127	effect
quinolone class antimicrobial	55-83	fenbufen	129-136	effect
nonsteroidal anti-inflammatory drug	93-127	fenbufen	129-136	false

Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
cinoxacin	110-118	nonsteroidal anti-inflammatory agents	132-168	advise

Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
cyclosporine	9-20	quinolones	82-91	false
cyclosporine	9-20	cyclosporine	97-108	false
quinolones	82-91	cyclosporine	97-108	mechanism

Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
quinolones	5-14	ciprofloxacin	27-39	false
quinolones	5-14	caffeine	99-106	mechanism
ciprofloxacin	27-39	caffeine	99-106	mechanism

Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
quinolones	5-14	ciprofloxacin	27-39	false
quinolones	5-14	cyclosporine	131-142	effect
ciprofloxacin	27-39	cyclosporine	131-142	effect

Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
Glyburide	0-8	ciprofloxacin	45-57	false
Glyburide	0-8	sulfonylurea	68-79	false
Glyburide	0-8	glyburide	81-89	false
ciprofloxacin	45-57	sulfonylurea	68-79	effect
ciprofloxacin	45-57	glyburide	81-89	effect
sulfonylurea	68-79	glyburide	81-89	false

Histamine H2-receptor antagonists: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.
Histamine H2-receptor antagonists	0-32	Histamine H2-receptor antagonists	35-67	false
Histamine H2-receptor antagonists	0-32	ciprofloxacin	132-144	false
Histamine H2-receptor antagonists	35-67	ciprofloxacin	132-144	false

Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
Methotrexate	0-11	methotrexate	40-51	false
Methotrexate	0-11	ciprofloxacin	103-115	false
Methotrexate	0-11	methotrexate	168-179	false
methotrexate	40-51	ciprofloxacin	103-115	mechanism
methotrexate	40-51	methotrexate	168-179	false
ciprofloxacin	103-115	methotrexate	168-179	false

Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
methotrexate	26-37	ciprofloxacin	94-106	advise

Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
quinolone	71-79	ciprofloxacin	92-104	false
quinolone	71-79	magnesium	159-167	mechanism
quinolone	71-79	aluminum	172-179	mechanism
quinolone	71-79	antacids	181-188	mechanism
quinolone	71-79	sucralfate	191-200	mechanism
quinolone	71-79	VIDEX	203-207	mechanism
quinolone	71-79	calcium	279-285	mechanism
quinolone	71-79	iron	288-291	mechanism
quinolone	71-79	zinc	297-300	mechanism
quinolone	71-79	ciprofloxacin	347-359	false
ciprofloxacin	92-104	magnesium	159-167	mechanism
ciprofloxacin	92-104	aluminum	172-179	mechanism
ciprofloxacin	92-104	antacids	181-188	mechanism
ciprofloxacin	92-104	sucralfate	191-200	mechanism
ciprofloxacin	92-104	VIDEX	203-207	mechanism
ciprofloxacin	92-104	calcium	279-285	mechanism
ciprofloxacin	92-104	iron	288-291	mechanism
ciprofloxacin	92-104	zinc	297-300	mechanism
ciprofloxacin	92-104	ciprofloxacin	347-359	mechanism
magnesium	159-167	aluminum	172-179	false
magnesium	159-167	antacids	181-188	false
magnesium	159-167	sucralfate	191-200	false
magnesium	159-167	VIDEX	203-207	false
magnesium	159-167	calcium	279-285	false
magnesium	159-167	iron	288-291	false
magnesium	159-167	zinc	297-300	false
magnesium	159-167	ciprofloxacin	347-359	false
aluminum	172-179	antacids	181-188	false
aluminum	172-179	sucralfate	191-200	false
aluminum	172-179	VIDEX	203-207	false
aluminum	172-179	calcium	279-285	false
aluminum	172-179	iron	288-291	false
aluminum	172-179	zinc	297-300	false
aluminum	172-179	ciprofloxacin	347-359	false
antacids	181-188	sucralfate	191-200	false
antacids	181-188	VIDEX	203-207	false
antacids	181-188	calcium	279-285	false
antacids	181-188	iron	288-291	false
antacids	181-188	zinc	297-300	false
antacids	181-188	ciprofloxacin	347-359	false
sucralfate	191-200	VIDEX	203-207	false
sucralfate	191-200	calcium	279-285	false
sucralfate	191-200	iron	288-291	false
sucralfate	191-200	zinc	297-300	false
sucralfate	191-200	ciprofloxacin	347-359	false
VIDEX	203-207	calcium	279-285	false
VIDEX	203-207	iron	288-291	false
VIDEX	203-207	zinc	297-300	false
VIDEX	203-207	ciprofloxacin	347-359	false
calcium	279-285	iron	288-291	false
calcium	279-285	zinc	297-300	false
calcium	279-285	ciprofloxacin	347-359	false
iron	288-291	zinc	297-300	false
iron	288-291	ciprofloxacin	347-359	false
zinc	297-300	ciprofloxacin	347-359	false

This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
ciprofloxacin	66-78	antacids	144-151	advise

Non-steroidal anti-inflammatory drugs (but not aspirin): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.
Non-steroidal anti-inflammatory drugs	0-36	aspirin	47-53	false
Non-steroidal anti-inflammatory drugs	0-36	quinolones	108-117	false
aspirin	47-53	quinolones	108-117	false

Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
Omeprazole	0-9	ciprofloxacin	49-61	false
Omeprazole	0-9	Proquin XR	86-95	false
Omeprazole	0-9	Proquin XR	121-130	false
Omeprazole	0-9	omeprazole	156-165	false
ciprofloxacin	49-61	Proquin XR	86-95	false
ciprofloxacin	49-61	Proquin XR	121-130	false
ciprofloxacin	49-61	omeprazole	156-165	false
Proquin XR	86-95	Proquin XR	121-130	false
Proquin XR	86-95	omeprazole	156-165	false
Proquin XR	121-130	omeprazole	156-165	false

Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..
Omeprazole	0-9	Proquin XR	43-52	false

Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
Phenytoin	0-8	phenytoin	35-43	false
Phenytoin	0-8	ciprofloxacin	124-136	false
phenytoin	35-43	ciprofloxacin	124-136	mechanism

Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
Probenecid	0-9	Probenecid	12-21	false
Probenecid	0-9	ciprofloxacin	66-78	false
Probenecid	0-9	ciprofloxacin	121-133	false
Probenecid	12-21	ciprofloxacin	66-78	mechanism
Probenecid	12-21	ciprofloxacin	121-133	mechanism
ciprofloxacin	66-78	ciprofloxacin	121-133	false

Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
Theophylline	0-11	quinolones	33-42	false
Theophylline	0-11	ciprofloxacin	74-86	false
Theophylline	0-11	theophylline	93-104	false
Theophylline	0-11	theophylline	151-162	false
quinolones	33-42	ciprofloxacin	74-86	false
quinolones	33-42	theophylline	93-104	mechanism
quinolones	33-42	theophylline	151-162	false
ciprofloxacin	74-86	theophylline	93-104	mechanism
ciprofloxacin	74-86	theophylline	151-162	false
theophylline	93-104	theophylline	151-162	false

Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
Warfarin	0-7	Quinolones	10-19	false
Warfarin	0-7	anticoagulant	75-87	false
Warfarin	0-7	warfarin	89-96	false
Quinolones	10-19	anticoagulant	75-87	false
Quinolones	10-19	warfarin	89-96	effect
anticoagulant	75-87	warfarin	89-96	false

In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.
cisapride	113-121	cisapride	211-219	false

Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antibiotics	0-10	clarithromycin	52-65	false
Antibiotics	0-10	erythromycin	68-79	false
Antibiotics	0-10	troleandomycin	86-99	false
Antibiotics	0-10	cisapride	136-144	false
Antibiotics	0-10	cisapride	189-197	false
clarithromycin	52-65	erythromycin	68-79	false
clarithromycin	52-65	troleandomycin	86-99	false
clarithromycin	52-65	cisapride	136-144	mechanism
clarithromycin	52-65	cisapride	189-197	false
erythromycin	68-79	troleandomycin	86-99	false
erythromycin	68-79	cisapride	136-144	mechanism
erythromycin	68-79	cisapride	189-197	false
troleandomycin	86-99	cisapride	136-144	mechanism
troleandomycin	86-99	cisapride	189-197	false
cisapride	136-144	cisapride	189-197	false

Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
Anticholinergics	0-15	anticholinergic compounds	55-79	false
Anticholinergics	0-15	belladonna alkaloids	90-109	false
Anticholinergics	0-15	dicyclomine	115-125	false
Anticholinergics	0-15	cisapride	186-194	false
anticholinergic compounds	55-79	belladonna alkaloids	90-109	false
anticholinergic compounds	55-79	dicyclomine	115-125	false
anticholinergic compounds	55-79	cisapride	186-194	effect
belladonna alkaloids	90-109	dicyclomine	115-125	false
belladonna alkaloids	90-109	cisapride	186-194	effect
dicyclomine	115-125	cisapride	186-194	effect

Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.
Anticoagulants	0-13	anticoagulants	50-63	false

It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
cisapride	107-115	anticoagulant	164-176	advise

Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antidepressants	0-14	nefazodone	45-54	false
Antidepressants	0-14	cisapride	83-91	false
Antidepressants	0-14	cisapride	136-144	false
nefazodone	45-54	cisapride	83-91	mechanism
nefazodone	45-54	cisapride	136-144	false
cisapride	83-91	cisapride	136-144	false

Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antifungals	0-10	fluconazole	56-66	false
Antifungals	0-10	itraconazole	69-80	false
Antifungals	0-10	ketoconazole	92-103	false
Antifungals	0-10	cisapride	140-148	false
Antifungals	0-10	cisapride	193-201	false
fluconazole	56-66	itraconazole	69-80	false
fluconazole	56-66	ketoconazole	92-103	false
fluconazole	56-66	cisapride	140-148	mechanism
fluconazole	56-66	cisapride	193-201	false
itraconazole	69-80	ketoconazole	92-103	false
itraconazole	69-80	cisapride	140-148	mechanism
itraconazole	69-80	cisapride	193-201	false
ketoconazole	92-103	cisapride	140-148	mechanism
ketoconazole	92-103	cisapride	193-201	false
cisapride	140-148	cisapride	193-201	false

Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
ketoconazole	46-57	cisapride	95-103	mechanism
ketoconazole	46-57	cisapride	156-164	false
cisapride	95-103	cisapride	156-164	false

A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
cisapride	82-90	ketoconazole	96-107	effect

H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
H2 Receptor Antagonists	0-22	Cimetidine	25-34	false
H2 Receptor Antagonists	0-22	cisapride	112-120	false
H2 Receptor Antagonists	0-22	cisapride	145-153	false
H2 Receptor Antagonists	0-22	ranitidine	197-206	false
Cimetidine	25-34	cisapride	112-120	mechanism
Cimetidine	25-34	cisapride	145-153	false
Cimetidine	25-34	ranitidine	197-206	false
cisapride	112-120	cisapride	145-153	false
cisapride	112-120	ranitidine	197-206	false
cisapride	145-153	ranitidine	197-206	false

The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
cimetidine	35-44	ranitidine	50-59	false
cimetidine	35-44	cisapride	110-118	mechanism
ranitidine	50-59	cisapride	110-118	mechanism

Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Protease Inhibitors	0-18	indinavir	49-57	false
Protease Inhibitors	0-18	ritonavir	63-71	false
Protease Inhibitors	0-18	cisapride	108-116	false
Protease Inhibitors	0-18	cisapride	160-168	false
indinavir	49-57	ritonavir	63-71	false
indinavir	49-57	cisapride	108-116	mechanism
indinavir	49-57	cisapride	160-168	false
ritonavir	63-71	cisapride	108-116	mechanism
ritonavir	63-71	cisapride	160-168	false
cisapride	108-116	cisapride	160-168	false

Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.
cisapride	49-57	cisapride	92-100	false

Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
Cisapride	0-8	antiarrhythmics	102-116	advise
Cisapride	0-8	quinidine	156-164	advise
Cisapride	0-8	procainamide	170-181	advise
Cisapride	0-8	sotalol	207-213	advise
antiarrhythmics	102-116	quinidine	156-164	false
antiarrhythmics	102-116	procainamide	170-181	false
antiarrhythmics	102-116	sotalol	207-213	false
quinidine	156-164	procainamide	170-181	false
quinidine	156-164	sotalol	207-213	false
procainamide	170-181	sotalol	207-213	false

tricyclic antidepressants (such as amitriptyline);
tricyclic antidepressants	0-24	amitriptyline	35-47	false

certain tetracyclic antidepressants (such as maprotiline);
tetracyclic antidepressants	8-34	maprotiline	45-55	false

certain antipsychotic medications (such as sertindole);
antipsychotic medications	8-32	sertindole	43-52	false

astemizole, bepridil, sparfloxacin, and terodiline.
astemizole	0-9	bepridil	12-19	false
astemizole	0-9	sparfloxacin	22-33	false
astemizole	0-9	terodiline	40-49	false
bepridil	12-19	sparfloxacin	22-33	false
bepridil	12-19	terodiline	40-49	false
sparfloxacin	22-33	terodiline	40-49	false

Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.
NIMBEX	39-44	succinylcholine	101-115	effect

The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
NIMBEX	45-50	succinylcholine	115-129	effect

Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX.
succinylcholine	24-38	NIMBEX	141-146	false

Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
NIMBEX	25-30	succinylcholine	57-71	false
NIMBEX	25-30	NIMBEX	95-100	false
NIMBEX	25-30	succinylcholine	151-165	false
succinylcholine	57-71	NIMBEX	95-100	effect
succinylcholine	57-71	succinylcholine	151-165	false
NIMBEX	95-100	succinylcholine	151-165	false

The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
NIMBEX	11-16	succinylcholine	25-39	false
NIMBEX	11-16	succinylcholine	82-96	false
succinylcholine	25-39	succinylcholine	82-96	false

Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX.
vecuronium	96-105	pancuronium	108-118	false
vecuronium	96-105	atracurium	124-133	false
vecuronium	96-105	NIMBEX	225-230	false
pancuronium	108-118	atracurium	124-133	false
pancuronium	108-118	NIMBEX	225-230	false
atracurium	124-133	NIMBEX	225-230	false

Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
Isoflurane	0-9	enflurane	14-22	false
Isoflurane	0-9	nitrous oxide	42-54	false
Isoflurane	0-9	oxygen	56-61	false
Isoflurane	0-9	NIMBEX	208-213	effect
Isoflurane	0-9	NIMBEX	258-263	effect
enflurane	14-22	nitrous oxide	42-54	false
enflurane	14-22	oxygen	56-61	false
enflurane	14-22	NIMBEX	208-213	effect
enflurane	14-22	NIMBEX	258-263	effect
nitrous oxide	42-54	oxygen	56-61	false
nitrous oxide	42-54	NIMBEX	208-213	effect
nitrous oxide	42-54	NIMBEX	258-263	effect
oxygen	56-61	NIMBEX	208-213	false
oxygen	56-61	NIMBEX	258-263	false
NIMBEX	208-213	NIMBEX	258-263	false

Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.
isoflurane	46-55	enflurane	60-68	false
isoflurane	46-55	NIMBEX	136-141	false
isoflurane	46-55	NIMBEX	217-222	false
enflurane	60-68	NIMBEX	136-141	false
enflurane	60-68	NIMBEX	217-222	false
NIMBEX	136-141	NIMBEX	217-222	false

In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
enflurane	35-43	isoflurane	48-57	false
enflurane	35-43	NIMBEX	159-164	advise
isoflurane	48-57	NIMBEX	159-164	advise

In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX.
propofol	20-27	NIMBEX	96-101	false

Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
nondepolarizing agents	67-88	NIMBEX	98-103	effect
nondepolarizing agents	67-88	antibiotics	121-131	effect
nondepolarizing agents	67-88	aminoglycosides	141-155	effect
nondepolarizing agents	67-88	tetracyclines	158-170	effect
nondepolarizing agents	67-88	bacitracin	173-182	effect
nondepolarizing agents	67-88	polymyxins	185-194	effect
nondepolarizing agents	67-88	lincomycin	197-206	effect
nondepolarizing agents	67-88	clindamycin	209-219	effect
nondepolarizing agents	67-88	colistin	222-229	effect
nondepolarizing agents	67-88	sodium colistemethate	236-256	effect
nondepolarizing agents	67-88	magnesium	260-268	effect
nondepolarizing agents	67-88	lithium	277-283	effect
nondepolarizing agents	67-88	anesthetics	292-302	effect
nondepolarizing agents	67-88	procainamide	305-316	effect
nondepolarizing agents	67-88	quinidine	323-331	effect
NIMBEX	98-103	antibiotics	121-131	effect
NIMBEX	98-103	aminoglycosides	141-155	effect
NIMBEX	98-103	tetracyclines	158-170	effect
NIMBEX	98-103	bacitracin	173-182	effect
NIMBEX	98-103	polymyxins	185-194	effect
NIMBEX	98-103	lincomycin	197-206	effect
NIMBEX	98-103	clindamycin	209-219	effect
NIMBEX	98-103	colistin	222-229	effect
NIMBEX	98-103	sodium colistemethate	236-256	effect
NIMBEX	98-103	magnesium	260-268	effect
NIMBEX	98-103	lithium	277-283	effect
NIMBEX	98-103	anesthetics	292-302	effect
NIMBEX	98-103	procainamide	305-316	effect
NIMBEX	98-103	quinidine	323-331	effect
antibiotics	121-131	aminoglycosides	141-155	false
antibiotics	121-131	tetracyclines	158-170	false
antibiotics	121-131	bacitracin	173-182	false
antibiotics	121-131	polymyxins	185-194	false
antibiotics	121-131	lincomycin	197-206	false
antibiotics	121-131	clindamycin	209-219	false
antibiotics	121-131	colistin	222-229	false
antibiotics	121-131	sodium colistemethate	236-256	false
antibiotics	121-131	magnesium	260-268	false
antibiotics	121-131	lithium	277-283	false
antibiotics	121-131	anesthetics	292-302	false
antibiotics	121-131	procainamide	305-316	false
antibiotics	121-131	quinidine	323-331	false
aminoglycosides	141-155	tetracyclines	158-170	false
aminoglycosides	141-155	bacitracin	173-182	false
aminoglycosides	141-155	polymyxins	185-194	false
aminoglycosides	141-155	lincomycin	197-206	false
aminoglycosides	141-155	clindamycin	209-219	false
aminoglycosides	141-155	colistin	222-229	false
aminoglycosides	141-155	sodium colistemethate	236-256	false
aminoglycosides	141-155	magnesium	260-268	false
aminoglycosides	141-155	lithium	277-283	false
aminoglycosides	141-155	anesthetics	292-302	false
aminoglycosides	141-155	procainamide	305-316	false
aminoglycosides	141-155	quinidine	323-331	false
tetracyclines	158-170	bacitracin	173-182	false
tetracyclines	158-170	polymyxins	185-194	false
tetracyclines	158-170	lincomycin	197-206	false
tetracyclines	158-170	clindamycin	209-219	false
tetracyclines	158-170	colistin	222-229	false
tetracyclines	158-170	sodium colistemethate	236-256	false
tetracyclines	158-170	magnesium	260-268	false
tetracyclines	158-170	lithium	277-283	false
tetracyclines	158-170	anesthetics	292-302	false
tetracyclines	158-170	procainamide	305-316	false
tetracyclines	158-170	quinidine	323-331	false
bacitracin	173-182	polymyxins	185-194	false
bacitracin	173-182	lincomycin	197-206	false
bacitracin	173-182	clindamycin	209-219	false
bacitracin	173-182	colistin	222-229	false
bacitracin	173-182	sodium colistemethate	236-256	false
bacitracin	173-182	magnesium	260-268	false
bacitracin	173-182	lithium	277-283	false
bacitracin	173-182	anesthetics	292-302	false
bacitracin	173-182	procainamide	305-316	false
bacitracin	173-182	quinidine	323-331	false
polymyxins	185-194	lincomycin	197-206	false
polymyxins	185-194	clindamycin	209-219	false
polymyxins	185-194	colistin	222-229	false
polymyxins	185-194	sodium colistemethate	236-256	false
polymyxins	185-194	magnesium	260-268	false
polymyxins	185-194	lithium	277-283	false
polymyxins	185-194	anesthetics	292-302	false
polymyxins	185-194	procainamide	305-316	false
polymyxins	185-194	quinidine	323-331	false
lincomycin	197-206	clindamycin	209-219	false
lincomycin	197-206	colistin	222-229	false
lincomycin	197-206	sodium colistemethate	236-256	false
lincomycin	197-206	magnesium	260-268	false
lincomycin	197-206	lithium	277-283	false
lincomycin	197-206	anesthetics	292-302	false
lincomycin	197-206	procainamide	305-316	false
lincomycin	197-206	quinidine	323-331	false
clindamycin	209-219	colistin	222-229	false
clindamycin	209-219	sodium colistemethate	236-256	false
clindamycin	209-219	magnesium	260-268	false
clindamycin	209-219	lithium	277-283	false
clindamycin	209-219	anesthetics	292-302	false
clindamycin	209-219	procainamide	305-316	false
clindamycin	209-219	quinidine	323-331	false
colistin	222-229	sodium colistemethate	236-256	false
colistin	222-229	magnesium	260-268	false
colistin	222-229	lithium	277-283	false
colistin	222-229	anesthetics	292-302	false
colistin	222-229	procainamide	305-316	false
colistin	222-229	quinidine	323-331	false
sodium colistemethate	236-256	magnesium	260-268	false
sodium colistemethate	236-256	lithium	277-283	false
sodium colistemethate	236-256	anesthetics	292-302	false
sodium colistemethate	236-256	procainamide	305-316	false
sodium colistemethate	236-256	quinidine	323-331	false
magnesium	260-268	lithium	277-283	false
magnesium	260-268	anesthetics	292-302	false
magnesium	260-268	procainamide	305-316	false
magnesium	260-268	quinidine	323-331	false
lithium	277-283	anesthetics	292-302	false
lithium	277-283	procainamide	305-316	false
lithium	277-283	quinidine	323-331	false
anesthetics	292-302	procainamide	305-316	false
anesthetics	292-302	quinidine	323-331	false
procainamide	305-316	quinidine	323-331	false

Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
nondepolarizing neuromuscular blocking agents	51-95	phenytoin	156-164	effect
nondepolarizing neuromuscular blocking agents	51-95	carbamazepine	169-181	effect
phenytoin	156-164	carbamazepine	169-181	false

While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
phenytoin	29-37	carbamazepine	42-54	false
phenytoin	29-37	NIMBEX	81-86	effect
carbamazepine	42-54	NIMBEX	81-86	effect

Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.
anticonvulsant agents	17-37	cisplatin	72-80	mechanism

Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
Central nervous system depressant	0-32	alcohol	56-62	false
Central nervous system depressant	0-32	antidepressants	65-79	false
Central nervous system depressant	0-32	antihistamines	82-95	false
Central nervous system depressant	0-32	antipsychotics	98-111	false
Central nervous system depressant	0-32	reserpine	142-150	false
Central nervous system depressant	0-32	methyldopa	153-162	false
Central nervous system depressant	0-32	beta-blockers	165-177	false
Central nervous system depressant	0-32	muscle relaxants	210-225	false
Central nervous system depressant	0-32	narcotics	228-236	false
Central nervous system depressant	0-32	sedatives	239-247	false
Central nervous system depressant	0-32	tranquilizers	269-281	false
alcohol	56-62	antidepressants	65-79	false
alcohol	56-62	antihistamines	82-95	false
alcohol	56-62	antipsychotics	98-111	false
alcohol	56-62	reserpine	142-150	false
alcohol	56-62	methyldopa	153-162	false
alcohol	56-62	beta-blockers	165-177	false
alcohol	56-62	muscle relaxants	210-225	false
alcohol	56-62	narcotics	228-236	false
alcohol	56-62	sedatives	239-247	false
alcohol	56-62	tranquilizers	269-281	false
antidepressants	65-79	antihistamines	82-95	false
antidepressants	65-79	antipsychotics	98-111	false
antidepressants	65-79	reserpine	142-150	false
antidepressants	65-79	methyldopa	153-162	false
antidepressants	65-79	beta-blockers	165-177	false
antidepressants	65-79	muscle relaxants	210-225	false
antidepressants	65-79	narcotics	228-236	false
antidepressants	65-79	sedatives	239-247	false
antidepressants	65-79	tranquilizers	269-281	false
antihistamines	82-95	antipsychotics	98-111	false
antihistamines	82-95	reserpine	142-150	false
antihistamines	82-95	methyldopa	153-162	false
antihistamines	82-95	beta-blockers	165-177	false
antihistamines	82-95	muscle relaxants	210-225	false
antihistamines	82-95	narcotics	228-236	false
antihistamines	82-95	sedatives	239-247	false
antihistamines	82-95	tranquilizers	269-281	false
antipsychotics	98-111	reserpine	142-150	false
antipsychotics	98-111	methyldopa	153-162	false
antipsychotics	98-111	beta-blockers	165-177	false
antipsychotics	98-111	muscle relaxants	210-225	false
antipsychotics	98-111	narcotics	228-236	false
antipsychotics	98-111	sedatives	239-247	false
antipsychotics	98-111	tranquilizers	269-281	false
reserpine	142-150	methyldopa	153-162	false
reserpine	142-150	beta-blockers	165-177	false
reserpine	142-150	muscle relaxants	210-225	false
reserpine	142-150	narcotics	228-236	false
reserpine	142-150	sedatives	239-247	false
reserpine	142-150	tranquilizers	269-281	false
methyldopa	153-162	beta-blockers	165-177	false
methyldopa	153-162	muscle relaxants	210-225	false
methyldopa	153-162	narcotics	228-236	false
methyldopa	153-162	sedatives	239-247	false
methyldopa	153-162	tranquilizers	269-281	false
beta-blockers	165-177	muscle relaxants	210-225	false
beta-blockers	165-177	narcotics	228-236	false
beta-blockers	165-177	sedatives	239-247	false
beta-blockers	165-177	tranquilizers	269-281	false
muscle relaxants	210-225	narcotics	228-236	false
muscle relaxants	210-225	sedatives	239-247	false
muscle relaxants	210-225	tranquilizers	269-281	false
narcotics	228-236	sedatives	239-247	false
narcotics	228-236	tranquilizers	269-281	false
sedatives	239-247	tranquilizers	269-281	false

The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
allopurinol	33-43	ampicillin	49-58	effect
allopurinol	33-43	ampicillin	175-184	false
ampicillin	49-58	ampicillin	175-184	false

It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
ampicillin	45-54	allopurinol	73-83	effect

In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.
AUGMENTIN XR	33-44	allopurinol	80-90	false
AUGMENTIN XR	33-44	AUGMENTIN XR	96-107	false
allopurinol	80-90	AUGMENTIN XR	96-107	false

However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.
AUGMENTIN XR	126-137	allopurinol	143-153	false

In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
broad-spectrum antibiotics	21-46	AUGMENTIN XR	49-60	false
broad-spectrum antibiotics	21-46	contraceptives	94-107	effect
AUGMENTIN XR	49-60	contraceptives	94-107	effect

Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
antihistamines	39-52	CNS depressants	96-110	effect
antihistamines	39-52	barbiturates	122-133	effect
antihistamines	39-52	tranquilizers	136-148	effect
antihistamines	39-52	alcohol	155-161	effect
CNS depressants	96-110	barbiturates	122-133	false
CNS depressants	96-110	tranquilizers	136-148	false
CNS depressants	96-110	alcohol	155-161	false
barbiturates	122-133	tranquilizers	136-148	false
barbiturates	122-133	alcohol	155-161	false
tranquilizers	136-148	alcohol	155-161	false

Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.
antihistamines	19-32	CNS depressant drugs	88-107	advise

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
Monoamine oxidase (MAO) inhibitors	0-33	antihistamines	88-101	effect

Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
Amantadine	0-9	tricyclic antidepressants	12-36	false
Amantadine	0-9	MAOIs	43-47	false
Amantadine	0-9	clidinium	88-96	effect
tricyclic antidepressants	12-36	MAOIs	43-47	false
tricyclic antidepressants	12-36	clidinium	88-96	effect
MAOIs	43-47	clidinium	88-96	effect

Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
Clidinium	0-8	phenothiazines	37-50	effect
Clidinium	0-8	levodopa	53-60	effect
Clidinium	0-8	ketoconazole	67-78	effect
phenothiazines	37-50	levodopa	53-60	false
phenothiazines	37-50	ketoconazole	67-78	false
levodopa	53-60	ketoconazole	67-78	false

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
Clindamycin	0-10	neuromuscular blocking agents	106-134	effect

Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
clindamycin	41-51	erythromycin	57-68	effect

Alcohol (increases bioavailability by 50%), cimetidine, and valproates.
Alcohol	0-6	cimetidine	44-53	false

Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
dapsone	36-42	Lamprene	90-97	effect

If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
dapsone	84-90	clofazimine	96-106	advise

Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
anticoagulants	33-46	Atromid-S	78-86	advise

Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
Atromid-S	0-8	phenytoin	44-52	mechanism
Atromid-S	0-8	tolbutamide	57-67	mechanism
phenytoin	44-52	tolbutamide	57-67	false

The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
tolbutamide	27-37	Atromid-S	74-82	effect

Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
fibrate	113-119	lovastatin	125-134	effect

For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
lovastatin	168-177	fibrate	185-191	effect

While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.
fibrates	59-66	gemfibrozil	79-89	false
fibrates	59-66	fibrates	170-177	false
fibrates	59-66	clofibrate	196-205	false
gemfibrozil	79-89	fibrates	170-177	false
gemfibrozil	79-89	clofibrate	196-205	false
fibrates	170-177	clofibrate	196-205	false

Therefore, the combined use of lovastatin with fibrates should generally be avoided.
lovastatin	31-40	fibrates	47-54	advise

Anafranil should not be used with MAO inhibitors.
Anafranil	0-8	MAO inhibitors	34-47	advise

Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
Anafranil	69-77	anticholinergic	100-114	advise
Anafranil	69-77	sympathomimetic drugs	119-139	advise
anticholinergic	100-114	sympathomimetic drugs	119-139	false

Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
tricyclic antidepressants	8-32	guanethidine	91-102	effect
tricyclic antidepressants	8-32	clonidine	105-113	effect
tricyclic antidepressants	8-32	CMI	178-180	effect
tricyclic antidepressants	8-32	tricyclic antidepressants	228-252	effect
guanethidine	91-102	clonidine	105-113	false
guanethidine	91-102	CMI	178-180	false
guanethidine	91-102	tricyclic antidepressants	228-252	false
clonidine	105-113	CMI	178-180	false
clonidine	105-113	tricyclic antidepressants	228-252	false
CMI	178-180	tricyclic antidepressants	228-252	false

The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
CMI	28-30	haloperidol	103-113	mechanism

plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
tricyclic antidepressants	41-65	methylphenidate	139-153	mechanism
tricyclic antidepressants	41-65	cimetidine	191-200	mechanism
tricyclic antidepressants	41-65	fluoxetine	203-212	mechanism
tricyclic antidepressants	41-65	barbiturates	297-308	mechanism
tricyclic antidepressants	41-65	phenytoin	311-319	mechanism
tricyclic antidepressants	41-65	CMI	366-368	false
methylphenidate	139-153	cimetidine	191-200	false
methylphenidate	139-153	fluoxetine	203-212	false
methylphenidate	139-153	barbiturates	297-308	false
methylphenidate	139-153	phenytoin	311-319	false
methylphenidate	139-153	CMI	366-368	mechanism
cimetidine	191-200	fluoxetine	203-212	false
cimetidine	191-200	barbiturates	297-308	false
cimetidine	191-200	phenytoin	311-319	false
cimetidine	191-200	CMI	366-368	mechanism
fluoxetine	203-212	barbiturates	297-308	false
fluoxetine	203-212	phenytoin	311-319	false
fluoxetine	203-212	CMI	366-368	mechanism
barbiturates	297-308	phenytoin	311-319	false
barbiturates	297-308	CMI	366-368	mechanism
phenytoin	311-319	CMI	366-368	mechanism

Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
CMI	18-20	phenobarbital	73-85	mechanism

Poor metabolizers have higher than expected lasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	68-92	TCAs	95-98	false

cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	0-9	antidepressants	66-80	false
cimetidine	0-9	phenothiazines	83-96	false
cimetidine	0-9	Type 1C antiarrhythmics	107-129	false
cimetidine	0-9	propafenone	131-141	false
cimetidine	0-9	flecainide	147-156	false
antidepressants	66-80	phenothiazines	83-96	false
antidepressants	66-80	Type 1C antiarrhythmics	107-129	false
antidepressants	66-80	propafenone	131-141	false
antidepressants	66-80	flecainide	147-156	false
phenothiazines	83-96	Type 1C antiarrhythmics	107-129	false
phenothiazines	83-96	propafenone	131-141	false
phenothiazines	83-96	flecainide	147-156	false
Type 1C antiarrhythmics	107-129	propafenone	131-141	false
Type 1C antiarrhythmics	107-129	flecainide	147-156	false
propafenone	131-141	flecainide	147-156	false

While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	14-52	SSRIs	55-59	false
selective serotonin reuptake inhibitors	14-52	fluoxetine	69-78	false
selective serotonin reuptake inhibitors	14-52	sertraline	81-90	false
selective serotonin reuptake inhibitors	14-52	paroxetine	93-102	false
selective serotonin reuptake inhibitors	14-52	fluvoxamine	109-119	false
SSRIs	55-59	fluoxetine	69-78	false
SSRIs	55-59	sertraline	81-90	false
SSRIs	55-59	paroxetine	93-102	false
SSRIs	55-59	fluvoxamine	109-119	false
fluoxetine	69-78	sertraline	81-90	false
fluoxetine	69-78	paroxetine	93-102	false
fluoxetine	69-78	fluvoxamine	109-119	false
sertraline	81-90	paroxetine	93-102	false
sertraline	81-90	fluvoxamine	109-119	false
paroxetine	93-102	fluvoxamine	109-119	false

Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
Fluvoxamine	0-10	TCA	81-83	mechanism

The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	20-23	TCA	25-27	int
SSRI	20-23	SSRI	140-143	false
TCA	25-27	SSRI	140-143	false

Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	63-66	SSRIs	84-88	advise

Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
TCA	72-74	fluoxetine	119-128	advise

Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.
tricyclic antidepressant class	33-62	Anafranil	80-88	false
tricyclic antidepressant class	33-62	tricyclic antidepressant agent	202-231	false
Anafranil	80-88	tricyclic antidepressant agent	202-231	false

It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).
TCA	27-29	tricyclic antidepressant class	69-98	false
TCA	27-29	Anafranil	110-118	false
tricyclic antidepressant class	69-98	Anafranil	110-118	false

Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
Anafranil	8-16	Anafranil	74-82	false
Anafranil	8-16	warfarin	155-162	false
Anafranil	8-16	digoxin	165-171	false
Anafranil	74-82	warfarin	155-162	mechanism
Anafranil	74-82	digoxin	165-171	mechanism
warfarin	155-162	digoxin	165-171	false

Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.
Clonazepam	10-19	Clonazepam	61-70	false
Clonazepam	10-19	phenytoin	121-129	false
Clonazepam	10-19	carbamazepine	132-144	false
Clonazepam	10-19	phenobarbital	150-162	false
Clonazepam	61-70	phenytoin	121-129	false
Clonazepam	61-70	carbamazepine	132-144	false
Clonazepam	61-70	phenobarbital	150-162	false
phenytoin	121-129	carbamazepine	132-144	false
phenytoin	121-129	phenobarbital	150-162	false
carbamazepine	132-144	phenobarbital	150-162	false

Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.
Clonazepam	49-58	ranitidine	93-102	false
Clonazepam	49-58	clonazepam	169-178	false
ranitidine	93-102	clonazepam	169-178	false

In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
clonazepam	29-38	propantheline	103-115	mechanism
clonazepam	29-38	anticholinergic agent	121-141	false
clonazepam	29-38	clonazepam	216-225	false
clonazepam	29-38	clonazepam	257-266	false
clonazepam	29-38	propantheline	335-347	false
propantheline	103-115	anticholinergic agent	121-141	false
propantheline	103-115	clonazepam	216-225	false
propantheline	103-115	clonazepam	257-266	false
propantheline	103-115	propantheline	335-347	false
anticholinergic agent	121-141	clonazepam	216-225	false
anticholinergic agent	121-141	clonazepam	257-266	false
anticholinergic agent	121-141	propantheline	335-347	false
clonazepam	216-225	clonazepam	257-266	false
clonazepam	216-225	propantheline	335-347	false
clonazepam	257-266	propantheline	335-347	mechanism

Fluoxetine does not affect the pharmacokinetics of clonazepam.
Fluoxetine	0-9	clonazepam	51-60	false

Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
phenytoin	35-43	carbamazepine	46-58	false
phenytoin	35-43	phenobarbital	64-76	false
phenytoin	35-43	clonazepam	86-95	mechanism
phenytoin	35-43	clonazepam	157-166	false
carbamazepine	46-58	phenobarbital	64-76	false
carbamazepine	46-58	clonazepam	86-95	mechanism
carbamazepine	46-58	clonazepam	157-166	false
phenobarbital	64-76	clonazepam	86-95	mechanism
phenobarbital	64-76	clonazepam	157-166	false
clonazepam	86-95	clonazepam	157-166	false

Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
clonazepam	113-122	antifungal agents	183-199	false
clonazepam	113-122	clonazepam	250-259	false
antifungal agents	183-199	clonazepam	250-259	advise

Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
benzodiazepine class	63-82	alcohol	115-121	effect
benzodiazepine class	63-82	narcotics	124-132	effect
benzodiazepine class	63-82	barbiturates	135-146	effect
benzodiazepine class	63-82	nonbarbiturate hypnotics	149-172	effect
benzodiazepine class	63-82	antianxiety agents	175-192	effect
benzodiazepine class	63-82	phenothiazines classes of antipsychotic agents	199-212;246-276	effect
benzodiazepine class	63-82	thioxanthene classes of antipsychotic agents	215-226;246-276	effect
benzodiazepine class	63-82	butyrophenone classes of antipsychotic agents	232-276	effect
benzodiazepine class	63-82	monoamine oxidase inhibitors	279-306	effect
benzodiazepine class	63-82	tricyclic antidepressants	316-340	effect
benzodiazepine class	63-82	anticonvulsant drugs	356-375	effect
alcohol	115-121	narcotics	124-132	false
alcohol	115-121	barbiturates	135-146	false
alcohol	115-121	nonbarbiturate hypnotics	149-172	false
alcohol	115-121	antianxiety agents	175-192	false
alcohol	115-121	phenothiazines classes of antipsychotic agents	199-212;246-276	false
alcohol	115-121	thioxanthene classes of antipsychotic agents	215-226;246-276	false
alcohol	115-121	butyrophenone classes of antipsychotic agents	232-276	false
alcohol	115-121	monoamine oxidase inhibitors	279-306	false
alcohol	115-121	tricyclic antidepressants	316-340	false
alcohol	115-121	anticonvulsant drugs	356-375	false
narcotics	124-132	barbiturates	135-146	false
narcotics	124-132	nonbarbiturate hypnotics	149-172	false
narcotics	124-132	antianxiety agents	175-192	false
narcotics	124-132	phenothiazines classes of antipsychotic agents	199-212;246-276	false
narcotics	124-132	thioxanthene classes of antipsychotic agents	215-226;246-276	false
narcotics	124-132	butyrophenone classes of antipsychotic agents	232-276	false
narcotics	124-132	monoamine oxidase inhibitors	279-306	false
narcotics	124-132	tricyclic antidepressants	316-340	false
narcotics	124-132	anticonvulsant drugs	356-375	false
barbiturates	135-146	nonbarbiturate hypnotics	149-172	false
barbiturates	135-146	antianxiety agents	175-192	false
barbiturates	135-146	phenothiazines classes of antipsychotic agents	199-212;246-276	false
barbiturates	135-146	thioxanthene classes of antipsychotic agents	215-226;246-276	false
barbiturates	135-146	butyrophenone classes of antipsychotic agents	232-276	false
barbiturates	135-146	monoamine oxidase inhibitors	279-306	false
barbiturates	135-146	tricyclic antidepressants	316-340	false
barbiturates	135-146	anticonvulsant drugs	356-375	false
nonbarbiturate hypnotics	149-172	antianxiety agents	175-192	false
nonbarbiturate hypnotics	149-172	phenothiazines classes of antipsychotic agents	199-212;246-276	false
nonbarbiturate hypnotics	149-172	thioxanthene classes of antipsychotic agents	215-226;246-276	false
nonbarbiturate hypnotics	149-172	butyrophenone classes of antipsychotic agents	232-276	false
nonbarbiturate hypnotics	149-172	monoamine oxidase inhibitors	279-306	false
nonbarbiturate hypnotics	149-172	tricyclic antidepressants	316-340	false
nonbarbiturate hypnotics	149-172	anticonvulsant drugs	356-375	false
antianxiety agents	175-192	phenothiazines classes of antipsychotic agents	199-212;246-276	false
antianxiety agents	175-192	thioxanthene classes of antipsychotic agents	215-226;246-276	false
antianxiety agents	175-192	butyrophenone classes of antipsychotic agents	232-276	false
antianxiety agents	175-192	monoamine oxidase inhibitors	279-306	false
antianxiety agents	175-192	tricyclic antidepressants	316-340	false
antianxiety agents	175-192	anticonvulsant drugs	356-375	false
phenothiazines classes of antipsychotic agents	199-212;246-276	thioxanthene classes of antipsychotic agents	215-226;246-276	false
phenothiazines classes of antipsychotic agents	199-212;246-276	butyrophenone classes of antipsychotic agents	232-276	false
phenothiazines classes of antipsychotic agents	199-212;246-276	monoamine oxidase inhibitors	279-306	false
phenothiazines classes of antipsychotic agents	199-212;246-276	tricyclic antidepressants	316-340	false
phenothiazines classes of antipsychotic agents	199-212;246-276	anticonvulsant drugs	356-375	false
thioxanthene classes of antipsychotic agents	215-226;246-276	butyrophenone classes of antipsychotic agents	232-276	false
thioxanthene classes of antipsychotic agents	215-226;246-276	monoamine oxidase inhibitors	279-306	false
thioxanthene classes of antipsychotic agents	215-226;246-276	tricyclic antidepressants	316-340	false
thioxanthene classes of antipsychotic agents	215-226;246-276	anticonvulsant drugs	356-375	false
butyrophenone classes of antipsychotic agents	232-276	monoamine oxidase inhibitors	279-306	false
butyrophenone classes of antipsychotic agents	232-276	tricyclic antidepressants	316-340	false
butyrophenone classes of antipsychotic agents	232-276	anticonvulsant drugs	356-375	false
monoamine oxidase inhibitors	279-306	tricyclic antidepressants	316-340	false
monoamine oxidase inhibitors	279-306	anticonvulsant drugs	356-375	false
tricyclic antidepressants	316-340	anticonvulsant drugs	356-375	false

Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
clonidine hydrochloride	30-52	tricyclic antidepressants	69-93	effect
clonidine hydrochloride	30-52	clonidine	110-118	false
tricyclic antidepressants	69-93	clonidine	110-118	false

Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
Clonidine hydrochloride	0-22	alcohol	66-72	effect
Clonidine hydrochloride	0-22	barbiturates	75-86	effect
Clonidine hydrochloride	0-22	sedatives	97-105	effect
alcohol	66-72	barbiturates	75-86	false
alcohol	66-72	sedatives	97-105	false
barbiturates	75-86	sedatives	97-105	false

Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
Amitriptyline	0-12	clonidine	34-42	effect
Amitriptyline	0-12	Clonidine	117-125	false
Amitriptyline	0-12	alcohol	171-177	false
Amitriptyline	0-12	barbiturates	180-191	false
Amitriptyline	0-12	sedating drugs	202-215	false
clonidine	34-42	Clonidine	117-125	false
clonidine	34-42	alcohol	171-177	false
clonidine	34-42	barbiturates	180-191	false
clonidine	34-42	sedating drugs	202-215	false
Clonidine	117-125	alcohol	171-177	effect
Clonidine	117-125	barbiturates	180-191	effect
Clonidine	117-125	sedating drugs	202-215	effect
alcohol	171-177	barbiturates	180-191	false
alcohol	171-177	sedating drugs	202-215	false
barbiturates	180-191	sedating drugs	202-215	false

Narcotic analgesics may potentiate the hypotensive effects of clonidine.
Narcotic analgesics	0-18	clonidine	62-70	effect

Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
Tricyclic antidepressants	0-24	clonidine	68-76	effect

The effects of tricyclic antidepressants on clonidines analgesic actions are not known.
tricyclic antidepressants	15-39	clonidine	44-52	false

Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
Beta blockers	0-12	clonidine	65-73	effect

Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
clonidine	125-133	digitalis	213-221	advise
clonidine	125-133	calcium channel blockers	224-247	advise
clonidine	125-133	beta-blockers	254-266	advise
digitalis	213-221	calcium channel blockers	224-247	false
digitalis	213-221	beta-blockers	254-266	false
calcium channel blockers	224-247	beta-blockers	254-266	false

There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
fluphenazine	100-111	clonidine	122-130	effect

Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.
clonidine	23-31	clonidine	99-107	false

Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
clonidine	9-17	anesthetics	87-97	effect

Aspirin, warfarin, heparin, NSAIDs
Aspirin	0-6	warfarin	9-16	false
Aspirin	0-6	heparin	19-25	false
Aspirin	0-6	NSAIDs	28-33	false
warfarin	9-16	heparin	19-25	false
warfarin	9-16	NSAIDs	28-33	false
heparin	19-25	NSAIDs	28-33	false

Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
clorazepate dipotassium	33-55	hexobarbital	90-101	effect
clorazepate dipotassium	33-55	ethyl alcohol	112-124	effect
clorazepate dipotassium	33-55	chlorpromazine	163-176	effect
hexobarbital	90-101	ethyl alcohol	112-124	false
hexobarbital	90-101	chlorpromazine	163-176	false
ethyl alcohol	112-124	chlorpromazine	163-176	false

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
benzodiazepines	19-33	barbiturates	57-68	effect
benzodiazepines	19-33	narcotics	71-79	effect
benzodiazepines	19-33	phenothiazines	82-95	effect
benzodiazepines	19-33	monoamine oxidase inhibitors	98-125	effect
benzodiazepines	19-33	antidepressants	136-150	effect
barbiturates	57-68	narcotics	71-79	false
barbiturates	57-68	phenothiazines	82-95	false
barbiturates	57-68	monoamine oxidase inhibitors	98-125	false
barbiturates	57-68	antidepressants	136-150	false
narcotics	71-79	phenothiazines	82-95	false
narcotics	71-79	monoamine oxidase inhibitors	98-125	false
narcotics	71-79	antidepressants	136-150	false
phenothiazines	82-95	monoamine oxidase inhibitors	98-125	false
phenothiazines	82-95	antidepressants	136-150	false
monoamine oxidase inhibitors	98-125	antidepressants	136-150	false

In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.
antacids	82-89	TRANXENE	168-175	false

Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.
Clozapine	33-41	alcohol	120-126	effect

similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.
psychotropic drugs	59-76	Clozapine	86-94	false

Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
Clozapine	74-82	benzodiazepines	88-102	false
Clozapine	74-82	psychotropics	113-125	false
Clozapine	74-82	clozapine	152-160	false
Clozapine	74-82	benzodiazepine	196-209	false
Clozapine	74-82	psychotropic drug	224-240	false
benzodiazepines	88-102	psychotropics	113-125	false
benzodiazepines	88-102	clozapine	152-160	false
benzodiazepines	88-102	benzodiazepine	196-209	false
benzodiazepines	88-102	psychotropic drug	224-240	false
psychotropics	113-125	clozapine	152-160	false
psychotropics	113-125	benzodiazepine	196-209	false
psychotropics	113-125	psychotropic drug	224-240	false
clozapine	152-160	benzodiazepine	196-209	advise
clozapine	152-160	psychotropic drug	224-240	advise
benzodiazepine	196-209	psychotropic drug	224-240	false

Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
Clozapine	0-8	antihypertensive drugs	52-73	effect
Clozapine	0-8	atropine	110-117	effect
antihypertensive drugs	52-73	atropine	110-117	false

The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.
epinephrine	22-32	epinephrine	127-137	false

Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
Phenytoin	0-8	nicotine	11-18	false
Phenytoin	0-8	rifampin	25-32	false
Phenytoin	0-8	Clozapine	47-55	mechanism
Phenytoin	0-8	Clozapine	139-147	false
nicotine	11-18	rifampin	25-32	false
nicotine	11-18	Clozapine	47-55	mechanism
nicotine	11-18	Clozapine	139-147	false
rifampin	25-32	Clozapine	47-55	mechanism
rifampin	25-32	Clozapine	139-147	false
Clozapine	47-55	Clozapine	139-147	false

Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
Cimetidine	0-9	caffeine	12-19	false
Cimetidine	0-9	erythromycin	26-37	false
Cimetidine	0-9	Clozapine	69-77	mechanism
caffeine	12-19	erythromycin	26-37	false
caffeine	12-19	Clozapine	69-77	mechanism
erythromycin	26-37	Clozapine	69-77	mechanism

Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
Clozapine	28-36	carbamazepine	42-54	advise
Clozapine	28-36	carbamazepine	131-143	false
Clozapine	28-36	Clozapine	189-197	false
carbamazepine	42-54	carbamazepine	131-143	false
carbamazepine	42-54	Clozapine	189-197	false
carbamazepine	131-143	Clozapine	189-197	mechanism

In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.
clozapine	50-58	fluvoxamine	91-101	false
clozapine	50-58	paroxetine	106-115	false
fluvoxamine	91-101	paroxetine	106-115	false

After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
clozapine	66-74	N-desmethylclozapine	97-116	false
clozapine	66-74	clozapine N-oxide	122-138	false
clozapine	66-74	fluvoxamine	160-170	false
N-desmethylclozapine	97-116	clozapine N-oxide	122-138	false
N-desmethylclozapine	97-116	fluvoxamine	160-170	false
clozapine N-oxide	122-138	fluvoxamine	160-170	false

Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
Paroxetine	0-9	clozapine	56-64	mechanism

However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
clozapine	84-92	clozapine	129-137	false
clozapine	84-92	paroxetine	154-163	false
clozapine	84-92	fluoxetine	166-175	false
clozapine	84-92	sertraline	182-191	false
clozapine	129-137	paroxetine	154-163	mechanism
clozapine	129-137	fluoxetine	166-175	mechanism
clozapine	129-137	sertraline	182-191	mechanism
paroxetine	154-163	fluoxetine	166-175	false
paroxetine	154-163	sertraline	182-191	false
fluoxetine	166-175	sertraline	182-191	false

Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
Clozapine	115-123	fluvoxamine	173-183	advise

Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.
debrisoquin	71-81	dextromethorphan	84-99	false
debrisoquin	71-81	tricyclic antidepressants	106-130	false
debrisoquin	71-81	clozapine	137-145	false
dextromethorphan	84-99	tricyclic antidepressants	106-130	false
dextromethorphan	84-99	clozapine	137-145	false
tricyclic antidepressants	106-130	clozapine	137-145	false

In addition, certain drugs that are metabolized by this isozyme, including many antidepressants (clozapine, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.
antidepressants	80-94	clozapine	97-105	false
antidepressants	80-94	selective serotonin reuptake inhibitors	108-146	false
clozapine	97-105	selective serotonin reuptake inhibitors	108-146	false

Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug.
clozapine	19-27	clozapine	140-148	false

Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
clozapine	32-40	antidepressants	107-121	advise
clozapine	32-40	phenothiazines	124-137	advise
clozapine	32-40	carbamazepine	140-152	advise
clozapine	32-40	Type 1C antiarrhythmics	159-181	advise
clozapine	32-40	propafenone	190-200	advise
clozapine	32-40	flecainide	203-212	advise
clozapine	32-40	encainide	218-226	advise
clozapine	32-40	quinidine	265-273	advise
antidepressants	107-121	phenothiazines	124-137	false
antidepressants	107-121	carbamazepine	140-152	false
antidepressants	107-121	Type 1C antiarrhythmics	159-181	false
antidepressants	107-121	propafenone	190-200	false
antidepressants	107-121	flecainide	203-212	false
antidepressants	107-121	encainide	218-226	false
antidepressants	107-121	quinidine	265-273	false
phenothiazines	124-137	carbamazepine	140-152	false
phenothiazines	124-137	Type 1C antiarrhythmics	159-181	false
phenothiazines	124-137	propafenone	190-200	false
phenothiazines	124-137	flecainide	203-212	false
phenothiazines	124-137	encainide	218-226	false
phenothiazines	124-137	quinidine	265-273	false
carbamazepine	140-152	Type 1C antiarrhythmics	159-181	false
carbamazepine	140-152	propafenone	190-200	false
carbamazepine	140-152	flecainide	203-212	false
carbamazepine	140-152	encainide	218-226	false
carbamazepine	140-152	quinidine	265-273	false
Type 1C antiarrhythmics	159-181	propafenone	190-200	false
Type 1C antiarrhythmics	159-181	flecainide	203-212	false
Type 1C antiarrhythmics	159-181	encainide	218-226	false
Type 1C antiarrhythmics	159-181	quinidine	265-273	false
propafenone	190-200	flecainide	203-212	false
propafenone	190-200	encainide	218-226	false
propafenone	190-200	quinidine	265-273	false
flecainide	203-212	encainide	218-226	false
flecainide	203-212	quinidine	265-273	false
encainide	218-226	quinidine	265-273	false

The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.
NovoSeven	44-52	coagulation factor	58-75	false

Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.
activated prothrombin complex concentrates	20-61	prothrombin complex concentrates	66-97	false

Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
tranexamic acid	170-184	aminocaproic acid	187-203	false
tranexamic acid	170-184	NovoSeven	210-218	false
aminocaproic acid	187-203	NovoSeven	210-218	false

Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
Codeine	0-6	narcotic analgesics	34-52	effect
Codeine	0-6	anesthetics	63-73	effect
Codeine	0-6	phenothiazines	76-89	effect
Codeine	0-6	tranquilizers	92-104	effect
Codeine	0-6	sedative-hypnotics	107-124	effect
Codeine	0-6	CNS depressants	136-150	effect
Codeine	0-6	alcohol	163-169	effect
narcotic analgesics	34-52	anesthetics	63-73	false
narcotic analgesics	34-52	phenothiazines	76-89	false
narcotic analgesics	34-52	tranquilizers	92-104	false
narcotic analgesics	34-52	sedative-hypnotics	107-124	false
narcotic analgesics	34-52	CNS depressants	136-150	false
narcotic analgesics	34-52	alcohol	163-169	false
anesthetics	63-73	phenothiazines	76-89	false
anesthetics	63-73	tranquilizers	92-104	false
anesthetics	63-73	sedative-hypnotics	107-124	false
anesthetics	63-73	CNS depressants	136-150	false
anesthetics	63-73	alcohol	163-169	false
phenothiazines	76-89	tranquilizers	92-104	false
phenothiazines	76-89	sedative-hypnotics	107-124	false
phenothiazines	76-89	CNS depressants	136-150	false
phenothiazines	76-89	alcohol	163-169	false
tranquilizers	92-104	sedative-hypnotics	107-124	false
tranquilizers	92-104	CNS depressants	136-150	false
tranquilizers	92-104	alcohol	163-169	false
sedative-hypnotics	107-124	CNS depressants	136-150	false
sedative-hypnotics	107-124	alcohol	163-169	false
CNS depressants	136-150	alcohol	163-169	false

Colchicine is inhibited by acidifying agents.
Colchicine	0-9	acidifying agents	27-43	mechanism

The action of colchicine is potentiated by alkalinizing agents.
colchicine	14-23	alkalinizing agents	43-61	mechanism

Colchicine may increase sensitivity to the CNS depressants.
Colchicine	0-9	CNS depressants	43-57	effect

Response to sympathomimetic agents may be enhanced by colchicine.
sympathomimetic agents	12-33	colchicine	54-63	effect

WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
WelChol	0-6	digoxin	75-81	false
WelChol	0-6	lovastatin	84-93	false
WelChol	0-6	metoprolol	96-105	false
WelChol	0-6	quinidine	108-116	false
WelChol	0-6	valproic acid	119-131	false
WelChol	0-6	warfarin	138-145	false
digoxin	75-81	lovastatin	84-93	false
digoxin	75-81	metoprolol	96-105	false
digoxin	75-81	quinidine	108-116	false
digoxin	75-81	valproic acid	119-131	false
digoxin	75-81	warfarin	138-145	false
lovastatin	84-93	metoprolol	96-105	false
lovastatin	84-93	quinidine	108-116	false
lovastatin	84-93	valproic acid	119-131	false
lovastatin	84-93	warfarin	138-145	false
metoprolol	96-105	quinidine	108-116	false
metoprolol	96-105	valproic acid	119-131	false
metoprolol	96-105	warfarin	138-145	false
quinidine	108-116	valproic acid	119-131	false
quinidine	108-116	warfarin	138-145	false
valproic acid	119-131	warfarin	138-145	false

WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
WelChol	0-6	verapamil	57-65	mechanism
WelChol	0-6	Calan SR	68-75	mechanism
verapamil	57-65	Calan SR	68-75	false

In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
WelChol	41-47	atorvastatin	55-66	false
WelChol	41-47	lovastatin	69-78	false
WelChol	41-47	simvastatin	84-94	false
WelChol	41-47	HMG-CoA reductase inhibitor	154-180	false
atorvastatin	55-66	lovastatin	69-78	false
atorvastatin	55-66	simvastatin	84-94	false
atorvastatin	55-66	HMG-CoA reductase inhibitor	154-180	false
lovastatin	69-78	simvastatin	84-94	false
lovastatin	69-78	HMG-CoA reductase inhibitor	154-180	false
simvastatin	84-94	HMG-CoA reductase inhibitor	154-180	false

Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids.
colestipol hydrochloride	6-29	anion exchange resin	37-56	false

Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
colestipol hydrochloride	18-41	propranolol	75-85	mechanism
colestipol hydrochloride	18-41	propranolol	134-144	false
propranolol	75-85	propranolol	134-144	false

However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;
colestipol hydrochloride	80-103	propranolol	109-119	false
colestipol hydrochloride	80-103	propranolol	207-217	false
propranolol	109-119	propranolol	207-217	false

Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
propranolol	23-33	COLESTID	59-66	advise

Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
chlorothiazide	46-59	colestipol hydrochloride	156-179	mechanism

The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
tetracycline	18-29	furosemide	32-41	false
tetracycline	18-29	penicillin G	44-55	false
tetracycline	18-29	hydrochlorothiazide	58-76	false
tetracycline	18-29	gemfibrozil	83-93	false
tetracycline	18-29	colestipol hydrochloride	154-177	mechanism
furosemide	32-41	penicillin G	44-55	false
furosemide	32-41	hydrochlorothiazide	58-76	false
furosemide	32-41	gemfibrozil	83-93	false
furosemide	32-41	colestipol hydrochloride	154-177	mechanism
penicillin G	44-55	hydrochlorothiazide	58-76	false
penicillin G	44-55	gemfibrozil	83-93	false
penicillin G	44-55	colestipol hydrochloride	154-177	mechanism
hydrochlorothiazide	58-76	gemfibrozil	83-93	false
hydrochlorothiazide	58-76	colestipol hydrochloride	154-177	mechanism
gemfibrozil	83-93	colestipol hydrochloride	154-177	mechanism

No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
colestipol hydrochloride	62-85	aspirin	137-143	false
colestipol hydrochloride	62-85	clindamycin	146-156	false
colestipol hydrochloride	62-85	clofibrate	159-168	false
colestipol hydrochloride	62-85	methyldopa	171-180	false
colestipol hydrochloride	62-85	nicotinic acid	183-196	false
colestipol hydrochloride	62-85	niacin	199-204	false
colestipol hydrochloride	62-85	tolbutamide	208-218	false
colestipol hydrochloride	62-85	phenytoin	221-229	false
colestipol hydrochloride	62-85	warfarin	234-241	false
aspirin	137-143	clindamycin	146-156	false
aspirin	137-143	clofibrate	159-168	false
aspirin	137-143	methyldopa	171-180	false
aspirin	137-143	nicotinic acid	183-196	false
aspirin	137-143	niacin	199-204	false
aspirin	137-143	tolbutamide	208-218	false
aspirin	137-143	phenytoin	221-229	false
aspirin	137-143	warfarin	234-241	false
clindamycin	146-156	clofibrate	159-168	false
clindamycin	146-156	methyldopa	171-180	false
clindamycin	146-156	nicotinic acid	183-196	false
clindamycin	146-156	niacin	199-204	false
clindamycin	146-156	tolbutamide	208-218	false
clindamycin	146-156	phenytoin	221-229	false
clindamycin	146-156	warfarin	234-241	false
clofibrate	159-168	methyldopa	171-180	false
clofibrate	159-168	nicotinic acid	183-196	false
clofibrate	159-168	niacin	199-204	false
clofibrate	159-168	tolbutamide	208-218	false
clofibrate	159-168	phenytoin	221-229	false
clofibrate	159-168	warfarin	234-241	false
methyldopa	171-180	nicotinic acid	183-196	false
methyldopa	171-180	niacin	199-204	false
methyldopa	171-180	tolbutamide	208-218	false
methyldopa	171-180	phenytoin	221-229	false
methyldopa	171-180	warfarin	234-241	false
nicotinic acid	183-196	niacin	199-204	false
nicotinic acid	183-196	tolbutamide	208-218	false
nicotinic acid	183-196	phenytoin	221-229	false
nicotinic acid	183-196	warfarin	234-241	false
niacin	199-204	tolbutamide	208-218	false
niacin	199-204	phenytoin	221-229	false
niacin	199-204	warfarin	234-241	false
tolbutamide	208-218	phenytoin	221-229	false
tolbutamide	208-218	warfarin	234-241	false
phenytoin	221-229	warfarin	234-241	false

Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
digitalis preparations	43-64	colestipol hydrochloride	120-143	effect
digitalis preparations	43-64	digoxin	168-174	false
digitalis preparations	43-64	digitoxin	180-188	false
colestipol hydrochloride	120-143	digoxin	168-174	mechanism
colestipol hydrochloride	120-143	digitoxin	180-188	mechanism
digoxin	168-174	digitoxin	180-188	false

Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.
colestipol hydrochloride	14-37	resin	132-136	false
colestipol hydrochloride	14-37	colestipol hydrochloride	208-231	false
resin	132-136	colestipol hydrochloride	208-231	false

Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
Bile acid binding resins	0-23	phosphate	72-80	mechanism
Bile acid binding resins	0-23	hydrocortisone	98-111	mechanism
phosphate	72-80	hydrocortisone	98-111	false

Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.
antibiotics	14-24	aminoglycosides	27-41	false
antibiotics	14-24	polymyxin	47-55	false
aminoglycosides	27-41	polymyxin	47-55	false

Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
Curariform muscle relaxants	0-26	tubocurarine	33-44	false
Curariform muscle relaxants	0-26	succinylcholine	81-95	false
Curariform muscle relaxants	0-26	gallamine	98-106	false
Curariform muscle relaxants	0-26	decamethonium	109-121	false
Curariform muscle relaxants	0-26	sodium citrate	127-140	false
Curariform muscle relaxants	0-26	Coly-Mycin M	259-270	effect
tubocurarine	33-44	succinylcholine	81-95	false
tubocurarine	33-44	gallamine	98-106	false
tubocurarine	33-44	decamethonium	109-121	false
tubocurarine	33-44	sodium citrate	127-140	false
tubocurarine	33-44	Coly-Mycin M	259-270	effect
succinylcholine	81-95	gallamine	98-106	false
succinylcholine	81-95	decamethonium	109-121	false
succinylcholine	81-95	sodium citrate	127-140	false
succinylcholine	81-95	Coly-Mycin M	259-270	effect
gallamine	98-106	decamethonium	109-121	false
gallamine	98-106	sodium citrate	127-140	false
gallamine	98-106	Coly-Mycin M	259-270	effect
decamethonium	109-121	sodium citrate	127-140	false
decamethonium	109-121	Coly-Mycin M	259-270	effect
sodium citrate	127-140	Coly-Mycin M	259-270	effect

Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
Sodium cephalothin	0-17	Coly-Mycin M	53-64	effect

The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
sodium cephalothin	23-40	Coly-Mycin M	46-57	advise

Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
Digoxin	0-6	digoxin	29-35	false
Digoxin	0-6	conivaptan	76-85	false
Digoxin	0-6	digoxin	143-149	false
digoxin	29-35	conivaptan	76-85	mechanism
digoxin	29-35	digoxin	143-149	false
conivaptan	76-85	digoxin	143-149	false

Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
digoxin	14-20	VAPRISOL	43-50	mechanism
digoxin	14-20	digoxin	118-124	false
VAPRISOL	43-50	digoxin	118-124	false

decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;
antithrombin III	39-54	antithrombin III	67-82	false

increased levels of fibrinogen and fibrinogen activity;
fibrinogen	20-29	fibrinogen	35-44	false

Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively.
corticosteroids	171-185	sex steroids	191-202	false

Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
Corticotropin	0-12	diuretic	66-73	effect

Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
phenobarbital	42-54	phenytoin	57-65	false
phenobarbital	42-54	rifampin	71-78	false
phenobarbital	42-54	corticosteroids	110-124	mechanism
phenobarbital	42-54	corticosteroid	155-168	advise
phenytoin	57-65	rifampin	71-78	false
phenytoin	57-65	corticosteroids	110-124	mechanism
phenytoin	57-65	corticosteroid	155-168	advise
rifampin	71-78	corticosteroids	110-124	mechanism
rifampin	71-78	corticosteroid	155-168	advise
corticosteroids	110-124	corticosteroid	155-168	false

Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
troleandomycin	14-27	ketoconazole	33-44	false
troleandomycin	14-27	corticosteroids	76-90	mechanism
ketoconazole	33-44	corticosteroids	76-90	mechanism

Corticosteroids may increase the clearance of chronic high dose aspirin.
Corticosteroids	0-14	aspirin	64-70	effect

This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
salicylate	29-38	salicylate	77-86	false
salicylate	29-38	corticosteroid	102-115	false
salicylate	77-86	corticosteroid	102-115	effect

Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
Aspirin	0-6	cortico-steroids	54-69	advise

The effect of corticosteroids on oral anticoagulants is variable.
corticosteroids	14-28	anticoagulants	38-51	effect

There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
anticoagulants	63-76	corticosteroids	107-121	effect

Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
Corticotropin	0-12	diuretic	66-73	effect

Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.
Cromolyn sodium	35-49	isoproterenol	55-67	false

The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
cromolyn sodium	33-47	isoproterenol	168-180	effect

Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.
antibiotics	20-30	methotrexate	33-44	false
antibiotics	20-30	pyrimethamine	50-62	false
antibiotics	20-30	folic acid	75-84	false
antibiotics	20-30	vitamin B12	90-100	false
methotrexate	33-44	pyrimethamine	50-62	false
methotrexate	33-44	folic acid	75-84	false
methotrexate	33-44	vitamin B12	90-100	false
pyrimethamine	50-62	folic acid	75-84	false
pyrimethamine	50-62	vitamin B12	90-100	false
folic acid	75-84	vitamin B12	90-100	false

Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
Colchicine	0-9	para-aminosalicylic acid	11-34	false
Colchicine	0-9	alcohol	46-52	false
Colchicine	0-9	vitamin B12	114-124	mechanism
para-aminosalicylic acid	11-34	alcohol	46-52	false
para-aminosalicylic acid	11-34	vitamin B12	114-124	mechanism
alcohol	46-52	vitamin B12	114-124	mechanism

FLEXERIL may have life-threatening interactions with MAO inhibitors.
FLEXERIL	0-7	MAO inhibitors	53-66	int

FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
FLEXERIL	0-7	alcohol	36-42	effect
FLEXERIL	0-7	barbiturates	45-56	effect
FLEXERIL	0-7	CNS depressants	69-83	effect
alcohol	36-42	barbiturates	45-56	false
alcohol	36-42	CNS depressants	69-83	false
barbiturates	45-56	CNS depressants	69-83	false

Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
Tricyclic antidepressants	0-24	guanethidine	67-78	effect

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
Tricyclic antidepressants	0-24	tramadol	74-81	effect

Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
Cyclopentolate	0-13	carbachol	62-70	effect
Cyclopentolate	0-13	pilocarpine	75-85	effect
carbachol	62-70	pilocarpine	75-85	false

The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
cyclophosphamide	54-69	phenobarbital	139-151	mechanism

The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
cyclophosphamide	102-117	cyclophosphamide	131-146	false

Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
Cyclophosphamide	0-15	succinylcholine chloride	130-153	effect

May interact with wthionamide (Trecator-SC) and isoniazid (Nydrazid).
Trecator-SC	31-41	isoniazid	48-56	false
Trecator-SC	31-41	Nydrazid	59-66	false
isoniazid	48-56	Nydrazid	59-66	false

MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
MAO inhibitors	0-13	antihistamines	68-81	effect

Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
Antihistamines	0-13	alcohol	46-52	effect
Antihistamines	0-13	CNS depressants	64-78	effect
Antihistamines	0-13	hypnotics	87-95	effect
Antihistamines	0-13	sedatives	98-106	effect
Antihistamines	0-13	tranquilizers	109-121	effect
Antihistamines	0-13	antianxiety agents	124-141	effect
alcohol	46-52	CNS depressants	64-78	false
alcohol	46-52	hypnotics	87-95	false
alcohol	46-52	sedatives	98-106	false
alcohol	46-52	tranquilizers	109-121	false
alcohol	46-52	antianxiety agents	124-141	false
CNS depressants	64-78	hypnotics	87-95	false
CNS depressants	64-78	sedatives	98-106	false
CNS depressants	64-78	tranquilizers	109-121	false
CNS depressants	64-78	antianxiety agents	124-141	false
hypnotics	87-95	sedatives	98-106	false
hypnotics	87-95	tranquilizers	109-121	false
hypnotics	87-95	antianxiety agents	124-141	false
sedatives	98-106	tranquilizers	109-121	false
sedatives	98-106	antianxiety agents	124-141	false
tranquilizers	109-121	antianxiety agents	124-141	false

Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.
Dactinomycin	33-44	antibacterial drug	110-127	false

However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.
phenobarbital	17-29	diazepam	35-42	false
phenobarbital	17-29	Dantrium	62-69	false
diazepam	35-42	Dantrium	62-69	false

Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.
diazepam	58-65	diphenylhydantoin	68-84	false
diazepam	58-65	phenylbutazone	90-103	false
diphenylhydantoin	68-84	phenylbutazone	90-103	false

Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide.
warfarin	41-48	tolbutamide	82-92	false

The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.
dantrolene sodium	52-68	verapamil	74-82	false
dantrolene sodium	52-68	halothane	87-95	false
verapamil	74-82	halothane	87-95	false

It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
dantrolene sodium	54-70	calcium channel blockers	76-99	advise
dantrolene sodium	54-70	verapamil	110-118	advise
calcium channel blockers	76-99	verapamil	110-118	false

Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
dantrolene	18-27	vecuronium	44-53	effect

A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX).
ACZONE	65-70	trimethoprim	133-144	false
ACZONE	65-70	sulfamethoxazole	146-161	false
ACZONE	65-70	TMP	164-166	false
ACZONE	65-70	SMX	168-170	false
trimethoprim	133-144	sulfamethoxazole	146-161	false
trimethoprim	133-144	TMP	164-166	false
trimethoprim	133-144	SMX	168-170	false
sulfamethoxazole	146-161	TMP	164-166	false
sulfamethoxazole	146-161	SMX	168-170	false
TMP	164-166	SMX	168-170	false

During co-administration, systemic levels of TMP and SMX were essentially unchanged.
TMP	45-47	SMX	53-55	false

Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX.
dapsone hydroxylamine	40-60	DHA	63-65	false
dapsone hydroxylamine	40-60	TMP	109-111	false
dapsone hydroxylamine	40-60	SMX	113-115	false
DHA	63-65	TMP	109-111	false
DHA	63-65	SMX	113-115	false
TMP	109-111	SMX	113-115	false

Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.
TMP	118-120	SMX	122-124	false

Certain concomitant medications (such as rifampin, anticonvulsants, St.
rifampin	41-48	anticonvulsants	51-65	false

John s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis.
dapsone hydroxylamine	43-63	dapsone	82-88	false

With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
dapsone	10-16	folic acid antagonists	29-50	effect
dapsone	10-16	pyrimethamine	60-72	effect
folic acid antagonists	29-50	pyrimethamine	60-72	false

Warfarin: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.
Warfarin	0-7	daptomycin	40-49	false
Warfarin	0-7	warfarin	96-103	false
daptomycin	40-49	warfarin	96-103	false

HMG-CoA Reductase Inhibitors: Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.
HMG-CoA Reductase Inhibitors	0-27	Inhibitors of HMG-CoA reductase	30-60	false

There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.
simvastatin	120-130	daptomycin	171-180	false

Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
HMG-CoA reductase inhibitors	37-64	Fentanyl	70-77	false
HMG-CoA reductase inhibitors	37-64	HMG-CoA reductase inhibitors	175-202	false
HMG-CoA reductase inhibitors	37-64	Fentanyl	226-233	false
Fentanyl	70-77	HMG-CoA reductase inhibitors	175-202	false
Fentanyl	70-77	Fentanyl	226-233	false
HMG-CoA reductase inhibitors	175-202	Fentanyl	226-233	advise

The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
ENABLEX	18-24	ketoconazole	108-119	advise
ENABLEX	18-24	itraconazole	122-133	advise
ENABLEX	18-24	ritonavir	136-144	advise
ENABLEX	18-24	nelfinavir	147-156	advise
ENABLEX	18-24	clarithromycin	159-172	advise
ketoconazole	108-119	itraconazole	122-133	false
ketoconazole	108-119	ritonavir	136-144	false
ketoconazole	108-119	nelfinavir	147-156	false
ketoconazole	108-119	clarithromycin	159-172	false
itraconazole	122-133	ritonavir	136-144	false
itraconazole	122-133	nelfinavir	147-156	false
itraconazole	122-133	clarithromycin	159-172	false
ritonavir	136-144	nelfinavir	147-156	false
ritonavir	136-144	clarithromycin	159-172	false
nelfinavir	147-156	clarithromycin	159-172	false

Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
ENABLEX	29-35	flecainide	173-182	advise
ENABLEX	29-35	thioridazine	185-196	advise
ENABLEX	29-35	tricyclic antidepressants	202-226	advise
flecainide	173-182	thioridazine	185-196	false
flecainide	173-182	tricyclic antidepressants	202-226	false
thioridazine	185-196	tricyclic antidepressants	202-226	false

The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
ENABLEX	23-29	anticholinergic agents	42-63	effect

Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.
dasatinib	24-32	Dasatinib	75-83	false

Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
SPRYCEL	19-25	ketoconazole	62-73	mechanism
SPRYCEL	19-25	itraconazole	76-87	mechanism
SPRYCEL	19-25	erythromycin	90-101	mechanism
SPRYCEL	19-25	clarithromycin	104-117	mechanism
SPRYCEL	19-25	ritonavir	120-128	mechanism
SPRYCEL	19-25	atazanavir	131-140	mechanism
SPRYCEL	19-25	indinavir	143-151	mechanism
SPRYCEL	19-25	nefazodone	154-163	mechanism
SPRYCEL	19-25	nelfinavir	166-175	mechanism
SPRYCEL	19-25	saquinavir	178-187	mechanism
SPRYCEL	19-25	telithromycin	190-202	mechanism
SPRYCEL	19-25	dasatinib	230-238	false
ketoconazole	62-73	itraconazole	76-87	false
ketoconazole	62-73	erythromycin	90-101	false
ketoconazole	62-73	clarithromycin	104-117	false
ketoconazole	62-73	ritonavir	120-128	false
ketoconazole	62-73	atazanavir	131-140	false
ketoconazole	62-73	indinavir	143-151	false
ketoconazole	62-73	nefazodone	154-163	false
ketoconazole	62-73	nelfinavir	166-175	false
ketoconazole	62-73	saquinavir	178-187	false
ketoconazole	62-73	telithromycin	190-202	false
ketoconazole	62-73	dasatinib	230-238	false
itraconazole	76-87	erythromycin	90-101	false
itraconazole	76-87	clarithromycin	104-117	false
itraconazole	76-87	ritonavir	120-128	false
itraconazole	76-87	atazanavir	131-140	false
itraconazole	76-87	indinavir	143-151	false
itraconazole	76-87	nefazodone	154-163	false
itraconazole	76-87	nelfinavir	166-175	false
itraconazole	76-87	saquinavir	178-187	false
itraconazole	76-87	telithromycin	190-202	false
itraconazole	76-87	dasatinib	230-238	false
erythromycin	90-101	clarithromycin	104-117	false
erythromycin	90-101	ritonavir	120-128	false
erythromycin	90-101	atazanavir	131-140	false
erythromycin	90-101	indinavir	143-151	false
erythromycin	90-101	nefazodone	154-163	false
erythromycin	90-101	nelfinavir	166-175	false
erythromycin	90-101	saquinavir	178-187	false
erythromycin	90-101	telithromycin	190-202	false
erythromycin	90-101	dasatinib	230-238	false
clarithromycin	104-117	ritonavir	120-128	false
clarithromycin	104-117	atazanavir	131-140	false
clarithromycin	104-117	indinavir	143-151	false
clarithromycin	104-117	nefazodone	154-163	false
clarithromycin	104-117	nelfinavir	166-175	false
clarithromycin	104-117	saquinavir	178-187	false
clarithromycin	104-117	telithromycin	190-202	false
clarithromycin	104-117	dasatinib	230-238	false
ritonavir	120-128	atazanavir	131-140	false
ritonavir	120-128	indinavir	143-151	false
ritonavir	120-128	nefazodone	154-163	false
ritonavir	120-128	nelfinavir	166-175	false
ritonavir	120-128	saquinavir	178-187	false
ritonavir	120-128	telithromycin	190-202	false
ritonavir	120-128	dasatinib	230-238	false
atazanavir	131-140	indinavir	143-151	false
atazanavir	131-140	nefazodone	154-163	false
atazanavir	131-140	nelfinavir	166-175	false
atazanavir	131-140	saquinavir	178-187	false
atazanavir	131-140	telithromycin	190-202	false
atazanavir	131-140	dasatinib	230-238	false
indinavir	143-151	nefazodone	154-163	false
indinavir	143-151	nelfinavir	166-175	false
indinavir	143-151	saquinavir	178-187	false
indinavir	143-151	telithromycin	190-202	false
indinavir	143-151	dasatinib	230-238	false
nefazodone	154-163	nelfinavir	166-175	false
nefazodone	154-163	saquinavir	178-187	false
nefazodone	154-163	telithromycin	190-202	false
nefazodone	154-163	dasatinib	230-238	false
nelfinavir	166-175	saquinavir	178-187	false
nelfinavir	166-175	telithromycin	190-202	false
nelfinavir	166-175	dasatinib	230-238	false
saquinavir	178-187	telithromycin	190-202	false
saquinavir	178-187	dasatinib	230-238	false
telithromycin	190-202	dasatinib	230-238	false

In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.
SPRYCEL	37-43	SPRYCEL	82-88	false

Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.
dasatinib	24-32	dasatinib	120-128	false

In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
dexamethasone	41-53	phenytoin	56-64	false
dexamethasone	41-53	carbamazepine	67-79	false
dexamethasone	41-53	rifampicin	82-91	false
dexamethasone	41-53	phenobarbital	94-106	false
phenytoin	56-64	carbamazepine	67-79	false
phenytoin	56-64	rifampicin	82-91	false
phenytoin	56-64	phenobarbital	94-106	false
carbamazepine	67-79	rifampicin	82-91	false
carbamazepine	67-79	phenobarbital	94-106	false
rifampicin	82-91	phenobarbital	94-106	false

If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.
SPRYCEL	3-9	SPRYCEL	74-80	false

Antacids: Nonclinical data demonstrate that the solubility of dasatinib is pH dependent.
Antacids	0-7	dasatinib	62-70	false

Simultaneous administration of SPRYCEL with antacids should be avoided.
SPRYCEL	31-37	antacids	44-51	advise

If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
antacid	3-9	SPRYCEL	125-131	advise

H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
H2 Blockers	0-10	Proton Pump Inhibitors	12-33	false
H2 Blockers	0-10	H2 blockers	87-97	false
H2 Blockers	0-10	proton pump inhibitors	102-123	false
H2 Blockers	0-10	famotidine	130-139	false
H2 Blockers	0-10	omeprazole	145-154	false
H2 Blockers	0-10	dasatinib	177-185	false
Proton Pump Inhibitors	12-33	H2 blockers	87-97	false
Proton Pump Inhibitors	12-33	proton pump inhibitors	102-123	false
Proton Pump Inhibitors	12-33	famotidine	130-139	false
Proton Pump Inhibitors	12-33	omeprazole	145-154	false
Proton Pump Inhibitors	12-33	dasatinib	177-185	false
H2 blockers	87-97	proton pump inhibitors	102-123	false
H2 blockers	87-97	famotidine	130-139	false
H2 blockers	87-97	omeprazole	145-154	false
H2 blockers	87-97	dasatinib	177-185	effect
proton pump inhibitors	102-123	famotidine	130-139	false
proton pump inhibitors	102-123	omeprazole	145-154	false
proton pump inhibitors	102-123	dasatinib	177-185	effect
famotidine	130-139	omeprazole	145-154	false
famotidine	130-139	dasatinib	177-185	effect
omeprazole	145-154	dasatinib	177-185	effect

The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
H2 blockers	23-33	proton pump inhibitors	38-59	false
H2 blockers	23-33	SPRYCEL	66-72	advise
proton pump inhibitors	38-59	SPRYCEL	66-72	advise

The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
antacids	11-18	H2 blockers	53-63	false
antacids	11-18	proton pump inhibitors	68-89	false
antacids	11-18	SPRYCEL	113-119	false
H2 blockers	53-63	proton pump inhibitors	68-89	false
H2 blockers	53-63	SPRYCEL	113-119	advise
proton pump inhibitors	68-89	SPRYCEL	113-119	advise

Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.
dasatinib	58-66	Dasatinib	87-95	false

Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
alfentanil	78-87	astemizole	90-99	false
alfentanil	78-87	terfenadine	102-112	false
alfentanil	78-87	cisapride	115-123	false
alfentanil	78-87	cyclosporine	126-137	false
alfentanil	78-87	fentanyl	140-147	false
alfentanil	78-87	pimozide	150-157	false
alfentanil	78-87	quinidine	160-168	false
alfentanil	78-87	sirolimus	171-179	false
alfentanil	78-87	tacrolimus	182-191	false
alfentanil	78-87	ergot alkaloids	197-211	false
alfentanil	78-87	ergotamine	214-223	false
alfentanil	78-87	dihydroergotamine	226-242	false
alfentanil	78-87	SPRYCEL	303-309	advise
astemizole	90-99	terfenadine	102-112	false
astemizole	90-99	cisapride	115-123	false
astemizole	90-99	cyclosporine	126-137	false
astemizole	90-99	fentanyl	140-147	false
astemizole	90-99	pimozide	150-157	false
astemizole	90-99	quinidine	160-168	false
astemizole	90-99	sirolimus	171-179	false
astemizole	90-99	tacrolimus	182-191	false
astemizole	90-99	ergot alkaloids	197-211	false
astemizole	90-99	ergotamine	214-223	false
astemizole	90-99	dihydroergotamine	226-242	false
astemizole	90-99	SPRYCEL	303-309	advise
terfenadine	102-112	cisapride	115-123	false
terfenadine	102-112	cyclosporine	126-137	false
terfenadine	102-112	fentanyl	140-147	false
terfenadine	102-112	pimozide	150-157	false
terfenadine	102-112	quinidine	160-168	false
terfenadine	102-112	sirolimus	171-179	false
terfenadine	102-112	tacrolimus	182-191	false
terfenadine	102-112	ergot alkaloids	197-211	false
terfenadine	102-112	ergotamine	214-223	false
terfenadine	102-112	dihydroergotamine	226-242	false
terfenadine	102-112	SPRYCEL	303-309	advise
cisapride	115-123	cyclosporine	126-137	false
cisapride	115-123	fentanyl	140-147	false
cisapride	115-123	pimozide	150-157	false
cisapride	115-123	quinidine	160-168	false
cisapride	115-123	sirolimus	171-179	false
cisapride	115-123	tacrolimus	182-191	false
cisapride	115-123	ergot alkaloids	197-211	false
cisapride	115-123	ergotamine	214-223	false
cisapride	115-123	dihydroergotamine	226-242	false
cisapride	115-123	SPRYCEL	303-309	advise
cyclosporine	126-137	fentanyl	140-147	false
cyclosporine	126-137	pimozide	150-157	false
cyclosporine	126-137	quinidine	160-168	false
cyclosporine	126-137	sirolimus	171-179	false
cyclosporine	126-137	tacrolimus	182-191	false
cyclosporine	126-137	ergot alkaloids	197-211	false
cyclosporine	126-137	ergotamine	214-223	false
cyclosporine	126-137	dihydroergotamine	226-242	false
cyclosporine	126-137	SPRYCEL	303-309	advise
fentanyl	140-147	pimozide	150-157	false
fentanyl	140-147	quinidine	160-168	false
fentanyl	140-147	sirolimus	171-179	false
fentanyl	140-147	tacrolimus	182-191	false
fentanyl	140-147	ergot alkaloids	197-211	false
fentanyl	140-147	ergotamine	214-223	false
fentanyl	140-147	dihydroergotamine	226-242	false
fentanyl	140-147	SPRYCEL	303-309	advise
pimozide	150-157	quinidine	160-168	false
pimozide	150-157	sirolimus	171-179	false
pimozide	150-157	tacrolimus	182-191	false
pimozide	150-157	ergot alkaloids	197-211	false
pimozide	150-157	ergotamine	214-223	false
pimozide	150-157	dihydroergotamine	226-242	false
pimozide	150-157	SPRYCEL	303-309	advise
quinidine	160-168	sirolimus	171-179	false
quinidine	160-168	tacrolimus	182-191	false
quinidine	160-168	ergot alkaloids	197-211	false
quinidine	160-168	ergotamine	214-223	false
quinidine	160-168	dihydroergotamine	226-242	false
quinidine	160-168	SPRYCEL	303-309	advise
sirolimus	171-179	tacrolimus	182-191	false
sirolimus	171-179	ergot alkaloids	197-211	false
sirolimus	171-179	ergotamine	214-223	false
sirolimus	171-179	dihydroergotamine	226-242	false
sirolimus	171-179	SPRYCEL	303-309	advise
tacrolimus	182-191	ergot alkaloids	197-211	false
tacrolimus	182-191	ergotamine	214-223	false
tacrolimus	182-191	dihydroergotamine	226-242	false
tacrolimus	182-191	SPRYCEL	303-309	advise
ergot alkaloids	197-211	ergotamine	214-223	false
ergot alkaloids	197-211	dihydroergotamine	226-242	false
ergot alkaloids	197-211	SPRYCEL	303-309	advise
ergotamine	214-223	dihydroergotamine	226-242	false
ergotamine	214-223	SPRYCEL	303-309	advise
dihydroergotamine	226-242	SPRYCEL	303-309	advise

Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
Cerubidine	7-16	doxorubicin	59-69	effect

Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
Cerubidine	0-9	doxorubicin	115-125	advise
Cerubidine	0-9	Cerubidine	130-139	false
doxorubicin	115-125	Cerubidine	130-139	false

Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
Cyclophosphamide	0-15	Cerubidine	40-49	effect

Anticholinesterases (neostgmine, physostigmine), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
Anticholinesterases	0-18	physostigmine	33-45	false
Anticholinesterases	0-18	lignocaine	49-58	false
Anticholinesterases	0-18	quinine	61-67	false
Anticholinesterases	0-18	procainamide	70-81	false
physostigmine	33-45	lignocaine	49-58	false
physostigmine	33-45	quinine	61-67	false
physostigmine	33-45	procainamide	70-81	false
lignocaine	49-58	quinine	61-67	false
lignocaine	49-58	procainamide	70-81	false
quinine	61-67	procainamide	70-81	false

In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
anesthetics	66-76	anesthetics	85-95	false
anesthetics	66-76	lidocaine	102-110	false
anesthetics	66-76	procaine	113-120	false
anesthetics	66-76	beta-blockers	123-135	false
anesthetics	66-76	metaclopramide	138-151	false
anesthetics	66-76	lithium carbonate	154-170	false
anesthetics	66-76	terbutaline	177-187	false
anesthetics	85-95	lidocaine	102-110	false
anesthetics	85-95	procaine	113-120	false
anesthetics	85-95	beta-blockers	123-135	false
anesthetics	85-95	metaclopramide	138-151	false
anesthetics	85-95	lithium carbonate	154-170	false
anesthetics	85-95	terbutaline	177-187	false
lidocaine	102-110	procaine	113-120	false
lidocaine	102-110	beta-blockers	123-135	false
lidocaine	102-110	metaclopramide	138-151	false
lidocaine	102-110	lithium carbonate	154-170	false
lidocaine	102-110	terbutaline	177-187	false
procaine	113-120	beta-blockers	123-135	false
procaine	113-120	metaclopramide	138-151	false
procaine	113-120	lithium carbonate	154-170	false
procaine	113-120	terbutaline	177-187	false
beta-blockers	123-135	metaclopramide	138-151	false
beta-blockers	123-135	lithium carbonate	154-170	false
beta-blockers	123-135	terbutaline	177-187	false
metaclopramide	138-151	lithium carbonate	154-170	false
metaclopramide	138-151	terbutaline	177-187	false
lithium carbonate	154-170	terbutaline	177-187	false

The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.
Exjade	34-39	aluminum	45-52	false
Exjade	34-39	antacid preparations	65-84	false
aluminum	45-52	antacid preparations	65-84	false

Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
deferasirox	9-19	aluminum	46-53	false
deferasirox	9-19	iron	64-67	false
deferasirox	9-19	Exjade	70-75	false
deferasirox	9-19	aluminum	102-109	false
deferasirox	9-19	antacid preparations	122-141	false
aluminum	46-53	iron	64-67	false
aluminum	46-53	Exjade	70-75	false
aluminum	46-53	aluminum	102-109	false
aluminum	46-53	antacid preparations	122-141	false
iron	64-67	Exjade	70-75	false
iron	64-67	aluminum	102-109	false
iron	64-67	antacid preparations	122-141	false
Exjade	70-75	aluminum	102-109	advise
Exjade	70-75	antacid preparations	122-141	false
aluminum	102-109	antacid preparations	122-141	false

In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin.
Exjade	23-28	digoxin	71-77	false

The effect of digoxin on Exjade pharmacokinetics has not been studied.
digoxin	14-20	Exjade	25-30	false

The concomitant administration of Exjade and vitamin C has not been formally studied.
Exjade	34-39	vitamin C	45-53	false

The interaction of Exjade with hydroxyurea has not been formally studied.
Exjade	19-24	hydroxyurea	31-41	false

No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.
deferasirox	17-27	hydroxyurea	43-53	false

Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
clarithromycin	10-23	Didanosine	26-35	false
clarithromycin	10-23	Fluconazole	38-48	false
clarithromycin	10-23	Fluoxetine	51-60	false
clarithromycin	10-23	Ketoconazole	74-85	false
clarithromycin	10-23	Phenytoin	88-96	false
clarithromycin	10-23	carbamazepine	114-126	false
clarithromycin	10-23	Rifabutin	129-137	false
clarithromycin	10-23	Rifampin	140-147	false
clarithromycin	10-23	Saquinavir	161-170	false
Didanosine	26-35	Fluconazole	38-48	false
Didanosine	26-35	Fluoxetine	51-60	false
Didanosine	26-35	Ketoconazole	74-85	false
Didanosine	26-35	Phenytoin	88-96	false
Didanosine	26-35	carbamazepine	114-126	false
Didanosine	26-35	Rifabutin	129-137	false
Didanosine	26-35	Rifampin	140-147	false
Didanosine	26-35	Saquinavir	161-170	false
Fluconazole	38-48	Fluoxetine	51-60	false
Fluconazole	38-48	Ketoconazole	74-85	false
Fluconazole	38-48	Phenytoin	88-96	false
Fluconazole	38-48	carbamazepine	114-126	false
Fluconazole	38-48	Rifabutin	129-137	false
Fluconazole	38-48	Rifampin	140-147	false
Fluconazole	38-48	Saquinavir	161-170	false
Fluoxetine	51-60	Ketoconazole	74-85	false
Fluoxetine	51-60	Phenytoin	88-96	false
Fluoxetine	51-60	carbamazepine	114-126	false
Fluoxetine	51-60	Rifabutin	129-137	false
Fluoxetine	51-60	Rifampin	140-147	false
Fluoxetine	51-60	Saquinavir	161-170	false
Ketoconazole	74-85	Phenytoin	88-96	false
Ketoconazole	74-85	carbamazepine	114-126	false
Ketoconazole	74-85	Rifabutin	129-137	false
Ketoconazole	74-85	Rifampin	140-147	false
Ketoconazole	74-85	Saquinavir	161-170	false
Phenytoin	88-96	carbamazepine	114-126	false
Phenytoin	88-96	Rifabutin	129-137	false
Phenytoin	88-96	Rifampin	140-147	false
Phenytoin	88-96	Saquinavir	161-170	false
carbamazepine	114-126	Rifabutin	129-137	false
carbamazepine	114-126	Rifampin	140-147	false
carbamazepine	114-126	Saquinavir	161-170	false
Rifabutin	129-137	Rifampin	140-147	false
Rifabutin	129-137	Saquinavir	161-170	false
Rifampin	140-147	Saquinavir	161-170	false

Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
HUMORSOL	30-37	succinylcholine	44-58	int
HUMORSOL	30-37	anticholinesterase agents	74-98	int
succinylcholine	44-58	anticholinesterase agents	74-98	false

Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	12-24	anticoagulant	102-114	advise
tetracyclines	12-24	anticoagulant	165-177	false
anticoagulant	102-114	anticoagulant	165-177	false

Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
tetracycline class	40-57	antibiotics	62-72	false
tetracycline class	40-57	penicillins	121-131	effect
antibiotics	62-72	penicillins	121-131	false

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
tetracyclines	18-30	contraceptives	42-55	effect
tetracyclines	18-30	contraceptives	73-86	false
contraceptives	42-55	contraceptives	73-86	false

Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
rauwolfia alkaloid	9-26	MAO inhibitors	77-90	effect

No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.
muscle relaxants	120-135	anesthetic agents	168-184	false

Like isoflurane, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.
isoflurane	5-14	desflurane	17-26	false
isoflurane	5-14	epinephrine	124-134	false
desflurane	17-26	epinephrine	124-134	false

Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	69-93	TCAs	96-99	false

cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).
cimetidine	0-9	antidepressants	66-80	false
cimetidine	0-9	phenothiazines	83-96	false
cimetidine	0-9	flecainide	148-157	false
antidepressants	66-80	phenothiazines	83-96	false
antidepressants	66-80	flecainide	148-157	false
phenothiazines	83-96	flecainide	148-157	false

While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	14-52	SSRIs	55-59	false
selective serotonin reuptake inhibitors	14-52	fluoxetine	69-78	false
selective serotonin reuptake inhibitors	14-52	paroxetine	97-106	false
SSRIs	55-59	fluoxetine	69-78	false
SSRIs	55-59	paroxetine	97-106	false
fluoxetine	69-78	paroxetine	97-106	false

The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	20-23	TCA	25-27	int
SSRI	20-23	SSRI	141-144	false
TCA	25-27	SSRI	141-144	false

Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
T.A.	63-66	SSRIs	84-88	advise

Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	19-43	tricyclic antidepressant	156-179	false

It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	27-29	TCA	56-58	false

Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.
anticholinergic	107-121	sympathomimetic drugs	126-146	false

If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
desipramine hydrochloride	3-27	psychotropic agents	58-76	effect
desipramine hydrochloride	3-27	tranquilizers	86-98	effect
desipramine hydrochloride	3-27	sedative	103-110	effect
desipramine hydrochloride	3-27	hypnotics	112-120	effect
desipramine hydrochloride	3-27	desipramine	234-244	false
desipramine hydrochloride	3-27	benzodiazepines	250-264	false
desipramine hydrochloride	3-27	chlordiazepoxide	273-288	false
desipramine hydrochloride	3-27	diazepam	293-300	false
psychotropic agents	58-76	tranquilizers	86-98	false
psychotropic agents	58-76	sedative	103-110	false
psychotropic agents	58-76	hypnotics	112-120	false
psychotropic agents	58-76	desipramine	234-244	false
psychotropic agents	58-76	benzodiazepines	250-264	false
psychotropic agents	58-76	chlordiazepoxide	273-288	false
psychotropic agents	58-76	diazepam	293-300	false
tranquilizers	86-98	sedative	103-110	false
tranquilizers	86-98	hypnotics	112-120	false
tranquilizers	86-98	desipramine	234-244	false
tranquilizers	86-98	benzodiazepines	250-264	false
tranquilizers	86-98	chlordiazepoxide	273-288	false
tranquilizers	86-98	diazepam	293-300	false
sedative	103-110	hypnotics	112-120	false
sedative	103-110	desipramine	234-244	false
sedative	103-110	benzodiazepines	250-264	false
sedative	103-110	chlordiazepoxide	273-288	false
sedative	103-110	diazepam	293-300	false
hypnotics	112-120	desipramine	234-244	false
hypnotics	112-120	benzodiazepines	250-264	false
hypnotics	112-120	chlordiazepoxide	273-288	false
hypnotics	112-120	diazepam	293-300	false
desipramine	234-244	benzodiazepines	250-264	effect
desipramine	234-244	chlordiazepoxide	273-288	effect
desipramine	234-244	diazepam	293-300	effect
benzodiazepines	250-264	chlordiazepoxide	273-288	false
benzodiazepines	250-264	diazepam	293-300	false
chlordiazepoxide	273-288	diazepam	293-300	false

Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
major tranquilizers	53-71	desipramine	103-113	effect

Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
cimetidine	29-38	tricyclic antidepressants	44-68	mechanism
cimetidine	29-38	tricyclic antidepressants	143-167	false
tricyclic antidepressants	44-68	tricyclic antidepressants	143-167	false

Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
tricyclic antidepressants	46-70	cimetidine	115-124	mechanism
tricyclic antidepressants	46-70	tricyclic antidepressant	190-213	false
cimetidine	115-124	tricyclic antidepressant	190-213	false

There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
tricyclic antidepressants	86-110	fluoxetine	117-126	mechanism

In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.
desloratadine	140-152	erythromycin	223-234	false
desloratadine	140-152	ketoconazole	260-271	false
erythromycin	223-234	ketoconazole	260-271	false

In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
desloratadine	76-88	azithromycin	148-159	false
desloratadine	76-88	fluoxetine	224-233	false
desloratadine	76-88	fluoxetine	303-312	false
desloratadine	76-88	cimetidine	329-338	false
azithromycin	148-159	fluoxetine	224-233	false
azithromycin	148-159	fluoxetine	303-312	false
azithromycin	148-159	cimetidine	329-338	false
fluoxetine	224-233	fluoxetine	303-312	false
fluoxetine	224-233	cimetidine	329-338	false
fluoxetine	303-312	cimetidine	329-338	false

Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.
desloratadine	69-81	3-hydroxydesloratadine	87-108	false
desloratadine	69-81	desloratadine	193-205	false
3-hydroxydesloratadine	87-108	desloratadine	193-205	false

Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
Desloratadine	19-31	3-Hydroxydesloratadine	37-58	false

Desloratadine 3-Hydroxydesloratadine
Desloratadine	0-12	3-Hydroxydesloratadine	14-35	false

Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.
Desmopressin	33-44	Desmopressin	112-123	false

A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)
barbiturates	67-78	phenytoin sodium	98-113	false
barbiturates	67-78	carbamazepine	116-128	false
barbiturates	67-78	griseofulvin	148-159	false
barbiturates	67-78	ampicillin	162-171	false
barbiturates	67-78	tetracyclines	178-190	false
phenytoin sodium	98-113	carbamazepine	116-128	false
phenytoin sodium	98-113	griseofulvin	148-159	false
phenytoin sodium	98-113	ampicillin	162-171	false
phenytoin sodium	98-113	tetracyclines	178-190	false
carbamazepine	116-128	griseofulvin	148-159	false
carbamazepine	116-128	ampicillin	162-171	false
carbamazepine	116-128	tetracyclines	178-190	false
griseofulvin	148-159	ampicillin	162-171	false
griseofulvin	148-159	tetracyclines	178-190	false
ampicillin	162-171	tetracyclines	178-190	false

Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
Aminoglutethimide	0-16	Aminoglutethimide	19-35	false
Aminoglutethimide	0-16	corticosteroids	73-87	false
Aminoglutethimide	19-35	corticosteroids	73-87	effect

Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
Amphotericin B	0-13	corticosteroids	62-76	false
Amphotericin B	0-13	amphotericin B	148-161	false
Amphotericin B	0-13	diuretics	164-172	false
corticosteroids	62-76	amphotericin B	148-161	advise
corticosteroids	62-76	diuretics	164-172	advise
amphotericin B	148-161	diuretics	164-172	false

In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
amphotericin B	72-85	hydrocortisone	91-104	effect

Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
Antibiotics	0-10	Macrolide antibiotics	13-33	false
Antibiotics	0-10	corticosteroid	89-102	false
Macrolide antibiotics	13-33	corticosteroid	89-102	mechanism

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
Anticholinesterases	0-18	anticholinesterase agents	40-64	false
Anticholinesterases	0-18	corticosteroids	70-84	false
anticholinesterase agents	40-64	corticosteroids	70-84	effect

If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
anticholinesterase agents	13-37	corticosteroid	95-108	advise

Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
Anticoagulants	0-13	corticosteroids	43-57	false
Anticoagulants	0-13	warfarin	63-70	false
Anticoagulants	0-13	warfarin	117-124	false
corticosteroids	43-57	warfarin	63-70	effect
corticosteroids	43-57	warfarin	117-124	false
warfarin	63-70	warfarin	117-124	false

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
Antidiabetics	0-12	corticosteroids	23-37	false
Antidiabetics	0-12	antidiabetic agents	104-122	false
corticosteroids	23-37	antidiabetic agents	104-122	effect

Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
Cholestyramine	0-13	Cholestyramine	16-29	false
Cholestyramine	0-13	corticosteroids	61-75	false
Cholestyramine	16-29	corticosteroids	61-75	mechanism

Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
Cyclosporine	0-11	cyclosporine	41-52	false
Cyclosporine	0-11	corticosteroids	58-72	false
cyclosporine	41-52	corticosteroids	58-72	effect

Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.
Digitalis glycosides	0-19	digitalis glycosides	34-53	false

Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
Ephedrine	0-8	Ephedrine	11-19	false
Ephedrine	0-8	corticosteroids	60-74	false
Ephedrine	0-8	corticosteroid	178-191	false
Ephedrine	11-19	corticosteroids	60-74	mechanism
Ephedrine	11-19	corticosteroid	178-191	false
corticosteroids	60-74	corticosteroid	178-191	false

Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens	0-8	contraceptives	26-39	false
Estrogens	0-8	Estrogens	42-50	false
Estrogens	0-8	corticosteroids	99-113	false
contraceptives	26-39	Estrogens	42-50	false
contraceptives	26-39	corticosteroids	99-113	false
Estrogens	42-50	corticosteroids	99-113	mechanism

Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
barbiturates	124-135	phenytoin	138-146	false
barbiturates	124-135	carbamazepine	149-161	false
barbiturates	124-135	rifampin	164-171	false
barbiturates	124-135	corticosteroids	204-218	mechanism
barbiturates	124-135	corticosteroid	255-268	false
phenytoin	138-146	carbamazepine	149-161	false
phenytoin	138-146	rifampin	164-171	false
phenytoin	138-146	corticosteroids	204-218	mechanism
phenytoin	138-146	corticosteroid	255-268	false
carbamazepine	149-161	rifampin	164-171	false
carbamazepine	149-161	corticosteroids	204-218	mechanism
carbamazepine	149-161	corticosteroid	255-268	false
rifampin	164-171	corticosteroids	204-218	mechanism
rifampin	164-171	corticosteroid	255-268	false
corticosteroids	204-218	corticosteroid	255-268	false

Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
ketoconazole	35-46	macrolide antibiotics	49-69	false
ketoconazole	35-46	erythromycin	79-90	false
ketoconazole	35-46	corticosteroids	160-174	mechanism
macrolide antibiotics	49-69	erythromycin	79-90	false
macrolide antibiotics	49-69	corticosteroids	160-174	mechanism
erythromycin	79-90	corticosteroids	160-174	mechanism

Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.
indinavir	74-82	erythromycin	85-96	false

Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
Ketoconazole	0-11	Ketoconazole	14-25	false
Ketoconazole	0-11	corticosteroids	83-97	false
Ketoconazole	0-11	corticosteroid	142-155	false
Ketoconazole	14-25	corticosteroids	83-97	mechanism
Ketoconazole	14-25	corticosteroid	142-155	false
corticosteroids	83-97	corticosteroid	142-155	false

In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
ketoconazole	13-24	corticosteroid	52-65	effect

Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
Nonsteroidal anti-inflammatory agents	0-36	NSAIDS	39-44	false
Nonsteroidal anti-inflammatory agents	0-36	aspirin	67-73	false
Nonsteroidal anti-inflammatory agents	0-36	nonsteroidal antiinflammatory agents	85-120	false
Nonsteroidal anti-inflammatory agents	0-36	corticosteroids	127-141	false
NSAIDS	39-44	aspirin	67-73	false
NSAIDS	39-44	nonsteroidal antiinflammatory agents	85-120	false
NSAIDS	39-44	corticosteroids	127-141	false
aspirin	67-73	nonsteroidal antiinflammatory agents	85-120	false
aspirin	67-73	corticosteroids	127-141	effect
nonsteroidal antiinflammatory agents	85-120	corticosteroids	127-141	effect

Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Aspirin	0-6	corticosteroids	54-68	advise

The clearance of salicylates may be increased with concurrent use of corticosteroids.
salicylates	17-27	corticosteroids	69-83	mechanism

Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
Phenytoin	0-8	phenytoin	100-108	false
Phenytoin	0-8	dexamethasone	122-134	false
phenytoin	100-108	dexamethasone	122-134	mechanism

Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.
Thalidomide	0-10	thalidomide	36-46	false

Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
Vaccines	0-7	corticosteroid	22-35	false
Vaccines	0-7	live vaccines	94-97;114-121	false
Vaccines	0-7	inactivated vaccines	102-121	false
corticosteroid	22-35	live vaccines	94-97;114-121	effect
corticosteroid	22-35	inactivated vaccines	102-121	effect
live vaccines	94-97;114-121	inactivated vaccines	102-121	false

Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
Corticosteroids	0-14	live attenuated vaccines	83-106	effect

Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
vaccines	26-33	corticosteroid	71-84	advise

Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
Dexbrompheniramine	0-17	alcohol	37-43	int
Dexbrompheniramine	0-17	CNS depressants	54-68	int
Dexbrompheniramine	0-17	antihistamines	144-157	false
Dexbrompheniramine	0-17	anticholinergics	161-176	int
Dexbrompheniramine	0-17	antihistamines	323-336	false
Dexbrompheniramine	0-17	monoamine oxidase (MAO) inhibitors	344-377	int
Dexbrompheniramine	0-17	antihistamines	400-413	false
Dexbrompheniramine	0-17	antihistamines	491-504	false
alcohol	37-43	CNS depressants	54-68	false
alcohol	37-43	antihistamines	144-157	false
alcohol	37-43	anticholinergics	161-176	false
alcohol	37-43	antihistamines	323-336	false
alcohol	37-43	monoamine oxidase (MAO) inhibitors	344-377	false
alcohol	37-43	antihistamines	400-413	false
alcohol	37-43	antihistamines	491-504	false
CNS depressants	54-68	antihistamines	144-157	false
CNS depressants	54-68	anticholinergics	161-176	false
CNS depressants	54-68	antihistamines	323-336	false
CNS depressants	54-68	monoamine oxidase (MAO) inhibitors	344-377	false
CNS depressants	54-68	antihistamines	400-413	false
CNS depressants	54-68	antihistamines	491-504	false
antihistamines	144-157	anticholinergics	161-176	false
antihistamines	144-157	antihistamines	323-336	false
antihistamines	144-157	monoamine oxidase (MAO) inhibitors	344-377	false
antihistamines	144-157	antihistamines	400-413	false
antihistamines	144-157	antihistamines	491-504	false
anticholinergics	161-176	antihistamines	323-336	false
anticholinergics	161-176	monoamine oxidase (MAO) inhibitors	344-377	false
anticholinergics	161-176	antihistamines	400-413	false
anticholinergics	161-176	antihistamines	491-504	false
antihistamines	323-336	monoamine oxidase (MAO) inhibitors	344-377	false
antihistamines	323-336	antihistamines	400-413	false
antihistamines	323-336	antihistamines	491-504	false
monoamine oxidase (MAO) inhibitors	344-377	antihistamines	400-413	false
monoamine oxidase (MAO) inhibitors	344-377	antihistamines	491-504	false
antihistamines	400-413	antihistamines	491-504	false

In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
monoamine oxidase inhibitors	35-62	MAOIs	65-69	false
monoamine oxidase inhibitors	35-62	selegiline hydrochloride	79-102	false
monoamine oxidase inhibitors	35-62	serotoninergic agents	125-145	effect
monoamine oxidase inhibitors	35-62	fluoxetine	154-163	effect
monoamine oxidase inhibitors	35-62	fluvoxamine	166-176	effect
monoamine oxidase inhibitors	35-62	paroxetine	179-188	effect
monoamine oxidase inhibitors	35-62	sertraline	191-200	effect
monoamine oxidase inhibitors	35-62	venlafaxine	203-213	effect
MAOIs	65-69	selegiline hydrochloride	79-102	false
MAOIs	65-69	serotoninergic agents	125-145	effect
MAOIs	65-69	fluoxetine	154-163	effect
MAOIs	65-69	fluvoxamine	166-176	effect
MAOIs	65-69	paroxetine	179-188	effect
MAOIs	65-69	sertraline	191-200	effect
MAOIs	65-69	venlafaxine	203-213	effect
selegiline hydrochloride	79-102	serotoninergic agents	125-145	effect
selegiline hydrochloride	79-102	fluoxetine	154-163	effect
selegiline hydrochloride	79-102	fluvoxamine	166-176	effect
selegiline hydrochloride	79-102	paroxetine	179-188	effect
selegiline hydrochloride	79-102	sertraline	191-200	effect
selegiline hydrochloride	79-102	venlafaxine	203-213	effect
serotoninergic agents	125-145	fluoxetine	154-163	false
serotoninergic agents	125-145	fluvoxamine	166-176	false
serotoninergic agents	125-145	paroxetine	179-188	false
serotoninergic agents	125-145	sertraline	191-200	false
serotoninergic agents	125-145	venlafaxine	203-213	false
fluoxetine	154-163	fluvoxamine	166-176	false
fluoxetine	154-163	paroxetine	179-188	false
fluoxetine	154-163	sertraline	191-200	false
fluoxetine	154-163	venlafaxine	203-213	false
fluvoxamine	166-176	paroxetine	179-188	false
fluvoxamine	166-176	sertraline	191-200	false
fluvoxamine	166-176	venlafaxine	203-213	false
paroxetine	179-188	sertraline	191-200	false
paroxetine	179-188	venlafaxine	203-213	false
sertraline	191-200	venlafaxine	203-213	false

Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
dexfenfluramine	8-22	dexfenfluramine	72-86	false
dexfenfluramine	8-22	MAO inhibitor	128-140	false
dexfenfluramine	72-86	MAO inhibitor	128-140	advise

At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
MAO inhibitor	60-72	dexfenfluramine	107-121	advise

At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
dexfenfluramine	58-72	MAO inhibitor	109-121	advise

A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
selective serotonin reuptake inhibitors	121-159	SSRIs	162-166	false
selective serotonin reuptake inhibitors	121-159	Imitrex	210-216	effect
selective serotonin reuptake inhibitors	121-159	sumatriptan succinate	219-239	effect
selective serotonin reuptake inhibitors	121-159	dihydroergotamine	246-262	effect
SSRIs	162-166	Imitrex	210-216	effect
SSRIs	162-166	sumatriptan succinate	219-239	effect
SSRIs	162-166	dihydroergotamine	246-262	effect
Imitrex	210-216	sumatriptan succinate	219-239	false
Imitrex	210-216	dihydroergotamine	246-262	false
sumatriptan succinate	219-239	dihydroergotamine	246-262	false

Dexfenfluramine should not be administered with other serotoninergic agents.
Dexfenfluramine	0-14	serotoninergic agents	54-74	advise

Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
Anesthetics	0-10	Sedatives	12-20	false
Anesthetics	0-10	Hypnotics	22-30	false
Anesthetics	0-10	Opioids	32-38	false
Anesthetics	0-10	PRECEDEX	62-69	false
Anesthetics	0-10	anesthetics	76-86	false
Anesthetics	0-10	sedatives	89-97	false
Anesthetics	0-10	hypnotics	100-108	false
Anesthetics	0-10	opioids	115-121	false
Sedatives	12-20	Hypnotics	22-30	false
Sedatives	12-20	Opioids	32-38	false
Sedatives	12-20	PRECEDEX	62-69	false
Sedatives	12-20	anesthetics	76-86	false
Sedatives	12-20	sedatives	89-97	false
Sedatives	12-20	hypnotics	100-108	false
Sedatives	12-20	opioids	115-121	false
Hypnotics	22-30	Opioids	32-38	false
Hypnotics	22-30	PRECEDEX	62-69	false
Hypnotics	22-30	anesthetics	76-86	false
Hypnotics	22-30	sedatives	89-97	false
Hypnotics	22-30	hypnotics	100-108	false
Hypnotics	22-30	opioids	115-121	false
Opioids	32-38	PRECEDEX	62-69	false
Opioids	32-38	anesthetics	76-86	false
Opioids	32-38	sedatives	89-97	false
Opioids	32-38	hypnotics	100-108	false
Opioids	32-38	opioids	115-121	false
PRECEDEX	62-69	anesthetics	76-86	effect
PRECEDEX	62-69	sedatives	89-97	effect
PRECEDEX	62-69	hypnotics	100-108	effect
PRECEDEX	62-69	opioids	115-121	effect
anesthetics	76-86	sedatives	89-97	false
anesthetics	76-86	hypnotics	100-108	false
anesthetics	76-86	opioids	115-121	false
sedatives	89-97	hypnotics	100-108	false
sedatives	89-97	opioids	115-121	false
hypnotics	100-108	opioids	115-121	false

Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.
sevoflurane	51-61	isoflurane	64-73	false
sevoflurane	51-61	propofol	76-83	false
sevoflurane	51-61	alfentanil	86-95	false
sevoflurane	51-61	midazolam	102-110	false
isoflurane	64-73	propofol	76-83	false
isoflurane	64-73	alfentanil	86-95	false
isoflurane	64-73	midazolam	102-110	false
propofol	76-83	alfentanil	86-95	false
propofol	76-83	midazolam	102-110	false
alfentanil	86-95	midazolam	102-110	false

No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.
dexmedetomidine	40-54	isoflurane	60-69	false
dexmedetomidine	40-54	propofol	72-79	false
dexmedetomidine	40-54	alfentanil	82-91	false
dexmedetomidine	40-54	midazolam	98-106	false
isoflurane	60-69	propofol	72-79	false
isoflurane	60-69	alfentanil	82-91	false
isoflurane	60-69	midazolam	98-106	false
propofol	72-79	alfentanil	82-91	false
propofol	72-79	midazolam	98-106	false
alfentanil	82-91	midazolam	98-106	false

However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
PRECEDEX	81-88	PRECEDEX	116-123	false
PRECEDEX	81-88	anesthetic	144-153	false
PRECEDEX	81-88	sedative	156-163	false
PRECEDEX	81-88	hypnotic	166-173	false
PRECEDEX	81-88	opioid	178-183	false
PRECEDEX	116-123	anesthetic	144-153	advise
PRECEDEX	116-123	sedative	156-163	advise
PRECEDEX	116-123	hypnotic	166-173	advise
PRECEDEX	116-123	opioid	178-183	advise
anesthetic	144-153	sedative	156-163	false
anesthetic	144-153	hypnotic	166-173	false
anesthetic	144-153	opioid	178-183	false
sedative	156-163	hypnotic	166-173	false
sedative	156-163	opioid	178-183	false
hypnotic	166-173	opioid	178-183	false

Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.
Neuromuscular Blockers	0-21	PRECEDEX	81-88	false
Neuromuscular Blockers	0-21	rocuronium	254-263	false
PRECEDEX	81-88	rocuronium	254-263	false

ZINECARD does not influence the pharmacokinetics of doxorubicin.
ZINECARD	0-7	doxorubicin	52-62	false

Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
Acidifying agents	0-16	Gastrointestinal acidifying agents	19-52	false
Acidifying agents	0-16	guanethidine	55-66	false
Acidifying agents	0-16	reserpine	69-77	false
Acidifying agents	0-16	glutamic acid HCl	80-96	false
Acidifying agents	0-16	ascorbic acid	99-111	false
Acidifying agents	0-16	amphetamines	154-165	false
Gastrointestinal acidifying agents	19-52	guanethidine	55-66	false
Gastrointestinal acidifying agents	19-52	reserpine	69-77	false
Gastrointestinal acidifying agents	19-52	glutamic acid HCl	80-96	false
Gastrointestinal acidifying agents	19-52	ascorbic acid	99-111	false
Gastrointestinal acidifying agents	19-52	amphetamines	154-165	mechanism
guanethidine	55-66	reserpine	69-77	false
guanethidine	55-66	glutamic acid HCl	80-96	false
guanethidine	55-66	ascorbic acid	99-111	false
guanethidine	55-66	amphetamines	154-165	mechanism
reserpine	69-77	glutamic acid HCl	80-96	false
reserpine	69-77	ascorbic acid	99-111	false
reserpine	69-77	amphetamines	154-165	mechanism
glutamic acid HCl	80-96	ascorbic acid	99-111	false
glutamic acid HCl	80-96	amphetamines	154-165	mechanism
ascorbic acid	99-111	amphetamines	154-165	mechanism

Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
Urinary acidifying agents	0-24	ammonium chloride	27-43	false
Urinary acidifying agents	0-24	sodium acid phosphate	46-66	false
Urinary acidifying agents	0-24	amphetamine	132-142	mechanism
ammonium chloride	27-43	sodium acid phosphate	46-66	false
ammonium chloride	27-43	amphetamine	132-142	mechanism
sodium acid phosphate	46-66	amphetamine	132-142	mechanism

Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
Adrenergic blockers	0-18	Adrenergic blockers	21-39	false
Adrenergic blockers	0-18	amphetamines	58-69	false
Adrenergic blockers	21-39	amphetamines	58-69	effect

Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
sodium bicarbonate	59-76	amphetamines	108-119	mechanism

Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
acetazolamide	29-41	thiazides	49-57	false
acetazolamide	29-41	amphetamine	121-131	mechanism
thiazides	49-57	amphetamine	121-131	mechanism

Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
Antidepressants	0-14	tricyclic	17-25	false
Antidepressants	0-14	Amphetamines	28-39	false
Antidepressants	0-14	tricyclic	69-77	false
Antidepressants	0-14	sympathomimetic agents	82-103	false
tricyclic	17-25	Amphetamines	28-39	false
tricyclic	17-25	tricyclic	69-77	false
tricyclic	17-25	sympathomimetic agents	82-103	false
Amphetamines	28-39	tricyclic	69-77	effect
Amphetamines	28-39	sympathomimetic agents	82-103	effect
tricyclic	69-77	sympathomimetic agents	82-103	false

d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
d-amphetamine	0-12	desipramine	19-29	mechanism
d-amphetamine	0-12	protriptyline	34-46	mechanism
d-amphetamine	0-12	tricyclics	67-76	mechanism
d-amphetamine	0-12	d-amphetamine	141-153	false
desipramine	19-29	protriptyline	34-46	false
desipramine	19-29	tricyclics	67-76	false
desipramine	19-29	d-amphetamine	141-153	false
protriptyline	34-46	tricyclics	67-76	false
protriptyline	34-46	d-amphetamine	141-153	false
tricyclics	67-76	d-amphetamine	141-153	false

MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
MAO inhibitors	0-13	MAOI antidepressants	16-35	false
MAO inhibitors	0-13	furazolidone	65-76	false
MAO inhibitors	0-13	amphetamine	84-94	false
MAOI antidepressants	16-35	furazolidone	65-76	false
MAOI antidepressants	16-35	amphetamine	84-94	mechanism
furazolidone	65-76	amphetamine	84-94	mechanism

Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
Antihistamines	0-13	Amphetamines	16-27	false
Antihistamines	0-13	antihistamines	67-80	false
Amphetamines	16-27	antihistamines	67-80	effect

Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
Antihypertensives	0-16	Amphetamines	19-30	false
Antihypertensives	0-16	antihypertensives	74-90	false
Amphetamines	19-30	antihypertensives	74-90	effect

Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
Chlorpromazine	0-13	Chlorpromazine	16-29	false
Chlorpromazine	0-13	amphetamines	125-136	false
Chlorpromazine	0-13	amphetamine	164-174	false
Chlorpromazine	16-29	amphetamines	125-136	effect
Chlorpromazine	16-29	amphetamine	164-174	false
amphetamines	125-136	amphetamine	164-174	false

Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
Ethosuximide	0-11	Amphetamines	14-25	false
Ethosuximide	0-11	ethosuximide	62-73	false
Amphetamines	14-25	ethosuximide	62-73	mechanism

Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
Haloperidol	0-10	Haloperidol	13-23	false
Haloperidol	0-10	amphetamines	119-130	false
Haloperidol	13-23	amphetamines	119-130	effect

Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
Lithium carbonate	0-16	amphetamines	46-57	false
Lithium carbonate	0-16	lithium carbonate	79-95	false
amphetamines	46-57	lithium carbonate	79-95	effect

Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
Meperidine	0-9	Amphetamines	12-23	false
Meperidine	0-9	meperidine	60-69	false
Amphetamines	12-23	meperidine	60-69	effect

Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
Methenamine	0-10	amphetamines	42-53	false
Methenamine	0-10	acidifying agents	97-113	false
Methenamine	0-10	methenamine	123-133	false
amphetamines	42-53	acidifying agents	97-113	mechanism
amphetamines	42-53	methenamine	123-133	false
acidifying agents	97-113	methenamine	123-133	false

Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
Norepinephrine	0-13	Amphetamines	16-27	false
Norepinephrine	0-13	norepinephrine	62-75	false
Amphetamines	16-27	norepinephrine	62-75	effect

Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
Phenobarbital	0-12	Amphetamines	15-26	false
Phenobarbital	0-12	phenobarbital	63-75	false
Amphetamines	15-26	phenobarbital	63-75	mechanism

Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
Phenytoin	0-8	Amphetamines	11-22	false
Phenytoin	0-8	phenytoin	59-67	false
Amphetamines	11-22	phenytoin	59-67	mechanism

Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
Propoxyphene	0-11	propoxyphene	26-37	false
Propoxyphene	0-11	amphetamine	51-61	false
propoxyphene	26-37	amphetamine	51-61	effect

Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
Veratrum alkaloids	0-17	Amphetamines	20-31	false
Veratrum alkaloids	0-17	veratrum alkaloids	67-84	false
Amphetamines	20-31	veratrum alkaloids	67-84	effect

Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
Amphetamines	35-46	corticosteroid	92-105	int

Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.
anesthetics	50-60	sedatives	63-71	false
anesthetics	50-60	antianxiety drugs	74-90	false
anesthetics	50-60	hypnotics	93-101	false
anesthetics	50-60	alcohol	104-110	false
anesthetics	50-60	opiate analgesics	123-139	false
sedatives	63-71	antianxiety drugs	74-90	false
sedatives	63-71	hypnotics	93-101	false
sedatives	63-71	alcohol	104-110	false
sedatives	63-71	opiate analgesics	123-139	false
antianxiety drugs	74-90	hypnotics	93-101	false
antianxiety drugs	74-90	alcohol	104-110	false
antianxiety drugs	74-90	opiate analgesics	123-139	false
hypnotics	93-101	alcohol	104-110	false
hypnotics	93-101	opiate analgesics	123-139	false
alcohol	104-110	opiate analgesics	123-139	false

May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
levothyroxine	44-56	iodine	60-65	false
levothyroxine	44-56	antacids	88-95	false
levothyroxine	44-56	H2-antagonists	98-111	false
levothyroxine	44-56	famotidine	120-129	false
levothyroxine	44-56	ranitidine	132-141	false
levothyroxine	44-56	proton pump inhibitors	149-170	false
levothyroxine	44-56	lansoprazole	179-190	false
levothyroxine	44-56	omeprazole	193-202	false
iodine	60-65	antacids	88-95	false
iodine	60-65	H2-antagonists	98-111	false
iodine	60-65	famotidine	120-129	false
iodine	60-65	ranitidine	132-141	false
iodine	60-65	proton pump inhibitors	149-170	false
iodine	60-65	lansoprazole	179-190	false
iodine	60-65	omeprazole	193-202	false
antacids	88-95	H2-antagonists	98-111	false
antacids	88-95	famotidine	120-129	false
antacids	88-95	ranitidine	132-141	false
antacids	88-95	proton pump inhibitors	149-170	false
antacids	88-95	lansoprazole	179-190	false
antacids	88-95	omeprazole	193-202	false
H2-antagonists	98-111	famotidine	120-129	false
H2-antagonists	98-111	ranitidine	132-141	false
H2-antagonists	98-111	proton pump inhibitors	149-170	false
H2-antagonists	98-111	lansoprazole	179-190	false
H2-antagonists	98-111	omeprazole	193-202	false
famotidine	120-129	ranitidine	132-141	false
famotidine	120-129	proton pump inhibitors	149-170	false
famotidine	120-129	lansoprazole	179-190	false
famotidine	120-129	omeprazole	193-202	false
ranitidine	132-141	proton pump inhibitors	149-170	false
ranitidine	132-141	lansoprazole	179-190	false
ranitidine	132-141	omeprazole	193-202	false
proton pump inhibitors	149-170	lansoprazole	179-190	false
proton pump inhibitors	149-170	omeprazole	193-202	false
lansoprazole	179-190	omeprazole	193-202	false

Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
aspirin	63-69	carbonic anhydrase inhibitors	75-103	advise

Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
Aspirin	0-6	diclofenac	39-48	false
Aspirin	0-6	aspirin	54-60	false
Aspirin	0-6	diclofenac	89-98	false
Aspirin	0-6	aspirin	177-183	false
diclofenac	39-48	aspirin	54-60	advise
diclofenac	39-48	diclofenac	89-98	false
diclofenac	39-48	aspirin	177-183	false
aspirin	54-60	diclofenac	89-98	false
aspirin	54-60	aspirin	177-183	false
diclofenac	89-98	aspirin	177-183	mechanism

Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
Anticoagulants	0-13	diclofenac	45-54	false
Anticoagulants	0-13	anticoagulants of the warfarin type	73-107	false
Anticoagulants	0-13	NSAIDs	197-202	false
diclofenac	45-54	anticoagulants of the warfarin type	73-107	false
diclofenac	45-54	NSAIDs	197-202	advise
anticoagulants of the warfarin type	73-107	NSAIDs	197-202	false

Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
NSAIDs	65-70	NSAIDs	134-139	false
NSAIDs	65-70	diclofenac	152-161	false
NSAIDs	65-70	warfarin	168-175	false
NSAIDs	65-70	anticoagulant	253-265	false
NSAIDs	134-139	diclofenac	152-161	false
NSAIDs	134-139	warfarin	168-175	advise
NSAIDs	134-139	anticoagulant	253-265	false
diclofenac	152-161	warfarin	168-175	advise
diclofenac	152-161	anticoagulant	253-265	false
warfarin	168-175	anticoagulant	253-265	false

Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
Digoxin	0-6	Methotrexate	9-20	false
Digoxin	0-6	Cyclosporine	23-34	false
Digoxin	0-6	Diclofenac	37-46	false
Digoxin	0-6	NSAIDs	60-65	false
Methotrexate	9-20	Cyclosporine	23-34	false
Methotrexate	9-20	Diclofenac	37-46	false
Methotrexate	9-20	NSAIDs	60-65	false
Cyclosporine	23-34	Diclofenac	37-46	false
Cyclosporine	23-34	NSAIDs	60-65	false
Diclofenac	37-46	NSAIDs	60-65	false

Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
diclofenac	13-22	digoxin	61-67	mechanism
diclofenac	13-22	methotrexate	73-84	mechanism
diclofenac	13-22	cyclosporine	99-110	effect
digoxin	61-67	methotrexate	73-84	false
digoxin	61-67	cyclosporine	99-110	false
methotrexate	73-84	cyclosporine	99-110	false

Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
diclofenac	26-35	diclofenac	59-68	false
diclofenac	26-35	NSAID	88-92	false
diclofenac	26-35	digoxin	107-113	effect
diclofenac	26-35	methotrexate	116-127	effect
diclofenac	26-35	cyclosporine	133-144	effect
diclofenac	59-68	NSAID	88-92	false
diclofenac	59-68	digoxin	107-113	false
diclofenac	59-68	methotrexate	116-127	false
diclofenac	59-68	cyclosporine	133-144	false
NSAID	88-92	digoxin	107-113	effect
NSAID	88-92	methotrexate	116-127	effect
NSAID	88-92	cyclosporine	133-144	effect
digoxin	107-113	methotrexate	116-127	false
digoxin	107-113	cyclosporine	133-144	false
methotrexate	116-127	cyclosporine	133-144	false

Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
Lithium	0-6	Diclofenac	9-18	false
Lithium	0-6	lithium	30-36	false
Lithium	0-6	lithium	68-74	false
Diclofenac	9-18	lithium	30-36	mechanism
Diclofenac	9-18	lithium	68-74	mechanism
lithium	30-36	lithium	68-74	false

In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
diclofenac	19-28	lithium	34-40	effect
diclofenac	19-28	lithium	57-63	false
lithium	34-40	lithium	57-63	false

Oral Hypoglycemics: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.
Hypoglycemics	5-17	Diclofenac	20-29	false
Hypoglycemics	5-17	hypoglycemic agents	122-140	false
Diclofenac	20-29	hypoglycemic agents	122-140	false

There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
insulin	86-92	hypoglycemic agents	102-120	false
insulin	86-92	diclofenac	141-150	effect
hypoglycemic agents	102-120	diclofenac	141-150	effect

A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
diclofenac	107-116	insulin	161-167	effect
diclofenac	107-116	hypoglycemic agents	177-195	effect
insulin	161-167	hypoglycemic agents	177-195	false

Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
Diuretics	0-8	Diclofenac	11-20	false
Diuretics	0-8	NSAIDs	32-37	false
Diuretics	0-8	diuretics	67-75	false
Diclofenac	11-20	NSAIDs	32-37	false
Diclofenac	11-20	diuretics	67-75	effect
NSAIDs	32-37	diuretics	67-75	effect

Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
azathioprine	101-112	gold	115-118	false
azathioprine	101-112	chloroquine	121-131	false
azathioprine	101-112	D-penicillamine	134-148	false
azathioprine	101-112	prednisolone	151-162	false
azathioprine	101-112	doxycycline	165-175	false
azathioprine	101-112	digitoxin	181-189	false
azathioprine	101-112	diclofenac	254-263	false
gold	115-118	chloroquine	121-131	false
gold	115-118	D-penicillamine	134-148	false
gold	115-118	prednisolone	151-162	false
gold	115-118	doxycycline	165-175	false
gold	115-118	digitoxin	181-189	false
gold	115-118	diclofenac	254-263	false
chloroquine	121-131	D-penicillamine	134-148	false
chloroquine	121-131	prednisolone	151-162	false
chloroquine	121-131	doxycycline	165-175	false
chloroquine	121-131	digitoxin	181-189	false
chloroquine	121-131	diclofenac	254-263	false
D-penicillamine	134-148	prednisolone	151-162	false
D-penicillamine	134-148	doxycycline	165-175	false
D-penicillamine	134-148	digitoxin	181-189	false
D-penicillamine	134-148	diclofenac	254-263	false
prednisolone	151-162	doxycycline	165-175	false
prednisolone	151-162	digitoxin	181-189	false
prednisolone	151-162	diclofenac	254-263	false
doxycycline	165-175	digitoxin	181-189	false
doxycycline	165-175	diclofenac	254-263	false
digitoxin	181-189	diclofenac	254-263	false

Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
Phenobarbital	0-12	phenobarbital	82-94	false
Phenobarbital	0-12	diclofenac	134-143	false
phenobarbital	82-94	diclofenac	134-143	effect

Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
diclofenac	26-35	salicylic acid	100-113	mechanism
diclofenac	26-35	tolbutamide	142-152	mechanism
diclofenac	26-35	prednisolone	155-166	mechanism
diclofenac	26-35	warfarin	198-205	mechanism
salicylic acid	100-113	tolbutamide	142-152	false
salicylic acid	100-113	prednisolone	155-166	false
salicylic acid	100-113	warfarin	198-205	false
tolbutamide	142-152	prednisolone	155-166	false
tolbutamide	142-152	warfarin	198-205	false
prednisolone	155-166	warfarin	198-205	false

Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
Benzylpenicillin	0-15	ampicillin	18-27	false
Benzylpenicillin	0-15	oxacillin	30-38	false
Benzylpenicillin	0-15	chlortetracycline	41-57	false
Benzylpenicillin	0-15	doxycycline	60-70	false
Benzylpenicillin	0-15	cephalothin	73-83	false
Benzylpenicillin	0-15	erythromycin	86-97	false
Benzylpenicillin	0-15	sulfamethoxazole	104-119	false
Benzylpenicillin	0-15	diclofenac	174-183	false
ampicillin	18-27	oxacillin	30-38	false
ampicillin	18-27	chlortetracycline	41-57	false
ampicillin	18-27	doxycycline	60-70	false
ampicillin	18-27	cephalothin	73-83	false
ampicillin	18-27	erythromycin	86-97	false
ampicillin	18-27	sulfamethoxazole	104-119	false
ampicillin	18-27	diclofenac	174-183	false
oxacillin	30-38	chlortetracycline	41-57	false
oxacillin	30-38	doxycycline	60-70	false
oxacillin	30-38	cephalothin	73-83	false
oxacillin	30-38	erythromycin	86-97	false
oxacillin	30-38	sulfamethoxazole	104-119	false
oxacillin	30-38	diclofenac	174-183	false
chlortetracycline	41-57	doxycycline	60-70	false
chlortetracycline	41-57	cephalothin	73-83	false
chlortetracycline	41-57	erythromycin	86-97	false
chlortetracycline	41-57	sulfamethoxazole	104-119	false
chlortetracycline	41-57	diclofenac	174-183	false
doxycycline	60-70	cephalothin	73-83	false
doxycycline	60-70	erythromycin	86-97	false
doxycycline	60-70	sulfamethoxazole	104-119	false
doxycycline	60-70	diclofenac	174-183	false
cephalothin	73-83	erythromycin	86-97	false
cephalothin	73-83	sulfamethoxazole	104-119	false
cephalothin	73-83	diclofenac	174-183	false
erythromycin	86-97	sulfamethoxazole	104-119	false
erythromycin	86-97	diclofenac	174-183	false
sulfamethoxazole	104-119	diclofenac	174-183	false

Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.
Tetracycline	0-11	bacteriostatic antibiotic	16-40	false
Tetracycline	0-11	penicillin	84-93	effect
bacteriostatic antibiotic	16-40	penicillin	84-93	false

The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
anticholinergic drugs	69-89	amantadine	92-101	false
anticholinergic drugs	69-89	antiarrhythmic agents	103-123	false
anticholinergic drugs	69-89	quinidine	140-148	false
anticholinergic drugs	69-89	antihistamines	152-165	false
anticholinergic drugs	69-89	antipsychotic agents	167-186	false
anticholinergic drugs	69-89	phenothiazines	194-207	false
anticholinergic drugs	69-89	benzodiazepines	211-225	false
amantadine	92-101	antiarrhythmic agents	103-123	false
amantadine	92-101	quinidine	140-148	false
amantadine	92-101	antihistamines	152-165	false
amantadine	92-101	antipsychotic agents	167-186	false
amantadine	92-101	phenothiazines	194-207	false
amantadine	92-101	benzodiazepines	211-225	false
antiarrhythmic agents	103-123	quinidine	140-148	false
antiarrhythmic agents	103-123	antihistamines	152-165	false
antiarrhythmic agents	103-123	antipsychotic agents	167-186	false
antiarrhythmic agents	103-123	phenothiazines	194-207	false
antiarrhythmic agents	103-123	benzodiazepines	211-225	false
quinidine	140-148	antihistamines	152-165	false
quinidine	140-148	antipsychotic agents	167-186	false
quinidine	140-148	phenothiazines	194-207	false
quinidine	140-148	benzodiazepines	211-225	false
antihistamines	152-165	antipsychotic agents	167-186	false
antihistamines	152-165	phenothiazines	194-207	false
antihistamines	152-165	benzodiazepines	211-225	false
antipsychotic agents	167-186	phenothiazines	194-207	false
antipsychotic agents	167-186	benzodiazepines	211-225	false
phenothiazines	194-207	benzodiazepines	211-225	false

MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
MAO inhibitors	0-13	narcotic analgesics	16-34	false
MAO inhibitors	0-13	meperidine	43-52	false
MAO inhibitors	0-13	nitrates	56-63	false
MAO inhibitors	0-13	nitrites	69-76	false
MAO inhibitors	0-13	sympathomimetic agents	79-100	false
MAO inhibitors	0-13	tricyclic antidepressants	103-127	false
narcotic analgesics	16-34	meperidine	43-52	false
narcotic analgesics	16-34	nitrates	56-63	false
narcotic analgesics	16-34	nitrites	69-76	false
narcotic analgesics	16-34	sympathomimetic agents	79-100	false
narcotic analgesics	16-34	tricyclic antidepressants	103-127	false
meperidine	43-52	nitrates	56-63	false
meperidine	43-52	nitrites	69-76	false
meperidine	43-52	sympathomimetic agents	79-100	false
meperidine	43-52	tricyclic antidepressants	103-127	false
nitrates	56-63	nitrites	69-76	false
nitrates	56-63	sympathomimetic agents	79-100	false
nitrates	56-63	tricyclic antidepressants	103-127	false
nitrites	69-76	sympathomimetic agents	79-100	false
nitrites	69-76	tricyclic antidepressants	103-127	false
sympathomimetic agents	79-100	tricyclic antidepressants	103-127	false

Anticholinergics antagonize the effects of antiglaucoma agents.
Anticholinergics	0-15	antiglaucoma agents	43-61	false

Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
Anticholinergic agents	0-21	digoxin	122-128	mechanism

Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
Anticholinergic drugs	0-20	metoclopramide	108-121	mechanism

Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
antacids	8-15	anticholinergic agents	54-75	mechanism

Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS).
stavudine	119-127	VIDEX	195-199	false

Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
Allopurinol	0-10	didanosine	24-33	false
Allopurinol	0-10	allopurinol	67-77	false
Allopurinol	0-10	VIDEX	141-145	false
didanosine	24-33	allopurinol	67-77	false
didanosine	24-33	VIDEX	141-145	false
allopurinol	67-77	VIDEX	141-145	mechanism

The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.
allopurinol	15-25	didanosine	30-39	false

Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
Antacids	0-7	antacids	40-47	false
Antacids	0-7	magnesium	60-68	false
Antacids	0-7	aluminum	73-80	false
Antacids	0-7	VIDEX	87-91	false
Antacids	0-7	antacid	219-225	false
antacids	40-47	magnesium	60-68	false
antacids	40-47	aluminum	73-80	false
antacids	40-47	VIDEX	87-91	effect
antacids	40-47	antacid	219-225	false
magnesium	60-68	aluminum	73-80	false
magnesium	60-68	VIDEX	87-91	effect
magnesium	60-68	antacid	219-225	false
aluminum	73-80	VIDEX	87-91	effect
aluminum	73-80	antacid	219-225	false
VIDEX	87-91	antacid	219-225	false

Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
ketoconazole	93-104	itraconazole	110-121	false
ketoconazole	93-104	VIDEX	184-188	advise
itraconazole	110-121	VIDEX	184-188	advise

Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
Ganciclovir	0-10	VIDEX	31-35	false
Ganciclovir	0-10	ganciclovir	78-88	false
Ganciclovir	0-10	didanosine	159-168	false
VIDEX	31-35	ganciclovir	78-88	mechanism
VIDEX	31-35	didanosine	159-168	false
ganciclovir	78-88	didanosine	159-168	false

A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
ganciclovir	47-57	VIDEX	77-81	false
ganciclovir	47-57	ganciclovir	117-127	false
VIDEX	77-81	ganciclovir	117-127	mechanism

Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
Quinolone Antibiotic	0-19	VIDEX	23-27	false
Quinolone Antibiotic	0-19	ciprofloxacin	105-117	false
Quinolone Antibiotic	0-19	ciprofloxacin	152-164	false
Quinolone Antibiotic	0-19	antacids	203-210	false
Quinolone Antibiotic	0-19	magnesium	223-231	false
Quinolone Antibiotic	0-19	calcium	234-240	false
Quinolone Antibiotic	0-19	aluminum	246-253	false
VIDEX	23-27	ciprofloxacin	105-117	advise
VIDEX	23-27	ciprofloxacin	152-164	false
VIDEX	23-27	antacids	203-210	false
VIDEX	23-27	magnesium	223-231	false
VIDEX	23-27	calcium	234-240	false
VIDEX	23-27	aluminum	246-253	false
ciprofloxacin	105-117	ciprofloxacin	152-164	false
ciprofloxacin	105-117	antacids	203-210	false
ciprofloxacin	105-117	magnesium	223-231	false
ciprofloxacin	105-117	calcium	234-240	false
ciprofloxacin	105-117	aluminum	246-253	false
ciprofloxacin	152-164	antacids	203-210	false
ciprofloxacin	152-164	magnesium	223-231	mechanism
ciprofloxacin	152-164	calcium	234-240	mechanism
ciprofloxacin	152-164	aluminum	246-253	mechanism
antacids	203-210	magnesium	223-231	false
antacids	203-210	calcium	234-240	false
antacids	203-210	aluminum	246-253	false
magnesium	223-231	calcium	234-240	false
magnesium	223-231	aluminum	246-253	false
calcium	234-240	aluminum	246-253	false

In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
ciprofloxacin	56-68	ciprofloxacin	127-139	false
ciprofloxacin	56-68	VIDEX	229-233	false
ciprofloxacin	127-139	VIDEX	229-233	mechanism

The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
ciprofloxacin	11-23	ciprofloxacin	90-102	false
ciprofloxacin	11-23	didanosine	108-117	false
ciprofloxacin	90-102	didanosine	108-117	mechanism

In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
ciprofloxacin	38-50	didanosine	76-85	mechanism
ciprofloxacin	38-50	ciprofloxacin	147-159	false
didanosine	76-85	ciprofloxacin	147-159	false

Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
quinolone antibiotics	25-45	antacids	84-91	false
quinolone antibiotics	25-45	magnesium	104-112	mechanism
quinolone antibiotics	25-45	calcium	115-121	mechanism
quinolone antibiotics	25-45	aluminum	127-134	mechanism
antacids	84-91	magnesium	104-112	false
antacids	84-91	calcium	115-121	false
antacids	84-91	aluminum	127-134	false
magnesium	104-112	calcium	115-121	false
magnesium	104-112	aluminum	127-134	false
calcium	115-121	aluminum	127-134	false

The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.
VIDEX	54-58	quinolone	111-119	false

Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
Antiretroviral Drugs	24-43	delavirdine	82-92	false
Antiretroviral Drugs	24-43	indinavir	104-112	false
Antiretroviral Drugs	24-43	VIDEX	188-192	false
delavirdine	82-92	indinavir	104-112	false
delavirdine	82-92	VIDEX	188-192	mechanism
indinavir	104-112	VIDEX	188-192	mechanism

To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
delavirdine	27-37	indinavir	42-50	false
delavirdine	27-37	VIDEX	96-100	advise
indinavir	42-50	VIDEX	96-100	advise

The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX.
nelfinavir	24-33	VIDEX	141-145	false

Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
estrogen	97-104	contraceptives	122-135	false

Antidiabetic drug requirements (i.e., insulin) may be altered.
Antidiabetic drug	0-16	insulin	38-44	false

conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
diethylpropion	12-25	antihypertensive drugs	46-67	int
diethylpropion	12-25	guanethidine	76-87	int
diethylpropion	12-25	a-methyldopa	90-101	int
antihypertensive drugs	46-67	guanethidine	76-87	false
antihypertensive drugs	46-67	a-methyldopa	90-101	false
guanethidine	76-87	a-methyldopa	90-101	false

Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
phenothiazines	18-31	diethylpropion	72-85	effect

May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
anticoagulants	13-26	barbiturates	67-78	false
anticoagulants	13-26	rifampin	81-88	false
anticoagulants	13-26	diethylstilbestrol	176-193	false
anticoagulants	13-26	corticosteroids	197-211	false
anticoagulants	13-26	corticosteroids	234-248	false
barbiturates	67-78	rifampin	81-88	false
barbiturates	67-78	diethylstilbestrol	176-193	false
barbiturates	67-78	corticosteroids	197-211	false
barbiturates	67-78	corticosteroids	234-248	false
rifampin	81-88	diethylstilbestrol	176-193	false
rifampin	81-88	corticosteroids	197-211	false
rifampin	81-88	corticosteroids	234-248	false
diethylstilbestrol	176-193	corticosteroids	197-211	false
diethylstilbestrol	176-193	corticosteroids	234-248	false
corticosteroids	197-211	corticosteroids	234-248	false

Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
Anticoagulants	5-18	diflunisal	82-91	false
Anticoagulants	5-18	warfarin	97-104	false
Anticoagulants	5-18	acenocoumarol	107-119	false
Anticoagulants	5-18	phenprocoumon	125-137	false
diflunisal	82-91	warfarin	97-104	effect
diflunisal	82-91	acenocoumarol	107-119	effect
diflunisal	82-91	phenprocoumon	125-137	effect
warfarin	97-104	acenocoumarol	107-119	false
warfarin	97-104	phenprocoumon	125-137	false
acenocoumarol	107-119	phenprocoumon	125-137	false

This may occur because diflunisal competitively displaces coumarins from protein binding sites.
diflunisal	23-32	coumarins	58-66	mechanism

Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
diflunisal	18-27	anticoagulants	55-68	advise

Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.
Tolbutamide	0-10	diflunisal	44-53	false
Tolbutamide	0-10	tolbutamide	59-69	false
Tolbutamide	0-10	tolbutamide	108-118	false
diflunisal	44-53	tolbutamide	59-69	false
diflunisal	44-53	tolbutamide	108-118	false
tolbutamide	59-69	tolbutamide	108-118	false

Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
Hydrochlorothiazide	0-18	diflunisal	73-82	false
Hydrochlorothiazide	0-18	hydrochlorothiazide	88-106	false
Hydrochlorothiazide	0-18	hydrochlorothiazide	161-179	false
diflunisal	73-82	hydrochlorothiazide	88-106	mechanism
diflunisal	73-82	hydrochlorothiazide	161-179	false
hydrochlorothiazide	88-106	hydrochlorothiazide	161-179	false

Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
Diflunisal	0-9	hydrochlorothiazide	49-67	effect

Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.
Furosemide	0-9	diflunisal	68-77	false
Furosemide	0-9	furosemide	83-92	false
Furosemide	0-9	furosemide	136-145	false
diflunisal	68-77	furosemide	83-92	false
diflunisal	68-77	furosemide	136-145	false
furosemide	83-92	furosemide	136-145	false

Diflunisal decreased the hyperuricemic effect of furosemide.
Diflunisal	0-9	furosemide	49-58	effect

Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
Antacids	0-7	antacids	40-47	false
Antacids	0-7	diflunisal	77-86	false
antacids	40-47	diflunisal	77-86	mechanism

This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.
antacids	46-53	antacids	95-102	false

Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
Acetaminophen	0-12	diflunisal	67-76	false
Acetaminophen	0-12	acetaminophen	82-94	false
Acetaminophen	0-12	acetaminophen	156-168	false
diflunisal	67-76	acetaminophen	82-94	mechanism
diflunisal	67-76	acetaminophen	156-168	false
acetaminophen	82-94	acetaminophen	156-168	false

Acetaminophen had no effect on plasma levels of diflunisal.
Acetaminophen	0-12	diflunisal	48-57	false

Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
acetaminophen	6-18	diflunisal	105-114	false
acetaminophen	6-18	acetaminophen	120-132	false
diflunisal	105-114	acetaminophen	120-132	advise

Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
diflunisal	30-39	acetaminophen	45-57	effect
diflunisal	30-39	diflunisal	188-197	false
diflunisal	30-39	acetaminophen	199-211	false
acetaminophen	45-57	diflunisal	188-197	false
acetaminophen	45-57	acetaminophen	199-211	false
diflunisal	188-197	acetaminophen	199-211	false

Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
Methotrexate	0-11	diflunisal	40-49	false
Methotrexate	0-11	methotrexate	86-97	false
diflunisal	40-49	methotrexate	86-97	advise

Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
Nonsteroidal anti-inflammatory drugs	0-35	methotrexate	93-104	mechanism

Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
Cyclosporine	0-11	nonsteroial anti-inflammatory drugs	32-66	false
Cyclosporine	0-11	cyclosporine	87-98	false
Cyclosporine	0-11	cyclosporine	140-151	false
nonsteroial anti-inflammatory drugs	32-66	cyclosporine	87-98	mechanism
nonsteroial anti-inflammatory drugs	32-66	cyclosporine	140-151	false
cyclosporine	87-98	cyclosporine	140-151	false

NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
NSAIDs	0-5	cyclosporine	54-65	advise

Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
Nonsteroidal Anti-Inflammatory Drugs	0-35	diflunisal	60-69	false
Nonsteroidal Anti-Inflammatory Drugs	0-35	indomethacin	102-113	false
Nonsteroidal Anti-Inflammatory Drugs	0-35	indomethacin	194-205	false
diflunisal	60-69	indomethacin	102-113	mechanism
diflunisal	60-69	indomethacin	194-205	false
indomethacin	102-113	indomethacin	194-205	false

In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
indomethacin	37-48	diflunisal	54-63	effect

Therefore, indomethacin and diflunisal should not be used concomitantly.
indomethacin	11-22	diflunisal	28-37	advise

The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
diflunisal	23-32	NSAIDs	52-57	effect

Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
Aspirin	0-6	diflunisal	51-60	false
Aspirin	0-6	diflunisal	105-114	false
Aspirin	0-6	aspirin	120-126	false
diflunisal	51-60	diflunisal	105-114	false
diflunisal	51-60	aspirin	120-126	false
diflunisal	105-114	aspirin	120-126	mechanism

Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
Sulindac	0-7	diflunisal	44-53	false
Sulindac	0-7	sulindac	59-66	false
diflunisal	44-53	sulindac	59-66	mechanism

Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
Naproxen	0-7	diflunisal	44-53	false
Naproxen	0-7	naproxen	59-66	false
Naproxen	0-7	naproxen	127-134	false
Naproxen	0-7	naproxen	190-197	false
diflunisal	44-53	naproxen	59-66	mechanism
diflunisal	44-53	naproxen	127-134	false
diflunisal	44-53	naproxen	190-197	false
naproxen	59-66	naproxen	127-134	false
naproxen	59-66	naproxen	190-197	false
naproxen	127-134	naproxen	190-197	false

Naproxen had no effect on plasma levels of diflunisal.
Naproxen	0-7	diflunisal	43-52	false

Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
Potassium-depleting diuretics	0-28	digitalis	65-73	effect

Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
Quinidine	0-8	verapamil	11-19	false
Quinidine	0-8	amiodarone	22-31	false
Quinidine	0-8	propafenone	34-44	false
Quinidine	0-8	indomethacin	47-58	false
Quinidine	0-8	itraconazole	61-72	false
Quinidine	0-8	alprazolam	75-84	false
Quinidine	0-8	spironolactone	91-104	false
Quinidine	0-8	digoxin	122-128	mechanism
Quinidine	0-8	digitalis	248-256	false
verapamil	11-19	amiodarone	22-31	false
verapamil	11-19	propafenone	34-44	false
verapamil	11-19	indomethacin	47-58	false
verapamil	11-19	itraconazole	61-72	false
verapamil	11-19	alprazolam	75-84	false
verapamil	11-19	spironolactone	91-104	false
verapamil	11-19	digoxin	122-128	mechanism
verapamil	11-19	digitalis	248-256	false
amiodarone	22-31	propafenone	34-44	false
amiodarone	22-31	indomethacin	47-58	false
amiodarone	22-31	itraconazole	61-72	false
amiodarone	22-31	alprazolam	75-84	false
amiodarone	22-31	spironolactone	91-104	false
amiodarone	22-31	digoxin	122-128	mechanism
amiodarone	22-31	digitalis	248-256	false
propafenone	34-44	indomethacin	47-58	false
propafenone	34-44	itraconazole	61-72	false
propafenone	34-44	alprazolam	75-84	false
propafenone	34-44	spironolactone	91-104	false
propafenone	34-44	digoxin	122-128	mechanism
propafenone	34-44	digitalis	248-256	false
indomethacin	47-58	itraconazole	61-72	false
indomethacin	47-58	alprazolam	75-84	false
indomethacin	47-58	spironolactone	91-104	false
indomethacin	47-58	digoxin	122-128	mechanism
indomethacin	47-58	digitalis	248-256	false
itraconazole	61-72	alprazolam	75-84	false
itraconazole	61-72	spironolactone	91-104	false
itraconazole	61-72	digoxin	122-128	mechanism
itraconazole	61-72	digitalis	248-256	false
alprazolam	75-84	spironolactone	91-104	false
alprazolam	75-84	digoxin	122-128	mechanism
alprazolam	75-84	digitalis	248-256	false
spironolactone	91-104	digoxin	122-128	mechanism
spironolactone	91-104	digitalis	248-256	false
digoxin	122-128	digitalis	248-256	false

Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
Erythromycin	0-11	clarithromycin	17-30	false
Erythromycin	0-11	macrolide antibiotics	52-72	false
Erythromycin	0-11	tetracycline	79-90	false
Erythromycin	0-11	digoxin	105-111	mechanism
Erythromycin	0-11	digoxin	151-157	false
Erythromycin	0-11	digitalis	215-223	false
clarithromycin	17-30	macrolide antibiotics	52-72	false
clarithromycin	17-30	tetracycline	79-90	false
clarithromycin	17-30	digoxin	105-111	mechanism
clarithromycin	17-30	digoxin	151-157	false
clarithromycin	17-30	digitalis	215-223	false
macrolide antibiotics	52-72	tetracycline	79-90	false
macrolide antibiotics	52-72	digoxin	105-111	mechanism
macrolide antibiotics	52-72	digoxin	151-157	false
macrolide antibiotics	52-72	digitalis	215-223	false
tetracycline	79-90	digoxin	105-111	mechanism
tetracycline	79-90	digoxin	151-157	false
tetracycline	79-90	digitalis	215-223	false
digoxin	105-111	digoxin	151-157	false
digoxin	105-111	digitalis	215-223	false
digoxin	151-157	digitalis	215-223	false

Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
Propantheline	0-12	diphenoxylate	18-30	false
Propantheline	0-12	digoxin	74-80	mechanism
diphenoxylate	18-30	digoxin	74-80	mechanism

Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
Antacids	0-7	kaolin	10-15	false
Antacids	0-7	sulfasalazine	25-37	false
Antacids	0-7	neomycin	40-47	false
Antacids	0-7	cholestyramine	50-63	false
Antacids	0-7	metoclopramide	96-109	false
Antacids	0-7	digoxin	141-147	mechanism
kaolin	10-15	sulfasalazine	25-37	false
kaolin	10-15	neomycin	40-47	false
kaolin	10-15	cholestyramine	50-63	false
kaolin	10-15	metoclopramide	96-109	false
kaolin	10-15	digoxin	141-147	mechanism
sulfasalazine	25-37	neomycin	40-47	false
sulfasalazine	25-37	cholestyramine	50-63	false
sulfasalazine	25-37	metoclopramide	96-109	false
sulfasalazine	25-37	digoxin	141-147	mechanism
neomycin	40-47	cholestyramine	50-63	false
neomycin	40-47	metoclopramide	96-109	false
neomycin	40-47	digoxin	141-147	mechanism
cholestyramine	50-63	metoclopramide	96-109	false
cholestyramine	50-63	digoxin	141-147	mechanism
metoclopramide	96-109	digoxin	141-147	mechanism

Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
Rifampin	0-7	digoxin	28-34	mechanism
Rifampin	0-7	digoxin	139-145	false
digoxin	28-34	digoxin	139-145	false

There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.
quinine	81-87	penicillamine	90-102	false
quinine	81-87	digoxin	114-120	false
penicillamine	90-102	digoxin	114-120	false

Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.
Thyroid	0-6	digoxin	98-104	advise

Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.
digoxin	19-25	sympathomimetics	31-46	effect

Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
beta-adrenergic blockers	9-32	calcium channel blockers	37-60	false
beta-adrenergic blockers	9-32	digoxin	66-72	effect
calcium channel blockers	37-60	digoxin	66-72	effect

Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.
digoxin	56-62	digoxin	230-236	false

Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
Vasoconstrictors	0-15	D.H.E. 45	18-26	false
Vasoconstrictors	0-15	dihydroergotamine mesylate	30-55	false
Vasoconstrictors	0-15	peripheral vasoconstrictors	97-123	false
D.H.E. 45	18-26	dihydroergotamine mesylate	30-55	false
D.H.E. 45	18-26	peripheral vasoconstrictors	97-123	effect
dihydroergotamine mesylate	30-55	peripheral vasoconstrictors	97-123	effect

Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
Sumatriptan	0-10	Sumatriptan	13-23	false
Sumatriptan	0-10	D.H.E. 45	117-125	false
Sumatriptan	0-10	dihydroergotamine mesylate	129-154	false
Sumatriptan	13-23	D.H.E. 45	117-125	effect
Sumatriptan	13-23	dihydroergotamine mesylate	129-154	effect
D.H.E. 45	117-125	dihydroergotamine mesylate	129-154	false

Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
Sumatriptan	0-10	D.H.E. 45	16-24	advise
Sumatriptan	0-10	dihydroergotamine mesylate	28-53	advise
D.H.E. 45	16-24	dihydroergotamine mesylate	28-53	false

Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
Beta Blockers	0-12	D.H.E. 45	126-134	false
Beta Blockers	0-12	dihydroergotamine mesylate	138-163	false
Beta Blockers	0-12	propranolol	211-221	false
Beta Blockers	0-12	propranolol	253-263	false
Beta Blockers	0-12	ergotamine	311-320	false
D.H.E. 45	126-134	dihydroergotamine mesylate	138-163	false
D.H.E. 45	126-134	propranolol	211-221	false
D.H.E. 45	126-134	propranolol	253-263	false
D.H.E. 45	126-134	ergotamine	311-320	false
dihydroergotamine mesylate	138-163	propranolol	211-221	false
dihydroergotamine mesylate	138-163	propranolol	253-263	false
dihydroergotamine mesylate	138-163	ergotamine	311-320	false
propranolol	211-221	propranolol	253-263	false
propranolol	211-221	ergotamine	311-320	false
propranolol	253-263	ergotamine	311-320	effect

Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
Nicotine	0-7	Nicotine	10-17	false
Nicotine	0-7	ergot	113-117	false
Nicotine	10-17	ergot	113-117	effect

Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
Macrolide Antibiotics	0-20	erythromycin	29-40	false
Macrolide Antibiotics	0-20	troleandomycin	46-59	false
Macrolide Antibiotics	0-20	ergot alkaloid class	77-96	false
Macrolide Antibiotics	0-20	D.H.E. 45	108-116	false
Macrolide Antibiotics	0-20	dihydroergotamine mesylate	120-145	false
Macrolide Antibiotics	0-20	antibiotics	209-219	false
Macrolide Antibiotics	0-20	macrolide class	228-242	false
erythromycin	29-40	troleandomycin	46-59	false
erythromycin	29-40	ergot alkaloid class	77-96	false
erythromycin	29-40	D.H.E. 45	108-116	false
erythromycin	29-40	dihydroergotamine mesylate	120-145	false
erythromycin	29-40	antibiotics	209-219	false
erythromycin	29-40	macrolide class	228-242	false
troleandomycin	46-59	ergot alkaloid class	77-96	false
troleandomycin	46-59	D.H.E. 45	108-116	false
troleandomycin	46-59	dihydroergotamine mesylate	120-145	false
troleandomycin	46-59	antibiotics	209-219	false
troleandomycin	46-59	macrolide class	228-242	false
ergot alkaloid class	77-96	D.H.E. 45	108-116	false
ergot alkaloid class	77-96	dihydroergotamine mesylate	120-145	false
ergot alkaloid class	77-96	antibiotics	209-219	false
ergot alkaloid class	77-96	macrolide class	228-242	mechanism
D.H.E. 45	108-116	dihydroergotamine mesylate	120-145	false
D.H.E. 45	108-116	antibiotics	209-219	false
D.H.E. 45	108-116	macrolide class	228-242	mechanism
dihydroergotamine mesylate	120-145	antibiotics	209-219	false
dihydroergotamine mesylate	120-145	macrolide class	228-242	mechanism
antibiotics	209-219	macrolide class	228-242	false

Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
ergotamine	67-76	antibiotics	127-137	effect

SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
SSRIs	0-4	5-HT1 agonists	81-94	false
SSRIs	0-4	SSRIs	127-131	false
5-HT1 agonists	81-94	SSRIs	127-131	effect

fluoxetine, fluvoxamine, paroxetine, sertraline).
fluoxetine	0-9	fluvoxamine	12-22	false
fluoxetine	0-9	paroxetine	25-34	false
fluoxetine	0-9	sertraline	37-46	false
fluvoxamine	12-22	paroxetine	25-34	false
fluvoxamine	12-22	sertraline	37-46	false
paroxetine	25-34	sertraline	37-46	false

There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
SSRIs	87-91	D.H.E. 45	97-105	false
SSRIs	87-91	dihydroergotamine mesylate	109-134	false
D.H.E. 45	97-105	dihydroergotamine mesylate	109-134	false

Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.
Contraceptives	5-18	contraceptives	40-53	false
Contraceptives	5-18	D.H.E. 45	82-90	false
Contraceptives	5-18	dihydroergotamine mesylate	94-119	false
contraceptives	40-53	D.H.E. 45	82-90	false
contraceptives	40-53	dihydroergotamine mesylate	94-119	false
D.H.E. 45	82-90	dihydroergotamine mesylate	94-119	false

Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.
thiazide diuretics	18-35	dihydrotachysterol	105-122	effect

Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
beta-blockers	105-117	digitalis	122-130	false
beta-blockers	105-117	Tiazac	151-156	effect
digitalis	122-130	Tiazac	151-156	effect

Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.
diltiazem hydrochloride	77-99	beta-blockers	105-117	false

Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
diltiazem hydrochloride	18-40	propranolol	61-71	mechanism
diltiazem hydrochloride	18-40	propranolol	121-131	false
diltiazem hydrochloride	18-40	propranolol	179-189	false
propranolol	61-71	propranolol	121-131	false
propranolol	61-71	propranolol	179-189	false
propranolol	121-131	propranolol	179-189	false

In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
propranolol	10-20	diltiazem	72-80	mechanism

If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.
propranolol	69-79	propranolol	103-113	false

A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
diltiazem	75-83	cimetidine	144-153	false
diltiazem	75-83	diltiazem	188-196	false
cimetidine	144-153	diltiazem	188-196	mechanism

The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
cimetidine	30-39	diltiazem	151-159	mechanism

Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
diltiazem	29-37	cimetidine	163-172	advise

Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
diltiazem hydrochloride	18-40	digoxin	47-53	mechanism
diltiazem hydrochloride	18-40	digoxin	100-106	false
digoxin	47-53	digoxin	100-106	false

Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
digoxin	66-72	digoxin	105-111	false
digoxin	66-72	diltiazem hydrochloride	179-201	false
digoxin	105-111	diltiazem hydrochloride	179-201	advise

The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
anesthetics	121-131	calcium channel blockers	155-178	effect

When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
anesthetics	25-35	calcium channel blockers	41-64	advise

A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
diltiazem	38-46	cyclosporine	52-63	int

In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
cyclosporine	59-70	cyclosporine	127-138	false
cyclosporine	59-70	diltiazem	209-217	mechanism
cyclosporine	127-138	diltiazem	209-217	false

If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
cyclosporine	53-64	diltiazem	118-126	advise

The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.
cyclosporine	14-25	diltiazem	30-38	false

Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
diltiazem	30-38	carbamazepine	45-57	mechanism
diltiazem	30-38	carbamazepine	115-127	false
carbamazepine	45-57	carbamazepine	115-127	false

Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
diltiazem	20-28	midazolam	51-59	mechanism
diltiazem	20-28	triazolam	65-73	mechanism
midazolam	51-59	triazolam	65-73	false

The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
midazolam	29-37	triazolam	43-51	false
midazolam	29-37	diltiazem	112-120	mechanism
triazolam	43-51	diltiazem	112-120	mechanism

These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
diltiazem	42-50	midazolam	144-152	effect
diltiazem	42-50	triazolam	158-166	effect
midazolam	144-152	triazolam	158-166	false

In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
diltiazem	44-52	lovastatin	72-81	mechanism
diltiazem	44-52	lovastatin	124-133	false
diltiazem	44-52	lovastatin	152-161	false
lovastatin	72-81	lovastatin	124-133	false
lovastatin	72-81	lovastatin	152-161	false
lovastatin	124-133	lovastatin	152-161	false

no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.
pravastatin	13-23	diltiazem	58-66	false

Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.
Diltiazem	0-8	lovastatin	59-68	false
Diltiazem	0-8	pravastatin	73-83	false
lovastatin	59-68	pravastatin	73-83	false

Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
rifampin	20-27	diltiazem	34-42	mechanism
rifampin	20-27	diltiazem	56-64	false
diltiazem	34-42	diltiazem	56-64	false

Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
diltiazem	20-28	rifampin	35-42	advise

Dimenhydrinate may decrease emetic response to apomorphine.
Dimenhydrinate	0-13	emetic	28-33	false
Dimenhydrinate	0-13	apomorphine	47-57	effect
emetic	28-33	apomorphine	47-57	false

Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
Oxytocin	0-7	oxytocics	18-26	false
Oxytocin	0-7	dinoprost	49-57	effect
oxytocics	18-26	dinoprost	49-57	effect

PROSTIN E2 may augment the activity of other oxytocic drugs.
PROSTIN E2	0-9	oxytocic drugs	45-58	effect

Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
Diphenhydramine hydrochloride	0-28	alcohol	56-62	effect
Diphenhydramine hydrochloride	0-28	CNS depressants	74-88	effect
Diphenhydramine hydrochloride	0-28	hypnotics	91-99	effect
Diphenhydramine hydrochloride	0-28	sedatives	102-110	effect
Diphenhydramine hydrochloride	0-28	tranquilizers	113-125	effect
alcohol	56-62	CNS depressants	74-88	false
alcohol	56-62	hypnotics	91-99	false
alcohol	56-62	sedatives	102-110	false
alcohol	56-62	tranquilizers	113-125	false
CNS depressants	74-88	hypnotics	91-99	false
CNS depressants	74-88	sedatives	102-110	false
CNS depressants	74-88	tranquilizers	113-125	false
hypnotics	91-99	sedatives	102-110	false
hypnotics	91-99	tranquilizers	113-125	false
sedatives	102-110	tranquilizers	113-125	false

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
MAO inhibitors	0-13	antihistamines	77-90	effect

anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;
anticholinergics	0-15	diphenidol	163-172	false

apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
apomorphine	0-10	diphenidol	33-42	false
apomorphine	0-10	emetic	61-66	false
apomorphine	0-10	apomorphine	80-90	false
diphenidol	33-42	emetic	61-66	false
diphenidol	33-42	apomorphine	80-90	effect
emetic	61-66	apomorphine	80-90	false

Known drug interactions include barbiturates, tranquilizers, and alcohol.
barbiturates	32-43	tranquilizers	46-58	false
barbiturates	32-43	alcohol	65-71	false
tranquilizers	46-58	alcohol	65-71	false

Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
Diphenoxylate HCl	0-16	atropine sulfate	22-37	false
Diphenoxylate HCl	0-16	MAO inhibitors	57-70	int
Diphenoxylate HCl	0-16	diphenoxylate hydrochloride	99-125	false
atropine sulfate	22-37	MAO inhibitors	57-70	int
atropine sulfate	22-37	diphenoxylate hydrochloride	99-125	false
MAO inhibitors	57-70	diphenoxylate hydrochloride	99-125	false

This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
alcohol	28-34	CNS depressants	45-59	false
alcohol	28-34	antihistamines	135-148	false
alcohol	28-34	anticholinergics	152-167	false
alcohol	28-34	antihistamines	314-327	false
alcohol	28-34	monoamine oxidase (MAO) inhibitors	335-368	false
alcohol	28-34	antihistamines	391-404	false
alcohol	28-34	antihistamines	482-495	false
CNS depressants	45-59	antihistamines	135-148	false
CNS depressants	45-59	anticholinergics	152-167	false
CNS depressants	45-59	antihistamines	314-327	false
CNS depressants	45-59	monoamine oxidase (MAO) inhibitors	335-368	false
CNS depressants	45-59	antihistamines	391-404	false
CNS depressants	45-59	antihistamines	482-495	false
antihistamines	135-148	anticholinergics	152-167	false
antihistamines	135-148	antihistamines	314-327	false
antihistamines	135-148	monoamine oxidase (MAO) inhibitors	335-368	false
antihistamines	135-148	antihistamines	391-404	false
antihistamines	135-148	antihistamines	482-495	false
anticholinergics	152-167	antihistamines	314-327	false
anticholinergics	152-167	monoamine oxidase (MAO) inhibitors	335-368	false
anticholinergics	152-167	antihistamines	391-404	false
anticholinergics	152-167	antihistamines	482-495	false
antihistamines	314-327	monoamine oxidase (MAO) inhibitors	335-368	false
antihistamines	314-327	antihistamines	391-404	false
antihistamines	314-327	antihistamines	482-495	false
monoamine oxidase (MAO) inhibitors	335-368	antihistamines	391-404	false
monoamine oxidase (MAO) inhibitors	335-368	antihistamines	482-495	false
antihistamines	391-404	antihistamines	482-495	false

No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE  (dipyridamole USP) Tablets.
PERSANTINE	69-78	dipyridamole	82-93	false

Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
Adenosine	0-8	Dipyridamole	11-22	false
Adenosine	0-8	adenosine	102-110	false
Dipyridamole	11-22	adenosine	102-110	mechanism

Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
Cholinesterase Inhibitors	0-24	Dipyridamole	27-38	false
Cholinesterase Inhibitors	0-24	cholinesterase inhibitors	88-112	false
Dipyridamole	27-38	cholinesterase inhibitors	88-112	effect

Terfenadine: In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of terfenadine.
Terfenadine	0-10	dirithromycin	75-87	false
Terfenadine	0-10	terfenadine	122-132	false
dirithromycin	75-87	terfenadine	122-132	false

These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.
terfenadine	30-40	terfenadine	92-102	false
terfenadine	30-40	dirithromycin	124-136	false
terfenadine	92-102	dirithromycin	124-136	false

The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.
terfenadine	24-34	terfenadine	143-153	false
terfenadine	24-34	terfenadine	171-181	false
terfenadine	24-34	dirithromycin	188-200	false
terfenadine	143-153	terfenadine	171-181	false
terfenadine	143-153	dirithromycin	188-200	false
terfenadine	171-181	dirithromycin	188-200	false

in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
terfenadine	25-35	terfenadine	56-66	false
terfenadine	25-35	terfenadine	93-103	false
terfenadine	25-35	dirithromycin	110-122	false
terfenadine	56-66	terfenadine	93-103	false
terfenadine	56-66	dirithromycin	110-122	false
terfenadine	93-103	dirithromycin	110-122	mechanism

The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
terfenadine	43-53	terfenadine	74-84	false
terfenadine	43-53	dirithromycin	91-103	false
terfenadine	74-84	dirithromycin	91-103	effect

Also, in vitro experiments demonstrated a lack of interaction between dirithromycin and terfenadine.
dirithromycin	70-82	terfenadine	88-98	false

Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
erythromycin	39-50	terfenadine	56-66	int
erythromycin	39-50	dirithromycin	88-100	false
terfenadine	56-66	dirithromycin	88-100	false

Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
terfenadine	91-101	macrolide antibiotics	128-148	effect

In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
macrolides	18-27	terfenadine	71-81	advise

Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.
Theophylline	0-11	dirithromycin	56-68	false
Theophylline	0-11	theophylline	114-125	false
Theophylline	0-11	theophylline	237-248	false
dirithromycin	56-68	theophylline	114-125	false
dirithromycin	56-68	theophylline	237-248	false
theophylline	114-125	theophylline	237-248	false

In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.
dirithromycin	39-51	theophylline	83-94	false
dirithromycin	39-51	theophylline	142-153	false
dirithromycin	39-51	theophylline	179-190	false
theophylline	83-94	theophylline	142-153	false
theophylline	83-94	theophylline	179-190	false
theophylline	142-153	theophylline	179-190	false

However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.
theophylline	9-20	theophylline	169-180	false
theophylline	9-20	theophylline	254-265	false
theophylline	169-180	theophylline	254-265	false

Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
Antacids	0-7	H 2 receptor antagonists	12-35	false
Antacids	0-7	dirithromycin	43-55	false
Antacids	0-7	antacids	95-102	false
Antacids	0-7	H 2 -receptor antagonists	107-131	false
Antacids	0-7	dirithromycin	152-164	false
H 2 receptor antagonists	12-35	dirithromycin	43-55	false
H 2 receptor antagonists	12-35	antacids	95-102	false
H 2 receptor antagonists	12-35	H 2 -receptor antagonists	107-131	false
H 2 receptor antagonists	12-35	dirithromycin	152-164	false
dirithromycin	43-55	antacids	95-102	mechanism
dirithromycin	43-55	H 2 -receptor antagonists	107-131	mechanism
dirithromycin	43-55	dirithromycin	152-164	false
antacids	95-102	H 2 -receptor antagonists	107-131	false
antacids	95-102	dirithromycin	152-164	false
H 2 -receptor antagonists	107-131	dirithromycin	152-164	false

Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
Triazolam	0-8	Erythromycin	11-22	false
Triazolam	0-8	triazolam	71-79	false
Triazolam	0-8	triazolam	133-141	false
Erythromycin	11-22	triazolam	71-79	mechanism
Erythromycin	11-22	triazolam	133-141	effect
triazolam	71-79	triazolam	133-141	false

Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
Digoxin	0-6	erythromycin	39-50	false
Digoxin	0-6	digoxin	56-62	false
Digoxin	0-6	digoxin	104-110	false
erythromycin	39-50	digoxin	56-62	mechanism
erythromycin	39-50	digoxin	104-110	false
digoxin	56-62	digoxin	104-110	false

Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
Anticoagulants	0-13	erythromycin	80-91	false
Anticoagulants	0-13	anticoagulants	102-115	false
erythromycin	80-91	anticoagulants	102-115	effect

Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Ergotamine	0-9	erythromycin	30-41	false
Ergotamine	0-9	ergotamine	47-56	false
Ergotamine	0-9	dihydroergotamine	61-77	false
erythromycin	30-41	ergotamine	47-56	effect
erythromycin	30-41	dihydroergotamine	61-77	effect
ergotamine	47-56	dihydroergotamine	61-77	false

Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
erythromycin	84-95	cyclosporine	130-141	int
erythromycin	84-95	hexobarbital	144-155	int
erythromycin	84-95	carbamazepine	158-170	int
erythromycin	84-95	alfentanil	173-182	int
erythromycin	84-95	disopyramide	185-196	int
erythromycin	84-95	phenytoin	199-207	int
erythromycin	84-95	bromocriptine	210-222	int
erythromycin	84-95	valproate	225-233	int
erythromycin	84-95	astemizole	236-245	int
erythromycin	84-95	lovastatin	252-261	int
cyclosporine	130-141	hexobarbital	144-155	false
cyclosporine	130-141	carbamazepine	158-170	false
cyclosporine	130-141	alfentanil	173-182	false
cyclosporine	130-141	disopyramide	185-196	false
cyclosporine	130-141	phenytoin	199-207	false
cyclosporine	130-141	bromocriptine	210-222	false
cyclosporine	130-141	valproate	225-233	false
cyclosporine	130-141	astemizole	236-245	false
cyclosporine	130-141	lovastatin	252-261	false
hexobarbital	144-155	carbamazepine	158-170	false
hexobarbital	144-155	alfentanil	173-182	false
hexobarbital	144-155	disopyramide	185-196	false
hexobarbital	144-155	phenytoin	199-207	false
hexobarbital	144-155	bromocriptine	210-222	false
hexobarbital	144-155	valproate	225-233	false
hexobarbital	144-155	astemizole	236-245	false
hexobarbital	144-155	lovastatin	252-261	false
carbamazepine	158-170	alfentanil	173-182	false
carbamazepine	158-170	disopyramide	185-196	false
carbamazepine	158-170	phenytoin	199-207	false
carbamazepine	158-170	bromocriptine	210-222	false
carbamazepine	158-170	valproate	225-233	false
carbamazepine	158-170	astemizole	236-245	false
carbamazepine	158-170	lovastatin	252-261	false
alfentanil	173-182	disopyramide	185-196	false
alfentanil	173-182	phenytoin	199-207	false
alfentanil	173-182	bromocriptine	210-222	false
alfentanil	173-182	valproate	225-233	false
alfentanil	173-182	astemizole	236-245	false
alfentanil	173-182	lovastatin	252-261	false
disopyramide	185-196	phenytoin	199-207	false
disopyramide	185-196	bromocriptine	210-222	false
disopyramide	185-196	valproate	225-233	false
disopyramide	185-196	astemizole	236-245	false
disopyramide	185-196	lovastatin	252-261	false
phenytoin	199-207	bromocriptine	210-222	false
phenytoin	199-207	valproate	225-233	false
phenytoin	199-207	astemizole	236-245	false
phenytoin	199-207	lovastatin	252-261	false
bromocriptine	210-222	valproate	225-233	false
bromocriptine	210-222	astemizole	236-245	false
bromocriptine	210-222	lovastatin	252-261	false
valproate	225-233	astemizole	236-245	false
valproate	225-233	lovastatin	252-261	false
astemizole	236-245	lovastatin	252-261	false

If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
phenytoin	3-11	Norpace	74-80	mechanism
phenytoin	3-11	Norpace CR	85-94	mechanism
phenytoin	3-11	disopyramide	120-131	false
Norpace	74-80	Norpace CR	85-94	false
Norpace	74-80	disopyramide	120-131	false
Norpace CR	85-94	disopyramide	120-131	false

Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.
antiarrhythmic drugs	6-25	quinidine	32-40	false
antiarrhythmic drugs	6-25	procainamide	43-54	false
antiarrhythmic drugs	6-25	lidocaine	57-65	false
antiarrhythmic drugs	6-25	propranolol	68-78	false
antiarrhythmic drugs	6-25	Norpace	127-133	false
quinidine	32-40	procainamide	43-54	false
quinidine	32-40	lidocaine	57-65	false
quinidine	32-40	propranolol	68-78	false
quinidine	32-40	Norpace	127-133	false
procainamide	43-54	lidocaine	57-65	false
procainamide	43-54	propranolol	68-78	false
procainamide	43-54	Norpace	127-133	false
lidocaine	57-65	propranolol	68-78	false
lidocaine	57-65	Norpace	127-133	false
propranolol	68-78	Norpace	127-133	false

In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam.
Norpace	76-82	propranolol	115-125	false
Norpace	76-82	diazepam	130-137	false
propranolol	115-125	diazepam	130-137	false

Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
Norpace	30-36	quinidine	42-50	mechanism
Norpace	30-36	disopyramide	91-102	false
Norpace	30-36	quinidine	142-150	false
quinidine	42-50	disopyramide	91-102	false
quinidine	42-50	quinidine	142-150	false
disopyramide	91-102	quinidine	142-150	false

Norpace does not increase serum digoxin levels.
Norpace	0-6	digoxin	32-38	false

Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
disopyramide phosphate	16-37	erythromycin	43-54	mechanism
disopyramide phosphate	16-37	disopyramide	116-127	false
erythromycin	43-54	disopyramide	116-127	false

Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
verapamil	44-52	disopyramide phosphate	58-79	false
verapamil	44-52	disopyramide	95-106	false
verapamil	44-52	verapamil	176-184	false
disopyramide phosphate	58-79	disopyramide	95-106	false
disopyramide phosphate	58-79	verapamil	176-184	false
disopyramide	95-106	verapamil	176-184	advise

DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
DISULFIRAM	0-9	PHENYTOIN	67-75	advise

SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
PHENYTOIN	68-76	DISULFIRAM	115-124	false
PHENYTOIN	68-76	PHENYTOIN	142-150	false
PHENYTOIN	68-76	PHENYTOIN	172-180	false
DISULFIRAM	115-124	PHENYTOIN	142-150	effect
DISULFIRAM	115-124	PHENYTOIN	172-180	false
PHENYTOIN	142-150	PHENYTOIN	172-180	false

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
anticoagulants	49-62	disulfiram	91-100	advise
anticoagulants	49-62	disulfiram	109-118	false
disulfiram	91-100	disulfiram	109-118	false

Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
isoniazid	16-24	disulfiram	31-40	advise

In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
disulfiram	35-44	nitrite	50-56	effect
disulfiram	35-44	disulfiram	149-158	false
disulfiram	35-44	nitrites	175-182	false
nitrite	50-56	disulfiram	149-158	false
nitrite	50-56	nitrites	175-182	false
disulfiram	149-158	nitrites	175-182	effect

Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
dobutamine	29-38	b-blocking drug	98-112	effect

Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
dobutamine	57-66	nitroprusside	72-84	effect

There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
dobutamine	72-81	digitalis preparations	141-162	false
dobutamine	72-81	furosemide	165-174	false
dobutamine	72-81	spironolactone	177-190	false
dobutamine	72-81	lidocaine	193-201	false
dobutamine	72-81	glyceryl trinitrate	204-222	false
dobutamine	72-81	isosorbide dinitrate	225-244	false
dobutamine	72-81	morphine	247-254	false
dobutamine	72-81	atropine	257-264	false
dobutamine	72-81	heparin	267-273	false
dobutamine	72-81	protamine	276-284	false
dobutamine	72-81	potassium chloride	287-304	false
dobutamine	72-81	folic acid	307-316	false
dobutamine	72-81	acetaminophen	323-335	false
digitalis preparations	141-162	furosemide	165-174	false
digitalis preparations	141-162	spironolactone	177-190	false
digitalis preparations	141-162	lidocaine	193-201	false
digitalis preparations	141-162	glyceryl trinitrate	204-222	false
digitalis preparations	141-162	isosorbide dinitrate	225-244	false
digitalis preparations	141-162	morphine	247-254	false
digitalis preparations	141-162	atropine	257-264	false
digitalis preparations	141-162	heparin	267-273	false
digitalis preparations	141-162	protamine	276-284	false
digitalis preparations	141-162	potassium chloride	287-304	false
digitalis preparations	141-162	folic acid	307-316	false
digitalis preparations	141-162	acetaminophen	323-335	false
furosemide	165-174	spironolactone	177-190	false
furosemide	165-174	lidocaine	193-201	false
furosemide	165-174	glyceryl trinitrate	204-222	false
furosemide	165-174	isosorbide dinitrate	225-244	false
furosemide	165-174	morphine	247-254	false
furosemide	165-174	atropine	257-264	false
furosemide	165-174	heparin	267-273	false
furosemide	165-174	protamine	276-284	false
furosemide	165-174	potassium chloride	287-304	false
furosemide	165-174	folic acid	307-316	false
furosemide	165-174	acetaminophen	323-335	false
spironolactone	177-190	lidocaine	193-201	false
spironolactone	177-190	glyceryl trinitrate	204-222	false
spironolactone	177-190	isosorbide dinitrate	225-244	false
spironolactone	177-190	morphine	247-254	false
spironolactone	177-190	atropine	257-264	false
spironolactone	177-190	heparin	267-273	false
spironolactone	177-190	protamine	276-284	false
spironolactone	177-190	potassium chloride	287-304	false
spironolactone	177-190	folic acid	307-316	false
spironolactone	177-190	acetaminophen	323-335	false
lidocaine	193-201	glyceryl trinitrate	204-222	false
lidocaine	193-201	isosorbide dinitrate	225-244	false
lidocaine	193-201	morphine	247-254	false
lidocaine	193-201	atropine	257-264	false
lidocaine	193-201	heparin	267-273	false
lidocaine	193-201	protamine	276-284	false
lidocaine	193-201	potassium chloride	287-304	false
lidocaine	193-201	folic acid	307-316	false
lidocaine	193-201	acetaminophen	323-335	false
glyceryl trinitrate	204-222	isosorbide dinitrate	225-244	false
glyceryl trinitrate	204-222	morphine	247-254	false
glyceryl trinitrate	204-222	atropine	257-264	false
glyceryl trinitrate	204-222	heparin	267-273	false
glyceryl trinitrate	204-222	protamine	276-284	false
glyceryl trinitrate	204-222	potassium chloride	287-304	false
glyceryl trinitrate	204-222	folic acid	307-316	false
glyceryl trinitrate	204-222	acetaminophen	323-335	false
isosorbide dinitrate	225-244	morphine	247-254	false
isosorbide dinitrate	225-244	atropine	257-264	false
isosorbide dinitrate	225-244	heparin	267-273	false
isosorbide dinitrate	225-244	protamine	276-284	false
isosorbide dinitrate	225-244	potassium chloride	287-304	false
isosorbide dinitrate	225-244	folic acid	307-316	false
isosorbide dinitrate	225-244	acetaminophen	323-335	false
morphine	247-254	atropine	257-264	false
morphine	247-254	heparin	267-273	false
morphine	247-254	protamine	276-284	false
morphine	247-254	potassium chloride	287-304	false
morphine	247-254	folic acid	307-316	false
morphine	247-254	acetaminophen	323-335	false
atropine	257-264	heparin	267-273	false
atropine	257-264	protamine	276-284	false
atropine	257-264	potassium chloride	287-304	false
atropine	257-264	folic acid	307-316	false
atropine	257-264	acetaminophen	323-335	false
heparin	267-273	protamine	276-284	false
heparin	267-273	potassium chloride	287-304	false
heparin	267-273	folic acid	307-316	false
heparin	267-273	acetaminophen	323-335	false
protamine	276-284	potassium chloride	287-304	false
protamine	276-284	folic acid	307-316	false
protamine	276-284	acetaminophen	323-335	false
potassium chloride	287-304	folic acid	307-316	false
potassium chloride	287-304	acetaminophen	323-335	false
folic acid	307-316	acetaminophen	323-335	false

In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
docetaxel	51-59	cyclosporine	197-208	mechanism
docetaxel	51-59	terfenadine	211-221	mechanism
docetaxel	51-59	ketoconazole	224-235	mechanism
docetaxel	51-59	erythromycin	238-249	mechanism
docetaxel	51-59	troleandomycin	256-269	mechanism
cyclosporine	197-208	terfenadine	211-221	false
cyclosporine	197-208	ketoconazole	224-235	false
cyclosporine	197-208	erythromycin	238-249	false
cyclosporine	197-208	troleandomycin	256-269	false
terfenadine	211-221	ketoconazole	224-235	false
terfenadine	211-221	erythromycin	238-249	false
terfenadine	211-221	troleandomycin	256-269	false
ketoconazole	224-235	erythromycin	238-249	false
ketoconazole	224-235	troleandomycin	256-269	false
erythromycin	238-249	troleandomycin	256-269	false

Drug-Drug Interactions Cimetidine: Concomitant use of cimetidine is contraindicated.
Cimetidine	23-32	cimetidine	54-63	false

Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
Cimetidine	0-9	TIKOSYN	76-82	mechanism
Cimetidine	0-9	dofetilide	136-145	false
TIKOSYN	76-82	dofetilide	136-145	false

Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
Cimetidine	0-9	dofetilide	75-84	mechanism

If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
TIKOSYN	22-28	anti-ulcer	34-43	false
TIKOSYN	22-28	omeprazole	75-84	false
TIKOSYN	22-28	ranitidine	87-96	false
TIKOSYN	22-28	antacids	102-109	false
TIKOSYN	22-28	aluminum hydroxide	112-119;135-143	false
TIKOSYN	22-28	magnesium hydroxide	125-143	false
TIKOSYN	22-28	cimetidine	174-183	advise
TIKOSYN	22-28	TIKOSYN	251-257	false
anti-ulcer	34-43	omeprazole	75-84	false
anti-ulcer	34-43	ranitidine	87-96	false
anti-ulcer	34-43	antacids	102-109	false
anti-ulcer	34-43	aluminum hydroxide	112-119;135-143	false
anti-ulcer	34-43	magnesium hydroxide	125-143	false
anti-ulcer	34-43	cimetidine	174-183	false
anti-ulcer	34-43	TIKOSYN	251-257	false
omeprazole	75-84	ranitidine	87-96	false
omeprazole	75-84	antacids	102-109	false
omeprazole	75-84	aluminum hydroxide	112-119;135-143	false
omeprazole	75-84	magnesium hydroxide	125-143	false
omeprazole	75-84	cimetidine	174-183	false
omeprazole	75-84	TIKOSYN	251-257	false
ranitidine	87-96	antacids	102-109	false
ranitidine	87-96	aluminum hydroxide	112-119;135-143	false
ranitidine	87-96	magnesium hydroxide	125-143	false
ranitidine	87-96	cimetidine	174-183	false
ranitidine	87-96	TIKOSYN	251-257	false
antacids	102-109	aluminum hydroxide	112-119;135-143	false
antacids	102-109	magnesium hydroxide	125-143	false
antacids	102-109	cimetidine	174-183	false
antacids	102-109	TIKOSYN	251-257	false
aluminum hydroxide	112-119;135-143	magnesium hydroxide	125-143	false
aluminum hydroxide	112-119;135-143	cimetidine	174-183	false
aluminum hydroxide	112-119;135-143	TIKOSYN	251-257	false
magnesium hydroxide	125-143	cimetidine	174-183	false
magnesium hydroxide	125-143	TIKOSYN	251-257	false
cimetidine	174-183	TIKOSYN	251-257	false

Verapamil: Concomitant use of verapamil is contraindicated.
Verapamil	0-8	verapamil	30-38	false

Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
TIKOSYN	21-27	verapamil	34-42	mechanism
TIKOSYN	21-27	dofetilide	69-78	false
TIKOSYN	21-27	dofetilide	136-145	false
verapamil	34-42	dofetilide	69-78	false
verapamil	34-42	dofetilide	136-145	false
dofetilide	69-78	dofetilide	136-145	false

In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
verapamil	117-125	dofetilide	132-141	effect

Ketoconazole: Concomitant use of ketoconazole is contraindicated.
Ketoconazole	0-11	ketoconazole	33-44	false

Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
Ketoconazole	0-11	TIKOSYN	91-97	mechanism
Ketoconazole	0-11	dofetilide	151-160	false
TIKOSYN	91-97	dofetilide	151-160	false

Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.
Trimethoprim	0-11	Sulfamethoxazole	42-57	false
Trimethoprim	0-11	trimethoprim	79-90	false
Trimethoprim	0-11	sulfamethoxazole	121-136	false
Sulfamethoxazole	42-57	trimethoprim	79-90	false
Sulfamethoxazole	42-57	sulfamethoxazole	121-136	false
trimethoprim	79-90	sulfamethoxazole	121-136	false

Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
Hydrochlorothiazide	0-18	HCTZ	21-24	false
Hydrochlorothiazide	0-18	Triamterene	56-66	false
Hydrochlorothiazide	0-18	HCTZ	88-91	false
Hydrochlorothiazide	0-18	triamterene	122-132	false
HCTZ	21-24	Triamterene	56-66	false
HCTZ	21-24	HCTZ	88-91	false
HCTZ	21-24	triamterene	122-132	false
Triamterene	56-66	HCTZ	88-91	false
Triamterene	56-66	triamterene	122-132	false
HCTZ	88-91	triamterene	122-132	false

HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
HCTZ	0-3	HCTZ	17-20	false
HCTZ	0-3	triamterene	22-32	false
HCTZ	0-3	TIKOSYN	72-78	false
HCTZ	0-3	diuretic	126-133	false
HCTZ	17-20	triamterene	22-32	false
HCTZ	17-20	TIKOSYN	72-78	false
HCTZ	17-20	diuretic	126-133	false
triamterene	22-32	TIKOSYN	72-78	false
triamterene	22-32	diuretic	126-133	false
TIKOSYN	72-78	diuretic	126-133	false

In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
HCTZ	22-25	dofetilide	34-43	mechanism

In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.
TIKOSYN	55-61	diuretics	67-75	false
TIKOSYN	55-61	diuretics	177-185	false
diuretics	67-75	diuretics	177-185	false

Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).
potassium depleting diuretics	28-56	TIKOSYN	136-142	false

In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
triamterene	68-78	metformin	81-89	false
triamterene	68-78	amiloride	95-103	false
triamterene	68-78	dofetilide	165-174	advise
metformin	81-89	amiloride	95-103	false
metformin	81-89	dofetilide	165-174	advise
amiloride	95-103	dofetilide	165-174	advise

Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
macrolide antibiotics	36-56	azole antifungal agents	59-81	false
macrolide antibiotics	36-56	protease inhibitors	84-102	false
macrolide antibiotics	36-56	serotonin reuptake inhibitors	105-133	false
macrolide antibiotics	36-56	amiodarone	136-145	false
macrolide antibiotics	36-56	cannabinoids	148-159	false
macrolide antibiotics	36-56	diltiazem	162-170	false
macrolide antibiotics	36-56	nefazadone	191-200	false
macrolide antibiotics	36-56	norfloxacin	203-213	false
macrolide antibiotics	36-56	quinine	216-222	false
macrolide antibiotics	36-56	zafirlukast	225-235	false
macrolide antibiotics	36-56	TIKOSYN	279-285	advise
macrolide antibiotics	36-56	dofetilide	320-329	false
azole antifungal agents	59-81	protease inhibitors	84-102	false
azole antifungal agents	59-81	serotonin reuptake inhibitors	105-133	false
azole antifungal agents	59-81	amiodarone	136-145	false
azole antifungal agents	59-81	cannabinoids	148-159	false
azole antifungal agents	59-81	diltiazem	162-170	false
azole antifungal agents	59-81	nefazadone	191-200	false
azole antifungal agents	59-81	norfloxacin	203-213	false
azole antifungal agents	59-81	quinine	216-222	false
azole antifungal agents	59-81	zafirlukast	225-235	false
azole antifungal agents	59-81	TIKOSYN	279-285	advise
azole antifungal agents	59-81	dofetilide	320-329	false
protease inhibitors	84-102	serotonin reuptake inhibitors	105-133	false
protease inhibitors	84-102	amiodarone	136-145	false
protease inhibitors	84-102	cannabinoids	148-159	false
protease inhibitors	84-102	diltiazem	162-170	false
protease inhibitors	84-102	nefazadone	191-200	false
protease inhibitors	84-102	norfloxacin	203-213	false
protease inhibitors	84-102	quinine	216-222	false
protease inhibitors	84-102	zafirlukast	225-235	false
protease inhibitors	84-102	TIKOSYN	279-285	advise
protease inhibitors	84-102	dofetilide	320-329	false
serotonin reuptake inhibitors	105-133	amiodarone	136-145	false
serotonin reuptake inhibitors	105-133	cannabinoids	148-159	false
serotonin reuptake inhibitors	105-133	diltiazem	162-170	false
serotonin reuptake inhibitors	105-133	nefazadone	191-200	false
serotonin reuptake inhibitors	105-133	norfloxacin	203-213	false
serotonin reuptake inhibitors	105-133	quinine	216-222	false
serotonin reuptake inhibitors	105-133	zafirlukast	225-235	false
serotonin reuptake inhibitors	105-133	TIKOSYN	279-285	advise
serotonin reuptake inhibitors	105-133	dofetilide	320-329	false
amiodarone	136-145	cannabinoids	148-159	false
amiodarone	136-145	diltiazem	162-170	false
amiodarone	136-145	nefazadone	191-200	false
amiodarone	136-145	norfloxacin	203-213	false
amiodarone	136-145	quinine	216-222	false
amiodarone	136-145	zafirlukast	225-235	false
amiodarone	136-145	TIKOSYN	279-285	advise
amiodarone	136-145	dofetilide	320-329	false
cannabinoids	148-159	diltiazem	162-170	false
cannabinoids	148-159	nefazadone	191-200	false
cannabinoids	148-159	norfloxacin	203-213	false
cannabinoids	148-159	quinine	216-222	false
cannabinoids	148-159	zafirlukast	225-235	false
cannabinoids	148-159	TIKOSYN	279-285	advise
cannabinoids	148-159	dofetilide	320-329	false
diltiazem	162-170	nefazadone	191-200	false
diltiazem	162-170	norfloxacin	203-213	false
diltiazem	162-170	quinine	216-222	false
diltiazem	162-170	zafirlukast	225-235	false
diltiazem	162-170	TIKOSYN	279-285	advise
diltiazem	162-170	dofetilide	320-329	false
nefazadone	191-200	norfloxacin	203-213	false
nefazadone	191-200	quinine	216-222	false
nefazadone	191-200	zafirlukast	225-235	false
nefazadone	191-200	TIKOSYN	279-285	advise
nefazadone	191-200	dofetilide	320-329	false
norfloxacin	203-213	quinine	216-222	false
norfloxacin	203-213	zafirlukast	225-235	false
norfloxacin	203-213	TIKOSYN	279-285	advise
norfloxacin	203-213	dofetilide	320-329	false
quinine	216-222	zafirlukast	225-235	false
quinine	216-222	TIKOSYN	279-285	advise
quinine	216-222	dofetilide	320-329	false
zafirlukast	225-235	TIKOSYN	279-285	advise
zafirlukast	225-235	dofetilide	320-329	false
TIKOSYN	279-285	dofetilide	320-329	false

Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin.
Digoxin	35-41	TIKOSYN	90-96	false
Digoxin	35-41	digoxin	138-144	false
TIKOSYN	90-96	digoxin	138-144	false

In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
digoxin	47-53	dofetilide	60-69	effect

It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin;
TIKOSYN	60-66	digoxin	139-145	false

Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
amlodipine	36-45	phenytoin	48-56	false
amlodipine	36-45	glyburide	59-67	false
amlodipine	36-45	ranitidine	70-79	false
amlodipine	36-45	omeprazole	82-91	false
amlodipine	36-45	estrogens	151-159	false
amlodipine	36-45	medroxyprogesterone	165-183	false
amlodipine	36-45	antacid	187-193	false
amlodipine	36-45	aluminum hydroxide	196-203;219-227	false
amlodipine	36-45	magnesium hydroxide	209-227	false
amlodipine	36-45	theophylline	235-246	false
amlodipine	36-45	TIKOSYN	287-293	false
phenytoin	48-56	glyburide	59-67	false
phenytoin	48-56	ranitidine	70-79	false
phenytoin	48-56	omeprazole	82-91	false
phenytoin	48-56	estrogens	151-159	false
phenytoin	48-56	medroxyprogesterone	165-183	false
phenytoin	48-56	antacid	187-193	false
phenytoin	48-56	aluminum hydroxide	196-203;219-227	false
phenytoin	48-56	magnesium hydroxide	209-227	false
phenytoin	48-56	theophylline	235-246	false
phenytoin	48-56	TIKOSYN	287-293	false
glyburide	59-67	ranitidine	70-79	false
glyburide	59-67	omeprazole	82-91	false
glyburide	59-67	estrogens	151-159	false
glyburide	59-67	medroxyprogesterone	165-183	false
glyburide	59-67	antacid	187-193	false
glyburide	59-67	aluminum hydroxide	196-203;219-227	false
glyburide	59-67	magnesium hydroxide	209-227	false
glyburide	59-67	theophylline	235-246	false
glyburide	59-67	TIKOSYN	287-293	false
ranitidine	70-79	omeprazole	82-91	false
ranitidine	70-79	estrogens	151-159	false
ranitidine	70-79	medroxyprogesterone	165-183	false
ranitidine	70-79	antacid	187-193	false
ranitidine	70-79	aluminum hydroxide	196-203;219-227	false
ranitidine	70-79	magnesium hydroxide	209-227	false
ranitidine	70-79	theophylline	235-246	false
ranitidine	70-79	TIKOSYN	287-293	false
omeprazole	82-91	estrogens	151-159	false
omeprazole	82-91	medroxyprogesterone	165-183	false
omeprazole	82-91	antacid	187-193	false
omeprazole	82-91	aluminum hydroxide	196-203;219-227	false
omeprazole	82-91	magnesium hydroxide	209-227	false
omeprazole	82-91	theophylline	235-246	false
omeprazole	82-91	TIKOSYN	287-293	false
estrogens	151-159	medroxyprogesterone	165-183	false
estrogens	151-159	antacid	187-193	false
estrogens	151-159	aluminum hydroxide	196-203;219-227	false
estrogens	151-159	magnesium hydroxide	209-227	false
estrogens	151-159	theophylline	235-246	false
estrogens	151-159	TIKOSYN	287-293	false
medroxyprogesterone	165-183	antacid	187-193	false
medroxyprogesterone	165-183	aluminum hydroxide	196-203;219-227	false
medroxyprogesterone	165-183	magnesium hydroxide	209-227	false
medroxyprogesterone	165-183	theophylline	235-246	false
medroxyprogesterone	165-183	TIKOSYN	287-293	false
antacid	187-193	aluminum hydroxide	196-203;219-227	false
antacid	187-193	magnesium hydroxide	209-227	false
antacid	187-193	theophylline	235-246	false
antacid	187-193	TIKOSYN	287-293	false
aluminum hydroxide	196-203;219-227	magnesium hydroxide	209-227	false
aluminum hydroxide	196-203;219-227	theophylline	235-246	false
aluminum hydroxide	196-203;219-227	TIKOSYN	287-293	false
magnesium hydroxide	209-227	theophylline	235-246	false
magnesium hydroxide	209-227	TIKOSYN	287-293	false
theophylline	235-246	TIKOSYN	287-293	false

In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
TIKOSYN	59-65	warfarin	127-134	false
TIKOSYN	59-65	propranolol	164-174	false
TIKOSYN	59-65	phenytoin	197-205	false
TIKOSYN	59-65	theophylline	208-219	false
TIKOSYN	59-65	contraceptives	230-243	false
warfarin	127-134	propranolol	164-174	false
warfarin	127-134	phenytoin	197-205	false
warfarin	127-134	theophylline	208-219	false
warfarin	127-134	contraceptives	230-243	false
propranolol	164-174	phenytoin	197-205	false
propranolol	164-174	theophylline	208-219	false
propranolol	164-174	contraceptives	230-243	false
phenytoin	197-205	theophylline	208-219	false
phenytoin	197-205	contraceptives	230-243	false
theophylline	208-219	contraceptives	230-243	false

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
ACE inhibitors	40-53	anticoagulants	61-74	false
ACE inhibitors	40-53	calcium channel blockers	77-100	false
ACE inhibitors	40-53	beta blockers	103-115	false
ACE inhibitors	40-53	cardiac glycosides	118-135	false
ACE inhibitors	40-53	nitrates	240-247	false
ACE inhibitors	40-53	sulphonylureas	250-263	false
ACE inhibitors	40-53	loop diuretics	266-279	false
ACE inhibitors	40-53	potassium sparing diuretics	282-308	false
ACE inhibitors	40-53	thiazide diuretics	311-328	false
anticoagulants	61-74	calcium channel blockers	77-100	false
anticoagulants	61-74	beta blockers	103-115	false
anticoagulants	61-74	cardiac glycosides	118-135	false
anticoagulants	61-74	nitrates	240-247	false
anticoagulants	61-74	sulphonylureas	250-263	false
anticoagulants	61-74	loop diuretics	266-279	false
anticoagulants	61-74	potassium sparing diuretics	282-308	false
anticoagulants	61-74	thiazide diuretics	311-328	false
calcium channel blockers	77-100	beta blockers	103-115	false
calcium channel blockers	77-100	cardiac glycosides	118-135	false
calcium channel blockers	77-100	nitrates	240-247	false
calcium channel blockers	77-100	sulphonylureas	250-263	false
calcium channel blockers	77-100	loop diuretics	266-279	false
calcium channel blockers	77-100	potassium sparing diuretics	282-308	false
calcium channel blockers	77-100	thiazide diuretics	311-328	false
beta blockers	103-115	cardiac glycosides	118-135	false
beta blockers	103-115	nitrates	240-247	false
beta blockers	103-115	sulphonylureas	250-263	false
beta blockers	103-115	loop diuretics	266-279	false
beta blockers	103-115	potassium sparing diuretics	282-308	false
beta blockers	103-115	thiazide diuretics	311-328	false
cardiac glycosides	118-135	nitrates	240-247	false
cardiac glycosides	118-135	sulphonylureas	250-263	false
cardiac glycosides	118-135	loop diuretics	266-279	false
cardiac glycosides	118-135	potassium sparing diuretics	282-308	false
cardiac glycosides	118-135	thiazide diuretics	311-328	false
nitrates	240-247	sulphonylureas	250-263	false
nitrates	240-247	loop diuretics	266-279	false
nitrates	240-247	potassium sparing diuretics	282-308	false
nitrates	240-247	thiazide diuretics	311-328	false
sulphonylureas	250-263	loop diuretics	266-279	false
sulphonylureas	250-263	potassium sparing diuretics	282-308	false
sulphonylureas	250-263	thiazide diuretics	311-328	false
loop diuretics	266-279	potassium sparing diuretics	282-308	false
loop diuretics	266-279	thiazide diuretics	311-328	false
potassium sparing diuretics	282-308	thiazide diuretics	311-328	false

The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
dofetilide	23-32	thiazide diuretics	72-89	mechanism

The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.
dolasetron	73-82	hydrodolasetron	88-102	false
dolasetron	73-82	hydrodolasetron	182-196	false
hydrodolasetron	88-102	hydrodolasetron	182-196	false

Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
hydrodolasetron	16-30	dolasetron	51-60	false
hydrodolasetron	16-30	cimetidine	86-95	false
hydrodolasetron	16-30	rifampin	197-204	false
dolasetron	51-60	cimetidine	86-95	mechanism
dolasetron	51-60	rifampin	197-204	mechanism
cimetidine	86-95	rifampin	197-204	false

In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
furosemide	19-28	nifedipine	31-40	false
furosemide	19-28	diltiazem	43-51	false
furosemide	19-28	ACE inhibitors	54-67	false
furosemide	19-28	verapamil	70-78	false
furosemide	19-28	glyburide	81-89	false
furosemide	19-28	propranolol	92-102	false
furosemide	19-28	hydrodolasetron	178-192	false
nifedipine	31-40	diltiazem	43-51	false
nifedipine	31-40	ACE inhibitors	54-67	false
nifedipine	31-40	verapamil	70-78	false
nifedipine	31-40	glyburide	81-89	false
nifedipine	31-40	propranolol	92-102	false
nifedipine	31-40	hydrodolasetron	178-192	false
diltiazem	43-51	ACE inhibitors	54-67	false
diltiazem	43-51	verapamil	70-78	false
diltiazem	43-51	glyburide	81-89	false
diltiazem	43-51	propranolol	92-102	false
diltiazem	43-51	hydrodolasetron	178-192	false
ACE inhibitors	54-67	verapamil	70-78	false
ACE inhibitors	54-67	glyburide	81-89	false
ACE inhibitors	54-67	propranolol	92-102	false
ACE inhibitors	54-67	hydrodolasetron	178-192	false
verapamil	70-78	glyburide	81-89	false
verapamil	70-78	propranolol	92-102	false
verapamil	70-78	hydrodolasetron	178-192	false
glyburide	81-89	propranolol	92-102	false
glyburide	81-89	hydrodolasetron	178-192	false
propranolol	92-102	hydrodolasetron	178-192	false

Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
hydrodolasetron	13-27	dolasetron mesylate	57-75	false
hydrodolasetron	13-27	atenolol	127-134	false
dolasetron mesylate	57-75	atenolol	127-134	mechanism

Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
Dolasetron mesylate	0-18	chemotherapeutic agents	67-89	false
Dolasetron mesylate	0-18	cisplatin	92-100	false
Dolasetron mesylate	0-18	5-fluorouracil	103-116	false
Dolasetron mesylate	0-18	doxorubicin	119-129	false
Dolasetron mesylate	0-18	cyclophosphamide	132-147	false
chemotherapeutic agents	67-89	cisplatin	92-100	false
chemotherapeutic agents	67-89	5-fluorouracil	103-116	false
chemotherapeutic agents	67-89	doxorubicin	119-129	false
chemotherapeutic agents	67-89	cyclophosphamide	132-147	false
cisplatin	92-100	5-fluorouracil	103-116	false
cisplatin	92-100	doxorubicin	119-129	false
cisplatin	92-100	cyclophosphamide	132-147	false
5-fluorouracil	103-116	doxorubicin	119-129	false
5-fluorouracil	103-116	cyclophosphamide	132-147	false
doxorubicin	119-129	cyclophosphamide	132-147	false

Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.
dopamine	8-15	dopamine	125-132	false

Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
MAO inhibitors	36-49	dopamine HCl	108-119	advise
MAO inhibitors	36-49	dopamine HCl	153-164	false
dopamine HCl	108-119	dopamine HCl	153-164	false

Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
dopamine HCl	38-49	diuretic agents	55-69	effect

Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
dopamine	19-26	beta-adrenergic blocking agents	47-77	effect
dopamine	19-26	propranolol	88-98	effect
dopamine	19-26	metoprolol	104-113	effect
beta-adrenergic blocking agents	47-77	propranolol	88-98	false
beta-adrenergic blocking agents	47-77	metoprolol	104-113	false
propranolol	88-98	metoprolol	104-113	false

The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
dopamine HCl	56-67	alpha-adrenergic blocking agents	87-118	effect

Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.
Dopamine	0-7	alpha-adrenergic blocking agents	80-85;95-120	false
Dopamine	0-7	beta-adrenergic blocking agents	90-120	false
alpha-adrenergic blocking agents	80-85;95-120	beta-adrenergic blocking agents	90-120	false

Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
Butyrophenones	0-13	haloperidol	24-34	false
Butyrophenones	0-13	phenothiazines	41-54	false
Butyrophenones	0-13	dopamine	73-80	effect
haloperidol	24-34	phenothiazines	41-54	false
haloperidol	24-34	dopamine	73-80	effect
phenothiazines	41-54	dopamine	73-80	effect

Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
Cyclopropane	0-11	halogenated hydrocarbon anesthetics	16-50	false
Cyclopropane	0-11	catecholamines	177-190	effect
Cyclopropane	0-11	dopamine	201-208	effect
halogenated hydrocarbon anesthetics	16-50	catecholamines	177-190	effect
halogenated hydrocarbon anesthetics	16-50	dopamine	201-208	effect
catecholamines	177-190	dopamine	201-208	false

Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
dopamine HCl	66-77	cyclopropane	101-112	advise
dopamine HCl	66-77	halogenated hydrocarbon anesthetics	117-151	advise
cyclopropane	101-112	halogenated hydrocarbon anesthetics	117-151	false

It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
dopamine	70-77	propranolol	148-158	effect

The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
vasopressor	23-33	ergonovine	70-79	false
vasopressor	23-33	oxytocic drugs	91-104	effect
ergonovine	70-79	oxytocic drugs	91-104	effect

Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
phenytoin	18-26	dopamine HCl	50-61	effect

It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
dopamine HCl	43-54	phenytoin	73-81	advise
dopamine HCl	43-54	anticonvulsant	101-114	false
phenytoin	73-81	anticonvulsant	101-114	false

Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
Pulmozyme	36-44	antibiotics	178-188	false
Pulmozyme	36-44	bronchodilators	191-205	false
Pulmozyme	36-44	vitamins	228-235	false
Pulmozyme	36-44	corticosteroids	254-268	false
Pulmozyme	36-44	analgesics	275-284	false
antibiotics	178-188	bronchodilators	191-205	false
antibiotics	178-188	vitamins	228-235	false
antibiotics	178-188	corticosteroids	254-268	false
antibiotics	178-188	analgesics	275-284	false
bronchodilators	191-205	vitamins	228-235	false
bronchodilators	191-205	corticosteroids	254-268	false
bronchodilators	191-205	analgesics	275-284	false
vitamins	228-235	corticosteroids	254-268	false
vitamins	228-235	analgesics	275-284	false
corticosteroids	254-268	analgesics	275-284	false

Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
dorzolamide	94-104	carbonic anhydrase inhibitors	155-183	effect
dorzolamide	94-104	salicylate	286-295	false
carbonic anhydrase inhibitors	155-183	salicylate	286-295	false

Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.
succinylcholine	24-38	NUROMAX	115-121	false

The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
NUROMAX	11-17	succinylcholine	26-40	false
NUROMAX	11-17	succinylcholine	83-97	false
succinylcholine	26-40	succinylcholine	83-97	false

There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents.
NUROMAX	49-55	neuromuscular blocking agents	83-111	false

Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
Isoflurane	0-9	enflurane	12-20	false
Isoflurane	0-9	halothane	27-35	false
Isoflurane	0-9	NUROMAX	58-64	mechanism
enflurane	12-20	halothane	27-35	false
enflurane	12-20	NUROMAX	58-64	mechanism
halothane	27-35	NUROMAX	58-64	mechanism

Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
NUROMAX	98-104	antibiotics	122-132	effect
NUROMAX	98-104	aminoglycosides	142-156	effect
NUROMAX	98-104	tetracyclines	159-171	effect
NUROMAX	98-104	bacitracin	174-183	effect
NUROMAX	98-104	polymyxins	186-195	effect
NUROMAX	98-104	lincomycin	198-207	effect
NUROMAX	98-104	clindamycin	210-220	effect
NUROMAX	98-104	colistin	223-230	effect
NUROMAX	98-104	sodium colistimethate	237-257	effect
NUROMAX	98-104	magnesium	261-269	effect
NUROMAX	98-104	lithium	278-284	effect
NUROMAX	98-104	anesthetics	293-303	effect
NUROMAX	98-104	procainamide	306-317	effect
NUROMAX	98-104	quinidine	324-332	effect
antibiotics	122-132	aminoglycosides	142-156	false
antibiotics	122-132	tetracyclines	159-171	false
antibiotics	122-132	bacitracin	174-183	false
antibiotics	122-132	polymyxins	186-195	false
antibiotics	122-132	lincomycin	198-207	false
antibiotics	122-132	clindamycin	210-220	false
antibiotics	122-132	colistin	223-230	false
antibiotics	122-132	sodium colistimethate	237-257	false
antibiotics	122-132	magnesium	261-269	false
antibiotics	122-132	lithium	278-284	false
antibiotics	122-132	anesthetics	293-303	false
antibiotics	122-132	procainamide	306-317	false
antibiotics	122-132	quinidine	324-332	false
aminoglycosides	142-156	tetracyclines	159-171	false
aminoglycosides	142-156	bacitracin	174-183	false
aminoglycosides	142-156	polymyxins	186-195	false
aminoglycosides	142-156	lincomycin	198-207	false
aminoglycosides	142-156	clindamycin	210-220	false
aminoglycosides	142-156	colistin	223-230	false
aminoglycosides	142-156	sodium colistimethate	237-257	false
aminoglycosides	142-156	magnesium	261-269	false
aminoglycosides	142-156	lithium	278-284	false
aminoglycosides	142-156	anesthetics	293-303	false
aminoglycosides	142-156	procainamide	306-317	false
aminoglycosides	142-156	quinidine	324-332	false
tetracyclines	159-171	bacitracin	174-183	false
tetracyclines	159-171	polymyxins	186-195	false
tetracyclines	159-171	lincomycin	198-207	false
tetracyclines	159-171	clindamycin	210-220	false
tetracyclines	159-171	colistin	223-230	false
tetracyclines	159-171	sodium colistimethate	237-257	false
tetracyclines	159-171	magnesium	261-269	false
tetracyclines	159-171	lithium	278-284	false
tetracyclines	159-171	anesthetics	293-303	false
tetracyclines	159-171	procainamide	306-317	false
tetracyclines	159-171	quinidine	324-332	false
bacitracin	174-183	polymyxins	186-195	false
bacitracin	174-183	lincomycin	198-207	false
bacitracin	174-183	clindamycin	210-220	false
bacitracin	174-183	colistin	223-230	false
bacitracin	174-183	sodium colistimethate	237-257	false
bacitracin	174-183	magnesium	261-269	false
bacitracin	174-183	lithium	278-284	false
bacitracin	174-183	anesthetics	293-303	false
bacitracin	174-183	procainamide	306-317	false
bacitracin	174-183	quinidine	324-332	false
polymyxins	186-195	lincomycin	198-207	false
polymyxins	186-195	clindamycin	210-220	false
polymyxins	186-195	colistin	223-230	false
polymyxins	186-195	sodium colistimethate	237-257	false
polymyxins	186-195	magnesium	261-269	false
polymyxins	186-195	lithium	278-284	false
polymyxins	186-195	anesthetics	293-303	false
polymyxins	186-195	procainamide	306-317	false
polymyxins	186-195	quinidine	324-332	false
lincomycin	198-207	clindamycin	210-220	false
lincomycin	198-207	colistin	223-230	false
lincomycin	198-207	sodium colistimethate	237-257	false
lincomycin	198-207	magnesium	261-269	false
lincomycin	198-207	lithium	278-284	false
lincomycin	198-207	anesthetics	293-303	false
lincomycin	198-207	procainamide	306-317	false
lincomycin	198-207	quinidine	324-332	false
clindamycin	210-220	colistin	223-230	false
clindamycin	210-220	sodium colistimethate	237-257	false
clindamycin	210-220	magnesium	261-269	false
clindamycin	210-220	lithium	278-284	false
clindamycin	210-220	anesthetics	293-303	false
clindamycin	210-220	procainamide	306-317	false
clindamycin	210-220	quinidine	324-332	false
colistin	223-230	sodium colistimethate	237-257	false
colistin	223-230	magnesium	261-269	false
colistin	223-230	lithium	278-284	false
colistin	223-230	anesthetics	293-303	false
colistin	223-230	procainamide	306-317	false
colistin	223-230	quinidine	324-332	false
sodium colistimethate	237-257	magnesium	261-269	false
sodium colistimethate	237-257	lithium	278-284	false
sodium colistimethate	237-257	anesthetics	293-303	false
sodium colistimethate	237-257	procainamide	306-317	false
sodium colistimethate	237-257	quinidine	324-332	false
magnesium	261-269	lithium	278-284	false
magnesium	261-269	anesthetics	293-303	false
magnesium	261-269	procainamide	306-317	false
magnesium	261-269	quinidine	324-332	false
lithium	278-284	anesthetics	293-303	false
lithium	278-284	procainamide	306-317	false
lithium	278-284	quinidine	324-332	false
anesthetics	293-303	procainamide	306-317	false
anesthetics	293-303	quinidine	324-332	false
procainamide	306-317	quinidine	324-332	false

As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
nondepolarizing neuromuscular blocking agents	19-63	NUROMAX	118-124	false
nondepolarizing neuromuscular blocking agents	19-63	phenytoin	201-209	effect
nondepolarizing neuromuscular blocking agents	19-63	carbamazepine	214-226	effect
NUROMAX	118-124	phenytoin	201-209	effect
NUROMAX	118-124	carbamazepine	214-226	effect
phenytoin	201-209	carbamazepine	214-226	false

Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
doxapram	18-25	sympathomimetic	57-71	effect
doxapram	18-25	monoamine oxidase inhibiting drugs	76-109	effect
sympathomimetic	57-71	monoamine oxidase inhibiting drugs	76-109	false

In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
muscle relaxants	30-45	doxapram	48-55	false
muscle relaxants	30-45	muscle relaxant drugs	102-122	false
doxapram	48-55	muscle relaxant drugs	102-122	effect

In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.
doxazosin mesylate	44-61	digoxin	99-105	false
doxazosin mesylate	44-61	warfarin	108-115	false
doxazosin mesylate	44-61	phenytoin	118-126	false
doxazosin mesylate	44-61	indomethacin	131-142	false
digoxin	99-105	warfarin	108-115	false
digoxin	99-105	phenytoin	118-126	false
digoxin	99-105	indomethacin	131-142	false
warfarin	108-115	phenytoin	118-126	false
warfarin	108-115	indomethacin	131-142	false
phenytoin	118-126	indomethacin	131-142	false

Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.
Doxazosin mesylate	0-17	thiazide diuretics	115-132	false
Doxazosin mesylate	0-17	beta-blocking agent	135-153	false
Doxazosin mesylate	0-17	nonsteroidal anti-inflammatory drugs	161-196	false
thiazide diuretics	115-132	beta-blocking agent	135-153	false
thiazide diuretics	115-132	nonsteroidal anti-inflammatory drugs	161-196	false
beta-blocking agent	135-153	nonsteroidal anti-inflammatory drugs	161-196	false

In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
doxazosin	96-104	cimetidine	145-154	mechanism
doxazosin	96-104	doxazosin	219-227	false
doxazosin	96-104	doxazosin	331-339	false
cimetidine	145-154	doxazosin	219-227	false
cimetidine	145-154	doxazosin	331-339	false
doxazosin	219-227	doxazosin	331-339	false

Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
Analgesic	0-8	anti-inflammatory	10-26	false
Analgesic	0-8	acetaminophen	35-47	false
Analgesic	0-8	aspirin	50-56	false
Analgesic	0-8	codeine	59-65	false
Analgesic	0-8	codeine	71-77	false
Analgesic	0-8	ibuprofen	93-101	false
Analgesic	0-8	indomethacin	104-115	false
anti-inflammatory	10-26	acetaminophen	35-47	false
anti-inflammatory	10-26	aspirin	50-56	false
anti-inflammatory	10-26	codeine	59-65	false
anti-inflammatory	10-26	codeine	71-77	false
anti-inflammatory	10-26	ibuprofen	93-101	false
anti-inflammatory	10-26	indomethacin	104-115	false
acetaminophen	35-47	aspirin	50-56	false
acetaminophen	35-47	codeine	59-65	false
acetaminophen	35-47	codeine	71-77	false
acetaminophen	35-47	ibuprofen	93-101	false
acetaminophen	35-47	indomethacin	104-115	false
aspirin	50-56	codeine	59-65	false
aspirin	50-56	codeine	71-77	false
aspirin	50-56	ibuprofen	93-101	false
aspirin	50-56	indomethacin	104-115	false
codeine	59-65	codeine	71-77	false
codeine	59-65	ibuprofen	93-101	false
codeine	59-65	indomethacin	104-115	false
codeine	71-77	ibuprofen	93-101	false
codeine	71-77	indomethacin	104-115	false
ibuprofen	93-101	indomethacin	104-115	false

Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).
Antibiotics	0-10	erythromycin	19-30	false
Antibiotics	0-10	trimethoprim	33-44	false
Antibiotics	0-10	sulfamethoxazole	50-65	false
Antibiotics	0-10	amoxicillin	68-78	false
erythromycin	19-30	trimethoprim	33-44	false
erythromycin	19-30	sulfamethoxazole	50-65	false
erythromycin	19-30	amoxicillin	68-78	false
trimethoprim	33-44	sulfamethoxazole	50-65	false
trimethoprim	33-44	amoxicillin	68-78	false
sulfamethoxazole	50-65	amoxicillin	68-78	false

Antihistamines (e.g., chlorpheniramine).
Antihistamines	0-13	chlorpheniramine	22-37	false

Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol).
atenolol	29-36	hydrochlorothiazide	39-57	false
atenolol	29-36	propranolol	60-70	false
hydrochlorothiazide	39-57	propranolol	60-70	false

Sedatives and tranquilizers (e.g., diazepam).
Sedatives	0-8	tranquilizers	14-26	false
Sedatives	0-8	diazepam	35-42	false
tranquilizers	14-26	diazepam	35-42	false

Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	69-93	TCAs	96-99	false

cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	0-9	antidepressants	66-80	false
cimetidine	0-9	phenothiazines	83-96	false
cimetidine	0-9	Type 1C antiarrhythmics	107-129	false
cimetidine	0-9	propafenone	131-141	false
cimetidine	0-9	flecainide	147-156	false
antidepressants	66-80	phenothiazines	83-96	false
antidepressants	66-80	Type 1C antiarrhythmics	107-129	false
antidepressants	66-80	propafenone	131-141	false
antidepressants	66-80	flecainide	147-156	false
phenothiazines	83-96	Type 1C antiarrhythmics	107-129	false
phenothiazines	83-96	propafenone	131-141	false
phenothiazines	83-96	flecainide	147-156	false
Type 1C antiarrhythmics	107-129	propafenone	131-141	false
Type 1C antiarrhythmics	107-129	flecainide	147-156	false
propafenone	131-141	flecainide	147-156	false

While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	14-52	SSRIs	55-59	false
selective serotonin reuptake inhibitors	14-52	citalopram	69-78	false
selective serotonin reuptake inhibitors	14-52	escitalopram	81-92	false
selective serotonin reuptake inhibitors	14-52	fluoxetine	95-104	false
selective serotonin reuptake inhibitors	14-52	sertraline	107-116	false
selective serotonin reuptake inhibitors	14-52	paroxetine	123-132	false
SSRIs	55-59	citalopram	69-78	false
SSRIs	55-59	escitalopram	81-92	false
SSRIs	55-59	fluoxetine	95-104	false
SSRIs	55-59	sertraline	107-116	false
SSRIs	55-59	paroxetine	123-132	false
citalopram	69-78	escitalopram	81-92	false
citalopram	69-78	fluoxetine	95-104	false
citalopram	69-78	sertraline	107-116	false
citalopram	69-78	paroxetine	123-132	false
escitalopram	81-92	fluoxetine	95-104	false
escitalopram	81-92	sertraline	107-116	false
escitalopram	81-92	paroxetine	123-132	false
fluoxetine	95-104	sertraline	107-116	false
fluoxetine	95-104	paroxetine	123-132	false
sertraline	107-116	paroxetine	123-132	false

The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	20-23	TCA	25-27	int
SSRI	20-23	SSRI	141-144	false
TCA	25-27	SSRI	141-144	false

Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	63-66	SSRIs	84-88	advise

Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	19-43	tricyclic antidepressant	156-179	false

It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	27-29	TCA	56-58	false

Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
quinidine	42-50	selective serotonin reuptake inhibitors	53-91	false
quinidine	42-50	SSRIs	94-98	false
quinidine	42-50	doxepin	143-149	mechanism
selective serotonin reuptake inhibitors	53-91	SSRIs	94-98	false
selective serotonin reuptake inhibitors	53-91	doxepin	143-149	mechanism
SSRIs	94-98	doxepin	143-149	mechanism

MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors.
MAO Inhibitors	0-13	MAO inhibitors	123-136	false

Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.
MAO inhibitors	11-24	SINEQUAN	117-124	advise

Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
Cimetidine	0-9	Cimetidine	12-21	false
Cimetidine	0-9	tricyclic antidepressants	136-160	false
Cimetidine	12-21	tricyclic antidepressants	136-160	mechanism

Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
tricyclic antidepressant	156-179	cimetidine	186-195	effect

Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
tricyclic antidepressant	35-58	cimetidine	133-142	mechanism

In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
tricyclic antidepressants	60-84	cimetidine	107-116	false
tricyclic antidepressants	60-84	cimetidine	146-155	false
tricyclic antidepressants	60-84	tricyclic antidepressant	218-241	false
cimetidine	107-116	cimetidine	146-155	false
cimetidine	107-116	tricyclic antidepressant	218-241	false
cimetidine	146-155	tricyclic antidepressant	218-241	mechanism

Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
Alcohol	0-6	alcohol	41-47	false
Alcohol	0-6	SINEQUAN	128-135	false
alcohol	41-47	SINEQUAN	128-135	mechanism

Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
Tolazamide	0-9	tolazamide	104-113	false
Tolazamide	0-9	doxepin	156-162	false
tolazamide	104-113	doxepin	156-162	effect

DOXIL  may interact with drugs known to interact with the conventional formulation of doxorubicin HCl.
DOXIL	0-4	doxorubicin HCl	86-100	false

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	8-20	anticoagulant	98-110	advise
tetracyclines	8-20	anticoagulant	161-173	false
anticoagulant	98-110	anticoagulant	161-173	false

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
penicillin	73-82	tetracyclines	117-129	false
penicillin	73-82	penicillin	151-160	false
tetracyclines	117-129	penicillin	151-160	advise

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
tetracyclines	14-26	antacids	43-50	false
tetracyclines	14-26	aluminum	63-70	mechanism
tetracyclines	14-26	calcium	73-79	mechanism
tetracyclines	14-26	magnesium	85-93	mechanism
tetracyclines	14-26	iron	100-103	mechanism
antacids	43-50	aluminum	63-70	false
antacids	43-50	calcium	73-79	false
antacids	43-50	magnesium	85-93	false
antacids	43-50	iron	100-103	false
aluminum	63-70	calcium	73-79	false
aluminum	63-70	magnesium	85-93	false
aluminum	63-70	iron	100-103	false
calcium	73-79	magnesium	85-93	false
calcium	73-79	iron	100-103	false
magnesium	85-93	iron	100-103	false

Absorption of tetracycline is impaired by bismuth subsalicylate.
tetracycline	14-25	bismuth subsalicylate	42-62	mechanism

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
Barbiturates	0-11	carbamazepine	14-26	false
Barbiturates	0-11	phenytoin	33-41	false
Barbiturates	0-11	doxycycline	69-79	mechanism
carbamazepine	14-26	phenytoin	33-41	false
carbamazepine	14-26	doxycycline	69-79	mechanism
phenytoin	33-41	doxycycline	69-79	mechanism

The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
tetracycline	22-33	Penthrane	39-47	effect
tetracycline	22-33	methoxyflurane	50-63	effect
Penthrane	39-47	methoxyflurane	50-63	false

Concurrent use of tetracycline may render oral contraceptives less effective.
tetracycline	18-29	contraceptives	47-60	effect

Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
doxylamine	32-41	doxylamine	74-83	false
doxylamine	32-41	CNS depressant drugs	108-127	false
doxylamine	74-83	CNS depressant drugs	108-127	effect

Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
Antihistamines	0-13	heparin	71-77	effect
Antihistamines	0-13	warfarin	82-89	effect
heparin	71-77	warfarin	82-89	false

Doxylamine may enhance the effects of epinephrine.
Doxylamine	0-9	epinephrine	38-48	effect

Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
oxyphenbutazone	29-43	androgens	49-57	mechanism
oxyphenbutazone	29-43	oxyphenbutazone	98-112	false
androgens	49-57	oxyphenbutazone	98-112	false

In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
androgens	47-55	insulin	99-105	effect

Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
CNS depressant drugs	6-25	barbiturates	33-44	false
CNS depressant drugs	6-25	tranquilizers	47-59	false
CNS depressant drugs	6-25	opioids	62-68	false
CNS depressant drugs	6-25	anesthetics	82-92	false
CNS depressant drugs	6-25	INAPSINE	138-145	effect
barbiturates	33-44	tranquilizers	47-59	false
barbiturates	33-44	opioids	62-68	false
barbiturates	33-44	anesthetics	82-92	false
barbiturates	33-44	INAPSINE	138-145	effect
tranquilizers	47-59	opioids	62-68	false
tranquilizers	47-59	anesthetics	82-92	false
tranquilizers	47-59	INAPSINE	138-145	effect
opioids	62-68	anesthetics	82-92	false
opioids	62-68	INAPSINE	138-145	effect
anesthetics	82-92	INAPSINE	138-145	effect

Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
INAPSINE	32-39	CNS depressant drugs	60-79	advise

However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.
Xigris	59-64	Xigris	99-104	false

Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.
heparin	93-99	unfractionated heparin	102-123	false
heparin	93-99	low molecular weight heparins	174-202	false
unfractionated heparin	102-123	low molecular weight heparins	174-202	false

Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.
heparin	41-47	Xigris	122-127	false

Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).
Xigris	41-46	Xigris	75-80	false

Potential for Other Drugs to Affect Duloxetine: Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.
Duloxetine	36-45	duloxetine	91-100	false

Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
duloxetine	41-50	fluvoxamine	57-67	mechanism
duloxetine	41-50	duloxetine	185-194	false
fluvoxamine	57-67	duloxetine	185-194	false

Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.
duloxetine	52-61	duloxetine	94-103	false
duloxetine	52-61	duloxetine	177-186	false
duloxetine	94-103	duloxetine	177-186	false

Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
Paroxetine	0-9	duloxetine	53-62	mechanism
Paroxetine	0-9	paroxetine	157-166	false
duloxetine	53-62	paroxetine	157-166	false

Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).
fluoxetine	77-86	quinidine	89-97	false

Potential for Duloxetine to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.
Duloxetine	14-23	duloxetine	128-137	false

When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
duloxetine	5-14	desipramine	101-111	mechanism
duloxetine	5-14	desipramine	145-155	false
desipramine	101-111	desipramine	145-155	false

Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
Duloxetine	32-41	antidepressants	170-184	advise
Duloxetine	32-41	tricyclic antidepressants	187-211	advise
Duloxetine	32-41	TCAs	214-217	advise
Duloxetine	32-41	nortriptyline	229-241	advise
Duloxetine	32-41	amitriptyline	244-256	advise
Duloxetine	32-41	imipramine	263-272	advise
Duloxetine	32-41	phenothiazines	276-289	advise
Duloxetine	32-41	Type 1C antiarrhythmics	295-317	advise
Duloxetine	32-41	propafenone	326-336	advise
Duloxetine	32-41	flecainide	339-348	advise
antidepressants	170-184	tricyclic antidepressants	187-211	false
antidepressants	170-184	TCAs	214-217	false
antidepressants	170-184	nortriptyline	229-241	false
antidepressants	170-184	amitriptyline	244-256	false
antidepressants	170-184	imipramine	263-272	false
antidepressants	170-184	phenothiazines	276-289	false
antidepressants	170-184	Type 1C antiarrhythmics	295-317	false
antidepressants	170-184	propafenone	326-336	false
antidepressants	170-184	flecainide	339-348	false
tricyclic antidepressants	187-211	TCAs	214-217	false
tricyclic antidepressants	187-211	nortriptyline	229-241	false
tricyclic antidepressants	187-211	amitriptyline	244-256	false
tricyclic antidepressants	187-211	imipramine	263-272	false
tricyclic antidepressants	187-211	phenothiazines	276-289	false
tricyclic antidepressants	187-211	Type 1C antiarrhythmics	295-317	false
tricyclic antidepressants	187-211	propafenone	326-336	false
tricyclic antidepressants	187-211	flecainide	339-348	false
TCAs	214-217	nortriptyline	229-241	false
TCAs	214-217	amitriptyline	244-256	false
TCAs	214-217	imipramine	263-272	false
TCAs	214-217	phenothiazines	276-289	false
TCAs	214-217	Type 1C antiarrhythmics	295-317	false
TCAs	214-217	propafenone	326-336	false
TCAs	214-217	flecainide	339-348	false
nortriptyline	229-241	amitriptyline	244-256	false
nortriptyline	229-241	imipramine	263-272	false
nortriptyline	229-241	phenothiazines	276-289	false
nortriptyline	229-241	Type 1C antiarrhythmics	295-317	false
nortriptyline	229-241	propafenone	326-336	false
nortriptyline	229-241	flecainide	339-348	false
amitriptyline	244-256	imipramine	263-272	false
amitriptyline	244-256	phenothiazines	276-289	false
amitriptyline	244-256	Type 1C antiarrhythmics	295-317	false
amitriptyline	244-256	propafenone	326-336	false
amitriptyline	244-256	flecainide	339-348	false
imipramine	263-272	phenothiazines	276-289	false
imipramine	263-272	Type 1C antiarrhythmics	295-317	false
imipramine	263-272	propafenone	326-336	false
imipramine	263-272	flecainide	339-348	false
phenothiazines	276-289	Type 1C antiarrhythmics	295-317	false
phenothiazines	276-289	propafenone	326-336	false
phenothiazines	276-289	flecainide	339-348	false
Type 1C antiarrhythmics	295-317	propafenone	326-336	false
Type 1C antiarrhythmics	295-317	flecainide	339-348	false
propafenone	326-336	flecainide	339-348	false

Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
TCA	7-9	TCA	71-73	false
TCA	7-9	TCA	103-105	false
TCA	7-9	Duloxetine	131-140	false
TCA	71-73	TCA	103-105	false
TCA	71-73	Duloxetine	131-140	false
TCA	103-105	Duloxetine	131-140	advise

Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
thioridazine	126-137	Duloxetine	140-149	false
thioridazine	126-137	thioridazine	155-166	false
Duloxetine	140-149	thioridazine	155-166	advise

Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
Duloxetine	0-9	Alcohol	87-93	false
Duloxetine	0-9	Duloxetine	101-110	false
Duloxetine	0-9	ethanol	116-122	false
Duloxetine	0-9	Duloxetine	214-223	false
Duloxetine	0-9	alcohol	294-300	false
Alcohol	87-93	Duloxetine	101-110	false
Alcohol	87-93	ethanol	116-122	false
Alcohol	87-93	Duloxetine	214-223	false
Alcohol	87-93	alcohol	294-300	false
Duloxetine	101-110	ethanol	116-122	false
Duloxetine	101-110	Duloxetine	214-223	false
Duloxetine	101-110	alcohol	294-300	false
ethanol	116-122	Duloxetine	214-223	false
ethanol	116-122	alcohol	294-300	false
Duloxetine	214-223	alcohol	294-300	false

In the Duloxetine clinical trials database, three Duloxetine-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.
Duloxetine	7-16	Duloxetine	50-59	false

However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
Duloxetine	30-39	aluminum	46-53	false
Duloxetine	30-39	magnesium	60-68	false
Duloxetine	30-39	antacids	81-88	false
Duloxetine	30-39	Duloxetine	102-111	false
Duloxetine	30-39	famotidine	118-127	false
Duloxetine	30-39	duloxetine	181-190	false
aluminum	46-53	magnesium	60-68	false
aluminum	46-53	antacids	81-88	false
aluminum	46-53	Duloxetine	102-111	false
aluminum	46-53	famotidine	118-127	false
aluminum	46-53	duloxetine	181-190	false
magnesium	60-68	antacids	81-88	false
magnesium	60-68	Duloxetine	102-111	false
magnesium	60-68	famotidine	118-127	false
magnesium	60-68	duloxetine	181-190	false
antacids	81-88	Duloxetine	102-111	false
antacids	81-88	famotidine	118-127	false
antacids	81-88	duloxetine	181-190	false
Duloxetine	102-111	famotidine	118-127	false
Duloxetine	102-111	duloxetine	181-190	false
famotidine	118-127	duloxetine	181-190	false

It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.
proton pump inhibitors	56-77	duloxetine	87-96	false

Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
xanthine bronchodilators	18-41	theophylline	50-61	false
xanthine bronchodilators	18-41	ephedrine	65-73	false
xanthine bronchodilators	18-41	sympathomimetic bronchodilators	86-116	effect
theophylline	50-61	ephedrine	65-73	false
theophylline	50-61	sympathomimetic bronchodilators	86-116	effect
ephedrine	65-73	sympathomimetic bronchodilators	86-116	effect

Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
dyphylline	29-38	probenecid	44-53	mechanism
dyphylline	29-38	dyphylline	145-154	false
probenecid	44-53	dyphylline	145-154	false

Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
Phospholine Iodide	0-17	cholinesterase inhibitors	37-61	effect
Phospholine Iodide	0-17	succinylcholine	71-85	effect
Phospholine Iodide	0-17	organophosphate insecticide	90-104;120-130	effect
Phospholine Iodide	0-17	carbamate insecticide	110-130	effect
cholinesterase inhibitors	37-61	succinylcholine	71-85	false
cholinesterase inhibitors	37-61	organophosphate insecticide	90-104;120-130	false
cholinesterase inhibitors	37-61	carbamate insecticide	110-130	false
succinylcholine	71-85	organophosphate insecticide	90-104;120-130	false
succinylcholine	71-85	carbamate insecticide	110-130	false
organophosphate insecticide	90-104;120-130	carbamate insecticide	110-130	false

Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
Steroids	0-7	edetate calcium disodium	39-62	effect
Steroids	0-7	Edetate calcium disodium	78-101	false
Steroids	0-7	zinc insulin	133-144	false
Steroids	0-7	zinc	176-179	false
edetate calcium disodium	39-62	Edetate calcium disodium	78-101	false
edetate calcium disodium	39-62	zinc insulin	133-144	false
edetate calcium disodium	39-62	zinc	176-179	false
Edetate calcium disodium	78-101	zinc insulin	133-144	mechanism
Edetate calcium disodium	78-101	zinc	176-179	false
zinc insulin	133-144	zinc	176-179	false

RAPTIVA should not be used with other immunosuppressive drugs.
RAPTIVA	0-6	immunosuppressive drugs	38-60	advise

Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
Acellular vaccines	0-8;36-43	live vaccines	11-14;36-43	false
Acellular vaccines	0-8;36-43	live-attenuated vaccines	20-43	false
Acellular vaccines	0-8;36-43	RAPTIVA	79-85	advise
live vaccines	11-14;36-43	live-attenuated vaccines	20-43	false
live vaccines	11-14;36-43	RAPTIVA	79-85	advise
live-attenuated vaccines	20-43	RAPTIVA	79-85	advise

Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz).
SUSTIVA	112-118	efavirenz	121-129	false

In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.
efavirenz	40-48	efavirenz	112-120	false

Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
phenobarbital	40-52	rifampin	55-62	false
phenobarbital	40-52	rifabutin	65-73	false
phenobarbital	40-52	efavirenz	123-131	mechanism
rifampin	55-62	rifabutin	65-73	false
rifampin	55-62	efavirenz	123-131	mechanism
rifabutin	65-73	efavirenz	123-131	mechanism

Antihistamines: Benzodiazepines GI Motility Agents Anti-Migraine Antifungal
Antihistamines	0-13	Benzodiazepines	16-30	false
Antihistamines	0-13	Anti-Migraine	51-63	false
Antihistamines	0-13	Antifungal	65-74	false
Benzodiazepines	16-30	Anti-Migraine	51-63	false
Benzodiazepines	16-30	Antifungal	65-74	false
Anti-Migraine	51-63	Antifungal	65-74	false

astemizole midazolam, triazolam cisapride ergot derivatives voriconazole
astemizole	0-9	midazolam	11-19	false
astemizole	0-9	triazolam	22-30	false
astemizole	0-9	cisapride	32-40	false
astemizole	0-9	voriconazole	60-71	false
midazolam	11-19	triazolam	22-30	false
midazolam	11-19	cisapride	32-40	false
midazolam	11-19	voriconazole	60-71	false
triazolam	22-30	cisapride	32-40	false
triazolam	22-30	voriconazole	60-71	false
cisapride	32-40	voriconazole	60-71	false

When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).
SUSTIVA	25-31	atazanavir	86-95	false
SUSTIVA	25-31	ritonavir	112-120	false
SUSTIVA	25-31	SUSTIVA	133-139	false
atazanavir	86-95	ritonavir	112-120	false
atazanavir	86-95	SUSTIVA	133-139	false
ritonavir	112-120	SUSTIVA	133-139	false

Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.
SUSTIVA	27-33	atazanavir	39-48	false

In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
SUSTIVA	61-67	clarithromycin	73-86	effect

No dose adjustment of SUSTIVA is recommended when given with clarithromycin.
SUSTIVA	22-28	clarithromycin	61-74	false

Alternatives to clarithromycin, such as azithromycin, should be considered.
clarithromycin	16-29	azithromycin	40-51	false

Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.
macrolide antibiotics	6-26	erythromycin	37-48	false
macrolide antibiotics	6-26	SUSTIVA	93-99	false
erythromycin	37-48	SUSTIVA	93-99	false

The optimal dose of indinavir, when given in combination with SUSTIVA, is not known.
indinavir	20-28	SUSTIVA	62-68	false

Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
indinavir	15-23	indinavir	93-101	false
indinavir	15-23	SUSTIVA	121-127	false
indinavir	93-101	SUSTIVA	121-127	mechanism

When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
indinavir	5-13	SUSTIVA	75-81	mechanism
indinavir	5-13	indinavir	108-116	false
indinavir	5-13	indinavir	210-218	false
SUSTIVA	75-81	indinavir	108-116	false
SUSTIVA	75-81	indinavir	210-218	false
indinavir	108-116	indinavir	210-218	false

Lopinavir/ritonavir
Lopinavir	0-8	ritonavir	10-18	false

A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
lopinavir	19-27	ritonavir	29-37	false
lopinavir	19-27	SUSTIVA	149-155	advise
ritonavir	29-37	SUSTIVA	149-155	advise

Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
methadone	121-129	opiate	144-149	false

Plasma concentrations increased by SUSTIVA (efavirenz);
SUSTIVA	35-41	efavirenz	44-52	false

Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
efavirenz	37-45	contraceptives	57-70	advise
efavirenz	37-45	contraceptives	184-197	false
contraceptives	57-70	contraceptives	184-197	false

Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.
rifabutin	22-30	rifabutin	55-63	false

Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
SUSTIVA	48-54	ritonavir	84-92	advise

Should not be used as sole protease inhibitor in combination with SUSTIVA.
protease inhibitor	27-44	SUSTIVA	66-72	false

Anticoagulants: Warfarin
Anticoagulants	0-13	Warfarin	16-23	false

Anticonvulsants: Phenytoin Phenobarbital Carbamazepine
Anticonvulsants	0-14	Phenytoin	17-25	false
Anticonvulsants	0-14	Phenobarbital	27-39	false
Anticonvulsants	0-14	Carbamazepine	41-53	false
Phenytoin	17-25	Phenobarbital	27-39	false
Phenytoin	17-25	Carbamazepine	41-53	false
Phenobarbital	27-39	Carbamazepine	41-53	false

Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
anticonvulsant	27-40	efavirenz	49-57	mechanism

Antifungals: Itraconazole Ketoconazole
Antifungals	0-10	Itraconazole	13-24	false
Antifungals	0-10	Ketoconazole	26-37	false
Itraconazole	13-24	Ketoconazole	26-37	false

Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.
SUSTIVA	30-36	imidazole antifungals	48-56;71-81	false
SUSTIVA	30-36	triazole antifungals	62-81	false
imidazole antifungals	48-56;71-81	triazole antifungals	62-81	false

SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
SUSTIVA	0-6	itraconazole	63-74	mechanism
SUSTIVA	0-6	ketoconazole	80-91	mechanism
itraconazole	63-74	ketoconazole	80-91	false

Anti-HIV protease inhibitors: Saquinavir/ritonavir combination
Anti-HIV protease inhibitors	0-27	Saquinavir	30-39	false
Anti-HIV protease inhibitors	0-27	ritonavir	41-49	false
Saquinavir	30-39	ritonavir	41-49	false

Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.
efavirenz	52-60	SUSTIVA	103-109	false

Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
SUSTIVA	104-110	efavirenz	113-121	false
SUSTIVA	104-110	aluminum/magnesium hydroxide antacids	153-189	false
SUSTIVA	104-110	azithromycin	192-203	false
SUSTIVA	104-110	cetirizine	206-215	false
SUSTIVA	104-110	famotidine	218-227	false
SUSTIVA	104-110	fluconazole	230-240	false
SUSTIVA	104-110	lamivudine	243-252	false
SUSTIVA	104-110	lorazepam	255-263	false
SUSTIVA	104-110	nelfinavir	266-275	false
SUSTIVA	104-110	paroxetine	278-287	false
SUSTIVA	104-110	zidovudine	294-303	false
efavirenz	113-121	aluminum/magnesium hydroxide antacids	153-189	false
efavirenz	113-121	azithromycin	192-203	false
efavirenz	113-121	cetirizine	206-215	false
efavirenz	113-121	famotidine	218-227	false
efavirenz	113-121	fluconazole	230-240	false
efavirenz	113-121	lamivudine	243-252	false
efavirenz	113-121	lorazepam	255-263	false
efavirenz	113-121	nelfinavir	266-275	false
efavirenz	113-121	paroxetine	278-287	false
efavirenz	113-121	zidovudine	294-303	false
aluminum/magnesium hydroxide antacids	153-189	azithromycin	192-203	false
aluminum/magnesium hydroxide antacids	153-189	cetirizine	206-215	false
aluminum/magnesium hydroxide antacids	153-189	famotidine	218-227	false
aluminum/magnesium hydroxide antacids	153-189	fluconazole	230-240	false
aluminum/magnesium hydroxide antacids	153-189	lamivudine	243-252	false
aluminum/magnesium hydroxide antacids	153-189	lorazepam	255-263	false
aluminum/magnesium hydroxide antacids	153-189	nelfinavir	266-275	false
aluminum/magnesium hydroxide antacids	153-189	paroxetine	278-287	false
aluminum/magnesium hydroxide antacids	153-189	zidovudine	294-303	false
azithromycin	192-203	cetirizine	206-215	false
azithromycin	192-203	famotidine	218-227	false
azithromycin	192-203	fluconazole	230-240	false
azithromycin	192-203	lamivudine	243-252	false
azithromycin	192-203	lorazepam	255-263	false
azithromycin	192-203	nelfinavir	266-275	false
azithromycin	192-203	paroxetine	278-287	false
azithromycin	192-203	zidovudine	294-303	false
cetirizine	206-215	famotidine	218-227	false
cetirizine	206-215	fluconazole	230-240	false
cetirizine	206-215	lamivudine	243-252	false
cetirizine	206-215	lorazepam	255-263	false
cetirizine	206-215	nelfinavir	266-275	false
cetirizine	206-215	paroxetine	278-287	false
cetirizine	206-215	zidovudine	294-303	false
famotidine	218-227	fluconazole	230-240	false
famotidine	218-227	lamivudine	243-252	false
famotidine	218-227	lorazepam	255-263	false
famotidine	218-227	nelfinavir	266-275	false
famotidine	218-227	paroxetine	278-287	false
famotidine	218-227	zidovudine	294-303	false
fluconazole	230-240	lamivudine	243-252	false
fluconazole	230-240	lorazepam	255-263	false
fluconazole	230-240	nelfinavir	266-275	false
fluconazole	230-240	paroxetine	278-287	false
fluconazole	230-240	zidovudine	294-303	false
lamivudine	243-252	lorazepam	255-263	false
lamivudine	243-252	nelfinavir	266-275	false
lamivudine	243-252	paroxetine	278-287	false
lamivudine	243-252	zidovudine	294-303	false
lorazepam	255-263	nelfinavir	266-275	false
lorazepam	255-263	paroxetine	278-287	false
lorazepam	255-263	zidovudine	294-303	false
nelfinavir	266-275	paroxetine	278-287	false
nelfinavir	266-275	zidovudine	294-303	false
paroxetine	278-287	zidovudine	294-303	false

Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.
SUSTIVA	63-69	NRTIs	75-79	false
SUSTIVA	63-69	lamivudine	92-101	false
SUSTIVA	63-69	zidovudine	107-116	false
NRTIs	75-79	lamivudine	92-101	false
NRTIs	75-79	zidovudine	107-116	false
lamivudine	92-101	zidovudine	107-116	false

Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
NRTIs	68-72	efavirenz	117-125	false

The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.
EMTRIVA	41-47	indinavir	86-94	false
EMTRIVA	41-47	stavudine	97-105	false
EMTRIVA	41-47	famciclovir	108-118	false
EMTRIVA	41-47	tenofovir disoproxil fumarate	125-153	false
indinavir	86-94	stavudine	97-105	false
indinavir	86-94	famciclovir	108-118	false
indinavir	86-94	tenofovir disoproxil fumarate	125-153	false
stavudine	97-105	famciclovir	108-118	false
stavudine	97-105	tenofovir disoproxil fumarate	125-153	false
famciclovir	108-118	tenofovir disoproxil fumarate	125-153	false

Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
diuretics	55-63	enalapril	238-246	effect
diuretics	55-63	enalaprilat	251-261	effect
enalapril	238-246	enalaprilat	251-261	false

The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
enalapril	44-52	enalaprilat	57-67	false
enalapril	44-52	diuretic	114-121	effect
enalapril	44-52	enalapril	191-199	false
enalapril	44-52	enalaprilat	204-214	false
enalaprilat	57-67	diuretic	114-121	effect
enalaprilat	57-67	enalapril	191-199	false
enalaprilat	57-67	enalaprilat	204-214	false
diuretic	114-121	enalapril	191-199	false
diuretic	114-121	enalaprilat	204-214	false
enalapril	191-199	enalaprilat	204-214	false

Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
enalapril	61-69	enalapril	75-83	false
enalapril	61-69	antihypertensive agents	104-126	effect
enalapril	61-69	diuretics	160-168	effect
enalapril	75-83	antihypertensive agents	104-126	effect
enalapril	75-83	diuretics	160-168	effect
antihypertensive agents	104-126	diuretics	160-168	false

Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
Non-steroidal Anti-inflammatory Agents	0-37	nonsteroidal anti-inflammatory drugs	116-151	false
Non-steroidal Anti-inflammatory Agents	0-37	enalapril	179-187	false
nonsteroidal anti-inflammatory drugs	116-151	enalapril	179-187	effect

In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC.
indomethacin	34-45	sulindac	50-57	false
indomethacin	34-45	VASOTEC	111-117	false
sulindac	50-57	VASOTEC	111-117	false

However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
NSAIDs	30-35	ACE inhibitors	81-94	effect

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	66-71	ACE inhibitors	92-105	advise

Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
Enalapril	29-37	enalapril	43-51	false
Enalapril	29-37	beta adrenergic-blocking agents	90-120	false
Enalapril	29-37	methyldopa	123-132	false
Enalapril	29-37	nitrates	135-142	false
Enalapril	29-37	calcium-blocking agents	145-167	false
Enalapril	29-37	hydralazine	170-180	false
Enalapril	29-37	prazosin	183-190	false
Enalapril	29-37	digoxin	196-202	false
enalapril	43-51	beta adrenergic-blocking agents	90-120	false
enalapril	43-51	methyldopa	123-132	false
enalapril	43-51	nitrates	135-142	false
enalapril	43-51	calcium-blocking agents	145-167	false
enalapril	43-51	hydralazine	170-180	false
enalapril	43-51	prazosin	183-190	false
enalapril	43-51	digoxin	196-202	false
beta adrenergic-blocking agents	90-120	methyldopa	123-132	false
beta adrenergic-blocking agents	90-120	nitrates	135-142	false
beta adrenergic-blocking agents	90-120	calcium-blocking agents	145-167	false
beta adrenergic-blocking agents	90-120	hydralazine	170-180	false
beta adrenergic-blocking agents	90-120	prazosin	183-190	false
beta adrenergic-blocking agents	90-120	digoxin	196-202	false
methyldopa	123-132	nitrates	135-142	false
methyldopa	123-132	calcium-blocking agents	145-167	false
methyldopa	123-132	hydralazine	170-180	false
methyldopa	123-132	prazosin	183-190	false
methyldopa	123-132	digoxin	196-202	false
nitrates	135-142	calcium-blocking agents	145-167	false
nitrates	135-142	hydralazine	170-180	false
nitrates	135-142	prazosin	183-190	false
nitrates	135-142	digoxin	196-202	false
calcium-blocking agents	145-167	hydralazine	170-180	false
calcium-blocking agents	145-167	prazosin	183-190	false
calcium-blocking agents	145-167	digoxin	196-202	false
hydralazine	170-180	prazosin	183-190	false
hydralazine	170-180	digoxin	196-202	false
prazosin	183-190	digoxin	196-202	false

Enalapril IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.
Enalapril	0-8	digitalis	46-54	false

Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
Enalapril	35-43	enalapril	49-57	false
Enalapril	35-43	thiazide-type diuretics	97-119	effect
enalapril	49-57	thiazide-type diuretics	97-119	effect

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Potassium-sparing diuretics	0-26	spironolactone	35-48	false
Potassium-sparing diuretics	0-26	triamterene	51-61	false
Potassium-sparing diuretics	0-26	amiloride	67-75	false
Potassium-sparing diuretics	0-26	potassium	79-87	false
Potassium-sparing diuretics	0-26	potassium	105-113	false
spironolactone	35-48	triamterene	51-61	false
spironolactone	35-48	amiloride	67-75	false
spironolactone	35-48	potassium	79-87	false
spironolactone	35-48	potassium	105-113	false
triamterene	51-61	amiloride	67-75	false
triamterene	51-61	potassium	79-87	false
triamterene	51-61	potassium	105-113	false
amiloride	67-75	potassium	79-87	false
amiloride	67-75	potassium	105-113	false
potassium	79-87	potassium	105-113	false

Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
Lithium	0-6	Lithium	9-15	false
Lithium	0-6	lithium	66-72	false
Lithium	0-6	ACE inhibitors	144-157	false
Lithium	9-15	lithium	66-72	false
Lithium	9-15	ACE inhibitors	144-157	false
lithium	66-72	ACE inhibitors	144-157	effect

It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
lithium	29-35	enalapril	71-79	false
lithium	29-35	lithium	116-122	false
enalapril	71-79	lithium	116-122	advise

If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.
Enflurane	145-153	halothane	165-173	false
Enflurane	145-153	nitrous oxide	178-190	false
halothane	165-173	nitrous oxide	178-190	false

Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.
Antiretroviral Agents	0-20	antiretroviral medications	55-80	false
Antiretroviral Agents	0-20	enfuvirtide	147-157	false
Antiretroviral Agents	0-20	antiretroviral medication	189-213	false
antiretroviral medications	55-80	enfuvirtide	147-157	false
antiretroviral medications	55-80	antiretroviral medication	189-213	false
enfuvirtide	147-157	antiretroviral medication	189-213	false

Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
Bismuth	0-6	Bismuth subsalicylate	9-29	false
Bismuth	0-6	enoxacin	57-64	false
Bismuth	0-6	enoxacin	90-97	false
Bismuth	0-6	enoxacin	125-132	false
Bismuth subsalicylate	9-29	enoxacin	57-64	mechanism
Bismuth subsalicylate	9-29	enoxacin	90-97	false
Bismuth subsalicylate	9-29	enoxacin	125-132	false
enoxacin	57-64	enoxacin	90-97	false
enoxacin	57-64	enoxacin	125-132	false
enoxacin	90-97	enoxacin	125-132	false

Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
enoxacin	36-43	bismuth subsalicylate	49-69	advise

Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
Caffeine	0-7	Enoxacin	10-17	false
Caffeine	0-7	methylxanthines	108-122	false
Enoxacin	10-17	methylxanthines	108-122	mechanism

In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
enoxacin	26-33	caffeine	103-110	mechanism
enoxacin	26-33	caffeine	149-156	false
enoxacin	26-33	caffeine	239-246	false
caffeine	103-110	caffeine	149-156	false
caffeine	103-110	caffeine	239-246	false
caffeine	149-156	caffeine	239-246	false

Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
enoxacin	14-21	caffeine	56-63	false
enoxacin	14-21	enoxacin	69-76	false
caffeine	56-63	enoxacin	69-76	mechanism

Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
Caffeine	0-7	caffeine	69-76	false
Caffeine	0-7	enoxacin	100-107	false
caffeine	69-76	enoxacin	100-107	effect

Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
Cyclosporine	0-11	cyclosporine	39-50	false
Cyclosporine	0-11	cyclosporine	95-106	false
Cyclosporine	0-11	quinolone class	134-148	false
cyclosporine	39-50	cyclosporine	95-106	false
cyclosporine	39-50	quinolone class	134-148	false
cyclosporine	95-106	quinolone class	134-148	mechanism

Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
Digoxin	0-6	Enoxacin	9-16	false
Digoxin	0-6	digoxin	34-40	false
Enoxacin	9-16	digoxin	34-40	mechanism

If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
digoxin	36-42	enoxacin	64-71	false
digoxin	36-42	digoxin	77-83	false
digoxin	36-42	digoxin	149-155	false
digoxin	36-42	digoxin	175-181	false
enoxacin	64-71	digoxin	77-83	effect
enoxacin	64-71	digoxin	149-155	false
enoxacin	64-71	digoxin	175-181	false
digoxin	77-83	digoxin	149-155	false
digoxin	77-83	digoxin	175-181	false
digoxin	149-155	digoxin	175-181	false

Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
Non-steroidal anti-inflammatory agents	0-37	enoxacin	87-94	false
Non-steroidal anti-inflammatory agents	0-37	nonsteroidal anti-inflammatory drug	119-153	false
Non-steroidal anti-inflammatory agents	0-37	fenbufen	155-162	false
enoxacin	87-94	nonsteroidal anti-inflammatory drug	119-153	false
enoxacin	87-94	fenbufen	155-162	effect
nonsteroidal anti-inflammatory drug	119-153	fenbufen	155-162	false

Sucralfate and antacids: Quinolones form chelates with metal cations.
Sucralfate	0-9	antacids	15-22	false
Sucralfate	0-9	Quinolones	25-34	false
antacids	15-22	Quinolones	25-34	false

Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;
quinolones	29-38	antacids	45-52	false
quinolones	29-38	calcium	65-71	false
quinolones	29-38	magnesium	74-82	false
quinolones	29-38	aluminum	88-95	false
antacids	45-52	calcium	65-71	false
antacids	45-52	magnesium	74-82	false
antacids	45-52	aluminum	88-95	false
calcium	65-71	magnesium	74-82	false
calcium	65-71	aluminum	88-95	false
magnesium	74-82	aluminum	88-95	false

or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
multivitamins	8-20	zinc	33-36	false
multivitamins	8-20	quinolone	132-140	false
zinc	33-36	quinolone	132-140	mechanism

Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
Antacids	0-7	aluminum hydroxide	20-37	false
Antacids	0-7	magnesium hydroxide	43-61	false
Antacids	0-7	enoxacin	93-100	false
aluminum hydroxide	20-37	magnesium hydroxide	43-61	false
aluminum hydroxide	20-37	enoxacin	93-100	mechanism
magnesium hydroxide	43-61	enoxacin	93-100	mechanism

The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
enoxacin	28-35	ranitidine	80-89	mechanism

Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
Theophylline	0-11	Enoxacin	14-21	false
Theophylline	0-11	methylxanthines	112-126	false
Enoxacin	14-21	methylxanthines	112-126	mechanism

Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
Enoxacin	0-7	theophylline	43-54	mechanism
Enoxacin	0-7	theophylline	107-118	false
theophylline	43-54	theophylline	107-118	false

Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
Theophylline	0-11	theophylline	68-79	false
Theophylline	0-11	enoxacin	85-92	false
theophylline	68-79	enoxacin	85-92	effect

Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
Warfarin	0-7	Quinolones	10-19	false
Warfarin	0-7	enoxacin	32-39	false
Warfarin	0-7	R-warfarin	68-77	false
Warfarin	0-7	warfarin	114-121	false
Quinolones	10-19	enoxacin	32-39	false
Quinolones	10-19	R-warfarin	68-77	mechanism
Quinolones	10-19	warfarin	114-121	false
enoxacin	32-39	R-warfarin	68-77	mechanism
enoxacin	32-39	warfarin	114-121	false
R-warfarin	68-77	warfarin	114-121	false

Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.
Enoxacin	0-7	enoxacin	120-127	false
Enoxacin	0-7	warfarin	133-140	false
enoxacin	120-127	warfarin	133-140	false

Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
warfarin	95-102	enoxacin	127-134	advise

These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
anticoagulants	42-55	platelet inhibitors	58-76	false
anticoagulants	42-55	acetylsalicylic acid	88-107	false
anticoagulants	42-55	NSAIDs	124-129	false
anticoagulants	42-55	ketorolac tromethamine	142-163	false
anticoagulants	42-55	dipyridamole	167-178	false
anticoagulants	42-55	sulfinpyrazone	184-197	false
platelet inhibitors	58-76	acetylsalicylic acid	88-107	false
platelet inhibitors	58-76	NSAIDs	124-129	false
platelet inhibitors	58-76	ketorolac tromethamine	142-163	false
platelet inhibitors	58-76	dipyridamole	167-178	false
platelet inhibitors	58-76	sulfinpyrazone	184-197	false
acetylsalicylic acid	88-107	NSAIDs	124-129	false
acetylsalicylic acid	88-107	ketorolac tromethamine	142-163	false
acetylsalicylic acid	88-107	dipyridamole	167-178	false
acetylsalicylic acid	88-107	sulfinpyrazone	184-197	false
NSAIDs	124-129	ketorolac tromethamine	142-163	false
NSAIDs	124-129	dipyridamole	167-178	false
NSAIDs	124-129	sulfinpyrazone	184-197	false
ketorolac tromethamine	142-163	dipyridamole	167-178	false
ketorolac tromethamine	142-163	sulfinpyrazone	184-197	false
dipyridamole	167-178	sulfinpyrazone	184-197	false

In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.
entacapone	60-69	warfarin	109-116	false
entacapone	60-69	salicylic acid	119-132	false
entacapone	60-69	phenylbutazone	135-148	false
entacapone	60-69	diazepam	155-162	false
warfarin	109-116	salicylic acid	119-132	false
warfarin	109-116	phenylbutazone	135-148	false
warfarin	109-116	diazepam	155-162	false
salicylic acid	119-132	phenylbutazone	135-148	false
salicylic acid	119-132	diazepam	155-162	false
phenylbutazone	135-148	diazepam	155-162	false

Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.
entacapone	15-24	levodopa	46-53	false
entacapone	15-24	dopa decarboxylase inhibitor	55-82	false
levodopa	46-53	dopa decarboxylase inhibitor	55-82	false

No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).
MAO-B inhibitor	34-48	selegiline	50-59	false
MAO-B inhibitor	34-48	entacapone	107-116	false
MAO-B inhibitor	34-48	levodopa	144-151	false
MAO-B inhibitor	34-48	dopa decarboxylase inhibitor	153-180	false
selegiline	50-59	entacapone	107-116	false
selegiline	50-59	levodopa	144-151	false
selegiline	50-59	dopa decarboxylase inhibitor	153-180	false
entacapone	107-116	levodopa	144-151	false
entacapone	107-116	dopa decarboxylase inhibitor	153-180	false
levodopa	144-151	dopa decarboxylase inhibitor	153-180	false

More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.
selegiline	71-80	entacapone	102-111	false
selegiline	71-80	levodopa	117-124	false
selegiline	71-80	dopa decarboxylase inhibitor	126-153	false
entacapone	102-111	levodopa	117-124	false
entacapone	102-111	dopa decarboxylase inhibitor	126-153	false
levodopa	117-124	dopa decarboxylase inhibitor	126-153	false

As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone.
entacapone	8-17	entacapone	207-216	false

These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
probenecid	14-23	cholestyramine	26-39	false
probenecid	14-23	antibiotics	51-61	false
probenecid	14-23	erythromycin	69-80	false
probenecid	14-23	ampicillin	96-105	false
probenecid	14-23	chloramphenicol	111-125	false
cholestyramine	26-39	antibiotics	51-61	false
cholestyramine	26-39	erythromycin	69-80	false
cholestyramine	26-39	ampicillin	96-105	false
cholestyramine	26-39	chloramphenicol	111-125	false
antibiotics	51-61	erythromycin	69-80	false
antibiotics	51-61	ampicillin	96-105	false
antibiotics	51-61	chloramphenicol	111-125	false
erythromycin	69-80	ampicillin	96-105	false
erythromycin	69-80	chloramphenicol	111-125	false
ampicillin	96-105	chloramphenicol	111-125	false

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.
tricyclic antidepressant	24-47	imipramine	49-58	false
tricyclic antidepressant	24-47	entacapone	98-107	false
tricyclic antidepressant	24-47	levodopa	132-139	false
tricyclic antidepressant	24-47	dopa-decarboxylase inhibitor	141-168	false
imipramine	49-58	entacapone	98-107	false
imipramine	49-58	levodopa	132-139	false
imipramine	49-58	dopa-decarboxylase inhibitor	141-168	false
entacapone	98-107	levodopa	132-139	false
entacapone	98-107	dopa-decarboxylase inhibitor	141-168	false
levodopa	132-139	dopa-decarboxylase inhibitor	141-168	false

Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
entecavir	6-14	BARACLUDE	76-84	false
entecavir	6-14	entecavir	208-216	false
BARACLUDE	76-84	entecavir	208-216	false

Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
entecavir	20-28	lamivudine	35-44	false
entecavir	20-28	adefovir dipivoxil	47-64	false
entecavir	20-28	tenofovir disoproxil fumarate	69-97	false
lamivudine	35-44	adefovir dipivoxil	47-64	false
lamivudine	35-44	tenofovir disoproxil fumarate	69-97	false
adefovir dipivoxil	47-64	tenofovir disoproxil fumarate	69-97	false

The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.
BARACLUDE	35-43	BARACLUDE	218-226	false

All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
vasopressors	4-15	monoamine oxidase (MAO) inhibitors	62-95	advise

Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
Epinephrine	0-10	sympathomimetic drugs	64-84	advise
Epinephrine	0-10	isoproterenol	95-107	advise
sympathomimetic drugs	64-84	isoproterenol	95-107	false

Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
epinephrine	18-28	cyclopropane	52-63	effect
epinephrine	18-28	halogenated hydrocarbon general anesthetics	68-110	effect
epinephrine	18-28	halothane	120-128	effect
cyclopropane	52-63	halogenated hydrocarbon general anesthetics	68-110	false
cyclopropane	52-63	halothane	120-128	false
halogenated hydrocarbon general anesthetics	68-110	halothane	120-128	false

Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
Epinephrine	0-10	digitalis	67-75	advise
Epinephrine	0-10	glycosides	78-87	advise
Epinephrine	0-10	sympathomimetic drugs	138-158	false
digitalis	67-75	glycosides	78-87	false
digitalis	67-75	sympathomimetic drugs	138-158	false
glycosides	78-87	sympathomimetic drugs	138-158	false

Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
Diuretic agents	0-14	epinephrine	72-82	effect

Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
Epinephrine	0-10	guanethidine	59-70	effect

Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
ELLENCE	19-25	calcium channel blockers	99-122	advise

Cimetidine increased the AUC of epirubicin by 50%.
Cimetidine	0-9	epirubicin	32-41	mechanism

Cimetidine treatment should be stopped during treatment with ELLENCE.
Cimetidine	0-9	ELLENCE	61-67	advise

A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
INSPRA	74-79	ketoconazole	93-104	mechanism
INSPRA	74-79	eplerenone	198-207	false
INSPRA	74-79	eplerenone	243-252	false
ketoconazole	93-104	eplerenone	198-207	false
ketoconazole	93-104	eplerenone	243-252	false
eplerenone	198-207	eplerenone	243-252	false

Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
eplerenone	18-27	erythromycin	65-76	mechanism
eplerenone	18-27	verapamil	90-98	mechanism
eplerenone	18-27	saquinavir	111-120	mechanism
eplerenone	18-27	fluconazole	135-145	mechanism
eplerenone	18-27	eplerenone	191-200	false
erythromycin	65-76	verapamil	90-98	false
erythromycin	65-76	saquinavir	111-120	false
erythromycin	65-76	fluconazole	135-145	false
erythromycin	65-76	eplerenone	191-200	false
verapamil	90-98	saquinavir	111-120	false
verapamil	90-98	fluconazole	135-145	false
verapamil	90-98	eplerenone	191-200	false
saquinavir	111-120	fluconazole	135-145	false
saquinavir	111-120	eplerenone	191-200	false
fluconazole	135-145	eplerenone	191-200	false

ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
ACE Inhibitors	0-13	Angiotensin II Receptor Antagonists	19-53	false
ACE Inhibitors	0-13	INSPRA	152-157	false
ACE Inhibitors	0-13	ACE inhibitors	185-198	false
ACE Inhibitors	0-13	angiotensin II receptor antagonists	203-237	false
ACE Inhibitors	0-13	ACEI	240-243	false
ACE Inhibitors	0-13	ARB	245-247	false
Angiotensin II Receptor Antagonists	19-53	INSPRA	152-157	false
Angiotensin II Receptor Antagonists	19-53	ACE inhibitors	185-198	false
Angiotensin II Receptor Antagonists	19-53	angiotensin II receptor antagonists	203-237	false
Angiotensin II Receptor Antagonists	19-53	ACEI	240-243	false
Angiotensin II Receptor Antagonists	19-53	ARB	245-247	false
INSPRA	152-157	ACE inhibitors	185-198	false
INSPRA	152-157	angiotensin II receptor antagonists	203-237	false
INSPRA	152-157	ACEI	240-243	false
INSPRA	152-157	ARB	245-247	false
ACE inhibitors	185-198	angiotensin II receptor antagonists	203-237	false
ACE inhibitors	185-198	ACEI	240-243	false
ACE inhibitors	185-198	ARB	245-247	false
angiotensin II receptor antagonists	203-237	ACEI	240-243	false
angiotensin II receptor antagonists	203-237	ARB	245-247	false
ACEI	240-243	ARB	245-247	false

Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of ACEI/ARB.
ACEI	97-100	ARB	102-104	false

ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
ACE Inhibitors	0-13	Angiotensin II Receptor Antagonists	19-53	false
ACE Inhibitors	0-13	INSPRA	138-143	false
ACE Inhibitors	0-13	ACE inhibitors	161-174	false
ACE Inhibitors	0-13	angiotensin II receptor antagonists	180-214	false
Angiotensin II Receptor Antagonists	19-53	INSPRA	138-143	false
Angiotensin II Receptor Antagonists	19-53	ACE inhibitors	161-174	false
Angiotensin II Receptor Antagonists	19-53	angiotensin II receptor antagonists	180-214	false
INSPRA	138-143	ACE inhibitors	161-174	effect
INSPRA	138-143	angiotensin II receptor antagonists	180-214	effect
ACE inhibitors	161-174	angiotensin II receptor antagonists	180-214	false

In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
INSPRA	46-51	ACE inhibitor	78-90	false
INSPRA	46-51	enalapril	92-100	effect
INSPRA	46-51	enalapril	189-197	false
ACE inhibitor	78-90	enalapril	92-100	false
ACE inhibitor	78-90	enalapril	189-197	false
enalapril	92-100	enalapril	189-197	false

Lithium-A drug interaction study of eplerenone with lithium has not been conducted.
Lithium	0-6	eplerenone	36-45	false
Lithium	0-6	lithium	52-58	false
eplerenone	36-45	lithium	52-58	false

Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
lithium	6-12	INSPRA	55-60	false
lithium	6-12	lithium	97-103	false
INSPRA	55-60	lithium	97-103	advise

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.
Nonsteroidal Anti-Inflammatory Drugs	0-35	NSAIDs	38-43	false
Nonsteroidal Anti-Inflammatory Drugs	0-35	eplerenone	74-83	false
Nonsteroidal Anti-Inflammatory Drugs	0-35	NSAID	93-97	false
NSAIDs	38-43	eplerenone	74-83	false
NSAIDs	38-43	NSAID	93-97	false
eplerenone	74-83	NSAID	93-97	false

The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
potassium-sparing antihypertensives	28-62	NSAIDs	69-74	effect

Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
INSPRA	16-21	NSAIDs	27-32	advise

Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
FLOLAN	55-60	diuretics	83-91	effect
FLOLAN	55-60	antihypertensive agents	94-116	effect
FLOLAN	55-60	vasodilators	128-139	effect
diuretics	83-91	antihypertensive agents	94-116	false
diuretics	83-91	vasodilators	128-139	false
antihypertensive agents	94-116	vasodilators	128-139	false

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
antiplatelet agents	11-29	anticoagulants	34-47	false
antiplatelet agents	11-29	FLOLAN	100-105	effect
anticoagulants	34-47	FLOLAN	100-105	effect

However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.
FLOLAN	41-46	anticoagulants	86-99	false

In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
FLOLAN	20-25	digoxin	41-47	false
FLOLAN	20-25	diuretics	50-58	false
FLOLAN	20-25	anticoagulants	61-74	false
FLOLAN	20-25	vasodilators	82-93	false
FLOLAN	20-25	oxygen	113-118	false
FLOLAN	20-25	furosemide	202-211	false
FLOLAN	20-25	digoxin	216-222	false
FLOLAN	20-25	FLOLAN	245-250	false
FLOLAN	20-25	furosemide	302-311	false
FLOLAN	20-25	digoxin	326-332	false
digoxin	41-47	diuretics	50-58	false
digoxin	41-47	anticoagulants	61-74	false
digoxin	41-47	vasodilators	82-93	false
digoxin	41-47	oxygen	113-118	false
digoxin	41-47	furosemide	202-211	false
digoxin	41-47	digoxin	216-222	false
digoxin	41-47	FLOLAN	245-250	false
digoxin	41-47	furosemide	302-311	false
digoxin	41-47	digoxin	326-332	false
diuretics	50-58	anticoagulants	61-74	false
diuretics	50-58	vasodilators	82-93	false
diuretics	50-58	oxygen	113-118	false
diuretics	50-58	furosemide	202-211	false
diuretics	50-58	digoxin	216-222	false
diuretics	50-58	FLOLAN	245-250	false
diuretics	50-58	furosemide	302-311	false
diuretics	50-58	digoxin	326-332	false
anticoagulants	61-74	vasodilators	82-93	false
anticoagulants	61-74	oxygen	113-118	false
anticoagulants	61-74	furosemide	202-211	false
anticoagulants	61-74	digoxin	216-222	false
anticoagulants	61-74	FLOLAN	245-250	false
anticoagulants	61-74	furosemide	302-311	false
anticoagulants	61-74	digoxin	326-332	false
vasodilators	82-93	oxygen	113-118	false
vasodilators	82-93	furosemide	202-211	false
vasodilators	82-93	digoxin	216-222	false
vasodilators	82-93	FLOLAN	245-250	false
vasodilators	82-93	furosemide	302-311	false
vasodilators	82-93	digoxin	326-332	false
oxygen	113-118	furosemide	202-211	false
oxygen	113-118	digoxin	216-222	false
oxygen	113-118	FLOLAN	245-250	false
oxygen	113-118	furosemide	302-311	false
oxygen	113-118	digoxin	326-332	false
furosemide	202-211	digoxin	216-222	false
furosemide	202-211	FLOLAN	245-250	mechanism
furosemide	202-211	furosemide	302-311	false
furosemide	202-211	digoxin	326-332	false
digoxin	216-222	FLOLAN	245-250	mechanism
digoxin	216-222	furosemide	302-311	false
digoxin	216-222	digoxin	326-332	false
FLOLAN	245-250	furosemide	302-311	false
FLOLAN	245-250	digoxin	326-332	false
furosemide	302-311	digoxin	326-332	false

However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
digoxin	21-27	digoxin	52-58	false
digoxin	21-27	FLOLAN	108-113	mechanism
digoxin	21-27	digoxin	173-179	false
digoxin	52-58	FLOLAN	108-113	false
digoxin	52-58	digoxin	173-179	false
FLOLAN	108-113	digoxin	173-179	false

Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.
Eprosartan	0-9	digoxin	71-77	false
Eprosartan	0-9	warfarin	107-114	false
Eprosartan	0-9	glyburide	120-128	false
digoxin	71-77	warfarin	107-114	false
digoxin	71-77	glyburide	120-128	false
warfarin	107-114	glyburide	120-128	false

Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.
eprosartan	8-17	ketoconazole	149-160	false
eprosartan	8-17	fluconazole	166-176	false
eprosartan	8-17	eprosartan	266-275	false
ketoconazole	149-160	fluconazole	166-176	false
ketoconazole	149-160	eprosartan	266-275	false
fluconazole	166-176	eprosartan	266-275	false

Ranitidine also has no effect on eprosartan pharmacokinetics.
Ranitidine	0-9	eprosartan	33-42	false

Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide).
Eprosartan	0-9	thiazide diuretic	97-113	false
Eprosartan	0-9	hydrochlorothiazide	116-134	false
thiazide diuretic	97-113	hydrochlorothiazide	116-134	false

Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
Eprosartan	0-9	calcium channel blockers	99-122	false
Eprosartan	0-9	nifedipine	143-152	false
calcium channel blockers	99-122	nifedipine	143-152	false

Enoxaparin dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of eptifibatide or the level of platelet aggregation in healthy adults.
Enoxaparin	0-9	eptifibatide	113-124	false

Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
Mineral oil	0-10	fat-soluble vitamins	46-65	mechanism
Mineral oil	0-10	vitamin D preparations	78-99	mechanism
fat-soluble vitamins	46-65	vitamin D preparations	78-99	false

Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
thiazide diuretics	18-35	ergocalciferol	105-118	effect

The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
ERGOMAR	15-21	triacetyloleandomycin	45-65	mechanism
ERGOMAR	15-21	ergotamine	100-109	false
triacetyloleandomycin	45-65	ergotamine	100-109	mechanism

The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
ERGOMAR	23-29	vasoconstrictor drugs	41-61	effect

Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
ketoconazole	46-57	erlotinib	69-77	mechanism

Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
TARCEVA	52-58	ketoconazole	65-76	advise
TARCEVA	52-58	atazanavir	142-151	advise
TARCEVA	52-58	clarithromycin	154-167	advise
TARCEVA	52-58	indinavir	170-178	advise
TARCEVA	52-58	itraconazole	181-192	advise
TARCEVA	52-58	nefazodone	195-204	advise
TARCEVA	52-58	nelfinavir	207-216	advise
TARCEVA	52-58	ritonavir	219-227	advise
TARCEVA	52-58	saquinavir	230-239	advise
TARCEVA	52-58	telithromycin	242-254	advise
TARCEVA	52-58	troleandomycin	257-270	advise
TARCEVA	52-58	TAO	273-275	advise
TARCEVA	52-58	voriconazole	283-294	advise
ketoconazole	65-76	atazanavir	142-151	false
ketoconazole	65-76	clarithromycin	154-167	false
ketoconazole	65-76	indinavir	170-178	false
ketoconazole	65-76	itraconazole	181-192	false
ketoconazole	65-76	nefazodone	195-204	false
ketoconazole	65-76	nelfinavir	207-216	false
ketoconazole	65-76	ritonavir	219-227	false
ketoconazole	65-76	saquinavir	230-239	false
ketoconazole	65-76	telithromycin	242-254	false
ketoconazole	65-76	troleandomycin	257-270	false
ketoconazole	65-76	TAO	273-275	false
ketoconazole	65-76	voriconazole	283-294	false
atazanavir	142-151	clarithromycin	154-167	false
atazanavir	142-151	indinavir	170-178	false
atazanavir	142-151	itraconazole	181-192	false
atazanavir	142-151	nefazodone	195-204	false
atazanavir	142-151	nelfinavir	207-216	false
atazanavir	142-151	ritonavir	219-227	false
atazanavir	142-151	saquinavir	230-239	false
atazanavir	142-151	telithromycin	242-254	false
atazanavir	142-151	troleandomycin	257-270	false
atazanavir	142-151	TAO	273-275	false
atazanavir	142-151	voriconazole	283-294	false
clarithromycin	154-167	indinavir	170-178	false
clarithromycin	154-167	itraconazole	181-192	false
clarithromycin	154-167	nefazodone	195-204	false
clarithromycin	154-167	nelfinavir	207-216	false
clarithromycin	154-167	ritonavir	219-227	false
clarithromycin	154-167	saquinavir	230-239	false
clarithromycin	154-167	telithromycin	242-254	false
clarithromycin	154-167	troleandomycin	257-270	false
clarithromycin	154-167	TAO	273-275	false
clarithromycin	154-167	voriconazole	283-294	false
indinavir	170-178	itraconazole	181-192	false
indinavir	170-178	nefazodone	195-204	false
indinavir	170-178	nelfinavir	207-216	false
indinavir	170-178	ritonavir	219-227	false
indinavir	170-178	saquinavir	230-239	false
indinavir	170-178	telithromycin	242-254	false
indinavir	170-178	troleandomycin	257-270	false
indinavir	170-178	TAO	273-275	false
indinavir	170-178	voriconazole	283-294	false
itraconazole	181-192	nefazodone	195-204	false
itraconazole	181-192	nelfinavir	207-216	false
itraconazole	181-192	ritonavir	219-227	false
itraconazole	181-192	saquinavir	230-239	false
itraconazole	181-192	telithromycin	242-254	false
itraconazole	181-192	troleandomycin	257-270	false
itraconazole	181-192	TAO	273-275	false
itraconazole	181-192	voriconazole	283-294	false
nefazodone	195-204	nelfinavir	207-216	false
nefazodone	195-204	ritonavir	219-227	false
nefazodone	195-204	saquinavir	230-239	false
nefazodone	195-204	telithromycin	242-254	false
nefazodone	195-204	troleandomycin	257-270	false
nefazodone	195-204	TAO	273-275	false
nefazodone	195-204	voriconazole	283-294	false
nelfinavir	207-216	ritonavir	219-227	false
nelfinavir	207-216	saquinavir	230-239	false
nelfinavir	207-216	telithromycin	242-254	false
nelfinavir	207-216	troleandomycin	257-270	false
nelfinavir	207-216	TAO	273-275	false
nelfinavir	207-216	voriconazole	283-294	false
ritonavir	219-227	saquinavir	230-239	false
ritonavir	219-227	telithromycin	242-254	false
ritonavir	219-227	troleandomycin	257-270	false
ritonavir	219-227	TAO	273-275	false
ritonavir	219-227	voriconazole	283-294	false
saquinavir	230-239	telithromycin	242-254	false
saquinavir	230-239	troleandomycin	257-270	false
saquinavir	230-239	TAO	273-275	false
saquinavir	230-239	voriconazole	283-294	false
telithromycin	242-254	troleandomycin	257-270	false
telithromycin	242-254	TAO	273-275	false
telithromycin	242-254	voriconazole	283-294	false
troleandomycin	257-270	TAO	273-275	false
troleandomycin	257-270	voriconazole	283-294	false
TAO	273-275	voriconazole	283-294	false

Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
rifampicin	38-47	erlotinib	59-67	mechanism

If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
TARCEVA	7-13	rifampicin	97-106	advise

Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.
rifabutin	55-63	rifapentine	66-76	false
rifabutin	55-63	phenytoin	79-87	false
rifabutin	55-63	carbamazepine	90-102	false
rifabutin	55-63	phenobarbital	105-117	false
rifapentine	66-76	phenytoin	79-87	false
rifapentine	66-76	carbamazepine	90-102	false
rifapentine	66-76	phenobarbital	105-117	false
phenytoin	79-87	carbamazepine	90-102	false
phenytoin	79-87	phenobarbital	105-117	false
carbamazepine	90-102	phenobarbital	105-117	false

Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR
warfarin	16-23	coumarin-derivative anticoagulants	34-67	false

When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
ertapenem	5-13	probenecid	39-48	false
ertapenem	5-13	probenecid	79-88	false
ertapenem	5-13	ertapenem	163-171	false
probenecid	39-48	probenecid	79-88	false
probenecid	39-48	ertapenem	163-171	false
probenecid	79-88	ertapenem	163-171	mechanism

Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
ertapenem	15-23	probenecid	41-50	mechanism

Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
probenecid	68-77	ertapenem	106-114	advise

In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
ertapenem	31-39	digoxin	95-101	false
ertapenem	31-39	vinblastine	106-116	false
ertapenem	31-39	ertapenem	127-135	false
digoxin	95-101	vinblastine	106-116	false
digoxin	95-101	ertapenem	127-135	false
vinblastine	106-116	ertapenem	127-135	false

Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
Erythromycin	0-11	theophylline	61-72	effect
Erythromycin	0-11	theophylline	118-129	false
Erythromycin	0-11	theophylline	152-163	false
theophylline	61-72	theophylline	118-129	false
theophylline	61-72	theophylline	152-163	false
theophylline	118-129	theophylline	152-163	false

In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
theophylline	11-22	theophylline	55-66	false
theophylline	11-22	theophylline	88-99	false
theophylline	11-22	erythromycin	162-173	false
theophylline	55-66	theophylline	88-99	false
theophylline	55-66	erythromycin	162-173	false
theophylline	88-99	erythromycin	162-173	advise

Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
erythromycin	30-41	digoxin	47-53	mechanism
erythromycin	30-41	digoxin	95-101	false
digoxin	47-53	digoxin	95-101	false

There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
erythromycin	64-75	anticoagulants	86-99	effect

Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
erythromycin	18-29	ergotamine	35-44	effect
erythromycin	18-29	dihydroergotamine	49-65	effect
ergotamine	35-44	dihydroergotamine	49-65	false

Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
Erythromycin	0-11	triazolam	60-68	mechanism
Erythromycin	0-11	midazolam	74-82	mechanism
Erythromycin	0-11	benzodiazepines	140-154	effect
triazolam	60-68	midazolam	74-82	false
triazolam	60-68	benzodiazepines	140-154	false
midazolam	74-82	benzodiazepines	140-154	false

There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
erythromycin	43-54	carbamazepine	61-73	int
erythromycin	43-54	cyclosporine	76-87	int
erythromycin	43-54	tacrolimus	90-99	int
erythromycin	43-54	hexobarbital	102-113	int
erythromycin	43-54	phenytoin	116-124	int
erythromycin	43-54	alfentanil	127-136	int
erythromycin	43-54	cisapride	139-147	int
erythromycin	43-54	disopyramide	150-161	int
erythromycin	43-54	lovastatin	164-173	int
erythromycin	43-54	bromocriptine	176-188	int
erythromycin	43-54	valproate	191-199	int
erythromycin	43-54	terfenadine	202-212	int
erythromycin	43-54	astemizole	219-228	int
carbamazepine	61-73	cyclosporine	76-87	false
carbamazepine	61-73	tacrolimus	90-99	false
carbamazepine	61-73	hexobarbital	102-113	false
carbamazepine	61-73	phenytoin	116-124	false
carbamazepine	61-73	alfentanil	127-136	false
carbamazepine	61-73	cisapride	139-147	false
carbamazepine	61-73	disopyramide	150-161	false
carbamazepine	61-73	lovastatin	164-173	false
carbamazepine	61-73	bromocriptine	176-188	false
carbamazepine	61-73	valproate	191-199	false
carbamazepine	61-73	terfenadine	202-212	false
carbamazepine	61-73	astemizole	219-228	false
cyclosporine	76-87	tacrolimus	90-99	false
cyclosporine	76-87	hexobarbital	102-113	false
cyclosporine	76-87	phenytoin	116-124	false
cyclosporine	76-87	alfentanil	127-136	false
cyclosporine	76-87	cisapride	139-147	false
cyclosporine	76-87	disopyramide	150-161	false
cyclosporine	76-87	lovastatin	164-173	false
cyclosporine	76-87	bromocriptine	176-188	false
cyclosporine	76-87	valproate	191-199	false
cyclosporine	76-87	terfenadine	202-212	false
cyclosporine	76-87	astemizole	219-228	false
tacrolimus	90-99	hexobarbital	102-113	false
tacrolimus	90-99	phenytoin	116-124	false
tacrolimus	90-99	alfentanil	127-136	false
tacrolimus	90-99	cisapride	139-147	false
tacrolimus	90-99	disopyramide	150-161	false
tacrolimus	90-99	lovastatin	164-173	false
tacrolimus	90-99	bromocriptine	176-188	false
tacrolimus	90-99	valproate	191-199	false
tacrolimus	90-99	terfenadine	202-212	false
tacrolimus	90-99	astemizole	219-228	false
hexobarbital	102-113	phenytoin	116-124	false
hexobarbital	102-113	alfentanil	127-136	false
hexobarbital	102-113	cisapride	139-147	false
hexobarbital	102-113	disopyramide	150-161	false
hexobarbital	102-113	lovastatin	164-173	false
hexobarbital	102-113	bromocriptine	176-188	false
hexobarbital	102-113	valproate	191-199	false
hexobarbital	102-113	terfenadine	202-212	false
hexobarbital	102-113	astemizole	219-228	false
phenytoin	116-124	alfentanil	127-136	false
phenytoin	116-124	cisapride	139-147	false
phenytoin	116-124	disopyramide	150-161	false
phenytoin	116-124	lovastatin	164-173	false
phenytoin	116-124	bromocriptine	176-188	false
phenytoin	116-124	valproate	191-199	false
phenytoin	116-124	terfenadine	202-212	false
phenytoin	116-124	astemizole	219-228	false
alfentanil	127-136	cisapride	139-147	false
alfentanil	127-136	disopyramide	150-161	false
alfentanil	127-136	lovastatin	164-173	false
alfentanil	127-136	bromocriptine	176-188	false
alfentanil	127-136	valproate	191-199	false
alfentanil	127-136	terfenadine	202-212	false
alfentanil	127-136	astemizole	219-228	false
cisapride	139-147	disopyramide	150-161	false
cisapride	139-147	lovastatin	164-173	false
cisapride	139-147	bromocriptine	176-188	false
cisapride	139-147	valproate	191-199	false
cisapride	139-147	terfenadine	202-212	false
cisapride	139-147	astemizole	219-228	false
disopyramide	150-161	lovastatin	164-173	false
disopyramide	150-161	bromocriptine	176-188	false
disopyramide	150-161	valproate	191-199	false
disopyramide	150-161	terfenadine	202-212	false
disopyramide	150-161	astemizole	219-228	false
lovastatin	164-173	bromocriptine	176-188	false
lovastatin	164-173	valproate	191-199	false
lovastatin	164-173	terfenadine	202-212	false
lovastatin	164-173	astemizole	219-228	false
bromocriptine	176-188	valproate	191-199	false
bromocriptine	176-188	terfenadine	202-212	false
bromocriptine	176-188	astemizole	219-228	false
valproate	191-199	terfenadine	202-212	false
valproate	191-199	astemizole	219-228	false
terfenadine	202-212	astemizole	219-228	false

Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
Erythromycin	0-11	antihistamines	84-97	false
Erythromycin	0-11	terfenadine	99-109	mechanism
Erythromycin	0-11	astemizole	115-124	mechanism
antihistamines	84-97	terfenadine	99-109	false
antihistamines	84-97	astemizole	115-124	false
terfenadine	99-109	astemizole	115-124	false

In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
terfenadine	81-91	erythromycin	97-108	effect

There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
erythromycin	64-75	cisapride	100-108	effect
erythromycin	64-75	cisapride	289-297	false
erythromycin	64-75	erythromycin	302-313	false
cisapride	100-108	cisapride	289-297	false
cisapride	100-108	erythromycin	302-313	false
cisapride	289-297	erythromycin	302-313	mechanism

Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
lovastatin	31-40	erythromycin	46-57	advise

Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
Alcohol	0-6	LEXAPRO	19-25	false
Alcohol	0-6	alcohol	81-87	false
Alcohol	0-6	psychotropic medications	124-147	false
Alcohol	0-6	alcohol	161-167	false
Alcohol	0-6	LEXAPRO	188-194	false
LEXAPRO	19-25	alcohol	81-87	false
LEXAPRO	19-25	psychotropic medications	124-147	false
LEXAPRO	19-25	alcohol	161-167	false
LEXAPRO	19-25	LEXAPRO	188-194	false
alcohol	81-87	psychotropic medications	124-147	false
alcohol	81-87	alcohol	161-167	false
alcohol	81-87	LEXAPRO	188-194	false
psychotropic medications	124-147	alcohol	161-167	false
psychotropic medications	124-147	LEXAPRO	188-194	advise
alcohol	161-167	LEXAPRO	188-194	advise

Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors	0-27	MAOIs	30-34	false

Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
NSAIDs	38-43	Aspirin	46-52	false
NSAIDs	38-43	Warfarin	55-62	false
Aspirin	46-52	Warfarin	55-62	false

Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
psychotropic drugs	115-132	NSAID	269-273	effect
psychotropic drugs	115-132	aspirin	278-284	effect
NSAID	269-273	aspirin	278-284	false

Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
Cimetidine	0-9	citalopram	71-80	false
Cimetidine	0-9	cimetidine	121-130	false
Cimetidine	0-9	citalopram	170-179	false
citalopram	71-80	cimetidine	121-130	mechanism
citalopram	71-80	citalopram	170-179	false
cimetidine	121-130	citalopram	170-179	false

Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
Digoxin	0-6	citalopram	68-77	false
Digoxin	0-6	citalopram	107-116	false
Digoxin	0-6	digoxin	122-128	false
Digoxin	0-6	citalopram	212-221	false
Digoxin	0-6	digoxin	226-232	false
citalopram	68-77	citalopram	107-116	false
citalopram	68-77	digoxin	122-128	false
citalopram	68-77	citalopram	212-221	false
citalopram	68-77	digoxin	226-232	false
citalopram	107-116	digoxin	122-128	false
citalopram	107-116	citalopram	212-221	false
citalopram	107-116	digoxin	226-232	false
digoxin	122-128	citalopram	212-221	false
digoxin	122-128	digoxin	226-232	false
citalopram	212-221	digoxin	226-232	false

Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.
Lithium	0-6	citalopram	38-47	false
Lithium	0-6	lithium	77-83	false
Lithium	0-6	citalopram	163-172	false
Lithium	0-6	lithium	177-183	false
citalopram	38-47	lithium	77-83	false
citalopram	38-47	citalopram	163-172	false
citalopram	38-47	lithium	177-183	false
lithium	77-83	citalopram	163-172	false
lithium	77-83	lithium	177-183	false
citalopram	163-172	lithium	177-183	false

Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.
lithium	21-27	lithium	91-97	false

Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
lithium	8-14	escitalopram	56-67	effect
lithium	8-14	LEXAPRO	103-109	false
lithium	8-14	lithium	115-121	false
escitalopram	56-67	LEXAPRO	103-109	false
escitalopram	56-67	lithium	115-121	false
LEXAPRO	103-109	lithium	115-121	advise

Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
Pimozide	0-7	Celexa	13-18	false
Pimozide	0-7	pimozide	62-69	false
Pimozide	0-7	citalopram	105-114	false
Pimozide	0-7	pimozide	238-245	false
Celexa	13-18	pimozide	62-69	false
Celexa	13-18	citalopram	105-114	false
Celexa	13-18	pimozide	238-245	false
pimozide	62-69	citalopram	105-114	effect
pimozide	62-69	pimozide	238-245	false
citalopram	105-114	pimozide	238-245	false

Racemic citalopram did not alter the mean AUC or Cmax of pimozide.
citalopram	8-17	pimozide	57-64	false

Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
Sumatriptan	0-10	selective serotonin reuptake inhibitor	149-186	false
Sumatriptan	0-10	SSRI	189-192	false
Sumatriptan	0-10	sumatriptan	199-209	false
selective serotonin reuptake inhibitor	149-186	SSRI	189-192	false
selective serotonin reuptake inhibitor	149-186	sumatriptan	199-209	effect
SSRI	189-192	sumatriptan	199-209	effect

If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
sumatriptan	30-40	SSRI	49-52	advise
sumatriptan	30-40	fluoxetine	61-70	advise
sumatriptan	30-40	fluvoxamine	73-83	advise
sumatriptan	30-40	paroxetine	86-95	advise
sumatriptan	30-40	sertraline	98-107	advise
sumatriptan	30-40	citalopram	110-119	advise
sumatriptan	30-40	escitalopram	122-133	advise
SSRI	49-52	fluoxetine	61-70	false
SSRI	49-52	fluvoxamine	73-83	false
SSRI	49-52	paroxetine	86-95	false
SSRI	49-52	sertraline	98-107	false
SSRI	49-52	citalopram	110-119	false
SSRI	49-52	escitalopram	122-133	false
fluoxetine	61-70	fluvoxamine	73-83	false
fluoxetine	61-70	paroxetine	86-95	false
fluoxetine	61-70	sertraline	98-107	false
fluoxetine	61-70	citalopram	110-119	false
fluoxetine	61-70	escitalopram	122-133	false
fluvoxamine	73-83	paroxetine	86-95	false
fluvoxamine	73-83	sertraline	98-107	false
fluvoxamine	73-83	citalopram	110-119	false
fluvoxamine	73-83	escitalopram	122-133	false
paroxetine	86-95	sertraline	98-107	false
paroxetine	86-95	citalopram	110-119	false
paroxetine	86-95	escitalopram	122-133	false
sertraline	98-107	citalopram	110-119	false
sertraline	98-107	escitalopram	122-133	false
citalopram	110-119	escitalopram	122-133	false

Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
Theophylline	0-11	citalopram	50-59	false
Theophylline	0-11	theophylline	110-121	false
Theophylline	0-11	theophylline	186-197	false
citalopram	50-59	theophylline	110-121	false
citalopram	50-59	theophylline	186-197	false
theophylline	110-121	theophylline	186-197	false

The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.
theophylline	14-25	citalopram	54-63	false

Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
Warfarin	0-7	citalopram	47-56	false
Warfarin	0-7	warfarin	109-116	false
citalopram	47-56	warfarin	109-116	false

Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
Carbamazepine	0-12	citalopram	51-60	false
Carbamazepine	0-12	carbamazepine	90-102	false
Carbamazepine	0-12	carbamazepine	194-206	false
citalopram	51-60	carbamazepine	90-102	false
citalopram	51-60	carbamazepine	194-206	false
carbamazepine	90-102	carbamazepine	194-206	false

Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
citalopram	16-25	carbamazepine	98-110	false
citalopram	16-25	carbamazepine	134-146	false
citalopram	16-25	escitalopram	180-191	false
carbamazepine	98-110	carbamazepine	134-146	false
carbamazepine	98-110	escitalopram	180-191	false
carbamazepine	134-146	escitalopram	180-191	mechanism

Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
Triazolam	0-8	citalopram	47-56	false
Triazolam	0-8	triazolam	119-127	false
Triazolam	0-8	citalopram	214-223	false
Triazolam	0-8	triazolam	228-236	false
citalopram	47-56	triazolam	119-127	false
citalopram	47-56	citalopram	214-223	false
citalopram	47-56	triazolam	228-236	false
triazolam	119-127	citalopram	214-223	false
triazolam	119-127	triazolam	228-236	false
citalopram	214-223	triazolam	228-236	false

Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
Ketoconazole	0-11	citalopram	50-59	false
Ketoconazole	0-11	ketoconazole	73-84	false
Ketoconazole	0-11	ketoconazole	125-136	false
Ketoconazole	0-11	citalopram	225-234	false
citalopram	50-59	ketoconazole	73-84	mechanism
citalopram	50-59	ketoconazole	125-136	false
citalopram	50-59	citalopram	225-234	false
ketoconazole	73-84	ketoconazole	125-136	false
ketoconazole	73-84	citalopram	225-234	false
ketoconazole	125-136	citalopram	225-234	false

Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
Ritonavir	0-8	ritonavir	56-64	false
Ritonavir	0-8	escitalopram	138-149	false
Ritonavir	0-8	ritonavir	205-213	false
Ritonavir	0-8	escitalopram	218-229	false
ritonavir	56-64	escitalopram	138-149	false
ritonavir	56-64	ritonavir	205-213	false
ritonavir	56-64	escitalopram	218-229	false
escitalopram	138-149	ritonavir	205-213	false
escitalopram	138-149	escitalopram	218-229	false
ritonavir	205-213	escitalopram	218-229	false

However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.
escitalopram	29-40	ritonavir	54-62	false
escitalopram	29-40	escitalopram	157-168	false
ritonavir	54-62	escitalopram	157-168	false

Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.
escitalopram	8-19	escitalopram	123-134	false

In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
citalopram	44-53	citalopram	181-190	false
citalopram	44-53	escitalopram	232-243	false
citalopram	44-53	escitalopram	332-343	false
citalopram	181-190	escitalopram	232-243	false
citalopram	181-190	escitalopram	332-343	false
escitalopram	232-243	escitalopram	332-343	false

However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
escitalopram	89-100	escitalopram	129-140	false
escitalopram	89-100	tricyclic antidepressant	175-198	false
escitalopram	89-100	desipramine	200-210	false
escitalopram	89-100	desipramine	325-335	false
escitalopram	129-140	tricyclic antidepressant	175-198	false
escitalopram	129-140	desipramine	200-210	mechanism
escitalopram	129-140	desipramine	325-335	false
tricyclic antidepressant	175-198	desipramine	200-210	false
tricyclic antidepressant	175-198	desipramine	325-335	false
desipramine	200-210	desipramine	325-335	false

Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
Metoprolol	0-9	LEXAPRO	41-47	false
Metoprolol	0-9	beta-adrenergic blocker	149-171	false
Metoprolol	0-9	metoprolol	173-182	false
LEXAPRO	41-47	beta-adrenergic blocker	149-171	false
LEXAPRO	41-47	metoprolol	173-182	mechanism
beta-adrenergic blocker	149-171	metoprolol	173-182	false

Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.
LEXAPRO	20-26	metoprolol	32-41	false

Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
Citalopram	40-49	Citalopram	51-60	false
Citalopram	40-49	escitalopram	70-81	false
Citalopram	40-49	citalopram	115-124	false
Citalopram	40-49	Celexa	127-132	false
Citalopram	51-60	escitalopram	70-81	false
Citalopram	51-60	citalopram	115-124	false
Citalopram	51-60	Celexa	127-132	false
escitalopram	70-81	citalopram	115-124	advise
escitalopram	70-81	Celexa	127-132	advise
citalopram	115-124	Celexa	127-132	false

Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
reserpine	37-45	beta blocking agents	92-111	effect

Patients treated concurrently with BREVIBLOC (esmolol HCl) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
BREVIBLOC	35-43	esmolol HCl	46-56	false

A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.
BREVIBLOC	31-39	warfarin	45-52	false
BREVIBLOC	31-39	BREVIBLOC	96-104	false
BREVIBLOC	31-39	warfarin	110-117	false
BREVIBLOC	31-39	warfarin	134-141	false
warfarin	45-52	BREVIBLOC	96-104	false
warfarin	45-52	warfarin	110-117	false
warfarin	45-52	warfarin	134-141	false
BREVIBLOC	96-104	warfarin	110-117	false
BREVIBLOC	96-104	warfarin	134-141	false
warfarin	110-117	warfarin	134-141	false

BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
BREVIBLOC	0-8	warfarin	65-72	mechanism

When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
digoxin	5-11	BREVIBLOC	17-25	mechanism
digoxin	5-11	digoxin	126-132	false
BREVIBLOC	17-25	digoxin	126-132	false

Digoxin did not affect BREVIBLOC pharmacokinetics.
Digoxin	0-6	BREVIBLOC	23-31	false

When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
morphine	17-24	BREVIBLOC	30-38	false
morphine	17-24	morphine	105-112	false
morphine	17-24	BREVIBLOC	141-149	false
morphine	17-24	morphine	218-225	false
BREVIBLOC	30-38	morphine	105-112	false
BREVIBLOC	30-38	BREVIBLOC	141-149	false
BREVIBLOC	30-38	morphine	218-225	false
morphine	105-112	BREVIBLOC	141-149	false
morphine	105-112	morphine	218-225	false
BREVIBLOC	141-149	morphine	218-225	mechanism

The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.
BREVIBLOC	14-22	succinylcholine	43-57	false

The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
succinylcholine	39-53	BREVIBLOC	73-81	effect

Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
BREVIBLOC	102-110	digoxin	188-194	advise
BREVIBLOC	102-110	morphine	197-204	advise
BREVIBLOC	102-110	succinylcholine	207-221	advise
BREVIBLOC	102-110	warfarin	226-233	advise
digoxin	188-194	morphine	197-204	false
digoxin	188-194	succinylcholine	207-221	false
digoxin	188-194	warfarin	226-233	false
morphine	197-204	succinylcholine	207-221	false
morphine	197-204	warfarin	226-233	false
succinylcholine	207-221	warfarin	226-233	false

Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
BREVIBLOC	56-64	verapamil	70-78	advise

Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
BREVIBLOC	14-22	dopamine	158-165	advise
BREVIBLOC	14-22	epinephrine	168-178	advise
BREVIBLOC	14-22	norepinephrine	185-198	advise
dopamine	158-165	epinephrine	168-178	false
dopamine	158-165	norepinephrine	185-198	false
epinephrine	168-178	norepinephrine	185-198	false

Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
esomeprazole	41-52	phenytoin	113-121	false
esomeprazole	41-52	warfarin	124-131	false
esomeprazole	41-52	quinidine	134-142	false
esomeprazole	41-52	clarithromycin	145-158	false
esomeprazole	41-52	amoxicillin	163-173	false
phenytoin	113-121	warfarin	124-131	false
phenytoin	113-121	quinidine	134-142	false
phenytoin	113-121	clarithromycin	145-158	false
phenytoin	113-121	amoxicillin	163-173	false
warfarin	124-131	quinidine	134-142	false
warfarin	124-131	clarithromycin	145-158	false
warfarin	124-131	amoxicillin	163-173	false
quinidine	134-142	clarithromycin	145-158	false
quinidine	134-142	amoxicillin	163-173	false
clarithromycin	145-158	amoxicillin	163-173	false

Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.
warfarin	107-114	esomeprazole	120-131	false

Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
proton pump inhibitors	22-43	warfarin	49-56	effect

Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme.
Esomeprazole	0-11	esomeprazole	63-74	false

Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
esomeprazole	20-31	diazepam	43-50	mechanism
esomeprazole	20-31	diazepam	117-124	false
diazepam	43-50	diazepam	117-124	false

Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
esomeprazole	11-22	ketoconazole	136-147	mechanism
esomeprazole	11-22	iron	150-153	mechanism
esomeprazole	11-22	digoxin	165-171	mechanism
ketoconazole	136-147	iron	150-153	false
ketoconazole	136-147	digoxin	165-171	false
iron	150-153	digoxin	165-171	false

Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
contraceptives	25-38	diazepam	41-48	false
contraceptives	25-38	phenytoin	51-59	false
contraceptives	25-38	quinidine	65-73	false
contraceptives	25-38	esomeprazole	129-140	false
diazepam	41-48	phenytoin	51-59	false
diazepam	41-48	quinidine	65-73	false
diazepam	41-48	esomeprazole	129-140	false
phenytoin	51-59	quinidine	65-73	false
phenytoin	51-59	esomeprazole	129-140	false
quinidine	65-73	esomeprazole	129-140	false

Concomitant administration of clarithromycin with pimozide is contraindicated.
clarithromycin	30-43	pimozide	50-57	advise

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
benzodiazepines	18-32	anticonvulsants	56-70	effect
benzodiazepines	18-32	antihistamines	73-86	effect
benzodiazepines	18-32	alcohol	89-95	effect
benzodiazepines	18-32	barbiturates	98-109	effect
benzodiazepines	18-32	monoamine oxidase inhibitors	112-139	effect
benzodiazepines	18-32	narcotics	142-150	effect
benzodiazepines	18-32	phenothiazines	153-166	effect
benzodiazepines	18-32	psychotropic medications	169-192	effect
anticonvulsants	56-70	antihistamines	73-86	false
anticonvulsants	56-70	alcohol	89-95	false
anticonvulsants	56-70	barbiturates	98-109	false
anticonvulsants	56-70	monoamine oxidase inhibitors	112-139	false
anticonvulsants	56-70	narcotics	142-150	false
anticonvulsants	56-70	phenothiazines	153-166	false
anticonvulsants	56-70	psychotropic medications	169-192	false
antihistamines	73-86	alcohol	89-95	false
antihistamines	73-86	barbiturates	98-109	false
antihistamines	73-86	monoamine oxidase inhibitors	112-139	false
antihistamines	73-86	narcotics	142-150	false
antihistamines	73-86	phenothiazines	153-166	false
antihistamines	73-86	psychotropic medications	169-192	false
alcohol	89-95	barbiturates	98-109	false
alcohol	89-95	monoamine oxidase inhibitors	112-139	false
alcohol	89-95	narcotics	142-150	false
alcohol	89-95	phenothiazines	153-166	false
alcohol	89-95	psychotropic medications	169-192	false
barbiturates	98-109	monoamine oxidase inhibitors	112-139	false
barbiturates	98-109	narcotics	142-150	false
barbiturates	98-109	phenothiazines	153-166	false
barbiturates	98-109	psychotropic medications	169-192	false
monoamine oxidase inhibitors	112-139	narcotics	142-150	false
monoamine oxidase inhibitors	112-139	phenothiazines	153-166	false
monoamine oxidase inhibitors	112-139	psychotropic medications	169-192	false
narcotics	142-150	phenothiazines	153-166	false
narcotics	142-150	psychotropic medications	169-192	false
phenothiazines	153-166	psychotropic medications	169-192	false

While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
estazolam	70-78	carbamazepine	153-165	mechanism
estazolam	70-78	phenytoin	168-176	mechanism
estazolam	70-78	rifampin	179-186	mechanism
estazolam	70-78	barbiturates	193-204	mechanism
estazolam	70-78	estazolam	237-245	mechanism
carbamazepine	153-165	phenytoin	168-176	false
carbamazepine	153-165	rifampin	179-186	false
carbamazepine	153-165	barbiturates	193-204	false
carbamazepine	153-165	estazolam	237-245	false
phenytoin	168-176	rifampin	179-186	false
phenytoin	168-176	barbiturates	193-204	false
phenytoin	168-176	estazolam	237-245	false
rifampin	179-186	barbiturates	193-204	false
rifampin	179-186	estazolam	237-245	false
barbiturates	193-204	estazolam	237-245	false

Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
Estazolam	0-8	estazolam	108-116	false
Estazolam	0-8	4-hydroxy-estazolam	154-172	false
Estazolam	0-8	triazolobenzodiazepines	202-224	false
estazolam	108-116	4-hydroxy-estazolam	154-172	false
estazolam	108-116	triazolobenzodiazepines	202-224	false
4-hydroxy-estazolam	154-172	triazolobenzodiazepines	202-224	false

Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
estazolam	14-22	ketoconazole	64-75	advise
estazolam	14-22	itraconazole	81-92	advise
ketoconazole	64-75	itraconazole	81-92	false

The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
benzodiazepines	85-99	nefazodone	142-151	mechanism
benzodiazepines	85-99	fluvoxamine	154-164	mechanism
benzodiazepines	85-99	cimetidine	167-176	mechanism
benzodiazepines	85-99	diltiazem	179-187	mechanism
benzodiazepines	85-99	isoniazide	190-199	mechanism
benzodiazepines	85-99	macrolide antibiotics	211-231	mechanism
nefazodone	142-151	fluvoxamine	154-164	false
nefazodone	142-151	cimetidine	167-176	false
nefazodone	142-151	diltiazem	179-187	false
nefazodone	142-151	isoniazide	190-199	false
nefazodone	142-151	macrolide antibiotics	211-231	false
fluvoxamine	154-164	cimetidine	167-176	false
fluvoxamine	154-164	diltiazem	179-187	false
fluvoxamine	154-164	isoniazide	190-199	false
fluvoxamine	154-164	macrolide antibiotics	211-231	false
cimetidine	167-176	diltiazem	179-187	false
cimetidine	167-176	isoniazide	190-199	false
cimetidine	167-176	macrolide antibiotics	211-231	false
diltiazem	179-187	isoniazide	190-199	false
diltiazem	179-187	macrolide antibiotics	211-231	false
isoniazide	190-199	macrolide antibiotics	211-231	false

Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.
Fluoxetine	22-31	fluoxetine	94-103	false
Fluoxetine	22-31	estazolam	142-150	false
fluoxetine	94-103	estazolam	142-150	false

The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.
estazolam	24-32	fluoxetine	88-97	false

Estazolam: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.
Estazolam	0-8	estazolam	157-165	false

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.
corticosteroids	170-184	sex steroids	190-201	false

Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
calcium	25-31	EMCYT	82-86	mechanism

CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
Ethanol	17-23	eszopiclone	105-115	false
Ethanol	17-23	ethanol	121-127	false
Ethanol	17-23	ethanol	163-169	false
eszopiclone	105-115	ethanol	121-127	effect
eszopiclone	105-115	ethanol	163-169	false
ethanol	121-127	ethanol	163-169	false

Paroxetine: Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
Paroxetine	0-9	eszopiclone	48-58	false
Paroxetine	0-9	paroxetine	69-78	false
eszopiclone	48-58	paroxetine	69-78	false

Lorazepam: Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.
Lorazepam	0-8	eszopiclone	47-57	false
Lorazepam	0-8	lorazepam	68-76	false
eszopiclone	47-57	lorazepam	68-76	false

Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
Olanzapine	0-9	eszopiclone	32-42	false
Olanzapine	0-9	olanzapine	53-62	false
eszopiclone	32-42	olanzapine	53-62	effect

Drugs That Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone.
Ketoconazole	27-38	eszopiclone	96-106	false

The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
eszopiclone	11-21	ketoconazole	69-80	mechanism

Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
itraconazole	41-52	clarithromycin	55-68	false
itraconazole	41-52	nefazodone	71-80	false
itraconazole	41-52	troleandomycin	83-96	false
itraconazole	41-52	ritonavir	99-107	false
itraconazole	41-52	nelfinavir	110-119	false
clarithromycin	55-68	nefazodone	71-80	false
clarithromycin	55-68	troleandomycin	83-96	false
clarithromycin	55-68	ritonavir	99-107	false
clarithromycin	55-68	nelfinavir	110-119	false
nefazodone	71-80	troleandomycin	83-96	false
nefazodone	71-80	ritonavir	99-107	false
nefazodone	71-80	nelfinavir	110-119	false
troleandomycin	83-96	ritonavir	99-107	false
troleandomycin	83-96	nelfinavir	110-119	false
ritonavir	99-107	nelfinavir	110-119	false

Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
Rifampicin	26-35	zopiclone	46-54	false
Rifampicin	26-35	rifampicin	104-113	false
zopiclone	46-54	rifampicin	104-113	mechanism

Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.
Digoxin	38-44	eszopiclone	63-73	false
Digoxin	38-44	digoxin	119-125	false
eszopiclone	63-73	digoxin	119-125	false

Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
Warfarin	0-7	Eszopiclone	10-20	false
Warfarin	0-7	(R)-warfarin	95-98;107-114	false
Warfarin	0-7	(S)-warfarin	104-115	false
Warfarin	0-7	warfarin	233-240	false
Eszopiclone	10-20	(R)-warfarin	95-98;107-114	false
Eszopiclone	10-20	(S)-warfarin	104-115	false
Eszopiclone	10-20	warfarin	233-240	false
(R)-warfarin	95-98;107-114	(S)-warfarin	104-115	false
(R)-warfarin	95-98;107-114	warfarin	233-240	false
(S)-warfarin	104-115	warfarin	233-240	false

However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.
ENBREL	54-59	methotrexate	91-102	false

In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).
ENBREL	92-97	anakinra	104-111	effect
ENBREL	92-97	ENBREL	209-214	false
anakinra	104-111	ENBREL	209-214	false

Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).
ENBREL	50-55	anakinra	62-69	effect

Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
sulfasalazine	66-78	ENBREL	90-95	effect
sulfasalazine	66-78	ENBREL	216-221	false
sulfasalazine	66-78	sulfasalazine	229-241	false
ENBREL	90-95	ENBREL	216-221	false
ENBREL	90-95	sulfasalazine	229-241	false
ENBREL	216-221	sulfasalazine	229-241	false

Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
Lithium	0-6	diuretics	43-51	mechanism
Lithium	0-6	lithium	116-122	false
diuretics	43-51	lithium	116-122	false

EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
EDECRIN	0-6	aminoglycoside	67-80	effect
EDECRIN	0-6	cephalosporin antibiotics	91-115	effect
aminoglycoside	67-80	cephalosporin antibiotics	91-115	false

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
ethacrynic acid	29-43	warfarin	74-81	mechanism

In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
non- steroidal antiinflammatory agent	42-78	loop diuretics	150-153;188-196	effect
non- steroidal antiinflammatory agent	42-78	potassium- sparing diuretics	156-173;188-196	effect
non- steroidal antiinflammatory agent	42-78	thiazide diuretics	179-196	effect
loop diuretics	150-153;188-196	potassium- sparing diuretics	156-173;188-196	false
loop diuretics	150-153;188-196	thiazide diuretics	179-196	false
potassium- sparing diuretics	156-173;188-196	thiazide diuretics	179-196	false

Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
EDECRIN	16-22	non- steroidal anti- inflammatory agents	28-67	effect
EDECRIN	16-22	diuretic	174-181	false
non- steroidal anti- inflammatory agents	28-67	diuretic	174-181	false

The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
ethambutol	46-55	aluminum hydroxide	76-93	mechanism
ethambutol	46-55	antacid	106-112	false
ethambutol	46-55	ethambutol	220-229	false
ethambutol	46-55	ethambutol	314-323	false
ethambutol	46-55	antacid products	349-364	false
aluminum hydroxide	76-93	antacid	106-112	false
aluminum hydroxide	76-93	ethambutol	220-229	false
aluminum hydroxide	76-93	ethambutol	314-323	false
aluminum hydroxide	76-93	antacid products	349-364	false
antacid	106-112	ethambutol	220-229	false
antacid	106-112	ethambutol	314-323	false
antacid	106-112	antacid products	349-364	false
ethambutol	220-229	ethambutol	314-323	false
ethambutol	220-229	antacid products	349-364	false
ethambutol	314-323	antacid products	349-364	false

It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
ethambutol	56-65	aluminum hydroxide	72-89	advise
ethambutol	56-65	antacids	102-109	false
ethambutol	56-65	ethambutol	142-151	false
aluminum hydroxide	72-89	antacids	102-109	false
aluminum hydroxide	72-89	ethambutol	142-151	false
antacids	102-109	ethambutol	142-151	false

Dicumarol and warfarin may decrease hypoprothrombinemic effect.
Dicumarol	0-8	warfarin	14-21	false

Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
alcohol	27-33	barbiturates	36-47	false
alcohol	27-33	MAOIs	54-58	false
alcohol	27-33	ethchlorvynol	110-122	effect
barbiturates	36-47	MAOIs	54-58	false
barbiturates	36-47	ethchlorvynol	110-122	effect
MAOIs	54-58	ethchlorvynol	110-122	effect

May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).
central nervous system (CNS) depressants	52-91	alcohol	185-191	false
central nervous system (CNS) depressants	52-91	ethinamate	320-329	false
alcohol	185-191	ethinamate	320-329	false

Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
estrogen	62-69	contraceptives	87-100	false

Trecator has been found to temporarily raise serum concentrations of isoniazid.
Trecator	0-7	isoniazid	69-77	mechanism

Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
Trecator	0-7	antituberculous drugs	53-73	effect

In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
ethionamide	51-61	cycloserine	84-94	effect

Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
Ethopropazine	0-12	alcohol	32-38	effect
Ethopropazine	0-12	CNS depressants	49-63	effect
alcohol	32-38	CNS depressants	49-63	false

It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.
amantadine	26-35	anticholinergic drugs	46-66	false
amantadine	26-35	MAOIs	71-75	false
anticholinergic drugs	46-66	MAOIs	71-75	false

Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
Ethopropazine	0-12	chlorpromazine	32-45	mechanism
Ethopropazine	0-12	chlorpromazine	77-90	false
chlorpromazine	32-45	chlorpromazine	77-90	false

Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
Zarontin	6-13	ethosuximide	16-27	false
Zarontin	6-13	antiepileptic drugs	74-92	int
Zarontin	6-13	ethosuximide	168-179	false
Zarontin	6-13	phenytoin	193-201	false
Zarontin	6-13	valproic acid	220-232	false
Zarontin	6-13	ethosuximide	282-293	false
ethosuximide	16-27	antiepileptic drugs	74-92	int
ethosuximide	16-27	ethosuximide	168-179	false
ethosuximide	16-27	phenytoin	193-201	false
ethosuximide	16-27	valproic acid	220-232	false
ethosuximide	16-27	ethosuximide	282-293	false
antiepileptic drugs	74-92	ethosuximide	168-179	false
antiepileptic drugs	74-92	phenytoin	193-201	false
antiepileptic drugs	74-92	valproic acid	220-232	false
antiepileptic drugs	74-92	ethosuximide	282-293	false
ethosuximide	168-179	phenytoin	193-201	mechanism
ethosuximide	168-179	valproic acid	220-232	false
ethosuximide	168-179	ethosuximide	282-293	false
phenytoin	193-201	valproic acid	220-232	false
phenytoin	193-201	ethosuximide	282-293	false
valproic acid	220-232	ethosuximide	282-293	mechanism

Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
PEGANONE	44-51	Phenurone	87-95	advise
PEGANONE	44-51	phenacemide	98-108	advise
Phenurone	87-95	phenacemide	98-108	false

A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
hydantoin antiepileptic	34-56	phenytoin	59-67	int
hydantoin antiepileptic	34-56	coumarin anticoagulant	78-99	int
phenytoin	59-67	coumarin anticoagulant	78-99	false

Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
phenytoin	12-20	coumarin	46-53	mechanism
phenytoin	12-20	coumarin anticoagulants	127-149	mechanism
coumarin	46-53	coumarin anticoagulants	127-149	false

Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
coumarin anticoagulants	16-38	phenytoin	123-131	mechanism

Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulants may occur.
ethotoin	74-81	coumarin anticoagulants	91-113	false

Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
PEGANONE	48-55	coumarin anticoagulants	79-101	advise

